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Staphylococcus aureus pathogenesis and physiology 
“The goal of a bacterium is to become bacteria,” stated by Stanley Falkow (1) 
underscores the critical requirement of replication for the success of a bacterial species. For 
bacterial pathogens, this replication must occur in the midst of nutrient limitation and the 
hostile host immune response.  
Staphylococcus aureus is an exemplar of sophisticated human bacterial pathogens, 
because of its global burden, variety of disease manifestations, highly evolved virulence 
factors, and pace of acquisition of antimicrobial resistance. S. aureus asymptomatically 
colonizes the skin and anterior nares of  about a third of the population (2), yet when host 
barrier defenses are compromised, it is capable of causing a spectrum of invasive diseases. 
S. aureus is a leading cause of osteomyelitis, endocarditis, Gram-positive sepsis, skin and 
soft tissue infections, and toxic shock syndrome (3). Each of these host infectious niches 
require staphylococcal replication and the elaboration of virulence factors to cause disease 
and inhibit the immune response. Clinical treatment for these diseases has been challenged 
by the rapid expansion of antimicrobial resistance in clinical isolates (4). 
 Supporting the success of S. aureus as a pathogen is a robust host-adapted 
metabolism. S. aureus is a Gram-positive facultative anaerobe capable of performing oxygen-
dependent cellular respiration or transitioning to anaerobic metabolism in the absence of 
oxygen. Cellular respiration can use environmental nitrate, nitrite, or sulfite as terminal 
electron acceptors for anaerobic respiration. In the absence of terminal electron acceptors, 
fermentation of a variety of carbon sources support S. aureus replication. S. aureus has 
evolved to derive energy from carbon sources (5), acquire divalent cations (6, 7), phosphate 
(8) and amino acids (9) available in the mammalian host. As such, the physiology of S. aureus 
that supports replication and virulence factor production is key to the success of this organism 
in both infectious and non-infectious niches. In this dissertation, I probe key aspects of 
staphylococcal physiology related to iron-sulfur clusters and virulence factor production, 
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heme-iron acquisition, and heme biosynthesis to further elucidate means by which S. aureus 
replicates in the host.  
 
Heme synthesis, acquisition, and toxicity in bacterial pathogens 
Introduction 
Heme and iron are essential for life 
The tetrapyrrole cofactor heme is important for the cellular processes of most 
organisms and essential to many lifeforms across domains of life. Heme, a porphyrin ring 
complexed with iron, serves as a redox active moiety required for the function of many cellular 
proteins. Heme functions as an electron shuttle in enzymes of the electron transport chain 
and is required for cellular respiration. Additionally, cells rely on heme for the function of many 
widely conserved enzymes including catalase, nitric oxide synthase, and hemoglobin. Heme 
is also an important molecule involved in diverse cellular processes including signaling, gas 
sensing, microRNA processing, and cellular differentiation (10-13). Thus, nearly all organisms 
must satisfy the requirement for heme through either synthesis or acquisition.  
Heme coordinates an iron atom at its center which is vital for heme’s electron transfer 
abilities and redox activity. Like heme, iron is nearly universally required for life, and only a 
few exceptions have been identified (14, 15). As an inorganic cofactor, iron can act alone or 
in iron-sulfur clusters as a prosthetic moiety for members of the oxidoreductase, nitrogenase, 
hydrogenase, dehydrogenase, and hydratase enzyme families (16-21). Therefore, organisms 
have evolved elaborate strategies to acquire, store, and regulate intracellular iron for heme-
dependent and other iron-dependent enzymes.  
 
Nutritional immunity limits host iron availability 
Nutritional immunity, a concept articulated originally by Eugene Weinberg in the 
1970s, describes the processes by which humans and other organisms sequester iron to limit 
acquisition by bacterial pathogens (22, 23). Nutritional immunity has since been expanded to 
include the host processes that manipulate local levels of manganese, zinc, and other 
transition metals in order to metal starve or intoxicate the invading pathogens (24-27). The 
limited access of pathogens to metals serves as an antimicrobial strategy and limits bacterial 
replication. For instance, free iron rarely exists in the mammalian host. The solubility of ferric 
iron in aerobic solution is exceedingly low, and high affinity iron-binding proteins, including 
transferrin, lactoferrin, albumin, and ferritin sequester iron extracellularly and intracellularly. 
Iron-binding proteins function to transport iron, protect host cells from iron-mediated oxidative 
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damage, and to keep iron from pathogens. However, bacterial pathogens have developed 
exquisite tactics to overcome iron limitation, and elaborate high affinity iron receptors and 
chelators. In this regard, an evolutionary arms race has developed at the host-pathogen 
interface involving host iron-binding proteins and the mechanisms bacteria encode to steal 
iron.  
 
Heme is an important host iron source 
Heme makes up the greatest reservoir of iron in the host and serves as an iron source 
for many bacterial pathogens. Humans and other metazoa synthesize heme through a variety 
of steps in the mitochondria and cytosol. This pathway, called the Shemin or four-carbon 
pathway, begins with the condensation of glycine and succinyl-CoA to form the committed 
precursor δ-aminolevulinic acid (ALA) (28-30). A series of enzymes produce protoporphyrin 
IX from ALA and iron is inserted, forming protoheme IX. For the sake of simplicity in this 
review, heme will refer to ferrous and ferric iron forms of protoheme IX. Heme is then bound 
by hemoproteins to serve a variety of intracellular and extracellular tasks. Catalase, 
peroxidase, and myeloperoxidase rely on heme to catalyze the hydrolysis of peroxide 
molecules. Energy generation by the electron transport chain relies on heme-dependent c- 
and b-type cytochromes of the ubiquinol-ferricytochrome-c oxidoreductase (Complex III) 
family (31, 32). Hemoproteins involved in tissue oxygen homeostasis include myoglobin and 
neuroglobin. Perhaps the most well-known hemoprotein is the oxygen transporter hemoglobin 
(Hb). Its abundance and location in erythrocytes make hemoglobin a rich heme source for 
pathogens. Hemoglobin contains about two-thirds of the body’s iron, and a single erythrocyte 
contains more than 280 million molecules of Hb (24, 33). Bacterial pathogens have evolved 
high affinity Hb binding proteins for the acquisition of heme, and these proteins will be 
described below.  
Owing in part to the reactive nature of heme-iron, free heme and hemoglobin are toxic 
to the human host and bacterial pathogens alike (34, 35). To prevent excess heme toxicity, 
eukaryotic heme synthesis is highly regulated and heme homeostasis and sequestration are 
well-orchestrated. When hemoglobin is released from erythrocytes or otherwise exists 
extracellularly, it is rapidly bound by haptoglobin (36). The abundance of cell-free Hb is 
thought to be very low in healthy adults, but a variety of genetic disorders, infections, and 
other disease states can increase the concentration of free Hb (37). Free hemoglobin and its 
modified forms, in the presence of reactive oxygen species, exhibit cytotoxic effects towards 
endothelial cells (38). However, the relevance of these in vivo studies is unclear, and a 
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comprehensive understanding of concentrations to achieve hemoglobin toxicity in healthy 
humans has not been achieved (34). On the other hand, in the absence of infection free heme 
that has been liberated from its hemoprotein likely only exists transiently in serum or in cells. 
In serum, heme is immediately bound by the highly abundant albumin (kd ≈10 nM) then 
transferred to hemopexin (kd <1 pM) (39). The heme is delivered to cells expressing the 
hemopexin receptor; these cells then degrade the heme using heme oxygenases. The rapid 
sequestration and degradation of free heme in the blood is vital to the survival of erythrocytes, 
as heme in the presence of reactive oxygen species exhibits cytotoxicity and lipid peroxidation 
at micromolar concentrations (40, 41). During infection of host heme- and hemoglobin-replete 
niches, bacterial pathogens likely experience heme toxicity and encode systems to protect 
from heme toxicity as well (42). Therefore, heme is at the center of a complex interplay 
between host and pathogen for survival.  
 
Bacterial heme synthesis 
Divergent heme synthesis pathways in Gram-negative and Gram-positive organisms 
While both humans and bacteria share the early heme precursor δ-aminolevulinic acid 
(ALA), most bacteria (Alphaproteobacteria are the exception), archaea, and plants synthesize 
ALA from charged glutamyl-tRNAGlu via the ‘C5 pathway’ (Figure 1) (30, 43, 44). Glutamyl-
tRNA reductase produces the highly reactive intermediate glutamate-1-semialdehyde and  
glutamate-1-semialdehyde-2,1-aminomutase converts to ALA (45, 46). The three steps, from 
ALA to uroporphyrinogen, are well conserved and thought to be the evolutionary core of heme 
biosynthesis. ALA dehydratase (also called porphobilinogen synthase) is responsible for the 
condensation of two ALA to porphobilinogen (PBG) (47). The linear tetrapyrrole 
hydroxymethylbilane (HMB) is produced by a head to tail condensation and deamination of 
four PBG molecules, catalyzed by HMB synthase (alternatively called PBG deaminase) (48, 
49). Under physiological conditions, HMB will spontaneously cyclize to form the 
uroporphyrinogen I isomer, a biosynthetic dead-end. Therefore, most bacteria utilize 
uroporphyrinogen III synthase to catalyze the cyclization of HMB through a spiro-intermediate 
to form uroporphyrinogen III (50).  
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Figure 1 Bacterial heme biosynthesis. The heme synthesis pathway of most bacteria 
begins with charged glutamyl-tRNAGlu to form the universal precursor ALA, and 
coproporphyrinogen III is formed through a series of conserved enzymatic steps. The classical 
pathway (blue), forms heme through the protoporphyrinogen IX intermediate; most organisms 
including Gram-negative bacteria and eukaryotes use this pathway. The noncanonical 
pathway (green) performed by most Gram-positive bacteria, produces heme through the 
coproporphyrin III intermediate. Shown for each step is the enzyme name followed by the 
previously used protein annotation in bold, and the new enzyme annotation set forth by Dailey 
and colleagues (51) in red.  
 
 Uroporphyrinogen III can be utilized for the synthesis of several tetrapyrrole-based 
cofactors. Uroporphyrinogen III decarboxylase decarboxylates the four acetate side chains to 
methyl groups, producing coproporphyrinogen III, the next step in heme synthesis (52). 
Additionally, uroporphyrinogen III can be shunted from heme synthesis and converted to 
precorrin-2 to synthesize vitamin B12, coenzyme F430, and siroheme (53). The Ahb enzymes 
of some archaea and sulfur-reducing bacteria can convert siroheme (produced from 
uroporphyrinogen) to heme (54, 55). The contribution of the Ahb alternative heme pathway 
has not been demonstrated in pathogenic bacteria.  
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 In Gram-negative organisms, as well as eukaryotes, coproporphyrinogen III is 
converted to protoporphyrinogen IX by coproporphyrinogen III oxidase. This step is the first 
of the terminal three steps in the classical heme synthesis pathway (in blue in Figure 1) and 
is catalyzed by oxygen-dependent and oxygen-independent enzymes (56, 57). 
Protoporphyrinogen IX is subsequently oxidized to form protoporphyrin IX, by a six-electron 
oxidation catalyzed by one of three protoporphyrinogen oxidase enzymes. So called HemG, 
in Gammaproteobacteria and some Alphaproteobacteria and Deltaproteobacteria, uses the 
respiratory chain as its electron acceptor and is not dependent on oxygen (58). The enzyme 
annotated as HemJ is poorly characterized but represents the most common 
protoporphyrinogen oxidase among Alphaproteobacteria and Deltaproteobacteria (59). The 
third protoporphyrinogen oxidase was formerly called HemY, an FAD- and oxygen-dependent 
protoporphyrinogen oxidase found in some Proteobacteria as well as eukaryotes (60). The 
final step of the classical pathway is the insertion of ferrous iron by protoporphyrin 
ferrochelatase to form protoheme IX, called heme (61). From ALA to heme, the steps of the 
classical synthesis pathway are shared by eukaryotes and Gram-negative bacteria. 
The terminal steps of the classical pathway were considered universally conserved for 
all heme-synthesizing organisms. However, just in the last few years, the terminal steps of 
heme synthesis in the Gram-positive phyla Firmicutes and Actinobacteria have been 
described with genomic and biochemical analysis and termed the non-canonical or 
coproporphyrin-dependent pathway (43, 62). Very few HemF or HemN coproporphyrinogen 
oxidases can be identified in Gram-positive genomes; instead it has been realized that the 
annotated HemY/CgoX in these organisms functions as a coproporphyrinogen oxidase to 
form coproporphyrin III (43, 63). The Gram-positive HemH/CpfC, a coproporphyrin 
ferrochelatase, inserts ferrous iron to form coproheme (62). Finally, coproheme is 
decarboxylated by HemQ/ChdC, an enzyme unique to members of the Firmicutes and 
Actinobacteria to form protoheme IX (64-67). It is now clear that Gram-positive organisms 
utilize a unique series of terminal steps to synthesize heme (in green in Figure 1). 
 
Regulation of heme synthesis 
 Despite the vital role of heme to bacterial physiology, the regulation of heme 
biosynthesis has not been well studied outside of a few model organisms. In bacteria, 
regulation has been recognized to occur largely at two steps, abundance of the initial enzyme 
GtrR and transcription of the coproporphyrinogen oxidase enzymes. Regulation of GtrR is 
typically heme-dependent, indicating that bacteria reduce synthesis of heme and all 
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intermediates in heme-replete conditions. This process has been extensively studied in 
Escherichia coli and Salmonella enterica serovar. Typhimurium. The addition of heme to cell 
extracts of E. coli reduces total GtrR activity, without inhibiting the activity of the purified 
enzyme (68, 69). This was explained by the observation that excess heme results in the 
proteolytic degradation of GtrR in Salmonella, suggesting that GtrR might bind excess heme 
(70). The Clp and Lon proteases are responsible for this reduction in GtrR levels (71). Further, 
mutations in GtrR have been described that render GtrR resistant to heme- and protease-
mediated degradation, indicating that GtrR binds excess heme, and holo-GtrR but not apo-
GtrR is a substrate for proteolytic degradation (72, 73). In this manner, cellular levels of heme 
can regulate the first step of heme synthesis and limit the unnecessary synthesis of heme 
intermediates as well as the consumption of iron. Recent metabolic engineering efforts to 
enhance ALA production in E. coli suggest that protoporphyrin IX post-translationally inhibits 
PbgS, an additional example of feedback inhibition (74). It is likely that for many organisms, 
heme and terminal heme intermediates can have post-translational regulatory effects on 
heme synthesis enzymes. Like Salmonella and E. coli, the Gram-positive bacterium Bacillus 
subtilis regulates levels of GtrR. While a mechanistic explanation has not been described, the 
membrane protein HemX post-transcriptionally regulates GtrR abundance in B. subtilis (47, 
75). Homologs of B. subtilis HemX exist in multiple Gram-positive pathogens; however, the 
function of HemX and GtrR regulation has yet to be detailed. 
 In addition to the regulation of GtrR enzyme levels, the transcription of gtrR is also a 
point of control for heme biosynthesis. Two promoters exist upstream of gtrR in the Gram-
negative pathogen Pseudomonas aeruginosa, and these promoters contain binding sites for 
the regulators Anr (oxygen sensing), Dnr (redox regulator), IHF (integration host factor), and 
NarL (nitrate regulator) (76, 77). Therefore, gtrR expression is induced in the presence of 
oxygen or when oxygen is lacking but an alternative electron acceptor such as nitrate is 
present for utilization of heme-dependent respiration. In B. subtilis, the uroD-cpfC-cgoX 
operon is induced anaerobically and the gtrR-hemX-hmbS-pbgS-gsaM operon is induced by 
peroxide through de-repression of PerR (47, 78). As in B. subtilis, PerR has been implicated 
as a regulator of the uroD-cpfC-cgoX operon in Staphylococcus aureus; yet recent work has 
demonstrated that major differences exist between B. subtilis and S. aureus PerR orthologs 
and therefore it is difficult to conclude that PerR plays a role in S. aureus heme synthesis (79, 
80). Corynebacterium diphtheria, a member of the Actinobacteria phylum, encodes two heme-
responsive two-component systems (TCS). The response regulator HrrA directly binds the 
promoters of gtrR, uroD, and cpfC to repress their transcription in heme-replete conditions 
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(81). Similarly, ChrA can repress transcription of gtrR in heme replete conditions (82, 83). 
These data suggest that in C. diphtheriae, heme utilization is preferred over synthesis when 
exogenous heme is available. Together, these examples point to the transcriptional and post-
translational control of GtrR as a central step in heme synthesis regulation. 
The expression of coproporphyrinogen oxidase genes is the second major point of 
heme synthesis regulation. In several species, hemF and hemN are regulated by different 
oxygen- or anaerobic-responsive regulators to ensure proper expression of oxygen-
dependent or oxygen-independent coproporphyrinogen oxidases. OxyR, a global regulator in 
E. coli, is responsible for the induction of oxygen-dependent hemF expression in hydrogen 
peroxide stress. It has been suggested that the Fe-S cluster in oxygen-independent HemN is 
vulnerable to peroxide damage, so HemF is produced to take the place of HemN (84). In B. 
subtilis, the transcription of coproporphyrinogen III oxidases hemN and hemZ (a second 
coproporphyrinogen oxidase, not to be confused with oxygen-dependent HemY) are induced 
anaerobically by the regulatory cascade of ResDE, Fnr, and YwiD to replace the oxygen-
dependent HemY (85-88). Similarly, Pseudomonas hemF and hemN are expressed 
anaerobically under the control of Anr and Dnr, while Anr induces the expression of only hemN 
aerobically (89). It has been suggested, but not validated, that the expression of oxygen-
dependent hemF in oxygen limited conditions by Anr and Dnr serves to consume residual 
oxygen during the transition to anaerobiosis, which would protect other anaerobically induced 
oxygen-sensitive proteins (89). Thus, oxygen is a key regulator of expression of 
coproporphyrinogen oxidase genes. 
 
Contribution of heme synthesis to pathogenesis 
With a few notable exceptions including Bartonella hensaela, Enterococcus faecalis, 
Haemophilus influenzae, and Streptococcus spp., most human pathogens encode complete 
heme biosynthetic pathways (90-93). However, the contribution of heme synthesis to the 
pathogenesis of bacterial pathogens is largely understudied. For S. aureus, whose reliance 
on heme acquisition during infection has been well established, it is now clear that heme 
biosynthesis is vital to cause disease in murine models of infection (94-96). Inactivation of 
gtrR, which renders S. aureus heme deficient, causes the small-colony variant (SCV) 
phenotype (97). During systemic infection, this mutant is highly defective at colonizing the 
murine heart and liver relative to wildtype S. aureus (97). A mutant lacking pbgS, also a heme 
deficient SCV, demonstrates reduced colonization and bone destruction in a murine model of 
osteomyelitis (98, 99). These data demonstrate that for S. aureus, heme acquisition is 
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insufficient to support organ colonization and therefore heme biosynthesis is critical to 
pathogenesis. Importantly, the SCV phenotype is encountered clinically. Despite their reduced 
virulence, SCVs are generally more resistant to antibiotics and oxidative stress, more 
equipped to evade the immune system by living intracellularly, and are likely the etiological 
agent of persistent staphylococcal infections (99-103).  
Less evidence for the role of heme synthesis during infection is available for other 
pathogens. For the intracellular pathogen Brucella abortus, hemH is required for virulence in 
a murine model of brucellosis (104). Therefore, like S. aureus, host heme utilization is 
insufficient and synthesis is required for full virulence. In addition to B. abortus and S. aureus, 
the advent of whole genome in vivo analysis of mutants using techniques such as transposon-
sequencing and signature tagged mutagenesis has highlighted the role of heme synthesis. In 
these infections, genes with marked mutations that are recovered at a lower frequency from 
the infected tissue relative to growth in vitro are considered important to infection. These types 
of experiments have demonstrated a role for different heme synthesis genes during infection. 
Transposon mutants disrupted in hemY were found to be defective for P. aeruginosa 
colonization of the murine gastrointestinal tract (105). hemN was found to be important for 
Yersinia pestis infection of deep tissue (106). Transposon mutants lacking uroD in 
Acinetobacter baumannii were less effective at colonizing the murine lung (107). Finally, cgoX 
was found to be important for Listeria monocytogenes oral infection (108). Based on these 
transposon library infections, and data described in above paragraph, heme synthesis is vital 
to the fitness of a variety of pathogens. 
 
Current challenges and opportunities in bacterial heme synthesis 
The divergence between the terminal steps of Gram-positive heme synthesis and the 
classical pathway utilized by Gram-negative organisms as well as humans presents the 
opportunity for targeted small molecule interventions to inhibit or activate Gram-positive heme 
synthesis. The terminal Gram-positive enzymes ChdC, which exists only in Actinobacteria and 
Firmicutes, as well as CgoX and CpfC, which recognize different substrates than the 
eukaryotic host enzymes, present three potential targets. Small molecules have been 
described that modulate heme synthesis in vivo while in vitro inhibitors of S. aureus CgoX 
have recently been reported, suggesting that Gram-positive heme synthesis is an attractive 
drug target (62, 109-111). 
Outside of a few model pathogens, very little is understood regarding the regulation of 
heme synthesis, particularly during pathogenesis. Regulation is a central question in 
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understanding the role of heme synthesis in infection. Considering that in some niches host 
heme is available and can reach toxic levels, pathogens with the capacity to both steal and 
synthesize heme must regulate both pathways. For S. aureus, in which heme synthesis and 
acquisition are vital during infection, the strategies for regulation of heme synthesis is 
unknown. This is despite the observation over half a century ago that the rate of 
staphylococcal heme synthesis is modulated by exogenous heme (112). For other pathogens 
the contribution of heme synthesis to disease is still unclear, but whole genome in vivo fitness 
experiments like transposon-sequencing suggest many bacterial pathogens rely on heme 
biosynthesis to cause disease, and this field of research provides ample opportunity for further 
exploration.  
 
Heme acquisition in Gram-positive bacteria 
 Bacterial pathogens utilize a variety of heme acquisition strategies during infection, 
ranging from surface receptors to secreted proteins that bind either heme or hemoproteins. 
Heme acquired from the host is used fully intact or degraded to liberate heme-iron and both 
processes are important during bacterial pathogenesis. Gram-positive pathogens, including 
S. aureus, Bacillus anthracis, and C. diphtheriae rely on heme acquisition during infection. 
The heme uptake pathways of these three pathogens will be presented as models for the 
Gram-positive processes, along with the regulation of the pathway and evidence for the role 
of heme uptake during pathogenesis. 
 
The Staphylococcus aureus Isd paradigm 
 The Iron-regulated surface determinant system (Isd), first described in S. aureus, is 
the paradigm for Gram-positive heme acquisition (113). During infection, S. aureus utilizes 
the leukocidins HlgAB and LukED to lyse erythrocytes and liberate hemoglobin into the 
bloodstream (114). This results in accessible free heme, heme bound by hemopexin (Hx), 
free hemoglobin (Hb), and hemoglobin bound by haptoglobin (Hp) to form the haptoglobin–
hemoglobin (Hp-Hb) complex. The Isd system enables utilization of free heme, or heme bound 
to Hb and Hp-Hb complexes. Isd proteins bind heme and hemoglobin at the cell wall surface 
with conserved near transporter (NEAT) domains. The NEAT domains are 120-125 amino 
acid domains that constitute a conserved eight-stranded β-sandwich fold (115, 116). Heme is 
bound in a hydrophobic pocket with critical coordination by tyrosine residues in a YXXXY 
motif. These NEAT-containing surface proteins (IsdB, IsdH, IsdA in S. aureus) shuttle heme 
to NEAT-containing IsdC. IsdC transfers heme to the membrane-associated transporter 
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IsdDEF for transit across the membrane. To access host heme and hemoproteins, IsdB, IsdH, 
and IsdA are covalently attached to the peptidoglycan by the canonical Sortase A cysteine 
transpeptidase [106]. IsdB contains two NEAT domains, NEAT1 (N1) binds Hb and Hb-Hp, 
but not Hp and N2 binds heme; as such IsdB is believed to be the primary Hb binding protein 
(95, 117-119). IsdH contains three NEAT domains, N1 and N2 bind both Hb and Hp, and N3 
binds heme (120, 121). IsdA, which is partially surface exposed, contains a single heme 
binding NEAT domain(113). The current model (Figure 2), supported by strong structural 
evidence, suggests that IsdB-N1 binds hemoglobin, and IsdB-N2 extracts heme (122). 
Similarly, IsdHN1 and N2 bind Hb and Hp, and IsdH-N3 extracts the heme. The heme is then 
transferred either directly to IsdC or shuttled via IsdA to IsdC.  
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Figure 2 Gram-positive heme uptake systems. The iron-regulated surface determinant 
(Isd) systems for heme acquisition in S. aureus and B. anthracis, as well as the non-Isd 
systems of C. diphtheriae are diagrammed. Host hemoglobin (Hb), haptoglobin (Hp) bound 
Hb, and free heme (Fe-containing ring) can serve as heme sources during infection. (A) In S. 
aureus IsdH is the primary Hp-Hb receptor and IsdB is the principle Hb receptor. Both are 
sortase-linked on the surface of the cell wall, bind host hemoproteins with NEAT domains, 
and extract heme using additional NEAT domains. IsdA can bind free heme or accept heme 
from IsdB and IsdH. Heme is transferred to IsdC, which is embedded in the cell wall and 
transits heme to the membrane complex IsdDEF. IsdDEF transports heme to the cytoplasm 
for utilization intact or for degradation by the heme oxygenases IsdG/I. (B) Similarly, B. 
anthracis uses Isd proteins to acquire heme. IsdX1 and IsdX2 are secreted hemophores that 
bind Hb, Hp-Hb, or free heme as depicted. IsdX2, which has five NEAT domains, may also 
serve as a heme storage protein. Additionally, the sortase anchored Hal serves as a Hb 
receptor on the cell surface and uses its NEAT and leucine-rich repeat domains to acquire 
heme. BslK is cell-wall associated and binds heme via its NEAT domain. IsdC transports heme 
to the IsdDEF membrane importer for utilization or degradation by IsdG. (C) C. diphtheriae 
utilizes a unique set of heme uptake proteins for heme utilization. HtaA is a cell wall spanning 
lipoprotein that can acquire heme from Hp-Hb in conjunction with ChtA or ChtC. HtaB can 
bind free heme or accept heme transfer from HtaA and transfers heme to the HmuTUV 
membrane transporter. A portion of HtaA may also serve as a secreted hemophore. C. 
diphtherae HmuO heme oxygenase can liberate iron from imported heme.  
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S. aureus encodes an iron-regulated Sortase B (SrtB) for which IsdC is the only 
substrate, and SrtB attaches IsdC to peptidoglycan in such a way that IsdC is not surface 
exposed but rather buried in the cell wall, which is 15-30 nm thick (123, 124). This organization 
allows heme transferred from surface Isd proteins to pass through the cell wall to the 
membrane by IsdC’s single heme binding NEAT domain. IsdC alone transfers heme to the 
IsdE of the IsdDEF transporter (125). At the membrane, IsdDEF transits heme across the 
membrane and into the cytosol. 
Upon import, heme is incorporated into staphylococcal proteins or degraded. 
Exogenous heme accumulates in the membrane and is also capable of complementing the 
growth of heme-deficient mutants (96) . Alternatively, the heme oxygenases IsdG and IsdI 
degrade heme to release iron (126, 127). IsdG and IsdI are structurally similar and are the 
first described members of the Isd heme oxygenase family, which catabolizes heme to 
staphylobilin instead of biliverdin (128-130). IsdG and IsdI are required for growth using heme 
as a sole iron source, and are expressed during infection (127, 131). 
The widely conserved ferric uptake regulator (Fur) is the principle regulator of the 
expression of heme acquisition systems in S. aureus. In iron-deplete conditions, Fur no longer 
represses its regulon, allowing the transcription of the isdB, isdA, isdCDEFsrtBisdG, and isdI 
loci (113). During infection of iron-deplete niches, the heme acquisition system and associated 
iron-liberating heme oxygenases are expressed. Further regulation of the heme oxygenases 
exist; IsdG abundance increases in the presence of heme and IsdG half-life is increased when 
heme-bound (131). Also, the Clp proteases have a role in Hb acquisition by modulating IsdB 
levels (132).  
Isd-mediated heme acquisition is vital to the virulence of S. aureus. Heme is the 
preferred iron-source during systemic infection, in part because a heme-responsive 
transcriptional regulator activates iron siderophore synthesis only when heme-iron is 
unavailable (96, 133). The role of the Isd system has been extensively demonstrated in murine 
infection models. Mutants lacking components of the Isd system are highly defective in 
pathogenesis, highlighting the importance of heme acquisition to staphylococcal disease (94-
96, 118, 131, 134, 135). 
 
Isd-dependent heme uptake by Bacillus anthracis 
B. anthracis encodes a heme uptake system that shares the core of the S. aureus Isd, 
but with additional unique proteins. B. anthracis encodes two secreted hemophores termed 
IsdX1 and IsdX2 (136). These are the first described Gram-positive hemophores and bind 
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heme, hemoglobin, and methemoglobin (136-140). IsdX1 contains one NEAT domain while 
IsdX2 contains five NEAT domains; both are secreted past the cell wall as they lack sortase 
signals or membrane spanning domains (136). B. anthracis also encodes other NEAT contain 
proteins; Hal contains a single NEAT domain and leucine-rich repeats, which extract heme 
from hemoglobin (141). Unlike IsdX1/2, Hal is sortase anchored to the cell wall (142). A 
second, recently described NEAT protein is BslK, which is non-covalently attached to the cell 
wall and transfers heme to IsdC (143). The current proposed model (Figure 2) is that IsdX1 is 
secreted, binds heme, and transfers heme to wall-anchored IsdC. IsdX2 can bind free heme, 
accept heme from IsdX1, and transfer heme to IsdC. The multiple NEAT domains of IsdX2 
have been proposed to be important for these multiple functions, and it has been suggested 
that IsdX2 can serve as a heme storage protein. IsdDEF transports heme across the 
membrane for utilization by IsdG, an orthologue of the S. aureus heme oxygenase (144). The 
diversity of heme and Hb binding proteins relative to S. aureus may be the result of the greater 
variety of environmental niches that germinant and sporulent B. anthracis inhabits. 
The role of B. anthracis heme acquisition during infection is not clear. A guinea pig 
infection model demonstrated that ΔisdCX1X2 was as virulent as wildtype, yet these proteins 
are expressed during infection (145). Also, a mutant of B. anthracis lacking Hal demonstrated 
reduced virulence in a model of inhalational anthrax (146). It is likely that the IsdX1/X2 
hemophores, BslK, and Hal are partially redundant, and a mutant lacking all four proteins 
would be highly defective in causing anthrax. 
In addition to S. aureus and B. anthracis, many other pathogens have evolved NEAT-
containing heme acquisition systems, including Staphylococcus lugdunensis, Listeria 
monocytogenes, and Streptococcus pyogenes (147-154). The conservation of NEAT-
mediated heme uptake highlights the contribution of host heme  to bacterial infection. 
 
Corynebacterium diphtheriae heme uptake 
C. diphtheriae utilizes non-NEAT mediated heme uptake systems for heme-iron 
acquisition, termed HmuTUV, HtaABC, and ChtABC/CirA. The Hmu (hemin-uptake) system 
was the first heme acquisition system described in Gram-positive organisms. The associated 
heme oxygenase, HmuO, was discovered and described first, and then HmuTUV was 
discovered for the ability of a plasmid encoding hmuTUV to complement a Corynebacterium 
ulcerans strain that cannot grow on hemoglobin as a sole iron source (155, 156). Sequence 
analysis suggests that HmuTUV acts as an ABC transporter that shuttles heme across the 
cell membrane (157). It was later discovered that an additional gene is encoded within the 
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hmuTUV operon, termed htaA (heme-transport associated) (158). Adjacent to this locus are 
the genes htaB and htaC. Unlike the sortase anchoring of other Gram-positive uptake 
systems, HtaA and HtaB contain N-terminal secretion signals as well as C-terminal 
intermembrane domains. This results in surface exposure of HtaA and HtaB, which both bind 
heme. Interestingly, a portion of HtaA is secreted and not anchored to the cell envelope. HtaA 
isolated from cell culture is unable to complement the growth of an htaA mutant, suggesting 
that surface bound HtaA may serve as a heme receptor and secreted HtaA may serve as a 
hemophore (158, 159). However, heme transfer between HtaA molecules, and further 
description of the function of HtaA on the surface has not been reported. In addition to heme, 
HtaA can acquire heme from Hb and transfer heme to HtaB, suggesting a heme shuttle from 
HtaA to HtaB to HmuT; HmuT is a surface-anchored lipoprotein which then transfers heme to 
the cognate ABC transporter HmuUV (159). While the Isd NEAT domains rely on tyrosine 
alone as the axial ligand for heme binding, HmuT relies on an N-terminal histidine and a C-
terminal tyrosine to coordinate heme (160). 
Inactivation of the Hmu/Hta systems does not completely eliminate growth with heme 
as a sole iron source, suggesting the involvement of an additional heme uptake system (158). 
This led to the characterization of the ChtAB and CirAChrC operons, which are regulated by 
iron levels via DtxR. DtxR is the Diphtheria Toxin regulator which activates the expression of 
Diphtheria Toxin as well as HmuTUV and HtaABC (161, 162). ChtAB and ChtC appear to be 
the result of gene duplication of HtaAB, as all three groups of proteins have sequence 
similarity, N-terminal secretion signals, C-terminal transmembrane domains, and contain the 
same heme-binding domain (163). Like HtaAB, ChtAB and CirAChtC are surface exposed 
and ChtAB and ChtC bind heme and hemoglobin. It appears that these heme binding proteins 
serve redundant functions, and as such a mutant lacking both HtaB and ChtB is deficient at 
utilizing Hb as an iron source (163). Recently, it has been shown that ChtA and ChtC are both 
capable of binding Hp-Hb for heme extraction, and acquisition of heme from Hp-Hb requires 
HtaA (164). The current model (Figure 2) for Hp-Hb heme acquisition involves binding of Hp-
Hb by a combination of HtaA and ChtA or ChtC, heme extraction either actively or passively, 
and transfer to HtaB, HmuT, and HmuUV (164). 
 
Heme acquisition in Gram-negative bacteria 
The outer membrane of the cellular envelope of Gram-negative organisms presents 
an additional barrier to heme acquisition. Therefore, Gram-negative heme uptake systems 
consist of outer membrane receptors that either bind heme and hemoproteins directly, or bind 
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heme-bound secreted hemophores. Heme then transits the periplasm and is brought into the 
cell via ABC transporters at the inner membrane. The versatile opportunistic pathogen 
Pseudomonas aeruginosa encodes direct heme uptake and hemophore systems at the outer 
membrane, Haemophilus influenzae uses a hemophore uptake system, and Neisseria 
meningitidis uses a unique bipartite receptor for heme acquisition from host hemoproteins. 
These pathogens are presented as models for Gram-negative heme uptake systems. 
 
Pseudomonas aeruginosa 
P. aeruginosa encodes direct and indirect systems for heme uptake. The Phu 
(Pseudomonas heme uptake) consists of a TonB-dependent PhuR which binds heme and 
transports it to the periplasm. PhuR activity is representative of Gram-negative TonB-
dependent outer membrane receptors. These β-barrel proteins bind substrates (often iron 
containing molecules) with high affinity, and rely on proton motive force and TonB for transport 
across the outer membrane (165). TonB is an inner membrane protein with a substantial 
periplasmic portion for direct interaction with periplasmic domains of the outer membrane 
proteins. Upon PhuR translocation of heme into the periplasm, the soluble periplasmic protein 
PhuT binds heme and brings it to PhuUV, an ABC transporter at the inner membrane.  
In addition, HasA/HasR (heme assimilation system) are utilized for heme uptake. 
HasA is a secreted hemophore which binds heme and transfers it to a second TonB-
dependent transporter, HasR. Like other Gram-negative heme-binding motifs, HasA 
coordinates heme using histidine and tyrosine residues with picomolar affinity. Data from the 
orthologous HasA hemophore of Serratia marcescens suggests HasA binds hemoglobin and 
extracts heme, then HasA transfers heme to HasR (166, 167). The present model (Figure 3) 
for these two heme uptake systems suggests that Phu is the principle heme acquisition 
system but full heme utilization requires HasA/HasR. HasA/HasR may be more relevant as a 
heme sensing system; in low heme conditions the inner membrane HasS binds the sigma 
factor inhibitor HasI. When heme is available, HasS instead binds HasR, and HasI is free to 
recruit RNA polymerase to activate the transcription of hasAR, hasSI, phuSTUV, and phuR 
(168).  
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Figure 3 Gram-negative heme acquisition. The heme uptake systems as described in the 
text are depicted. (A) P. aeruginosa PhuR binds heme at the outer membrane and imports 
heme into the periplasm in a TonB-dependent manner. Heme is transferred to PhuT, which 
subsequently transfers heme to the PhuUV inner membrane transporter for transit into the 
cytoplasm. There, PhuS binds and stores heme or transfers heme to the heme oxygenase 
HemO for iron utilization. P. aeruginosa also secretes the hemophore HasA which binds 
hemoglobin (Hb) or free heme, and transfers heme to the TonB-dependent outer membrane 
receptor HasR. The fate of HasR imported heme is not fully understood, but may be trafficked 
to PhuTUV for import. HasS serves as an inner membrane sensor and regulates expression 
of the has and phu systems through the sigma factor HasI (not shown). (B) H. influenzae can 
utilize a variety of host heme sources. Secreted HxuA specifically binds hemopexin (Hx), and 
heme from Hx is transferred into the periplasm when HxuA interacts with HxuBC at the outer 
membrane. Independent of HxuA, HxuC can also import heme from serum albumin (Alb). 
HgpA, HgpB, and HgpC are highly similar outer membrane receptors for heme acquisition 
from Hb complexed with haptoglobin (Hp), free Hb, and Hp bound to myoglobin (not shown). 
The inner membrane heme transporter has not been clearly defined, but the Hip system has 
been implicated for heme transit into the cytoplasm. Interestingly, all imported heme may be 
utilized intact, as no heme oxygenase has been identified yet. (C) The N. meningitidis outer 
membrane, TonB dependent complex of HpuAB can acquire heme from Hb and Hp-Hb and 
bring heme into the periplasm. Additionally, the HmbR outer membrane receptor specifically 
extracts heme from Hb for transport. The identity of the inner membrane heme transporter is 
unclear at this time, but heme somehow enters the cytoplasm where it can be utilized or 
degraded by the HemO heme oxygenase.  
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The P. aeruginosa heme uptake system PhuSTUV/PhuR is regulated by Fur in 
addition to the HasI sigma factor detailed above. Recently, small regulatory RNAs have been 
described that impact phuS mRNA levels, suggesting another layer of heme-responsive 
regulation (169, 170). 
In contrast to many other organisms, Pseudomonas encodes a soluble cytoplasmic 
heme binding protein that is not a heme oxygenase. This protein, PhuS, transfers heme to the 
heme-oxygenase HemO for iron liberation. PhuS, unlike many hemoproteins, binds ferric-iron 
heme and subsequently transfers it to HemO under iron-deplete conditions (171). The 
dissociation constant of the heme-PhuS-HemO complex is in the nanomolar range, 
suggesting PhuS transfers heme to HemO specifically and not to the second Pseudomonas 
heme oxygenase, BphO (171). While the PhuS heme transfer has not been described 
completely, PhuS has been shown to bind heme as a monomer utilizing one of two histidine 
residues (His209 and His212), and a third binding site exists when PhuS is in dimeric form 
(172). Further in vitro characterization and structural analysis has led to a model whereby 
heme coordination occurs primarily at the His212 ligand and induces a conformational change 
required for interaction with HemO (173, 174). Additionally, in vitro heme oxygenase activity 
has been attributed to PhuS, however the in vivo relevance of this function is unclear as no 
biliverdin-β (the product of HemO heme catabolism) is detected in a mutant lacking hemO 
(175, 176). 
A recent clinical evaluation of genetic changes to P. aeruginosa during infection of 
cystic fibrosis lungs revealed the importance of heme acquisition during infection (177). Long-
term infection led to the selection of mutations in the promoters of the phuSTUWV and phuR 
loci, resulting in greater Phu expression. These changes to phu transcription confer a growth 
advantage enabling the utilization of heme from Hb as the sole iron source and suggest that 
heme is an important iron source during chronic Pseudomonas infection. The infections also 
selected for mutants that demonstrate enhanced expression of the feo ferrous-iron acquisition 
genes, indicating that ferrous iron is also a source of bioavailable iron. These clinical data 
confirm experimental findings suggesting that P. aeruginosa heme acquisition contributes to 
chronic infection. 
 
Haemophilus influenzae  
H. influenzae is a notable exception to the other pathogens outlined here, as it is 
incapable of synthesizing heme and therefore requires heme uptake for aerobic respiration 
(178). It is capable of acquiring heme from diverse host sources (Figure 3), including 
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hemopexin, free heme, albumin-bound heme, myoglobin and hemoglobin; the variety of heme 
sources is in accordance with its absolute reliance on exogenous heme (179). H. influenzae 
has evolved a variety of heme uptake systems important for growth in vitro using various host 
heme sources. While some systems are well described, less is known about others, and a 
global understanding of the utilization of these heme uptake systems during infection is 
lacking.  
The HxuCBA system, described primarily in H. influenzae type B, is capable of heme 
acquisition from free heme and heme-hemopexin (Hx). HxuA is a secreted hemophore that is 
released from the outer membrane by its transporter HxuB (180-182). HxuA exhibits no heme-
binding motif but rather demonstrates high affinity binding specifically to Hx with little 
distinction between apo- and holo-Hx (183). HxuC is a TonB-dependent transporter that binds 
heme after release from the Hx-heme-HxuA complex and imports it into the periplasm (184). 
Additionally, HxuC is capable of acquiring heme from serum albumin (Alb) independent of 
HxuA (185). HpbA is another heme acquisition protein identified in nontypeable and type B H. 
influenzae. A lipoprotein, HbpA is important for growth using Hb, Hp-Hb, and human serum 
albumin as heme sources (186, 187). The inner membrane heme transporter has not been 
definitively identified, but the Hip proteins have been implicated.  
Additionally, H. influenza encodes three receptors, HgpA, HgpB, and HgpC, that can 
acquire heme from Hp-Hb and haptoglobin bound myoglobin, albeit it at greater 
concentrations than thought to be physiologically relevant (188, 189). While the contribution 
of the Hgps seem redundant, HgpB has been demonstrated to be most important for utilization 
of Hp-Hb and Hp-myoglobin. 
There are many outstanding questions regarding H. influenzae heme uptake. Many 
proteins have been attributed to be involved in heme uptake, but their function requires further 
investigation (190-194). The regulation of the heme uptake system expression is not well 
described, except that hxuCBA and the hgp genes are expressed under in vitro iron/heme 
deplete conditions during experimental infection of the chinchilla ear (195). Lastly, a heme 
oxygenase of Haemophilus has not been described, suggesting that acquired heme is utilized 
intact and that other iron acquisition pathways, from transferrin and lactoferrin sources, are 
sufficient for cellular iron needs. However, it is also possible that a heme oxygenase exists 
and has not yet been identified. 
Genetic evidence from clinical isolates suggests that heme uptake is vital to 
pathogenic strains of H. influenzae. Isolates from otitis media infection in children relative to 
commensal throat isolates exhibit greater rates of hxuA, hxuB, hxuC, and hgpB gene 
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prevalence, indicating that heme uptake may be a virulence determinant (196, 197). Several 
animal models have been used to demonstrate the role of heme uptake during H. influenzae 
infection. In a model of H. influenzae bacteremia, infant rats infected with a mutant lacking 
HbpA completely clear the infection after one week while rats infected with wildtype remain 
infected (187). Likewise, a mutant lacking both HxuC and HgpABC uptake proteins is unable 
to cause bacteremia in the same rat model (198). Additionally, the Hgp proteins are required 
to cause otitis media in a chinchilla model (199). It is clear that for H. influenzae pathogenesis, 
heme uptake is a critical virulence determinant. 
 
Neisseria meningitidis 
N. meningitidis encodes a bipartite heme uptake system consisting of HpuAB and 
HmbR (Figure 3). HpuAB is expressed from an iron-repressed operon and consists of the 
HpuA lipoprotein and HpuB, the TonB-dependent receptor capable of binding Hb, apo-Hp, 
and Hp-Hb  (200, 201). Upon heme transport into the cytoplasm, the HemO heme oxygenase 
degrades heme to biliverdin and liberates iron. As such, HemO is required for survival using 
heme, Hb, or Hp-Hb as a sole iron source (202, 203). Heme is extracted from these 
hemoproteins and is imported intact, as hemoglobin can complement the deficiencies of a 
heme synthesis mutant in an HpuAB-dependent manner (204). The inner membrane 
transporter has not yet been identified, but a zinc transporter has been implicated (205).  
Initial studies of the individual function of HpuA and HpuB failed to describe the role of 
HpuA in heme acquisition. HpuB is sufficient to bind Hb, but a high affinity HpuB-Hb complex 
requires the presence of HpuA, even though HpuA-Hb binding was not detected by a flow 
cytometry assay (206, 207). Additionally, HpuA is required for growth with Hb as a sole iron 
source and heme import (208). However, a recent structural characterization has described a 
direct, albeit weak, interaction between HpuA and Hb, and a co-crystal structure of Hb and an 
HpuA homolog from Kingella denitrificans has been solved (209). While these data are not 
conclusive, they suggest that HpuA and HpuA homologs interact with Hb, and this interaction 
is required for HpuAB-mediate heme uptake.  
HmbR (hemoglobin receptor) is an additional N. meningitidis heme uptake protein that 
binds host Hb with species specificity, exhibiting a greater utilization of human Hb. but is 
unable to bind the Hp-Hb complex and therefore likely binds free Hb only (210). Like HpuAB, 
it is subject to phase variation (211). HmbR, based on spectroscopy and mutational analysis, 
also coordinates heme with a Tyr residue, which further confirms that diverse heme binding 
domains have evolved to utilize tyrosine as the axial ligand (212). The mechanism of heme 
21 
 
extraction by HmbR, the associated inner membrane heme transporter that partners with 
HmbR extraction, and structural descriptions of ligand binding are still undescribed for HmbR 
heme uptake. 
 In N. meningitidis, expression of hemO and hmbR is regulated by Fur as well as the 
MisRS TCS (213, 214). MisRS activates the expression of hemO and hmbR independent of 
Hb and iron concentration, which suggests an additional layer of regulation for Hb acquisition. 
However, the activating signal of MisRS has not yet been described. 
The genetic diversity of N. meningitidis clinical isolates has highlighted the importance 
of heme uptake to meningococcal virulence. While not all N. meningitidis strains express both 
the HmbR and HpuAB systems, most express at least one. Most pathogenic isolates express 
at least HmbR, but HpuAB expression is equally associated with disease and carriage 
isolates, which indicates HmbR is an indicator of pathogenesis (215, 216). N. meningitidis 
serotype B isolates associated with disease also exhibit “on” phase variation of HmbR, 
correlating virulence with the expression of HmbR  (217). Additionally, HmbR is required for 
virulence in an infant rat model of meningitis (210). These data implicate heme uptake, 
particularly HmbR, as an important component of Neisseria infection. 
 
Current challenges and opportunities in bacterial heme acquisition 
Study of heme uptake strategies has offered great insight into bacterial pathogenesis 
and nutrient acquisition. There is still great opportunity for discovery. For most bacterial heme-
binding motifs, the transfer from host hemoprotein has not been demonstrated as either 
passive dissociation or active extraction. The redundancy of heme uptake systems in 
pathogens like B. anthracis, P. aeruginosa, and H. influenzae is well-appreciated, but the role 
of each system during infection of various niches has yet to be fully elucidated. The relative 
contribution of host heme to iron acquisition by bacterial pathogens during infection is 
understudied. It is unclear if pathogens rely on heme for iron in unique spatiotemporal niches 
and rely on ferrous iron and siderophore acquisition systems in other niches. Opportunity 
abounds to understand the role of heme-iron utilization across time and tissues during 
infection. Finally, while global abundance of heme and hemoglobin in the host has been 
measured, the local availability of heme and hemoproteins during infection has not been 
described and presents an opportunity to understand the microenvironment of an infectious 
niche as well as the host response to infection. 
In terms of clinical application, heme uptake systems may be attractive therapeutic 
targets. S. aureus Isd proteins have been the target of vaccine development with mixed 
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success and monoclonal antibodies against IsdB have been studied for therapeutic use (218-
222). Considering the importance of heme acquisition to infection, using surface exposed 
heme uptake proteins as targets for vaccine and antibodies should continue to be 
investigated. Additionally, the Mycobacterium tuberculosis heme uptake system, which 
comprises three unique proteins and is sufficient to rescue the growth of a heme auxotroph, 
has been proposed as a new mycobacteria-specific antimicrobial target to be explored (223-
225). 
The interactions between host hemoproteins and bacterial hemoprotein binding 
proteins offer an excellent opportunity to study host-pathogen co-evolution. It has been 
recently demonstrated that the human and primate iron binding protein transferrin has 
undergone positive selection at the interface of binding by bacterial transferrin receptors, 
suggesting that the co-evolution of humans and pathogens has produced an evolutionary 
arms race in the context of nutritional immunity (226, 227). In the same vein, the Hb-binding 
IsdB of S. aureus exhibits species specificity and more efficiently utilizes human hemoglobin 
relative to mouse hemoglobin (94). In keeping with this, transgenic mice expressing human 
hemoglobin are more susceptible to S. aureus disease (94). The contribution of bacterial 
heme acquisition to human evolution presents ample opportunity to further investigate co-
evolution and nutritional immunity.  
 
Heme toxicity and tolerance 
 Bacterial pathogens dedicate extensive cellular machinery to the synthesis and 
acquisition of heme. Paradoxically, excess heme is toxic and thus during infection, invading 
pathogens must contend with heme toxicity as a component of pathogenesis. While heme 
toxicity is well-studied in eukaryotes, less is known in bacteria (34, 228, 229). A brief 
description of heme toxicity in bacteria and strategies utilized to combat toxicity follow.  
 
Multi-faceted mechanism of heme toxicity 
 The reactive nature of heme that makes it such a versatile cofactor also results in 
toxicity at excess concentrations. While the toxicity of heme towards bacteria has been 
observed for over 60 years, a complete understanding of the mechanisms of heme toxicity is 
lacking (35, 230). Free heme is rapidly bactericidal toward various Gram-positive and Gram-
negative pathogens in low- to mid-micromolar concentrations (42, 231-234). However, 
investigation of heme toxicity in a variety of bacterial species has led to a model of heme 
inducing iron- and non-iron related damage to the cell.  
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 The accumulation of heme results in excess iron by one of two mechanisms, both of 
which are likely at play under aerobic conditions. First, a portion of iron is freed by the heme 
oxygenases. Secondly, iron itself may be liberated from the porphyrin ring upon reaction with 
reactive oxygen species (ROS). Irrespective of the source, iron can cycle between ferrous 
and ferric states via Fenton chemistry and the Haber-Weiss reaction (reaction 1), yielding a 
regenerating supply of ROS.  
(1) Fe2+ + H2O2 → Fe3+ + HO• + OH− 
(2) Fe3+ + H2O2 → Fe2+ + HOO• + H+ 
Iron-mediated production of ROS can damage DNA, lipids, and proteins (235, 236). Further 
evidence for the contribution of oxidative stress to heme toxicity comes from S. aureus. In 
conditions of excess heme toxicity, membrane proteins are highly oxidized and superoxide is 
formed by redox cycling of heme-iron through membrane menaquinone (237). Superoxide 
production is a separate source of oxidative damage from ferrous iron mediated ROS and is 
a major component of heme damage in S. aureus (237). In addition to experimentally 
validating that heme-mediated ROS is a key to heme toxicity, this work also localized heme 
toxicity primarily to the membrane. The lipophilic nature of heme suggests it partitions to the 
membrane of bacteria, and this has been demonstrated in S. aureus, likely resulting in 
damage to membrane proteins and lipids (96).  
 Further evidence suggests iron-mediated ROS production and subsequent membrane 
damage is an insufficient description of heme toxicity. First, heme is toxic in anaerobic 
conditions and secondly, non-iron protoporphyrins are toxic to bacteria and activate the 
cellular response to heme toxicity (238-240). Also, porphyrins cause significant damage to 
bacterial DNA (241). Finally, resistance to heme toxicity is in part mediated in N. meningitidis 
by Ght (gene of hydrophobic agent tolerance), suggesting that damage by heme is similar to 
other hydrophobic molecules and may disrupt the Gram-negative outer membrane (233, 242). 
The toxicity of heme is likely the result of a combination of membrane disruption, membrane 
protein and lipid oxidation, and DNA damage. However, a total understanding of heme-
mediated damage is far from complete. 
 
Strategies to overcome heme toxicity 
 While the direct result of excess heme is unclear, it is evident that bacteria must 
contend with heme damage and have evolved a variety of strategies to overcome heme 
toxicity (Figure 4). These systems consist primarily of efflux and sequestration. Additionally, 
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the heme oxygenase outlined as part of heme acquisition strategies may contribute to the 
reduction of heme toxicity by cleaving the porphyrin ring and liberating iron for use. 
 
 
Figure 4 Strategies to avoid heme toxicity. Heme toxicity (center) is a combination of heme 
damage to membrane lipids, membrane proteins, DNA, and oxidative damage. Oxidative 
damage is mediated by the production of superoxide dismutase (O2-·), hydroxyl radical (HO·), 
and hydroperoxyl radical (HOO·). To reduce heme damage, many Gram-positive organisms 
(the S. aureus system is diagrammed here) encode the HrtAB efflux pump. The HssRS two 
component system responds to excess heme and activates the transcription of the hrtAB 
system, thus preventing the accumulation of toxic levels of heme. Alternatively, Gram-
negative organisms rely on intracellular heme sequestration proteins (PhuS of P. aeruginosa, 
HemS of Yersinia), the periplasmic heme-binding, copper and zinc dependent superoxide 
dismutase (Cu,Zn SOD, of H. ducreyi), and systems that respond to hydrophobic molecules, 
including heme (MtrCDE efflux and Ght of Neisseria).  
 
 Heme efflux strategies have been primarily characterized in Gram-positive organisms, 
potentially because efflux across a single membrane barrier is simpler to achieve than in 
Gram-negative pathogens. Three systems have been described, HrtAB, PefAB/CD, and 
MtrCDE. The S. aureus heme-regulated transporter HrtAB is required for survival in toxic 
concentrations of heme. hrtAB expression is activated by the HssRS heme sensing TCS (232, 
243, 244). While the ligand of the HssS histidine kinase has remained elusive, excess 
exogenous or endogenous heme leads to activation, either directly or indirectly (110). HrtA is 
an ATPase that drives efflux by HrtB permease of its ligand, likely heme. Orthologues of HrtAB 
have been described in B. anthracis and Lactococcus lactis, and are required for resistance 
to heme toxicity in these organisms (245). When the Hrt efflux pump is inactivated in both S. 
aureus and L. lactis, levels of intracellular heme increase, suggesting that heme is the 
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substrate of HrtAB export (238, 246). In B. anthracis, an HssRS orthologue controls the 
expression of HrtAB and cross-talks with a second TCS that responds to cellular envelope 
stresses, further implicating membrane damage as a component of heme stress (247). HrtAB 
is actively expressed during murine anthrax, suggesting organisms that replicate in the 
bloodstream must tolerate heme toxicity (42). 
 Additional efflux systems exist, suggesting that this strategy is well conserved. 
Streptococcus agalactiae encodes an orthologue of HrtAB, as well as a dual efflux system 
PefAB and PefRCD (231). In heme stress, hrtAB and pefAB/RCD are expressed at high 
levels, and the Pef systems are required for resistance to heme toxicity (231). The Gram-
negative N. gonorrhoeae encodes an efflux pump, MtrCDE, for hydrophobic molecules that is 
required for resistance to heme stress (248). 
 Heme sequestration and storage is a second theme in strategies to resist heme 
toxicity. The conserved HemS family has been described in Yersinia enterocolitica, Y. pestis, 
Shigella dysenteriae (termed ShuS), P. aeruginosa (called PhuS, detailed above), and E. coli 
(ChuS, which also has heme oxygenase activity) (157, 171, 234, 249-254). While a variety of 
heme storage, transfer, and degradation properties have been assigned to these proteins, 
their involvement in resisting heme toxicity is clear. Additionally, non-HemS family proteins 
have been found to bind heme and play a role in heme homeostasis, including the small outer 
membrane Protein E of H. influenzae and the Cu,Zn superoxide dismutase of Haemophilus 
ducreyi (253, 254). 
 
Current challenges and opportunities in bacterial heme toxicity  
 While numerous systems are involved in detoxifying heme, there are many 
outstanding questions. The efflux systems have been described genetically, but a complete 
understanding of the ligands exported is still murky. For Gram-positive pathogens, the efflux 
systems may provide an additional therapeutic target for infection. Inhibition of efflux may offer 
a treatment option for bloodstream infections by S. aureus and B. anthracis; presumably the 
effects of heme toxicity would be deadly to the bacterium if the HrtAB pump were 
pharmacologically inactivated. This strategy could also pair well with small molecule activation 
of heme synthesis, which has been developed (111). In terms of heme sequestration proteins, 
it has been difficult to fully interpret the contribution of heme sequestration because additional 
properties like oxygenase (PhuS and ChuS) and DNA binding (ShuS) been observed. Finally, 
the role of heme oxygenases in resisting heme stress has not been well studied, but heme 
degradation likely reduces heme toxicity in a variety of organisms.  
26 
 
Outstanding questions in S. aureus heme homeostasis 
S. aureus relies on heme dependent enzymes including the terminal cytochrome oxidases of 
cellular respiration and the antioxidant proteins bacterial nitric oxide synthase and catalase. 
To fulfill the requirement for heme, S. aureus synthesizes heme via glutamyl-tRNA. During 
infection, when host heme becomes available, the IsdB system can acquire heme, while 
HssRS may respond to excess heme (Figure 5).  
 
Figure 5 A model of heme acquisition, synthesis, utilization and detoxification in S. 
aureus. 
 
Despite this experimentally supported model, a series of outstanding questions regarding S. 
aureus heme homeostasis remain.  
1. Unidentified hemoproteins-the heme binding proteins of the Isd system (255), 
terminal oxidases (QoxABCD, CydAB (256)) bacterial nitric oxide synthase (bNOS), 
catalase (KatA), coproheme decarboxylase (ChdC (67, 257)), flavohemoprotein 
(Hmp;(258), and SbnI (133) have been studied in vitro or in vivo, yet no exhaustive 
investigation of S. aureus heme binding proteins has been completed. The non-
covalent coordination by heme makes unbiased identification approaches difficult. 
However, as investigation continues into S. aureus heme homeostasis, more 
hemoproteins will be identified, adding to the quantity of heme-dependent physiology 
and more elaboration of the heme systems in Figure 5. In this thesis, GtrR is tentatively 
added to the list of S. aureus heme binding proteins.  
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2. Biochemistry of terminal synthetic enzymes- the field of study regarding 
coproporphyrin-dependent heme synthesis is new, and one of the most outstanding 
questions is how the terminal heme biosynthesis enzymes UroD, CgoX, CpfC, and 
ChdC coordinate their functions to ensure heme synthesis without toxic intermediate 
buildup, to ensure sufficient iron is available for insertion by CpfC, and the fate of the 
heme once formed by ChdC. 
3. Endogenous activation of HssRS-previous work in our laboratory has found that 
HssRS can be activated by pharmacological activation of heme synthesis (109-111). 
Therefore, the true function of HssS may be to sense levels of endogenously 
synthesized heme rather than host-derived heme. The potential that HssS is a sensor 
for heme biosynthesis is explored further in this thesis. 
4. Toxicity of heme-the basis for the toxicity of heme, as discussed above, is largely 
unknown for S. aureus. Considering that the regulon of HssS has been validated to 
contain only four genes, the transcriptional and proteomic response to heme toxicity 
has not offered much data to understand how heme kills S. aureus.  
5. Host heme utilized intact-when host heme is bound and imported by the Isd system, 
the heme oxygenases IsdG and IsdI degrade heme to liberate iron. The fraction, if 
any, of host heme that can be incorporated intact into hemoproteins has not been 
measured. A heme synthesis mutant was able to infect kidneys to the same extent as 
WT S. aureus, but unable to replicate in the heart or liver, in a murine model of 
systemic infection. It is therefore unclear whether the kidney provides more available 
host heme to complement the heme deficiency, or if the kidney microenvironment is 
such that heme-independent fermentation is sufficient for replication in this niche.  
6. Function of heme degradation products-the heme oxygenases degrade heme to 
staphylobilin and formaldehyde, yet no known function of these degradation products 
has been identified. Based on the analogous signaling roles that the heme degradation 
products in eukaryotes (carbon monoxide, biliverdin, and bilirubin) play, it is likely that 
staphylobilin and formaldehyde are important signaling molecules that affect S. aureus 
physiology. 
7. Regulation of heme synthesis is the major question addressed in this thesis. Despite 
the duality of heme’s necessity and toxicity, little is known regarding regulatory 
pathways guiding heme synthesis. Additionally, evidence of cross-talk between heme 
synthesis, uptake, utilization, and toxicity is lacking, despite the integrated functions of 
these heme systems. It is expected that the presence of exogenous heme would 
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impact heme synthesis, and that changes in the need for heme-dependent proteins 
would increase heme synthesis, while taking into account endogenous and exogenous 
heme availability to avoid toxicity.  
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CHAPTER II 
 
 
A SMALL-MOLECULE INHIBITOR OF IRON-SULFUR CLUSTER ASSEMBLY 
UNCOVERS A LINK BETWEEN VIRULENCE REGULATION AND METABOLISM IN 
STAPHYLOCOCCUS AUREUS 
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Introduction 
The Gram-positive pathogen Staphylococcus aureus is a leading cause of a wide range of 
devastating infections, including skin and soft tissue infections, osteomyelitis, infective 
endocarditis, and bacteremia (3). To infect, S. aureus employs a multitude of toxins, 
exoenzymes, and immune modulators, and its virulence regulators have long been 
appreciated as vital to pathogenesis. SaeRS is a key global regulator of toxin and exoenzyme 
production (259). SaeS is a two-component system (TCS) histidine kinase that responds to 
molecular components of neutrophils and activates the response regulator SaeR, which up-
regulates transcription of the Sae regulon (260, 261). SaeRS is encoded in the saePQRS 
operon along with SaePQ, a membrane complex that aids the return of SaeRS to basal levels 
of activity (262). Complementary to its arsenal of virulence factors, S. aureus has also evolved 
antibiotic resistance. Methicillin resistant S. aureus accounts for the majority of clinical isolates 
(3). The dearth of antibiotics in the pharmaceutical development pipeline has led to renewed 
efforts to discover small molecules that probe the physiology of pathogens for the 
development of novel antimicrobials. In this regard, central metabolic pathways have become 
an attractive target in bacterial pathogens (263).  
S. aureus is a facultative anaerobe, relying on both respiration and fermentation to 
cause disease (97, 264). In aerobic environments, respiration utilizes oxygen as the terminal 
electron acceptor and provides higher rates of ATP generation. However, S. aureus 
experiences many conditions in the host which makes fermentation vital.  Fermentation is 
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utilized in hypoxic or anaerobic niches devoid of alternative terminal electron acceptors, 
including the bone and tissue abscess (97, 265). Host-produced nitric oxide directly inhibits 
the respiratory chain and the TCA cycle is inhibited in iron-deplete niches because of the iron 
dependency of many TCA cycle enzymes (264, 266). Additionally, respiration-deficient 
menaquinone or heme auxotrophs, called small colony variants (SCVs), are common isolates 
and etiological agents of persistent infections, an enormous clinical problem (101). 
Respiration-deficient SCVs rely on fermentation for growth and are intrinsically resistant to 
antibiotics that rely on membrane potential to enter the cell. Therefore, targeting of processes 
essential for fermentation is an exciting therapeutic option for the elimination of these cell 
populations.  
Iron is crucial to the infectious lifecycle of S. aureus and a large portion of internalized 
iron is incorporated into proteins as Fe-S cluster cofactors. Fe-S cluster cofactors are required 
for a variety of cellular processes and the synthesis of Fe-S clusters is essential for S. aureus 
viability (267). Fe-S cluster-dependent enzymes play key roles in central carbon metabolism 
(268), branched chain amino acid synthesis (269), antibiotic resistance (270), and signal 
transduction (271). S. aureus factors required for Fe-S cluster assembly and maturation of 
apo-protein targets include SufS, SufBCD, SufU, SufT, SufA, and Nfu. SufS provides sulfur 
from cysteine to SufU or SufBCD, which synthesize [Fe2-S2] or [Fe4-S4] clusters (272). These 
Fe-S clusters are inserted into apo-proteins with or without the aid of the Fe-S cluster carriers 
Nfu or SufA, facilitating the maturation of holo-proteins (267, 273). SufT is an auxiliary factor 
involved in the maturation of apo-proteins that has an increased role during conditions that 
impose a high demand for Fe-S clusters (274). The genes encoding for Nfu and SufT display 
synergism for multiple phenotypes. Analyses of a Δnfu ΔsufT strain have revealed the 
pleiotropic effects of defective Fe-S assembly upon central metabolism, iron homeostasis, 
oxidative stress, vancomycin resistance, biofilm formation and virulence (267, 274) 
Previously, we identified small molecule VU0038882 (‘882) that activates endogenous 
heme biosynthesis in S. aureus while toxic to S. aureus grown anaerobically (275). ‘882 
exhibits an IC50 of ~162 µM to aerobic S. aureus and an IC50 of ~5 µM to anaerobic S. aureus 
(275). Further experimentation revealed that ‘882 is toxic to S. aureus relying solely on 
fermentation for energy generation, as ‘882 is bacteriostatic to mutants that are respiration-
deficient, regardless of oxygen availability. Through extensive structure-activity relationship 
(SAR) studies, we showed that the toxicity of ‘882 can be uncoupled from the capacity to 
activate heme synthesis, suggesting that ‘882 affects two distinct targets in S. aureus (276).  
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In this work, we sought to identify the mechanism of ‘882 toxicity in order to probe the 
physiology of S. aureus and uncover novel therapeutic targets. Genetic and proteomic 
approaches uncovered the SaeRS TCS as essential for ‘882 toxicity and the Suf Fe-S cluster 
biogenesis machinery as a likely target of ‘882. Here, we identify a unique link between 
virulence regulation and metabolic fitness in S. aureus. Additionally, this work employs a 
breadth of approaches to understand the effects of a small molecule and emphasizes the 
importance of Fe-S cluster metabolism in staphylococcal physiology. This study establishes 
‘882 as a first-in-class manipulator of Fe-S cluster assembly, which may guide the 
development of new antimicrobials that target this essential pathway.  
 
Materials and methods 
Bacterial growth conditions 
Strains, plasmids, and primers used are described in Tables 1-3. S. aureus strains 
Newman (wildtype is referred to throughout as NM), USA300 LAC, and JE2 and their mutants 
were grown on tryptic soy agar (TSA) or broth (TSB) and at 37°C unless noted otherwise. 
When appropriate, chloramphenicol or erythromycin was added to a final concentration of 10 
µg/mL. ‘882 was dissolved in DMSO and added to media at concentrations noted throughout; 
an equivalent volume of DMSO was added as vehicle control to non-treated cultures. For 
routine anaerobic growth, a Coy (Grass Lake, MI) anaerobic chamber was used. 
 
Table 1 Bacterial strains used in Chapter II 
Species Strain Genotype Description Source 
S. aureus Newman  Wildtype Methicillin sensitive strain (277) 
S. aureus USA300 LAC Wildtype Methicillin resistant strain (278) 
S. aureus USA300 LAC 
JE2 
Wildtype Methicillin resistant strain, 
erythromycin sensitive  
(279) 
S. aureus RN4220 Wildtype Restriction deficient cloning 
intermediate strain 
(280) 
S. aureus Newman ΔsaeRS Isogenic deletion of saeRS (281) 
S. aureus Newman saeSP18L Allelic replacement with repaired 
saeS 
(281) 
S. aureus Newman ΔsaeQRS::specR Allelic replacement of saeQRS with 
spectinomycinR 
(282) 
S. aureus Newman rimJ (NWMN_1957) Transduced from transposon 
insertion in JE2, 
SAUSA300_2003::ermB; NE1321 
NARSA/BEI 
(279) 
S. aureus Newman fakA (NWMN_1136) Transduced from transposon 
insertion in JE2, 
SAUSA300_1119::ermB; NE221 
NARSA/BEI; 
(279)  
S. aureus Newman fakB1 (NWMN_0718) Transduced from transposon 
insertion in JE2, 
SAUSA300_0733::ermB; NE1540 
NARSA/BEI; 
(279)  
S. aureus Newman ΔclpX In-frame deletion (132) 
S. aureus USA300 LAC ΔsufA (SAUSA300_0843) In-frame deletion (283) 
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S. aureus USA300 LAC ΔsufA::tetM Tetracycline resistant allelic 
replacement 
(283) 
S. aureus USA300 LAC Δnfu (SAUSA300_0839) In-frame deletion (283) 
S. aureus USA300 LAC nfu::tetM Tetracycline resistant allelic 
replacement 
(283) 
S. aureus USA300 LAC ΔsufT (SAUSA300_0875) In-frame deletion (274) 
S. aureus USA300 LAC nfu::ermB ΔsufT nfu::ermB transposon allele 
transduced into ΔsufT  
(274) 
S. aureus USA300 LAC acnA::ermB Transposon mutation; NE861  (283) 
S. aureus Newman acnA::ermB Transposon allele transduced into 
strain Newman; NE861  
 This work  
S. aureus USA300 LAC attP::pLL39_acnA_FLAG, 
acnA::ermB 
Chromosomal integration of FLAG-
tagged aconitase 
(283) 
E. coli DH5α  Cloning Strain  
     
E. coli PX5  Cloning Strain Protein 
Express 
 
Table 2 Plasmids used in Chapter II 
Plasmid Description Source 
pOS1Plgt S. aureus shuttle vector with lgt (constitutive) 
promoter 
(284) 
pOS1PlgtsaeQRS (NM) saeQRS cloned from Newman Victor Torres 
pOS1PlgtsaeQRS (LAC) saeQRS cloned from LAC Victor Torres 
pCM11 Cloning vector for transcriptional reporters (285) 
pCM11_sufC Reporter construct for sufC (274) 
pET24a Protein production EMD Millipore 
pET24a_acnA SAUSA300_1246 (283) 
pEPSA5  (286) 
pEPSA5_Flag_acnA AcnA assays and immunoblots (283) 
 
 
Table 3 Primers used in Chapter II 
Primer name Sequence 
L202 GACCCCTATTTATTTAAATCAG 
L197 AGCCCTCATTAATGGGAGCTTC 
L186 GAGGTTTGTTTAGCTTAAGC 
L190 GGGGCTCGAGATGACCCACTTACTGATCGTGG 
L191 GGGGCTCGAGATGGTGTTATCAATTAGAAGTC 
D474 GATGCTCAAGCACCAAAAGC 
D475 ACTTTATGCTTCCGGCTCG 
D476 GAAGAGATGTAAGAGTAGGG 
 
Generation of spontaneously resistant mutants 
Stationary phase cultures of aerobically grown NM in TSB alone were back-diluted 
1:10,000 into TSB and 10 µl was spread onto TSA containing 20 or 40 µM ‘882 and moved 
into an anaerobic jar (Difco). After 24 h, colonies that appeared were restreaked onto TSA 
without ‘882, allowed to grow for 24 h, restreaked again on TSA alone, and after 24 h 
restreaked on TSA containing ‘882 to confirm resistance. For spontaneous resistance in NM 
pOS1PlgtsaeQRS, mutants were generated in the same manner except media contained 
chloramphenicol in addition to ‘882.  
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For resistant mutants, genomic DNA was purified using Wizard Genomic Kit 
(Promega) and the sae locus from the genome was amplified with primers L202 and L197 and 
Sanger sequenced (GenHunter) using primers L202, L186, L190, and L191. The plasmid from 
each resistant strain was purified using Plasmid Mini-prep kit (Thermo) and Sanger 
sequenced (GenHunter) using primers D474, D475, and D476 to check for mutations in the 
sae locus before whole genome sequencing.  
 
Whole genome sequencing 
Genomic DNA was isolated from mutant strains using the Wizard Genomic Kit 
(Promega) and sequenced along with the parental strain (NM or NM pOS1PlgtsaeQRS) by 
Perkin Elmer on the MiSeq Platform and analyzed for mutations using the Integrated 
Genomics Viewer available from the Broad Institute. Mutations were confirmed by Sanger 
sequencing. 
 
Growth curves  
Growth was monitored spectrophotometrically in 96-well plates containing 200 μL 
volume after stationary phase cultures were back-diluted into fresh medium. Percent (%) 
growth relative to vehicle is calculated from OD600 for each strain in ‘882 compared to DMSO.    
For anaerobic growth curve, stationary phase statically grown anaerobic cultures in 5 
mL of TSB of S. aureus strains were back-diluted to a calculated OD600 of 0.0001 (relative to 
media alone) in round-bottomed 96-well plates containing 200 μL of TSB (stored in anaerobic 
chamber at least 24 h prior to use) and covered with Breathe-Easy gas permeable seal 
(Sigma). Growth was monitored by optical density over time in a BioTek Synergy H1 or BioTek 
808E Spectrophotometer. For growth with ‘882, 40 µM ‘882 or DMSO was added to the 
medium in the 96 well immediately before back-dilution. For pantothenate addition, TSB 
contained 20 µM ‘882 with or without 200 µM calcium pantothenate. For growth in defined 
medium, culture optical density was monitored at 630 nm. The staphylococcal-defined 
medium has been described previously (283) and contains all the canonical amino acids 
except leucine and isoleucine and glucose as a source of carbon (18AA glucose medium). 
Strains cultured overnight in TSB were harvested by centrifugation at 14,000 rpm for 1 min. 
The resulting cell pellet was washed twice to prevent the carryover of rich medium 
components. The optical density of the washed cultures was determined and strains were 
inoculated into minimal medium to an OD600 of 0.025. '882 or vehicle were added at point of 
inoculation. For microaerobic growth, the plate was depleted of dioxygen by passage through 
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an airlock into a Coy anaerobic chamber. The plate was sealed inside the chamber and 
subsequently removed to an aerobic environment and incubated statically. The data obtained 
were normalized with respect to the initial reading to negate for changes in absorbance 
between compound and vehicle. For growth curves comparing anaerobic growth of NM, 
ΔsaeRS, and saeSP18L, strains were grown to stationary phase in 5 mL of TSB in a Coy 
anaerobic chamber. OD600 was used to normalize strains, and each culture was diluted with 
anaerobic TSB to equivalent OD600. One µl was added to 199 µl of TSB and OD600 was 
monitored over time. To compare these strain in a semi-defined carbon-limited medium (CLM; 
modified from (287)), strains were grown to stationary phase in 5 mL of TSB. OD600 was used 
to normalize strains, and then equal OD units were centrifuged and the cells were washed 
thrice in PBS, and then resuspended in equal volume of PBS. One µl of the cell suspension 
was added to 199 µl of CLM medium and OD600 was monitored over time. CLM consisted of 
0.64 g/L NaCl, 0.15 g/L KCl, 0.01 g/L MgSO4-7H2O, 7 g/L K2HPO4, 2 g/L KH2PO4, 1 g/L 
(NH4)2SO4, 1 mg/L thiamine, 1.2 mg/L niacin, 0.25 mg/L calcium pantothenate, 5 µg/ml 
biotin, and 0.5% cas-amino acids. Glucose was added to 0.02% and glycerol to 0.04%. For 
anaerobic pantothenate rescue in CLM, washed cells from overnight cultures as above were 
back-diluted to a calculated OD600 of 0.0001 (relative to media alone). CLM contained 0.04% 
glycerol and 10 mM potassium nitrate. 
 
Microarray 
Strains NM and ΔsaeRS were grown to stationary phase in 5 mL TSB anaerobically, 
and 100 μL was diluted into 10 mL of fresh, anaerobic TSB. After 5 h of growth (mid-log), ‘882 
was added to a final concentration of 25 μM. After 10 min, the cultures were added to equal 
volume of ice-cold acetone:ethanol and stored at -80°C. To purify RNA, cells were collected 
by centrifugation at 10,000x g for 10 min at 4°C and then resuspended in 500 μL TE (10mM 
Tris, 1mM EDTA, pH 7.6). The cells were lysed in Bio101 FastPROTEIN BLUE lysing matrix 
tube using Bio101/Savant #FP120 FastPrep cell disruptor for 20 s at setting 5.0, cooled on 
ice, disrupted again 40 s at setting 4.5, and cooled on ice. The aqueous phase was separated 
by centrifugation at 10,000 x g for 15 min at 4°C. and transferred to a fresh tube. The RNA 
was isolated using Qiagen RNeasy kit according to directions. 
RNA was reverse transcribed, cDNA fragmented, 3′ biotinylated, and hybridized to 
commercially available S. aureus GeneChips following the manufacturer's recommendations 
for antisense prokaryotic arrays (Affymetrix, Santa Clara, CA). GeneChips were washed, 
stained, and scanned as previously described (Beenken et al., 2004). The microarray data 
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has been uploaded to the National Center for Biotechnology Information Gene Expression 
Omnibus under accession number GSE85379. 
 
Transductions 
The USA300 LAC derivative JE2 strain containing the erythromycin-resistant NARSA 
(Network on Antimicrobial Resistance in S. aureus; available from BEI Resources) allele of 
interest was grown to stationary-phase in 5 mL of a 1:1 mix of TSB and lysogeny broth (LB), 
then subcultured 1:100 into 5 mL of 1:1 mix of TSB and LB containing 5 mM CaCl2 and grown 
for 3 h. ϕ85 phage lysate was added (0.1-1 µl of high titer stock) and incubated at room 
temperature for 30 min. The culture was added to 6 mL of molten top agar and spread on 
TSA. After 16 h, the donor phage was collected as follows: the top agar was collected into 10 
mL of sterile phage buffer (1.21 g Tris base, 1.20 g MgSO4-7 H2O, 0.10 g gelatin per liter; 
adjust to pH 7.4 with 6 M HCl), mixed, 250 µl chloroform was added, and mixed. The donor 
phage lysate from the supernatant is sterile filtered. The recipient strain is grown to stationary-
phase in 20 mL TSB + 5 mM CaCl2. The cells are collected by centrifugation and resuspended 
in 5 mL of 1:1 TSB:LB + 5 mM CaCl2. 106-107 plaque forming units of the donor phage lysate 
are added to 500 µl of recipient strain and incubated together for 15 min at 37°C. The cells 
are then washed thrice in ice-cold 40 mM sodium citrate, resuspended in 40 mM sodium 
citrate, and spread on TSA + 40 mM sodium citrate + 10 µg/mL erythromycin. Colonies are 
patched on TSA containing erythromycin to confirm resistance, and the location of the 
transposon was confirmed by inverse PCR as described previously (279). 
 
 Hemolysis 
5 μL of stationary-phase cultures of NM and resistant mutants grown in 5 mL TSB 
aerobically was spotted on blood agar plates (TSA+5% sheep’s blood; BD) and allowed to 
incubate overnight at 37°C aerobically. 
 
SaeQ immunoblot 
5 mL of stationary-phase cultures were grown in TSB and were collected by 
centrifugation. Cell walls were removed by lysostaphin (8 μg/mL final) treatment in TSM (100 
mM Tris, pH7; 500 mM sucrose; 10 mM MgCl2) and protoplasts were collected by 
centrifugation. Protoplasts were lysed by sonication and total protein was quantified by BCA 
(Thermo). Sixty μg of protein per lane was loaded to a 15% acrylamide gel and subject to 
SDS-PAGE. Gel was transferred to Odyssey nitrocellulose membrane (Li-Cor) and probed 
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with a 1:2000 dilution of anti-SaeQ antibodies (Taeok Bae, Indiana University School of 
Medicine-Northwest) for 1 h in 5% milk in TBST. Secondary antibodies were a 1:5,000 dilution 
of goat anti-rabbit Alexa Fluor 660 (Thermo) and visualized with Odyssey Imaging System (Li-
Cor)  
 
Exoprotein profile 
NM and resistant mutants were grown to stationary phase in 5 mL of TSB. Cells were 
removed by centrifugation and the spent medium was concentrated in a 3 kDa molecular 
weight cut-off spin column (Millipore Amicon) by centrifugation for 60 min at 3,200 x g. The 
concentrated medium was mixed with loading buffer and subjected to SDS-PAGE in 15% 
acrylamide gels. The gels were stained for total protein (BioRad Protein Assay) and imaged. 
 
‘882 and ‘882-biotin synthesis 
‘882 was synthesized as previously described (110). Synthesis of biotinylated ‘882 
probe was performed as follows: 
 
General Procedures 
All non-aqueous reactions were performed in flame-dried flasks under an atmosphere 
of argon. Stainless steel syringes were used to transfer air- and moisture-sensitive liquids. 
Reaction temperatures were controlled using a thermocouple thermometer and analog 
hotplate stirrer. Reactions were conducted at room temperature (rt, approximately 23° C) 
unless otherwise noted. Flash column chromatography was conducted using silica gel 230-
400 mesh. Analytical thin-layer chromatography (TLC) was performed on E. Merck silica gel 
60 F254 plates and visualized using UV and iodine stain.  
 
Materials 
All solvents and chemicals were purchased from Sigma-Aldrich unless otherwise 
noted. Dry dichloromethane was collected from an MBraun MB-SPS solvent system. N,N-
dimethylformamide (DMF), tetrahydrofuran (THF), and acetonitrile (MeCN) were used as 
received in a bottle with a Sure/Seal. Triethylamine was distilled from calcium hydride and 
stored over KOH. Deuterated solvents were purchased from Cambridge Isotope Laboratories. 
Methyl-4-bromo-3-methoxybenzoate was purchased from Combi-Blocks. 
Trimethylsilylacetylene and 1-(Chloro-1-pyrrolidinylmethylene) pyrrolidinium 
hexafluorophosphate were purchased from Oakwood Chemicals.  
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Instrumentation 
 1H NMR spectra were recorded on Bruker 400 or 600 MHz spectrometers and are 
reported relative to deuterated solvent signals. Data for 1H NMR spectra are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, m = multiplet, br = broad, app = apparent), coupling constants (Hz), and integration. 
13C NMR spectra were recorded on Bruker 100 or 150 MHz spectrometers and are reported 
relative to deuterated solvent signals. Low-resolution mass spectrometry (LRMS) was 
conducted and recorded on an Agilent Technologies 6130 Quadrupole instrument. 
 
                                          S1 
Methyl 4-ethynyl-3-methoxybenzoate (S1) 
To a stirred solution of 2.08 g (8.49 mmol, 1.0 eq) methyl-4-bromo-3-methoxybenzoate 
in 25 mL of triethylamine was added 455 mg (0.394 mmol, 0.046 eq) palladium 
tetrakistriphenylphosphine, 160 mg (0.842 mmol, 0.099 eq) copper(I) iodide, and 2.50 mL 
(17.6 mmol, 2.1 eq) trimethylsilylacetylene. The reaction was refluxed for 2 h when it was 
judged complete by LC-MS. The reaction was diluted with ethyl acetate (50 mL), filtered 
through celite, washed with saturated ammonium chloride (3x) and brine (2x), dried (MgSO4), 
and concentrated. The crude residue was dissolved in 25 mL of methanol and 1.80 g of 
potassium carbonate was added. The reaction was stirred for 15 min when judged complete 
by LC-MS. The reaction was concentrated and partitioned between 50 mL of ethyl acetate 
and 20 mL of brine. The organic layer was filtered through silica gel, concentrated, and the 
residue purified by flash chromatography to provide 1.24 g (77 %) of S1 as a brown solid over 
2 steps. 1H-NMR (400 MHz, CDCl3) δ 7.56 (dd, J=7.88 Hz, J=1.44 Hz, 1H), 7.51 (d, J=1.28 
Hz, 1H), 7.47 (d, J=7.88 Hz, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 3.43 (s, 1H); 13C-NMR (100 MHz) 
δ 166.4, 160.5, 134.0, 131.6, 121.7, 116.0, 111.3, 83.9, 79.4, 56.1, 52.4; LRMS calculated for 
C11H10O3 [M+H]+ m/z: 191.1, measured 191.1.  
 
               S2 
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Methyl 4-(5-(furan-2-yl)-1H-pyrazol-3-yl)-3-methoxybenzoate (S2) 
To a stirred solution of 2.97 g (15.6 mmol, 1.0 eq) S1 in 50 mL of THF was added 2.18 
mL (15.6 mmol, 1.0 eq) of triethylamine, 118 mg (0.167 mmol, 0.011 eq) of 
bis(triphenylphosine)palladium chloride, 111 mg (0.584 mmol, 0.037 eq) of copper(I) iodide, 
and 2.30 mL (23.3 mmol, 1.5 eq) 2-furoyl chloride. The reaction was stirred at room 
temperature for 1 h until it was judged complete by TLC. The reaction was diluted with 25 mL 
of acetonitrile, 1.50 mL (23.4 mmol, 1.5 eq) of hydrazine hydrate was added, and the mixture 
was heated to 60° C for 2 h until judged complete by TLC. The reaction was filtered through 
celite, concentrated, and purified by flash chromatography to give 3.98 g (86 %) of S2 as a 
yellow solid. 1H-NMR (600 MHz, CDCl3) δ 7.76 (d, J=8.10 Hz, 1H), 7.71 (dd, J=8.04 Hz, J=1.44 
Hz, 1H), 7.67 (d, J=1.26 Hz, 1H), 7.46 (d, J=1.14 Hz, 1H), 6.93 (s, 1H), 6.72 (d, J=3.28 Hz, 
1H), J=3.30 Hz, J=1.74 Hz, 1H), 4.0δ2 (s, 3H), 3.94 (s, 3H); 13C-NMR (150 MHz) δ 166.5, 
155.8, 148.7, 142.0, 141.2, 130.8, 127.8, 122.9, 121.9, 112.7, 111.5, 106.0, 101.0, 56.2, 52.3; 
LRMS calculated for C16H14N2O4 [M+H]+ m/z: 299.1, measured 299.1. 
 
                                        S3 
4-(5-(furan-2-yl)-1H-pyrazol-3-yl)-3-hydroxybenzoic acid (S3) 
To a stirred solution of 258 mg (0.864 mmol, 1.0 eq) of S3 dissolved in 1 mL 
dichloromethane in a microwave vial was added 3.45 mL (3.45 mmol, 4.0 eq) of a 1 M solution 
of boron tribromide in dichloromethane. The vial was sealed and maintained at 90° C for 20 
min. The reaction was quenched in15 mL of saturated sodium bicarbonate, extracted with 30 
mL of ethyl acetate (2x). The aqueous layer was acidified with 1 N HCl and extracted with 30 
mL of ethyl acetate (2x) and set aside. The organic layer from the bicarbonate wash was 
concentrated and the residue dissolved in 2 mL THF. To the stirred THF solution was added 
2.0 mL of 2 M lithium hydroxide and the resulting mixture was maintained at 50° C for 3 h until 
the reaction was judged complete by TLC. The mixture was acidified with 1 N HCl, extracted 
with ethyl acetate, and the organic layer combined with the organic layer from the acid wash 
from the previous step. The organics were concentrated and the residue purified by flash 
chromatography to provide 143 mg (61 %) of S3 as a light brown solid. 1H-NMR (600 MfHz, 
acetone-d6) δ 7.90 (br, 1H), 7.73 (br, 1H), 7.61 (br, 2H), 7.25 – 7.22 (m, 1H), 6.98 – 6.94 (m, 
1H), 6.64 (br, 1H); 13C-NMR (150 MHz) δ 167.3, 156.7, 145.5, 144.2, 132.0, 127.7, 121.5, 
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121.4, 118.7, 112.7, 108.7, 100.0: LRMS calculated for C14H10N2O4 [M+H]+ m/z: 271.1, 
measured 271.1.                                                                          
 
                   S4 
tert-butyl (1-(4-(5-(furan-2-yl)-1H-pyrazol-3-yl)-3-hydroxyphenyl)-1-oxo-5,8,11,14,17,20,23-
heptaoxa-2-azapentacosan-25-yl)carbamate (S4)  
To a stirred solution of 15.0 mg (0.555 mmol, 1.0 eq) of S3 in 1 mL THF was added 
51.9 mg (0.111 mmol, 2.0 eq) of O-(2-Aminoethyl)-O′-[2-(Boc-amino)ethyl]hexaethylene 
glycol, 15.5 μL (0.111 mmol, 2.0 eq) of triethylamine, and 36.9 mg (0.111 mmol, 2.0 eq) of 1-
(Chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate. The reaction was stirred 
at room temperature for 1 h when it was judged complete by LC-MS. The solvent was 
removed, the residue was dissolved in DMSO and purified by preparative scale reverse phase 
HPLC (MeCN:H2O mobile phase) to provide 14.9 mg (37 %) of S4. 1H-NMR (400 MHz, CDCl3) 
δ 10.77 (br, 1H), 7.65 (d, J=8.00 Hz, 1H), 7.50 (d, J=1.24 Hz, 1H), 7.46 – 7.40 (m, 2H), 6.98 
(br, 1H), 6.76 (d, J=3.32 Hz, 1H), 6.52 (dd, J=3.24 Hz, J=1.76 Hz, 1H), 5.08 (br, 1H), 3.71 – 
3.48 (m, 30H), 3.33 – 3.26 (m, 2H), 1.43 (s, 9H).  
 
4-(5-(furan-2-yl)-1H-pyrazol-3-yl)-3-hydroxy-N-(25-oxo-29-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)-3,6,9,12,15,18,21-heptaoxa-24-azanonacosyl)benzamide 
(‘882-biotin)  
A total of 200 μL TFA was added to a solution of 14.9 mg (20.6 μmol, 1.0 eq) of S4 in 
1 mL dichloromethane. The reaction was stirred at room temperature for 1 h when it was 
judged complete by TLC. The volatiles were removed in vacuo and the residue dissolved in 1 
mL of DMF.  To this stirred solution was added 8.6 μL (61.8 μmol, 3.0 eq) of triethylamine and 
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8.4 mg (24.4 μmol, 1.2 eq) of biotin-NHS ester.  The reaction was stirred at room temperature 
for 1 h when it was judged complete by LCMS. The reaction was concentrated and the residue 
purified by preparative scale HPLC to provide 9.5 mg (48 %) of ‘882 biotin probe as TFA salt. 
1H-NMR (600 MHz, MeOD) δ 7.80 (d, J=8.04 Hz, 1H), 7.63 (d, J=1.20 Hz, 1H), 7.44 – 7.38 
(m, 2H), 7.10 (br. 1H), 6.85 (d, J=3.30 Hz, 1H), 6.58 (dd, J=3.24 Hz, J=1.74 Hz, 1H), 4.49 – 
4.45 (m, 1H), 4.29 – 4.26 (m, 1H), 3.71 – 3.55 (m, 30H), 3.51 (t, J=5.43 Hz, 2H), 3.34 (t, 
J=5.43 Hz, 2H), 3.19 – 3.14 (m, 1H), 2.90 (dd, J=12.75 Hz, J=5.01 Hz, 1H), 2.70 (d, J=12.72 
Hz, 1H), 2.20 (t, J=7.35 Hz, 2H), 1.75 – 1.54 (m, 4H), 1.44 – 1.38 (m, 2H); LRMS calculated 
for C40H58N6O12S [M+H]+  m/z: 847.4, measured 847.2.  
 
‘882-biotin pull-down sample preparation 
The cellular lysate of mid-exponential cultures was collected from NM grown in TSB; 
the cells were collected by centrifugation and resuspended in PBS containing 30 μL of 2 
mg/mL lysostaphin and 100 μM PMSF protease inhibitor. Cells were incubated at 37° C for 
20 min to remove the cell wall and then sonicated. 500 μL of lysed cells were added to 50 μL 
of DMSO or ‘882-biotin (10 μg/μL concentration) and incubated for 30 min at room 
temperature. 500 μL of the lysate and probe solution was added to 500 μL of washed 
streptavidin-agarose resin (Thermo) and incubated at room temperature for 1 h. The resin 
was centrifuged and washed in PBS five times, and then bound proteins were eluted after the 
addition of SDS buffer and boiling for 10 min. 20 μL of each elution was run in 15% acrylamide 
SDS-PAGE and bands were visualized by PlusOne silver stain (GE) according to the 
manufacturer’s directions, and destained before proteomic analysis. 
 
‘882 MudPIT sample preparation  
5 mL of cultures of NM were started from single colonies in TSB containing 20 μM ‘882 
or DMSO and grown aerobically for 15 h. The cells were collected by centrifugation. Cell walls 
were removed by lysostaphin (8 μg/mL final) treatment in TSM and protoplasts were collected 
by centrifugation. The protoplasts were resuspended in 450 μL PBS + 100 μM 
phenylmethanesulfonyl fluoride (PMSF; Thermo), and lysed by sonication. The suspension 
was clarified by ultracentrifugation for 30 min at 4°C at 100,000 x g. The protein was quantified 
by BCA (Thermo) and subjected briefly to SDS-PAGE before proteomic analysis. 
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LC-MS/MS analysis and protein identification 
Proteins subject to SDS-PAGE after ‘882-biotin pull-down and ‘882 MudPIT 
experiments were excised and subjected to in-gel trypsin digestion and peptide extraction as 
previously described (288). The resulting peptides were analyzed using a Thermo Finnigan 
LTQ ion trap instrument equipped with a Thermo MicroAS autosampler and a Thermo 
Surveyor high-performance liquid chromatography (HPLC) pump, a nanospray source, and 
an Xcalibur 2.0 SR2 instrument control. Peptides were separated using a packed capillary tip 
(100 mm by 11 cm; Polymicro Technologies) with Jupiter C18 resin (5 mm; 300 Å; 
Phenomenex) and an in-line trapping column (100 μm by 6 cm) packed with the same C18 
resin (using a frit generated with liquid silicate Kasil) similar to the column described previously 
(Tabb et al., 2007). The flow from the HPLC pump was split prior to the injection valve to 
obtain flow rates of 700 nL min−1 to 1,000 μL min−1 at the column tip. Mobile phase A 
consisted of 0.1% formic acid, and mobile phase B consisted of 0.1% formic acid in 
acetonitrile. A 95-min gradient was used with a 15-min washing period (100% mobile phase 
A for the first 10 min, followed by a gradient to 98% mobile phase A at 15 min) to allow loading 
and flushing of any residual salts. Following the washing period, the gradient was changed to 
25% mobile phase B at 50 min and then to 90% mobile phase B by 65 min, which was used 
for 9 min before the conditions were returned to the initial conditions. Tandem spectra were 
acquired using a data-dependent scanning mode in which one full mass spectrometry (MS) 
scan (m/z 400 to 2,000) was followed by nine MS/MS scans. Tandem spectra were compared 
with data for the Newman strain of the S. aureus subset in the UniRef100 database using the 
SEQUEST algorithm. The database was concatenated with the reverse sequences of all 
proteins in the database to allow determination of false-positive rates. The Sequest outputs 
were filtered through the ID Picker suite, which allows the user to set a false discovery rate 
threshold (e.g., 0.05 or 5%) based on reverse sequence hits in the database, and proteins 
were required to be identified by two or more unique peptides. Reassembly of a protein from 
identified peptide sequences was done with the aid of a parsimony method (289). 
 
Fe-S cluster reconstitution 
All steps were performed under strictly anaerobic conditions inside a Coy chamber (<1 
ppm oxygen). Recombinant purified AcnA  was incubated with reconstitution buffer (50 mM 
Tris, 150 mM NaCl, 5 mM DTT, pH 7.5) anaerobically for 1 h. Cluster reconstitution was 
initiated by the addition of a 5-fold excess of ferrous ammonium sulfate and lithium sulfide as 
previously described (283, 290). The reaction mixture was allowed to proceed for 1 h before 
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excess Fe, S, and DTT were removed by desalting using a PD-10 column (GE Healthcare) 
that had been pre-equilibrated with reconstitution buffer. Reconstituted protein was 
concentrated using YM-3 Centriplus Centrifugal Concentrators (Millipore), prior to use in 
activity assays.  
 
Recombinant protein purification 
Escherichia coli strains BL21(AI*) containing a protein production vector were grown 
at 37 °C in a 3 L Fernbach flasks containing 1 L of 2X standard lysogeny broth (LB) medium. 
Cultures that had been grown to an OD600 of 0.6 were cooled to 25 °C and arabinose (1 mM) 
and IPTG (0.1 mM) were added. Cultures were grown for an additional 12 h before cells were 
harvested by centrifugation. Cell paste was flash frozen with liquid nitrogen and stored at -80 
°C. Subsequently, AcnA was purified as described earlier (283). Protein concentrations were 
determined using a copper/bicinchonic acid based colorimetric assay modified for a 96-well 
plate (291).  Bovine serum albumin (2 mg mL-1) was used as a standard. 
 
Cell-free extract and purified AcnA enzyme assays 
Strains cultured overnight in TSB were diluted into fresh TSB to a final OD600 of 0.1. 
The culture medium was amended with 1% xylose to induce gene expression for the acnA 
gene (for strains carrying pacnA). Cells were subsequently cultured for 8 h (~OD of 8) and at 
a culture vessel headspace to culture medium volume ratio (hereafter HV ratio) of either 10, 
2.5 or 0. The HV ratios were altered as per experimental requirements and details are 
mentioned in each figure legend.  
 For AcnA assays using anaerobically cultured S. aureus, strains were cultured in 2 
mL microcentrifuge tubes containing 2 mL of culture medium at a HV ratio of zero, as 
described earlier (283). The culture medium was as described above. Anaerobic conditions 
were verified by the addition of 0.001% resazurin to control tubes and the medium color was 
monitored over time, as described earlier (292). Anaerobiosis was achieved by 3 h post 
inoculation. To examine the requirement of de novo protein synthesis, cells were treated by 
the addition of anaerobic 100 μg/mL rifampicin inside a Coy chamber, prior to treatment with 
'882 or vehicle. 
To assess AcnA activity, cell pellets were harvested by centrifugation, placed inside a 
Coy anaerobic chamber, and were re-suspended in 100 μL anaerobic lysis buffer (50 mM 
Tris, 150 mM NaCl, pH 7.4). Cells were lysed by the addition of 4 μg lysostaphin and 8 μg 
DNase and incubated at 37 °C until confluent lysis was observed. The cellular lysates were 
43 
 
clarified using a 10 min high-speed spin. Lysates were removed from the anaerobic chamber 
and between 15-25 μL of lysate was added to 985-975 μL (total volume of 1 mL) of lysis buffer 
containing 20 mM DL-isocitrate. Aconitase activity was determined by monitoring the 
conversion of isocitrate to cis-aconitate spectrophotometrically using a Beckman Coulter 
DU530 UV-Vis absorption spectrophotometer (cis-aconitate ε240 nm = 3.6 mM-1cm-1) (293). 
Enzymatic activity was standardized with respect to the total protein concentration and 
subsequently as indicated in the figure legend. 
 
Transcriptional reporter fusion assay 
Strains cultured overnight in TSB-Erm medium were diluted into fresh TSB-Erm 
medium to a final OD600 of 0.1 and cultured, with shaking, at a HV ratio of 6. At periodic 
intervals culture density and fluorescence were assessed as described previously 
(Mashruwala et al., 2015). Fluorescence data were normalized to the culture OD600.  
  
FLAG_AcnA immunoblot analyses 
Immunoblots were conducted as described earlier (283). 40 μg of total protein was 
separated using a 12% SDS-PAGE gel. Proteins were then transferred to a PVDF membrane 
and incubated with mouse monoclonal anti-FLAG primary antibody (Sigma-Aldrich) (1:4000 
dilution) and subsequently HRP conjugated secondary antibody (Bio-Rad) (1:12000 dilution). 
The blots were developed using chemiluminescent detection (ECL kit, Pierce). The blots were 
scanned as high quality TIFF images.  
 
Results 
Constitutive Sae TCS signaling is required for ‘882 toxicity 
To identify the cellular target of ‘882 toxicity in anaerobic S. aureus, we selected for 
spontaneously resistant mutants of S. aureus strain Newman (NM) growing fermentatively 
(anaerobically in the absence of alternative terminal electron acceptors) on medium 
containing 20 or 40 µM ‘882. Seven independently isolated mutants grew under these 
conditions, at a rate of ~7x10-7 and were stably ‘882 resistant after multiple passages on 
medium alone. To evaluate the growth of these mutants relative to NM, strains were back-
diluted from stationary phase cultures in medium alone into medium containing 40 µM ‘882 
and the optical density was measured after 18 h of anaerobic growth (Figure 7A). These 
conditions allowed a demarcation between ‘882 sensitivity and resistance based on the 
growth of NM (Figure 6). To identify the mutations that allowed growth in the presence of ‘882, 
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we sequenced the genomes of the 7 isolates, and each was found to have a mutation in the 
saePQRS locus and no other nonsynonymous mutations were found in the genome (Figure 
7B). Each mutation is predicted to disrupt the function of the Sae system by altering the 
protein-coding sequence or disrupting both promoters (P1, P3), thereby changing expression. 
Indeed, the ‘882 resistant isolates demonstrate phenotypes consistent with inactivation of the 
Sae system, as evidenced by reduced hemolysis, diminished exoprotein secretion, and 
undetectable SaeQ expression (Figure 8). These data suggest that Sae activity is required for 
sensitivity to ‘882, and mutations that reduce Sae signaling are sufficient to abrogate ‘882 
toxicity. 
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Figure 6 Toxicity of ‘882 to anaerobic S. aureus. Growth of NM grown anaerobically in the 
concentration of ‘882 shown at right, backdiluted to approximately (A) OD600 0.001 and (B) 
OD600 0.0001 from overnight cultures at time=0 h. Error bars indicate SEM, from means 
combined from three independent experiments with n>3 for each.  
 
Importantly, SaeS of S. aureus NM is unique due to an amino acid substitution of 
leucine to proline at residue 18, located in the first transmembrane helix of SaeS (294). The 
Leu18 residue is encoded by nearly every other sequenced S. aureus genome. The L18P 
mutation renders NM SaeS constitutively active and resistant to SaeQ regulation, resulting in 
high levels of exoprotein transcription, translation, and secretion. Therefore, I hypothesized 
that constitutive Sae activity may be required for sensitivity to ‘882. Consistent with this, strains 
of S. aureus that do not express constitutively active SaeS: ΔsaeRS (NM) and saeSL18P allele 
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repaired to saeSP18L (NM), as well as the clinical isolate USA300 LAC (LAC), are more 
resistant to ‘882 than NM (Figure 7C). The NM sae locus (carrying saeSL18P) expressed in 
trans in a LAC ΔsaeQRS strain increased sensitivity to ‘882 while the LAC sae locus (carrying 
saeSL18) expressed in trans did not make NM ΔsaeRS sensitive to ‘882, confirming that 
constitutive Sae activity is sufficient for sensitivity to ‘882 (Figure 7D). These data demonstrate 
that increased Sae activity is required for ‘882 toxicity and decreased Sae signaling is 
sufficient for resistance to ‘882. 
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Figure 7 S. aureus constitutive Sae function is required for ‘882 toxicity [L.A.M. 
in part]. Spontaneously resistant mutants of strain Newman (NM) were isolated in the 
presence of 20 or 40 µM ‘882 in anaerobic conditions.  (A) After four passages on 
plain medium, the spontaneous mutants still grew robustly by fermentation in medium 
containing 40 μM ‘882 relative to NM, indicating stable resistance to ‘882. (B) Whole 
genome sequencing of the isolates in (A) revealed mutations in the saePQRS locus. 
R1 has a nucleotide substitution at position -54 of the genome sequence (g.) relative 
to the start of saeP. Mutations resulting in changes to amino acid sequence are shown, 
where del signifies a deletion of noted amino acids and ins signifies insertion.  (C) 
Strains that do not encode a constitutive SaeS: ΔsaeRS, saeSP18L, and the USA300 
LAC (LAC) clinical isolate are resistant to ‘882. (D) trans-expression of constitutively 
active Sae (NM) under control of the lgt promoter in plasmid pOS1 is sufficient to 
induce ‘882 enhanced susceptibility in LAC, and the non-constitutively active saeQRS 
(LAC) locus provides ‘882 resistance to NM. For A, C, and D, error bars represent 
SEM from data combined from at least three independent experiments with n>2 for 
each. * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001, calculated by 
one-way ANOVA with Sidak correction for multiple comparisons.   
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Figure 8 Spontaneously resistant mutants phenocopy ΔsaeRS [L.A.M.]. Mutants in 
Figure 7A-B had similar (A) hemolytic, (B) exoprotein, and (C) SaeQ expression profiles as 
ΔsaeRS. (A) hemolysin activity was assayed by spotting a suspension of each strain on 
blood agar plates and examining the zone of hemolysis. (B) Coomassie stained SDS-PAGE 
of culture supernatant from each strain. (C) Immunoblot for SaeQ expression in each strain. 
Protein size (kDa) is shown on left in B and C. 
 
Inactivation of genes implicated in Sae signaling provides increased resistance to ‘882  
To identify additional factors required for ‘882 toxicity, we again selected for 
spontaneously resistant mutants that grew by fermentation on medium containing ‘882. 
However, due to the strong selection for mutations in sae, we chose to create NM with a 
plasmid encoding an additional copy of the native sae locus (psae) to prevent the identification 
of additional Sae mutants, and increase the likelihood of identifying genes other than sae that 
could provide ‘882 resistance. We isolated eight spontaneously resistant mutants in strain NM 
carrying psae at a rate of ~1.3x10-5, sequenced their genomes, and found mutations in three 
separate genes. Six of the isolates have changes in the protein-coding sequence of the fatty 
acid kinase FakA, a seventh isolate encodes a change in an additional fatty acid kinase 
FakB1, and the eighth has a stop codon incorporated in the coding sequence of the chaperone 
ClpX (Figure 9A). No other nonsynonymous mutations were identified in these isolates. To 
determine whether mutations in these genes were sufficient to increase ‘882 resistance in a 
NM background, I tested the growth of NM and strains inactivated for these genes in the 
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presence of ‘882 (Figure 9B). These strains all displayed increased resistance to ‘882 relative 
to NM, which indicates that FakA, FakB1, and ClpX are required for ‘882 toxicity. Interestingly, 
previous findings established that the Fak system impacts Sae function in strain USA300 
(295). Also, SaeR was identified as a substrate of the ClpXP complex in NM, suggesting SaeR 
might be affected post-translationally (296). Therefore, I hypothesized that these resistant 
mutants were identified because they alter Sae activity, and are not themselves the target of 
‘882. 
 
Constitutive Sae is deleterious to growth in energy-limiting conditions 
The strong selective pressure against Sae indicated that constitutive Sae activity may 
prevent anaerobic S. aureus from overcoming the toxic effects of ‘882. Under growth 
conditions devoid of a terminal electron acceptor, S. aureus relies on fermentation, which is 
less efficient at energy generation than respiration. Based on the large SaeR regulon, 
including the expression and secretion of many exoproteins, I hypothesized that the 
constitutive Sae activity in NM would be deleterious during fermentative growth. First, SaeQ 
abundance in aerobic and anaerobic conditions was measured as a proxy for transcription 
from promoter 1 of two different transcripts: saePQRS (transcript T1) and saeQRS (transcript 
T2) (297).  Indeed, LAC did not express SaeQ during fermentation, indicating that transcription 
from Sae promoter 1 is inactive regardless of the presence or absence of ‘882 (Figure 9C-D). 
This suggested that the increased Sae activity during fermentation may impact growth in NM. 
As predicted, ΔsaeRS and saeSP18L grew better than NM undergoing fermentation in rich 
medium (Figure 9E). Additionally, ΔsaeRS and saeSP18L displayed enhanced growth in 
carbon-limited medium utilizing glucose or glycerol as the primary carbon source aerobically 
(Figure 9F,G respectively). These data confirm that constitutive SaeS activity is deleterious to 
growth during energy limiting conditions and are consistent with the hypothesis that the 
constitutively active SaeS contributes to the toxic effects of ‘882.  
 
 
50 
 
 
Figure 9 Genes required for toxicity are implicated in Sae signaling, which is a 
metabolic drain to NM [L.A.M.: panels A,C]. (A) Genomes of 8 spontaneously ‘882 resistant 
mutants in the NM pOS1PlgtsaeQRS strain were sequenced. Non-synonymous mutations 
were found in fakA, fakB1, and clpX. Changes to the protein sequence are shown in 
uppercase, as well as a deletion. (B) Strains inactivated for saeRS, fakA, fakB1, and clpX 
grow better than NM anaerobically in the presence of 40 µM ‘882. (C) Immunoblot with α-
SaeQ at ~17 kDa from strains NM and (D) LAC during aerobic respiration and anaerobic 
fermentation in the presence or absence of 40 μM (aerobic) or 4 μM (anaerobic) ‘882 or 
DMSO. Growth of NM, ΔsaeS, and saeSP18L without ‘882 (E) anaerobically in TSB, and 
aerobically in carbon limited medium containing (F) glucose or (G) glycerol as the sole carbon 
source. Error bars represent SEM from data combined from at least three independent 
experiments with n>3 for each. For E-G, * and # indicate p<0.05, ** and ## indicate p<0.001, 
calculated by two-way ANOVA with Sidak correction for multiple comparisons, comparing 
*ΔsaeRS or #saeSP18L to NM at each time point.  
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‘882 disrupts coenzyme A pathways in S. aureus 
I next hypothesized that Sae may additionally contribute to ‘882 toxicity by 
transcriptionally activating or repressing expression of the gene encoding the target of ‘882. 
To test this hypothesis, transcriptional differences between NM and ΔsaeRS in the presence 
of ‘882 were identified using microarray (Appendix A Table 1). In addition to changes in 
expected virulence factor and exoprotein genes, the transcription of many genes involved in 
protein synthesis, energy production, and amino acid metabolism were altered. To test 
whether any of these genes encode the target of ‘882, strains lacking each of the non-
essential or non-virulence factor genes were tested for resistance to ‘882. The inactivation of 
only two genes, rimJ and NWMN_2021, provided increased resistance to ‘882 (Figure 10). 
RimJ is a ribosomal protein N-acetyltransferase that is predicted to use acetyl-CoA as its 
substrate (298). I hypothesized that the presence of RimJ increases ‘882 toxicity due to 
increased cellular consumption of acetyl-CoA. To further test this hypothesis, I inactivated four 
other putative acetyl-CoA consuming enzymes. These proteins were significantly increased 
in abundance in NM grown in the presence of ‘882 relative to DMSO as identified by 
proteomics (Appendix A Table 2). Genetic inactivation of two of these four genes also provided 
resistance to ‘882, suggesting that acetyl-CoA consumption by non-essential proteins 
contributes to the anaerobic toxicity of ‘882 (Figure 11A).  Together, these data indicate that 
‘882 disrupts acetyl-CoA or CoA homeostasis. As the effect of CoA limitation by ‘882 would 
affect the growth of NM undergoing fermentation as well as anaerobic respiration, I tested 
whether increasing CoA abundance would rescue ‘882 toxicity. Indeed, the addition of the 
CoA precursor pantothenate rescued growth of NM anaerobically in rich medium containing 
‘882 (Figure 11B) as well as in carbon-limited medium containing the non-fermentable carbon 
source glycerol and terminal electron acceptor nitrate (Figure 11C). In sum, these data 
suggest that ‘882 alters CoA homeostasis which can be rescued by reducing acetyl-CoA 
consumption through genetic manipulation or increasing CoA precursor availability. 
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Figure 10 Two Sae-regulated genes are required for ‘882 toxicity. Strains lacking either 
rimJ or NWMN_2021, genes that were identified by microarray to be differentially transcribed 
after treatment with ‘882 between strains NM and ΔsaeRS, are resistant to 40 µM ‘882 relative 
to NM. Error bars represent SEM from data combined from at least three independent 
experiments with n>3 for each. % growth relative to vehicle is calculated from OD600 for each 
strain in ‘882 compared to DMSO (vehicle) after 18 h. * indicates p<0.05, ** indicates p<0.01, 
and *** indicates p<0.001, calculated by one-way ANOVA with Sidak correction for multiple 
comparisons. 
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Figure 11 ‘882 alters coenzyme A pathways. (A) Inactivation of certain acetyltransferases 
provides resistance to ‘882. (B-C) Anaerobic growth of NM can be rescued by addition of the 
CoA precursor pantothenate in (B) rich medium containing ‘882 or (C) semi-defined medium 
containing glycerol as the primary carbon source, ‘882, and nitrate as the terminal electron 
acceptor. For A, * indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001, calculated 
by one-way ANOVA with Sidak correction for multiple comparisons. For B-C, ** indicates 
p<0.01, calculated by Student’s t-test comparing the absence or presence of pantothenate.  
 
‘882 interacts with the Fe-S cluster biogenesis machinery  
While these genetic approaches illuminated the role of Sae in ‘882 toxicity and 
fermentative growth, as well as the effects of ‘882 on CoA homeostasis, they did not identify 
a target of ‘882 toxicity. Therefore, in an attempt to identify a cellular target of ‘882, we 
performed a pull-down with cellular lysate and biotin-conjugated ‘882. One protein band 
visualized by SDS-PAGE exhibited differential abundance between the ‘882-biotin sample 
and the control. This band was excised and subjected to MudPIT LC-MS/MS for peptide 
identification (Figure 12A). Peptides from three proteins were enriched by the ‘882 pull-down, 
representing putative targets including SufC, NWMN_0632, and PdxS (Figure 12B). We 
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repeated the pull-down experiment and performed proteomics on the entire lanes of the 
control and ’882-biotin pull-down in an attempt to identify protein complexes bound by ‘882. 
We found that proteins of the Suf complex (SufB, SufC, and SufD) displayed greater 
enrichment in the ‘882 pull-down, while NWMN_0632 and PdxS were not enriched (Figure 
12C-D). 
 
Figure 12 ‘882 associates with Fe-S cluster biogenesis machinery. [L.A.M.] (A) SDS-
PAGE of NM proteins collected by streptavidin after pull-down with DMSO or biotinylated ‘882. 
The boxed section of the gel was excised and subjected to proteomics. (B) Spectral counts 
of peptides from the boxed area in (A) most enriched in ‘882-biotin include SufC; the molecular 
weight of SufC is ~28 kDa. (C) SDS-PAGE of NM proteins collected by streptavidin after pull-
down with DMSO or biotinylated ‘882. (D) Spectral counts of Suf protein peptides detected by 
proteomics after whole lane digest of (C) and mass spectrometry.  
 
To further investigate the interaction between ‘882 and SufC, we measured direct 
binding using biolayer interferometry (BLI). Purified biotinylated SufC bound ‘882 with a KD of 
~ 4 µM (Table 4). We then repeated the BLI using purified SufC and biotinylated ‘882 and 
measured binding with a KD of ~2 µM (Table 4).  Additionally, purified NWMN_0632 did not 
bind ‘882, demonstrating that the SufC-‘882 interaction is specific and the enrichment of 
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NWMN_0632 peptides in the initial ‘882 pull-down was likely not the result of direct binding 
(Table 4). These data are consistent with a direct interaction between ‘882 and SufC. 
 
Biotinylated ligand Analyte KD (μM) Kon (M-1s-1) [error] Koff (s-1)   [error] 
SufC ‘882 4.4 3.27x104 [5.72x103] 1.45x10-1 [1.02x10-2] 
‘882 SufC 2.1 9.46x103 [4.16x102] 1.96x10-2 [2.66x10-4] 
NWMN_0632 ‘882 N.D. -- -- 
 
Table 4 Direct binding between SufC and ‘882. [L.A.M.] Interactions with low micromolar 
KD between purified SufC and ‘882, regardless of which served as the ligand, was observed 
by biolayer interferometry. Binding was not detected (N.D.) between ‘882 and NWMN_0632. 
 
Assembly of FeS clusters upon aconitase is disrupted by ‘882 
SufC is essential in S. aureus and forms a complex with SufB and SufD to assemble 
Fe-S clusters using sulfur from SufS and SufU (299). Monitoring in vitro Fe-S cluster assembly 
by the Suf machinery is technically challenging, and can produce non-physiologically relevant 
Fe-S clusters (299). As an alternative readout, the effect of ‘882 supplementation upon the 
activity of the Fe-S cluster-dependent enzyme aconitase (AcnA) were interrogated. These 
experiments revealed that ‘882 treatment results in decreased activity of AcnA in vivo in 
strains NM and LAC (Figure 13A). Because the transcription of sufC is decreased during 
fermentative growth (267), we hypothesized that the relative ratio of ‘882 to SufC would 
increase under these conditions and result in greater inhibition of AcnA activity by ‘882, 
relative to aerobic growth. Indeed, as the oxygenation during growth was reduced, the 
inhibitory effect of ‘882 increased (Figure 13B). Likewise, the effect of ‘882 on AcnA function 
was greater during anaerobiosis and a concentration of 25 μM ‘882 was sufficient to reduce 
AcnA activity to 50% (Figure 13C).  
Six explanations could underpin the inhibitory effects of ‘882 on AcnA activity: 1) 
decreased transcription of the suf operon, 2) decreased abundance of the Suf machinery or 
auxiliary factors required for apo-protein maturation, 3) decreased transcription of acnA, 4) 
decreased abundance of AcnA, 5) direct inhibition of holo-AcnA activity by ‘882, or 6) inhibition 
of assembly of the Fe-S cluster on AcnA.  We found that the transcriptional activity of sufC 
(first gene in the suf operon) was not decreased upon supplementing media with ‘882 (Figure 
14A and Appendix A Table 1) and the abundances of Suf machinery proteins were increased 
upon treatment with ‘882 (Appendix A Table 2).  The abundances of auxiliary factors involved 
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in Fe-S protein maturation such as SufT were also increased upon ‘882 supplementation 
(Appendix A Table 2). Next, AcnA activity was monitored in an acnA::TN strain containing a 
plasmid with an acnA_FLAG allele under the transcriptional control of a xylose inducible 
promoter (pacnA). Introduction of pacnA allowed for the control of acnA transcription and the 
determination of AcnA_FLAG abundance (267). ‘882 supplementation resulted in decreased 
AcnA activity in the acnA::TN strain carrying pacnA, but did not alter abundance of 
AcnA_FLAG (Figure 14B).  Further, the inhibitory effect of ‘882 on AcnA function was not 
observed if ‘882 was added to purified AcnA containing an in vitro reconstituted Fe-S cluster 
(Figure 13D). Inhibition of protein synthesis prior to supplementation of the medium with ‘882 
did not result in inhibition of AcnA activity in vivo (Figure 14C). The data presented in Figures 
13 and 14 lend support to a model wherein ‘882 diminishes AcnA function by disrupting the 
assembly of the FeS cofactor upon AcnA.  
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Figure 13 ‘882 impairs aconitase function. [A.A.M. and J.M.B.] (A) Aconitase activity is 
reduced in NM and LAC cultured in the presence of ‘882 after xylose induction of acnA 
transcription. * indicates p<0.001 by Student’s t-test with Holm-Sidak correction for multiple 
comparisons, compared to induced + DMSO. (B) Aconitase activity in LAC is inhibited by 50 
µM ‘882 to a greater extent as oxygen availability is reduced by decreasing the volume of gas 
above growth medium. * indicates p<0.05 relative to headspace:culture volume of 10, 
calculated by one-way ANOVA with Sidak correction for multiple comparisons (C) The 
inhibition of aconitase by ‘882 is greater under anaerobic conditions in LAC, where ~50% 
inhibition is achieved by 25 µM ‘882, compared to 50 µM ‘882 in (B). * indicates p<0.05 relative 
to no ‘882 calculated by one-way ANOVA with Sidak correction for multiple comparisons. (D) 
‘882 does not inhibit the activity of purified aconitase protein that has been chemically 
reconstituted with Fe-S cofactor in vitro prior to exposure to ‘882. For A-D, error bars represent 
SD combined from two independent experiments. For panels A-D, the acnA::Tn strain carried 
pacnA, which encodes for acnA under the transcriptional control of a xylose inducible 
promoter.  
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Figure 14 ‘882 disruption of aconitase function is post-translational. [A.A.M. and J.M.B.] 
(A) expression of sufC as measured by PsufC.gfp is unchanged in ‘882 or DMSO treatment, 
shown in relative fluorescence units (RFU) normalized to optical density over time. (B) The 
relative protein abundance of aconitase is unchanged by ‘882 or DMSO treatment. Shown is 
an immunoblot of FLAG-tagged AcnA using α-FLAG antibodies, and the relative density of 
the band is quantified. (C) The inhibition of aconitase by ‘882 requires de novo protein 
synthesis, as ‘882 does not inhibit aconitase activity when it is added to the culture medium 
after pre-treatment of the culture with a protein synthesis inhibitor. (D) AcnA activity is 
decreased upon treatment with ‘882 in both the NM as well as the LAC strains and this 
phenotype is independent of relative AcnA protein abundance. For A-D, error bars represent 
SD. 
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Strains defective in the maturation of Fe-S proteins are sensitive to ‘882 intoxication  
We hypothesized that if ‘882 inhibits Fe-S cluster assembly in vivo, then strains 
deficient in the maturation of Fe-S proteins would display increased sensitivity to ‘882 with 
respect to AcnA activity, as well as growth. Consistent with our prediction, LAC strains 
deficient in Fe-S cluster assembly (ΔsufT and ΔsufA) exhibit reduced AcnA activity, which was 
further decreased by co-culture with ‘882 (Figure 15A). Growth upon defined media lacking 
the amino acids isoleucine and leucine (18AA medium) is reliant upon the Fe-S cluster 
dependent enzymes LeuCD and IlvD. Growth of a Δnfu ΔsufT double mutant in 18AA medium 
was diminished by ‘882 (Figure 15B). These data support a model whereby ‘882 inhibits the 
function of Fe-S cluster dependent processes by targeting the Suf machinery. 
 
 
Figure 15 Strains defective in Fe-S cluster assembly are sensitive to ‘882. [A.A.M. and 
J.M.B.]  (A) Aconitase activity is reduced in mutants lacking Fe-S cluster assembly factors 
when cultured in the presence of 50 µM ‘882. * indicates p<0.05 by Student’s t-test for each 
strain comparing DMSO to ‘882. (B) A LAC strain defective in Fe-S protein maturation is 
sensitive to 10 µM ‘882 under microaerobic conditions in defined media lacking Ile and Leu. * 
indicates p<0.05 by Student’s t-test for each time point comparing Δnfu ΔsufT + ’882 to Δnfu 
ΔsufT + DMSO. For A and B, error bars indicate SD combined from two independent 
experiments. 
 
 
Discussion 
In this study, we sought to characterize the factors responsible for ‘882 toxicity. Our 
attempts using genetic selection offered insight into the interplay between the SaeRS 
virulence regulation system and energy generation (Figure 8). The toxicity of ‘882 was first 
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observed in S. aureus strain NM, which has a constitutively active SaeS as the result of a 
mutation resulting in a proline at amino acid 18 (294). The genetic strategies employed here 
point to a strong selection against SaeS signaling during anaerobic growth. In addition to 
showing that inactivation of Sae is sufficient to make NM resistant to ‘882, our findings (Figure 
9A-B) that genetic inactivation of fakA, fakB1, and clpX also provide increased resistance to 
‘882 are consistent with previous work connecting fatty acid kinases (Fak) and the ClpXP 
protease complex with Sae signaling (295, 296). FakA (previously called VfrB) and FakB1, 
along with FakB2, constitute a fatty acid incorporation system required for hemolysis, biofilm 
formation, and the transcription of SaeR target genes (295, 300, 301). The direct mechanism 
of Fak regulation of these virulence determinants is unclear. ClpX is an ATPase that serves 
as a chaperone as well as forms a complex with the peptidase ClpP (302). While the complete 
interaction between ClpX and Sae signaling has not been elucidated, ClpX likely affects Sae 
signaling by altering SaeR abundance in NM, as SaeR has been identified as a substrate of 
ClpXP (296). The effects on Sae of ClpX and the Fak system highlight the diverse cellular 
processes that intersect with Sae virulence regulation. 
The inhibition of fermentative growth by ‘882 may be observed because the 
constitutive SaeS activity in NM reduces growth even in the absence of ‘882. The finding that 
LAC and presumably other strains with non-constitutive SaeS alter Sae signaling in anaerobic 
conditions is consistent with the hypothesis that pathogens have evolved control of 
metabolically expensive virulence factor production to ensure synthesis occurs only when 
required (Figure 9C-G). This is similar to the description of the metabolic cost associated with 
expression of the Salmonella Type III Secretion System 1 (303). Cells that express this 
virulence factor in vitro demonstrate reduced fitness relative to non-expressing cells. It seems 
that the canonical SaeS of S. aureus has evolved to limit the metabolically expensive 
synthesis of its regulon during energetically unfavorable conditions. 
Our finding that ‘882 alters CoA homeostasis (Figure 10) substantiates the effects of 
Suf disruption on S. aureus undergoing fermentation. Genetic inactivation of rimJ and other 
non-essential acetyl-CoA consuming enzymes provided increased resistance to ‘882, and 
based on this I hypothesized that ‘882 may reduce available CoA levels during anaerobic 
growth. The ‘882 inhibition of Fe-S cluster assembly are consistent with our model that ‘882 
disrupts the CoA pool. First, the Fe-S cluster-dependent enzyme dihydroxy-acid dehydratase 
(IlvD) is required for pantothenate and CoA synthesis. In addition, under anaerobiosis, 
pyruvate formate lyase (PflB) is the probable source of acetyl-CoA as the transcription of pflA 
and pflB increase anaerobically while transcription of the pyruvate dehydrogenase complex 
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decreases (304). PflB is activated by PflA, which is an Fe-S cluster-dependent radical S-
adenosyl methionine dependent activase (305). This information is consistent with the model 
that ‘882 disrupts CoA pathways during fermentation by potentially impeding the function of 
Fe-S cluster-dependent IlvD and PflA enzymes in CoA synthesis and consumption. 
The SufBCD proteins were pulled down with biotinylated ‘882 and ‘882 interacted with 
purified SufC with high affinity (Figure 12, Table 4), which support our model that ‘882 inhibits 
Fe-S cluster assembly. The effects of ‘882 on Fe-S cluster assembly are widespread. A strain 
deficient in Fe-S cluster assembly (Δnfu ΔsufT) was more sensitive to ‘882 intoxication when 
cultured in a medium wherein the growth is reliant upon the Fe-S cluster dependent enzymes 
IlvD and LeuCD (Figure 6) (269, 306). Under these conditions, ‘882 inhibits the growth of LAC, 
suggesting that even in the absence of constitutive Sae activity, the pleiotropic effects of ‘882 
can be observed, which would be expected if ‘882 inhibits Fe-S cluster assembly. The 
inhibitory effects of ‘882 are most pronounced under anaerobic growth, and evidence 
suggests this is the result of (1) reduced energy generation and the metabolic burden of 
constitutive Sae, (2) reduced expression of Fe-S cluster assembly factors, which decreases 
the effective concentration of ‘882 required to inhibit Fe-S cluster assembly, and (3) the 
dependency of CoA homeostasis on Fe-S cluster requiring enzymes. 
 The investigations into the effect of ‘882 on aconitase (AcnA) support the model that 
‘882 disrupts the Suf machinery (Figure 13). It was recently demonstrated that AcnA function 
is reduced in strains with inhibited Fe-S cluster assembly (267), and here we show that ‘882 
decreases AcnA activity. The magnitude of inhibition of AcnA activity by ‘882 is amplified as 
culture dioxygen levels are reduced. These data agree well with the decreased expression of 
sufC during anaerobic conditions (267). Lending further support to the idea that ‘882 inhibits 
the assembly of the Fe-S cluster upon apo-AcnA but does not directly inhibit AcnA, ‘882 does 
not alter the activity of purified AcnA containing a chemically reconstituted Fe-S cluster. 
Consistent with the in vitro data, we find that in vivo the inhibitory effect of ‘882 upon AcnA 
requires de novo protein synthesis (307). These findings support the conclusion that ‘882 
decreases AcnA activity through the inhibition of Suf-mediated Fe-S cluster biogenesis.  
Proteomics analysis found that cells toxified by ‘882 increase the abundance of the 
core Suf machinery proteins. The transcription of sufC is increased under growth conditions 
that impose an increased demand for Fe-S cluster biogenesis (267, 274). SufT is a Fe-S 
maturation factor selectively utilized under growth conditions that impose an increased 
demand for Fe-S cluster biogenesis and the transcription of sufT increases under such 
conditions (267, 274). The abundance of SufT increases in cells toxified by ‘882, further 
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emphasizing that intoxication by ‘882 results in an increased need for the Fe-S cluster 
assembly machinery. Thus, taken with the other findings presented in this study, one 
explanation is that cells toxified by ‘882 increase abundance of the Suf proteins to aid in 
mediating resistance towards this molecule and bypassing toxicity.  
In summary, this work has identified ‘882 as an inhibitor of Fe-S cluster assembly and 
our data suggest that inhibition of Fe-S cluster dependent enzymes is, in part, responsible for 
the toxicity of ‘882. Fe-S cluster assembly is one of the two distinct cellular targets of ‘882 that 
also include activation of heme biosynthesis. Our medicinal chemistry efforts have 
demonstrated the structural components of ‘882 required for each of these activities (276). 
Our previous findings demonstrated the utility of ‘882 as an inhibitor of S. aureus undergoing 
fermentation; treatment of mice with a derivative of ‘882 reduced the burden of S. aureus in 
the liver during systemic infection (275). Here, we demonstrate a candidate staphylococcal 
target for this therapeutic effect. The Suf proteins are not conserved in humans, which rely on 
an E. coli-like Isc system, making Suf an attractive pathogen-specific drug target (308, 309). 
This work underscores the opportunity to develop small molecule inhibitors of the Suf 
machinery as potential novel therapeutics.  
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CHAPTER III 
 
 
GENETIC DISSECTION OF S. AUREUS HEME BIOSYNTHESIS 
 
 
Introduction 
 The biosynthetic route to heme in S. aureus remains an under-explored physiological 
process. As discussed in Chapter I, recent work has illuminated novel intermediates in the 
terminal steps of heme synthesis, ascribed new functions to the enzymes responsible for 
these intermediates, and identifed the enzyme responsible for the final step in S. aureus heme 
synthesis. However, in this Chapter I investigate a series of outstanding questions in 
staphylococcal heme synthesis. While many groups are working diligently to investigate the 
unexplored enzymology of the coproporphyrin-dependent heme synthesis route, particularly 
focused on ChdC and CgoX, in this study I turn to genetics to answer the following question: 
which steps in S. aureus heme synthesis produce heme auxotrophy?  
 The general consensus for heme biosynthesis (and most co-factor and secondary 
metabolite synthesis) contends that each step is required for production of heme. However, 
some outstanding data and observations suggest this might not be entirely true for S. aureus. 
First, there are conflicting data regarding the conversion of glutamate-1-semialdehyde to δ-
aminolevulinic acid (ALA). In vitro experiments demonstrated that the conversion can occur 
in the absence of enzyme (45), yet a gsaM (annotated as hemL) mutant in Salmonella is a 
heme auxotroph that can be complemented with ALA, suggesting the enzyme is required in 
vivo (310). Additionally, S. aureus and other members of the Firmicutes phylum encode a 
second annottated gsaM at a separate chrmomosal locus. Therefore, I sought to determine 
the contributation of each GsaM to heme synthesis.  
 A second outstanding question is the identity of an anaerobic CgoX. CgoX performs 
the oxidation of coproporphyrinogen III to coproporphyrin, and in vitro this reaction uses 
molecular oxygen. This suggests the existence of an anaerobic enzyme capable of the same 
reaction with a different proton acceptor. Existence of oxygen-dependent and -independent 
enyzmes for this step would be in line with the protoporphyrin-dependent heme synthesis 
pathway (43) as discussed in Chapter I. Three potential options exist to resolve this question-
the annotated HemN described as an oxygen-independent coproporphyinogen III oxidase fills 
this gap, the DUF1444 enzyme (NWMN_1636) is the enyzme in question, or CgoX functions 
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anaerobically and aerobically. This Chapter investigates these possibilities and finds that 
CgoX is required for aerobic and anerobic heme synthesis.  
 
Materials and methods 
Bacterial strains (Table 5), plasmids (Table 6), and primers (Table 7) are listed in the 
specified table. S. aureus strains were grown routinely on tryptic soy agar (TSA) or broth (TSB) 
supplemented with 10 µg/mL chloramphenicol or 10 µg/mL erythromycin when necessary. 
When used, heme (hemin chloride) was used at concentrations noted. Heme was prepared 
fresh at 10 mM in 0.1 M NaOH; for experiments in which heme was used, an equal volume of 
0.1 M NaOH was used for all conditions. E. coli strains were grown on lysogeny broth (LB) or 
LB agar (LBA), supplemented with 50 µg/mL carbenicillin or kanamycin when necessary. For 
growth in liquid medium, an Innova44 incubator shaking at 180 rpm was used. For standard 
cultures of 4-5 mL, 15 mL round bottomed polypropylene tubes with aeration lids were used, 
at a 45° angle in the incubator. For cloning and mutagenesis in plasmids, all constructs were 
confirmed by sequencing (GeneWiz). Unless noted otherwise, all chemicals are from Sigma. 
All molecular biology reagents were New England Biolabs and used according to 
manufacturer’s instructions, unless otherwise noted. Phusion 2X Hi-fidelity master mix was 
used for all PCR reactions for cloning.  As necessary, plasmids were transformed by 
electroporation from E. coli into the S. aureus cloning intermediate strain RN4220 before 
isolation and subsequent electroporation into final S. aureus strains. 
 
Inactivation of S. aureus heme biosynthesis enzymes 
Deletion of genes were performed by allelic exchange as described in (311) with some 
modifications. The pKOR1 plasmids containing ~1kb homologous regions flanking upstream 
and downstream of the gene to be deleted were prepared using NEB Hi-Fi assembly 
according to manufacturer’s suggestions. The pKOR1 backbone was amplified by PCR using 
JC291/292 which produces a linear product not including the attB recombination sites. The 
~1kb flanking regions were amplified from S. aureus Newman genomic DNA. Deletions were 
confirmed by PCR using isolated genomic DNA and complemented by providing the gene in 
trans.   
For gsaM2, flanking regions were amplified using JC29/30 (upstream flanking) and 
JC31/32 (downstream flanking). The deletion was confirmed with PCR using primers JC49/46. 
For uroS, flanking regions were amplified using JC415/416 (upstream flanking) and 
JC417/418 (downstream flanking). The deletion was confirmed with PCR using primers 
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JC184/189. For uroD, flanking regions were amplified using JC419/420 (upstream flanking) 
and JC421/422 (downstream flanking). For uroD-cpfC, flanking regions were amplified using 
JC500/501 (upstream flanking) and JC502/503 (downstream flanking). For uroD-cgoX, 
flanking regions were amplified using JC500/504 (upstream flanking) and JC507/508 
(downstream flanking), and JC505/506 amplify cpfC; for this plasmid, the upstream and 
downstream flanking regions are on either side of cpfC so that deletion of uroD and cgoX is 
in-frame and retains cpfC. For uroD-cpfC-cgoX, flanking regions were amplified using 
JC419/423 (upstream flanking) and JC424/425 (downstream flanking). For cgoX, flanking 
regions were amplified using JC631/632 (upstream flanking) and JC633/508 (downstream 
flanking). Mutagenesis of this locus was confirmed with PCR using primers JC427/428. 
For inactivation of gsaM, the transposon insertion mutant was transduced to S. aureus 
Newman WT and ΔgsaM2 as described previously (312) using bacteriophage φ-85. 
Inactivation of isdC was performed by transducing the isdC::erm allele into Newman ΔgtrR as 
described previously (312) using bacteriophage φ-85 and confirmed with PCR using primers 
AF75 and AF1-4. 
 
Complementation of S. aureus heme synthesis phenotypes 
To complement heme synthesis phenotypes, the gene(s) were cloned from S. aureus 
Newman genomic DNA with homology to pOS1 Plgt digested with NdeI and BamHI (NEB), 
and ligated using NEB Hi-fi assembly mix. Complementation plasmids were confirmed by 
restriction digest after isolated from DH5α following transformation, transformed to S. aureus 
RN4220 by electroporation, and transduced as described previously (312) using 
bacteriophage φ-85. Primers used were JC P447/448 for uroS, JC449/450 for uroD, 
JC449/451 for uroD-cpfC-cgoX, JC449/4509 for uroD-cpfC, and JC449/510 for uroD with 
homology to cgoX, and JC511/512 with homology to uroD for uroD-cgoX. After generation of 
merodiploids, 2 µM heme was included in every step to complement heme deficiency.  
 
Growth in carbon-limited medium 
For growth in a semi-defined carbon-limited medium (CLM; modified from (287)), 
strains were grown to stationary phase in 5 mL of TSB. The cultures were diluted 1:100 into 
CLM medium with or without 0.02% glucose and OD600 was monitored over time. CLM 
consisted of 0.64 g/L NaCl, 0.15 g/L KCl, 0.01 g/L MgSO4-7H2O, 7 g/L K2HPO4, 2 g/L 
KH2PO4, 1 g/L (NH4)2SO4, 1 mg/L thiamine, 1.2 mg/L niacin, 0.25 mg/L calcium 
pantothenate, 5 µg/ml biotin, and 0.5% cas-amino acids.  
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Inactivation of E. coli gsaM 
gsaM of E. coli MG1655 was inactivated using lambda red recombination as described 
elsewhere (313).  Primers JC85/86 were used to amplify the kanamycin resistance casette 
from pKD4, in which the 5’ 40 bp of JC85 aligns to the 5’ of gsaM, and the 5’ 40 bp of JC 86 
aligns 3’ of gsaM. 50 µg/ml aminolevulinic acid was included in each step following 
transformation of the PCR product. Insertional inactivation was confirmed with colony PCR 
using JC P87/88. To demonstrate ALA auxotrophy, MG1655 and gsaM::kan were streaked to 
LBA or LBA supplemented with 50 µg/ml ALA.  
 
Anaerobic growth 
For anaerobic experiments, a Coy (Grass Lake, MI) anaerobic chamber was used, 
filled with a mix of 90% nitrogen, 5% carbon dioxide, and 5% hydrogen gases, and hydrogen 
levels are monitored to ensure a minimum of 2% hydrogen concentration. Palladium catalysts 
(Coy) were used to remove any residual oxygen by reaction with hydrogen. A Coy static 
incubator was maintained at 37° C. Solutions and plastic-ware were allowed to equilibrate for 
>24 h inside the glove-box before use. For anaerobic samples, strains were streaked to TSA 
and grown aerobically for 24 h at 37° C.  Single colonies of WT, and a few colonies for each 
other strains were used to overnight cultures in 2 ml TSB in aeration tubes and grown 
anaerobically without shaking at 37° in four biological replicates. After 14 h, the cultures were 
diluted 1:100 into 200 µl of TSB or RPMI + 1% cas-amino acids, both supplemented with water 
(vehicle) or 40 mM nitrate (from sodium nitrate; Fisher). Growth was monitored in a BioTek 
plate reader with shaking at 37°.   
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Table 5 Bacterial strains used in Chapter III 
Species Genotype Description Reference 
S. aureus strain Newman WT  Wildtype laboratory stock (277) 
S. aureus strain Newman ΔgtrR In frame deletion of NWMN_1566 (97) 
S. aureus strain Newman gsaM 
Transposon insertion in 
NWMN_1561 
This study; 
(279) 
S. aureus strain Newman Δgsam2 In frame deletion of NWMN_1756 This study 
S. aureus strain Newman gsaM ΔgsaM2 
gsaM transposon allele transduced 
into ΔgsaM2 
This study 
S. aureus strain Newman pbgS 
In frame allelic exchange with ermC 
gene, transduced into Newman; 
NWMN_1562 
(97) 
S. aureus strain Newman ΔuroS In frame deletion of NWMN_1563 This study 
S. aureus strain Newman ΔuroD In frame deletion of NWMN_1725 This study 
S. aureus strain Newman ΔuroD ΔcpfC 
In frame deletion of NWMN_1724 
and NWMN_1725 
This study 
S. aureus strain Newman ΔuroD ΔcgoX 
In frame deletion of NWMN_1723 
and NWMN_1725 
This study 
S. aureus strain Newman ΔuroD ΔcgoX ΔcgoX 
In frame deletion of NWMN_1723, 
NWMN_1725, and NWMN_1725 
This study 
S. aureus strain Newman ΔcgoX In frame deletion of NWMN_1723 This study 
S. aureus strain Newman ΔchdC In frame deletion of NWMN_0550 (64) 
S. aureus strain Newman ΔisdC::erm 
Allelic exchange inactivation of isdC 
(NWMN_1042) 
(113) 
S. aureus strain Newman ΔisdC::erm ΔgtrR ΔisdC::erm transduced to ΔgtrR This study 
E. coli MG1655 WT   
E. coli MG1655 gsaM::kan 
Insertional inactivation of gsaM 
(b0154) 
This study 
 
 
Table 6 Plasmids used in Chapter III 
Plasmid Description Reference 
pKOR1 Allelic exchange vector for S. aureus (311) 
pKOR1-uroS Vector to delete uroS This study 
pKOR1-uroD Vector to delete uroD This study 
pKOR1-uroD-cpfC Vector to delete uroD and cpfC This study 
pKOR1-uroD-cgoX Vector to delete uroD and cgoX This study 
pKOR1-uroD-cpfC-cgoX Vector to delete uroD, cpfC, and cgoX This study 
pKOR1-cgoX Vector to delete cgoX This study 
pOS1 Plgt  (314) 
pOS1 PlgturoS uroS complementation vector This study 
pOS1 PlgturoD uroD complementation vector This study 
pOS1 PlgturoD-cpfC uroD-cpfC complementation vector This study 
pOS1 PlgturoD-cgoX uroD-cgoX complementation vector This study 
pOS1 PlgturoD-cpfC-cgoX uroD-cpfC-cgoX complementation vector This study 
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Table 7 Primers used in Chapter III 
Primer 
name 
Sequence 
JC291 GGGCCCGAGCTTAAGACT 
JC292 GATATCCCCTATAGTGAGTCGTATTAC 
JC29 TAAGCTCGGGCCCCGCAGTTCTAGTAGC  
JC30 CTTCCTTAAAAGTTATTATATCAACCTCTTTTAA 
JC31 TTAAAAGAGGTTGATATAATAACTTTTAAGGAAG  
JC32 GTAATACGACTTACTTCATAAGCTTGTCTAG  
JC49 ATTGTCGCAACACTTATATTTGGA 
JC46 GTCATAATTTAAAACAACGTGTCG 
JC415 TATAGGGGATATCAGAAAATAATCTAGAGCAATCCG 
JC416 AAATTTCATTTATTTAAACGTCACTCCATTATTTAATG 
JC417 GACGTTTAAATAAATGAAATTTGATAGACATAGAAG 
JC418 GGCCAGTCTTAAGCTCGGGCCCAAGTAAATTCCTCCTACAGTTTATG 
JC184 GATATGGACCCAGACGATACAATTG 
JC189 CAGAACCAGCTTTGATTAATAACGAATCAC 
JC419 TATAGGGGATATCTGACATTTATTATAAAACATATGACG 
JC420 TAAAACTATGATATGCACCATAAAGGCCTC 
JC421 TATGGTGCATATCATAGTTTTACATTGAAGCAC 
JC422 GGCCAGTCTTAAGCTCGGGCCCAACGTTTCACGCTTCTTTC 
JC500 CACTATAGGGGATATCTGACATTTATTATAAAACATATGACG 
JC501 TCTTTCGTCATTAATTATGCACCATAAAGGCCTC 
JC502 ATGGTGCATAATTAATGACGAAAGAAGCGTGAAAC 
JC503 CCAGTCTTAAGCTCGGGCCCACTTACAACTCTGCGATTACTTC 
JC504 TGTAAAACTATGATTAATTATGCACCATAAAGGCCTC 
JC507 GTCTATATTTTAAGTTAATTGTTGGATGGTGTTG 
JC508 GACGGCCAGTCTTAAGCTCGGGCCCAACGCCTATACCTTCTGAAAAAG 
JC505 TTTATGGTGCATAATTAATCATAGTTTTACATTGAAGCAC 
JC506 TCCAACAATTAACTTAAAATATAGACTTGATTTCATCAAC 
JC423 ATCCAACAATTAACTATGCACCATAAAGGCCTC 
JC424 TATGGTGCATAGTTAATTGTTGGATGGTGTTG 
JC425 GGCCAGTCTTAAGCTCGGGCCCAACGCCTATACCTTCTGAAAAAG 
JC631 CGACTCACTATAGGGGATATCTTATTAGCACCATGGAATG 
JC632 CATCCAACAATTAACAACGTTTCACGCTTCTTTC 
JC633 GAAGCGTGAAACGTTGTTAATTGTTGGATGGTGTTG 
JC427 GCAATGGTATCAATCGGGACTTAAAAC 
JC428 GAATGGTTCAGGACAGAGTCGAA 
AF75 CAT AGC TGATGAACGTTGTTCTG 
AF1-4 GGGGACCACTTTGTACAAGAAAGCTGGGTGCAAATAACATATATTGCTTTTTAT 
JC447 GGGGCATATGAAGCCAGTTGTAGTTATG 
JC448 GGGCGGATCCGCCTTAGCCCCTACTTTCTAAAATC 
JC449 AAATACAATTGAGGTGAACATATGATGGTGCATAATAAAAACAATAC 
JC450 AAACACTACCCCCTTGTTTGGATCCTTATCTTTGTGTATATGTGTGTACG 
JC451 AAACACTACCCCCTTGTTTGGATCCTTACAACTCTGCGATTACTTC 
JC509 AAACACTACCCCCTTGTTTGGATCCTTAAAATATAGACTTGATTTCATCAAC 
JC510 TCTTTCGTCATTATCTTTGTGTATATGTGTGTACG 
JC511 ACAAAGATAATGACGAAAGAAGCGTGAAAC 
JC512 AAACACTACCCCCTTGTTTGGATCCTTAACTTACAACTCTGCGATTACTTC 
JC85 ATGAGTAAGTCTGAAAATCTTTACAGCGCAGCGCGCGAGCGTGTAGGCTGGAGCTGCTTC 
JC86 TCACAACTTCGCAAACACCCGACGTGCAGCATCGATGGTGCATATGAATATCCTCCTTAG 
JC87 GCGGCTCGAGATGAGTAAGTCTGAAAATCTTTACAGCGCAGCGCGC 
JC88 GGCCGCGGCAGATCCTCTTCTGAGATGAGTTTTTGTTCCAACTTCGCAAACACCCGA 
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Results 
 S. aureus synthesizes heme de novo using nine enzymes encoded from three (and 
potentially four) genomic loci (Figure 16A). Glutamyl-tRNA is committed to heme biosynthesis 
by GtrR (Figure 16B) and proceeds to heme. To first assess the essentiality and redundancy 
of each biosynthetic enzyme to S. aureus heme synthesis, I created a series of mutants and 
compared their growth to previously characterized heme synthesis mutants. (Figure 16C). 
Inactivation of gtrR (97), pbgS (97), uroS, uroD, cgoX, and chdC (64) results in heme 
auxotrophy and these mutants adopt the small colony variant phenotype associated with 
inactive cellular respiration. Inactivation of hmbS has not been attempted to date. Inactivation 
of cpfC was extensively attempted without success, which is likely due to the inherent toxicity 
of coproporphyrin III, which would build up in a strain lacking cpfC but with intact upstream 
heme biosynthesis. However, cpfC has been deleted by another group in S. aureus, albeit 
without demonstrating complementation (62). To confirm that cpfC can be inactivated if 
upstream enzymes are inactivated to eliminate coproporphyrin III build up, uroD and cpfC 
were deleted together. This mutant strain is viable and is a small colony variant, and is 
complemented by both genes in trans (Figure 17).  The ΔuroD ΔcpfC mutant has similar 
growth to the ΔuroD ΔcgoX and ΔuroD ΔcpfC ΔcgoX mutant strains.  
 Of note, inactivation of either gsaM, gsaM2, or both does not create heme deficiciency 
(Figure 16). While ΔgsaM2 appears wildtype in colony morphology, a mutant lacking gsaM or 
gsaM and gsaM2 has slightly smaller and hyperpigmented colonies.  
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Figure 16 Genetic inactivation of most heme biosynthesis genes blocks heme 
synthesis. (A) The genes encoding heme biosynthesis enzymes are located at four 
chromosomal loci. (B) An overview of the S. aureus heme biosynthetic pathway. In red are 
the updated enzyme names set forth by Dailey and colleagues (51), which correspond to the 
previously used gene locus names in gray. (C) Genetic inactivation of most of the steps of the 
heme biosynthesis pathway blocks heme synthesis. TSA plate was imaged 24 h after 
streaking strains from freezer stock. 
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Figure 17 Complementation of terminal heme synthesis mutants. Previously 
uncharacterized mutants with in-frame deletions of terminal heme synthesis genes are shown, 
encoding the vector pOS1 Plgt with or without the complementing gene(s). Shown is growth 
after 24 h on TSA containing chloramphenicol. 
 
 In performing these studies, I routinely complemented the small colony variants with 
exogenous heme. While the Isd system (Chapter I) is the only known active heme uptake 
system in S. aureus, it is expressed only under iron limitation and co-expressed with heme 
oxygenases. Therefore, I hypothesized that complementation of heme auxotroph SCVs is 
likely through passive diffusion of the lipophilic heme molecule. Consistent with this 
hypothesis, inactivation of the Isd system by deleting isdC does not affect the ability of low 
concentrations of exogenous heme to complement the ΔgtrR small colony variant (Figure 18).  
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Figure 18 Heme synthesis mutants do not require Isd heme uptake for 
complementation with exogenous heme. S. aureus WT and strains lacking either isdC, 
gtrR, or both after 24 h of growth on (A) TSA (B) TSA supplemented with 100 nM heme. 
  
Next, to investigate further the contribution of either gsaM genes to heme biosynthesis, 
I turned to aerobic growth to more sensitively measure growth of strains lacking one or both 
of the annotated gsaM genes. Growth in a semi-defined carbon limited medium, with glucose 
supplemented as the primary carbon source, shows that inactivation of either gsaM does not 
affect growth (Figure 19A). These conditions require heme synthesis, as the ΔgtrR mutant 
grows very poorly. However, in conditions without glucose and heme-independent glycolysis, 
a modest growth defect is observed in strains lacking gsaM but not gsaM2 (Figure 19B). 
These data suggest that gsaM is only partially required for heme synthesis, and gsaM2 may 
not be at all.  
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Figure 19 GsaM contributes modestly to respiration dependent growth. S. aureus strains 
as shown were grown aerobically in carbon-limited medium (A) with glucose or (B) without 
glucose supplementation. Growth was monitored over time by measuring OD600.  
 
 To corroborate findings in Salmonella and create a resource to investigate S. aureus 
GsaM function, we insertionally inactivated gsaM in E. coli MG1655. This mutant is a heme 
auxotroph (not shown) that can be complemented with exogenous ALA (Figure 20). This 
mutant can be used to measure the contribution of S. aureus gsaM and gsaM2 to the 
conversion of ALA when ectopically expressed in E. coli gsaM::kan. 
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Figure 20 E. coli GsaM is required for heme biosynthesis. [M.R. in part] E. coli MG1655 
WT or a strain with gsaM inactivated grown on (A) LBA or (B) LBA containing 50 µg/ml ALA. 
Shown is growth after 24 h.  
 
Thus far, I have demonstrated that most genes are required for heme biosynthesis, in 
the presence of oxygen. I next turned to CgoX to investigate the presence or absence of a 
second oxygen-independent coproporphyrinogen oxidase. The obvious gene is hemN, 
NWMN_1486, annotated as oxygen-independent coproporphyrinogen oxidase. However, 
recent work in E. coli and Lactococcus lactis (315, 316) has found that often this annotation 
is incorrect for reasons that are true for S. aureus (Figure 21). NWMN_1486, when aligned to 
a bona fide coproporphyrinogen oxidase from E. coli, is missing the N-terminal 47 amino acids 
that are critical for substrate recognition, and the fourth cysteine of the radical SAM motif has 
been mutagenized to a phenylalanine in S. aureus. As such, NWMN_1486 is likely not an 
anaerobic coproporphyrinogen oxidase.  
 
 
 
 
75 
 
 
Figure 21 S. aureus NWMN_1486 lacks key features of an anaerobic 
coproporphyrinogen oxidase. A model of the primary sequence of the annotated 
HemN/anaerobic coproporphyrinogen oxidase of S. aureus (top) and E. coli (bottom). Gray 
indicates amino acids conserved between proteins, red indicates divergent amino acids that 
are critical to function of E. coli HemN.  
 
 Therefore, I considered the other remaining possibilities-that an enzyme of the 
DUF1444 domain-containing family performs as an oxygen-independent coproporphyrinogen 
oxidase as previously suggested (51), or that CgoX functions anaerobically and aerobically. 
To test the latter hypothesis, I compared growth under anaerobic conditions in medium that 
requires heme synthesis for full growth rate and yield. In both TSB (which contains glucose) 
and RPMI supplemented with cas-amino acids and the non-fermentable carbon source 
glycerol, the alternative terminal electron acceptor nitrate enhances growth by allowing 
anaerobic respiration, which relies on heme. However, inactivation of either cgoX or the uroD-
cpfC-cgoX operon prevents heme-dependent respiration in anaerobic media (Figure 22). 
These data suggest that cgoX is required for anaerobic heme synthesis.  
 
 
76 
 
 
 
Figure 22 CgoX is required for anaerobic heme-dependent growth. Growth of S. aureus 
WT, ΔcgoX, and ΔuroD ΔcpfC ΔcgoX was monitored over time in an anaerobic chamber in 
(A) TSB or (B) RPMI supplemented with cas-amino acids and glycerol in the presence or 
absence of the alternative terminal electron acceptor nitrate. Shown are the means of a single 
experiment in biological quadruplicate for each medium. 
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Discussion 
 In this chapter, I find that while most of S. aureus heme synthesis enzymes function 
as expected from annotation and the literature of other species, there are a few exceptions. 
First, the enzymatic conversion of glutamate-1-semialdehyde to ALA by GsaM remains a 
question. The genes annotated as gsaM and gsaM2 are not required for heme production, 
but GsaM may contribute modestly (Figures 16, 19). This is consistent with the rapid non-
enzymatic conversion of glutamate-1-semialdehyde to ALA, but inconsistent with in vivo 
evidence in E. coli (Figure 20). Experimentally, there is no evidence that GsaM2 is a 
glutamate-1-semialdehyde-2,1-aminomutase. However, expression of GsaM and GsaM2 in 
E. coli gsaM::kan could test if these proteins can perform glutamate-1-semialdehyde-2,1-
aminomutase function. Further work is needed to determine if another gene encodes a 
glutamate-1-semialdehyde-2,1-aminomutase that is responsible for heme synthesis in the 
absence of gsaM.  
 Most notably, in this chapter I present evidence that the annotated CgoX is required 
for heme synthesis anaerobically and anaerobically (Figures 21 and 22). This is consistent 
with an incorrect annotation of HemN (NWMN_1486) as an anaerobic coproporphyrinogen 
oxidase, and underscores the need for further biochemicil analyses of CgoX in the presence 
and absence of oxygen. Taken together, work in this chapter has helped define genetically 
the requirements for S. aureus heme synthesis and provides preliminary evidence to 
suggest that more is to be learned in both early and late steps of heme production by this 
organism.  
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CHAPTER IV 
 
 
STAPHYLOCOCCUS AUREUS HEMX MODULATES GLUTAMYL-TRNA REDUCTASE 
ABUNDANCE TO REGULATE HEME BIOSYNTHESIS 
 
 
A version of the following section (Chapter IV, Staphylococcus aureus HemX modulates 
glutamyl-tRNA reductase abundance to regulate heme biosynthesis was previously 
published in mBio 9(1). pii: e02287-17 (February 2018) 
doi: 10.1128/mBio.02287-17. 
© 2018 Article Authors. All Rights Reserved. 
 
Introduction 
The tetrapyrrole cofactor heme is critical to the physiology of organisms from humans 
to bacteria. Heme is composed of a porphyrin ring complexed to iron at its center, making it 
an excellent redox-active moiety for a variety of enzymes. Across kingdoms, heme is used to 
shuttle electrons in the respiratory chain and is also required for the function of many critical 
proteins including nitric oxide synthase, catalase, and hemoglobin.  To satisfy the cellular 
need for heme, most heme-dependent organisms synthesize heme de novo from simple and 
abundant precursors.  
The versatility of heme as a cofactor is based on its reactivity, which also results in its 
toxicity at high concentrations through a largely unknown mechanism. Excess heme can 
cause damage to cellular macromolecules, accumulate in the membrane and likely cause 
damage (96, 237) and the redox cycling of heme-iron may produce reactive oxygen species 
via Fenton chemistry (317). Bacteria encode a variety of mechanisms to resist heme toxicity 
(317), but the most important of these strategies may be the prevention of self-imposed toxicity 
by regulating endogenous heme synthesis. A variety of transcriptional and post-transcriptional 
strategies have evolved to regulate heme synthesis centered around providing sufficient heme 
to occupy hemoproteins while preventing excess heme synthesis to limit unnecessary 
consumption of substrates and preclude toxicity.  
In this study, I sought to uncover regulatory pathways controlling heme synthesis in 
the human pathogen, Staphylococcus aureus. S. aureus is a Gram-positive bacterium that 
causes a variety of devastating diseases including skin and soft tissue infections, 
osteomyelitis, endocarditis, and bacteremia (318). S. aureus, as a facultative anaerobe, 
generates energy through aerobic respiration, anaerobic respiration, or fermentation. The final 
step in aerobic respiration is reduction of oxygen to water, which S. aureus performs with 
79 
 
either of the heme-dependent QoxABCD or CydAB terminal oxidases (97, 256).  Although a 
great deal is known about heme synthesis, heme utilization, and heme toxicity in S. aureus, 
no heme synthesis regulatory pathway has been identified in this organism. S. aureus 
encodes the newly appreciated coproporphyrin-dependent heme synthesis pathway to 
populate its hemoproteins (43, 62). These include the terminal oxidases, catalase, and 
bacterial nitric oxide synthase, all of which contribute to growth, protection from host defenses, 
and pathogenesis (97, 319-321). In conditions of excess exogenous heme, the heme stress 
response in S. aureus is activated by the heme sensing two-component system HssRS which 
regulates the transcription of a putative efflux pump HrtAB. This system is critical for growth 
and survival in toxic concentrations of heme and modulates pathogenesis in a murine model 
of disease (244). Sensing or regulatory pathways that connect heme synthesis with heme 
availability, hemoprotein abundance, or HssRS activation have not been identified. 
S. aureus synthesizes δ–aminolevulinic acid (ALA), the first dedicated and universal 
precursor for protoheme synthesis, via the conversion of glutamyl-tRNA to glutamate-1-
semialdehyde by glutamyl-tRNA reductase (GtrR) and subsequent production of ALA by 
glutamate-1-semialdehyde 2,1- aminomutase (322-324).  Uroporphyrinogen is the precursor 
to heme, siroheme, and other tetrapyrroles, and the stepwise transformation of ALA to 
uroporphyrinogen comprises the core of the synthesis pathway. The pathway from 
uroporphyrinogen to heme was historically considered to be universally conserved for all 
organisms. However, the field’s understanding of bacterial heme synthesis has undergone a 
revolution as recent studies uncovered diversity in bacterial strategies to convert 
uroporphyrinogen to heme (reviewed in ((51)). Gram-positive bacteria proceed through a 
coproporphyrin-dependent branch (43, 62, 63) which is unique from the classic 
protoporphyrin-dependent branch in humans and many Gram-negative model organisms.  
In this work, I identify GtrR abundance as a critical regulator of S. aureus heme 
synthesis. GtrR is post-transcriptionally maintained at low abundance in heme-proficient cells 
by the membrane protein HemX, but levels increase when S. aureus is deprived of heme. 
Without HemX regulation, GtrR abundance increases which results in the concomitant 
increase in flux through the heme synthesis pathway and accumulation of heme. This excess 
heme synthesis activates HssRS and disrupts iron homeostasis. Together, this report reveals 
that S. aureus regulates heme synthesis by modulating GtrR abundance via intracellular heme 
levels and the widely conserved HemX. 
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Materials and methods 
Bacterial strains and reagents 
Bacterial strains (Table 8), plasmids (Table 9), and primers (Table 10) are listed in the 
specified table. S. aureus strains were grown routinely on tryptic soy agar (TSA) or broth (TSB) 
supplemented with 10 µg/mL chloramphenicol or 10 µg/mL erythromycin when necessary. 
When used, heme (hemin chloride) was used at concentrations noted. Heme was prepared 
fresh at 10 mM in 0.1 M NaOH; for experiments in which heme was used, an equal volume of 
0.1 M NaOH was used for all conditions. E. coli strains were grown on lysogeny broth (LB) or 
LB agar (LBA), supplemented with 50 µg/mL carbenicillin when necessary. For growth in liquid 
medium, an Innova44 incubator shaking at 180 rpm was used. For standard cultures of 4-5 
mL, 15 mL round bottomed polypropylene tubes with aeration lids were used, at a 45° angle 
in the incubator. For cloning and mutagenesis in plasmids, all constructs were confirmed by 
sequencing (GeneWiz). Unless noted otherwise, all chemicals are from Sigma. All molecular 
biology reagents were New England Biolabs and used according to manufacturer’s 
instructions, unless otherwise noted. Phusion 2X Hi-fidelity master mix was used for all PCR 
reactions for cloning.  As necessary, plasmids were transformed by electroporation from E. 
coli into the S. aureus cloning intermediate strain RN4220 before isolation and subsequent 
electroporation into final S. aureus strains. 
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Table 8 Bacterial strains used in Chapter IV 
Species Strain Genotype Description Source 
S. aureus Newman WT Wildtype, methicillin sensitive clinical isolate  (277) 
S. aureus Newman pbgS pbgS (NWMN_1562) gene interrupted with 
erythromycin resistance gene ermB by homologous 
recombination, transduced into Newman 
(97) 
S. aureus Newman ΔchdC In-frame unmarked deletion of chdC (NWMN_0550) 
generated by allelic exchange 
(64) 
S. aureus Newman ΔhemX 
ΔchdC 
In-frame unmarked deletion of chdC (NWMN_0550) 
generated by allelic exchange in ΔhemX 
This work 
S. aureus Newman ΔmenB In-frame unmarked deletion of menB generated by 
allelic exchange 
(237) 
S. aureus Newman ΔqoxB 
cydB 
In-frame unmarked deletion of qoxB and cydB::Tn (97) 
S. aureus JE2 katA katA::Tn (NE1366) BEI; (279) 
S. aureus Newman katA katA::Tn (NE1366), transduced into Newman  This work 
S. aureus Newman ΔhemX In-frame unmarked deletion of hemX (NWMN_1565)  This work 
S. aureus  RN9011  RN4220 carrying pRN7023 integrase plasmid (325) 
S. aureus RN9011 ::Plgt pJC1111 Plgt integrated into chromosome at attC locus This work 
 RN9011 ::PlgthemX pJC1111 PlgthemX integrated into chromosome at attC 
locus 
This work 
S. aureus  ΔhemX::Plgt pJC1111 Plgt integrated into chromosome at attC locus This work 
S. aureus  ΔhemX 
::PlgthemX 
pJC1111 PlgthemX integrated into chromosome at attC 
locus 
This work 
S. aureus Newman ::Plgt pJC1111 Plgt integrated into chromosome at attC locus This work 
S. aureus Newman sodA sodM Antibiotic cassette insertion mutants (326) 
S. aureus Newman ΔhemX 
sodA sodM 
In-frame unmarked deletion of hemX (NWMN_1565) in 
sodA sodM  strain 
This work 
S. aureus Newman ΔhemX 
pbgS 
In-frame unmarked deletion of hemX (NWMN_1565) in 
pbgS strain 
This work 
S. aureus Newman ΔhssRS In-frame unmarked deletion of hssRS generated by 
allelic exchange 
(42) 
S. aureus Newman ΔhrtB In-frame unmarked deletion of hrtB generated by allelic 
exchange 
(327) 
S. aureus Newman hrtB hrtB::Tn(PhiNE01762) (244) 
S. aureus Newman ΔhemX 
hrtB 
hrtB::Tn(PhiNE01762) allele transduced to ΔhemX  This work 
S. aureus JE2 cysG cysG::Tn (NE1931; SAUSA300_2553::Tn) BEI;(279) 
S. aureus Newman cysG cysG::Tn (NE1931) transduced into Newman This work 
S. aureus Newman ΔhemX 
cysG 
cysG::Tn (NE1931) transduced into Newman ΔhemX This work 
S. aureus JE2 nirD nirD::Tn (NE1279 )  BEI; (328) 
S. aureus Newman nirD nirD::Tn (NE1279) transduced into Newman  This work 
S. aureus Newman ΔhemX 
nirD 
nirD::Tn (NE1279) transduced into Newman ΔhemX This work 
S. aureus Newman ΔgtrR-
hemX 
In-frame unmarked deletion of gtrR and hemX 
(NWMN_1566-1565) generated by single allelic 
exchange 
This work 
S. aureus  RN4220  Restriction deficient cloning intermediate strain (280) 
S. aureus Newman hrtAB::kan Allelic exchange of hrtAB with kanR (ahpA-3) This work 
S. aureus Newman ΔhemX 
hrtAB::kan 
Allelic exchange of hrtAB with kanR (ahpA-3) in ΔhemX This work 
S. aureus Newman ΔhssRS 
hrtAB::kan 
Allelic exchange of hrtAB with kanR (ahpA-3) in ΔhssRS This work 
E. coli BL21 DE3  Protein expression strain  NEB 
E. coli  EC55 ΔphoA phoA mutant Horswill 
lab (329) 
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Table 9 Plasmids used in Chapter IV 
Plasmid Description Source 
pKOR1 Temperature sensitive allelic exchange vector (311) 
pKOR1-hemX Allelic exchange vector for deletion of hemX This work  
pKOR1-hrtAB::kan Allelic exchange vector for exchange of hrtAB with kanR 
(ahpA-3) 
This work 
pXen1 (luxABCDE) Promoterless plasmid encoding Photorhabdus 
luminescens luciferase operon (luxABCDE), carbenicillin 
(E. coli) and chloramphenicol (S. aureus) selection 
Xenogen; (110) 
pXen1 PhrtluxABCDE hrtAB promoter cloned in pXen1 (110) 
pOS1 PhrtxylE hrtAB promoter driving xylE expression; carbenicillin (E. 
coli) and chloramphenicol (S. aureus) selection 
(244) 
pOS1 PisdAgfp isdA promoter driving gfp expression This work 
pOS1 Plgt lgt (constitutive) promoter  (314) 
pOS1 PlgthemX hemX cloned in pOS1 Plgt This work 
pJC1111 carbenicillin (E. coli) and cadmium chloride (S. aureus) 
selection 
Torres lab; (325) 
pJC1111 Plgt Integration vector with constitutive promoter This work 
pJC1111 PlgthemX hemX cloned in pJC1111 Plgt This work 
pOS1 PlgtgtrR gtrR cloned in pOS1 Plgt This work 
pOS1 PlgtgtrR-hemX gtrR-hemX cloned in pOS1 Plgt This work 
pET15b.gtrR gtrR cloned in pET15b for His-tagged affinity purification  This work  
pOS1 PlgthemX_Y17A Y17A point mutation in HemX This work 
pOS1 PlgthemX_H135A H135A point mutation in HemX This work 
pOS1 PlgthemX_G203A G203A point mutation in HemX This work 
pBAD33 E. coli expression vector; IPTG inducible promoter Hadjifrangiskou 
lab; (330) 
pBAD33.hemX_phoA C-terminal fusion of phoA to hemX This work  
pBAD33.hemX:N244_phoA phoA inserted between N244 and S245 of hemX This work  
pBAD33.hemX_phoA Y17A Y17A point mutation in HemX This work  
pBAD33.hemX_phoA H135A H135A point mutation in HemX This work  
pBAD33.hemX_phoA G203A G203A point mutation in HemX This work  
pBAD33.hemX_phoA Y231A Y231A point mutation in HemX This work  
 
Table 10 Primers used in Chapter IV 
Primer 
name 
Sequence 
JC291 GGGCCCGAGCTTAAGACT 
JC292 GATATCCCCTATAGTGAGTCGTATTAC 
JC105 TCACTATAGGGGATATCGCGTTTCAAATGCATTTTATTG 
JC106 TTATTTCTCATTATTCAAAACTAAAGATACGTCG 
JC108 GTTTTGAATAATGAGAAATAATCTAGAGCAATCC 
JC109 CTTAAGCTCGGGCCCTTTATAAAAGAATTTCACAGCATTTTTAG 
JC103 TCACTATAGGGGATATCTTGATGTGTTATAAAAGTGAAAAGC 
JC104 TTATTTCTCATTGAAACGCCCCCATATATAC 
JC107 GCGTTTCAATGAGAAATAATCTAGAGCAATCC 
JC157 GGGGGGCATATGCAAGAAAACCTGTTTATTCGATTCAATG 
JC155 GGGCGGATCCGGCTCAATTCACAAAATGTGTTGC 
CG38 ACGATCCGGGGAATTCCATATGTTATTTGTAGAGCTCATCCATGCCATG 
CG39 CTTGTTTGGATCCTCGAGGGATCCATGCCCGGGAGCAAAGGA 
CG50 GCCGAAGAATTCCAAAACATAATCCTCCTTTTTATG 
CG51 GCCAAGCATATGGTTGTTTTCCTCCTAAGGATACAA 
JC101 GCGGCATATGGCCATGCATTTTATTGCAATTAGTAT 
JC102 GCGGGGATCCGCCTTATTCAAAACTAAAGATACGTC 
JC83 GTGATTTTAGTCATACGCGCTTC 
JC84 GAACCCTGATATTTCAATTGCTG 
JC53 TTTGTTCCGAAATTGTTGCA 
JC54 GAAAGATCCTATTAAACAGGCCAAA 
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JC55 AACCAATCATTGAACCTGCTC 
JC56 CATTTGATACGGCTTTAAGTCGT 
JC81 CAGTCTTACCTGCTCGATTCC 
JC82 GTGGAATATTCGTTGCCATACC 
HS1 TGTTGGGTGTTGTTCCAGTG 
HS2 GCTTAACCCTGGCAATTTACG 
HS3 CGAGAAATGGCAAAAGAAGG 
HS4 TTCTTTCGTGTGTGCCGTAG 
JC158 GCCGTCGACGCCACTAATGATTTATTATGTAGTGGTTC 
JC229 GGGGGAAACACTACCCCCTTG 
JC184 GATATGGACCCAGACGATACAATTG 
JC185 GCACCACGACGTAATGAACTAG 
JC228 TAAGAAGAGATGTAAGAGTAGGG 
JC229 GGGGGAAACACTACCCCCTTG 
JC283 ATTATTAATAGCATTAATCAGTATCATTTGCTATTTTTATGATTTTG 
JC284 ATAATTTCATTGAATCGAATAAAC 
JC285 ACTGTTAGTCGCAATCGGTCTAGCTGTGTTAAG 
JC286 AACTCGTCTACAACAGCAATTTTC 
JC287 TATTATTTTAGCAACACAGTGGGGTG 
JC288 CTAAATATGAGAATTATCCACC 
JC289 TACAGTATTAGCAGGAAGTTATATTTTACTTAGAATCAAC 
JC290 ATAATTGAAGAGAGTATTACCTTC 
JC240 GCTAGCGAATTCGAGCTCGGTACCCGGGATTAAGGAGGAATAAATAATGCAAGAAAACCTG
TTTATTC 
JC241 CAGGAACTGCAACTGCATTCACAAAATGTGTTGCAAAAAATAAATTAATC 
JC242 ACATTTTGTGAATGCAGTTGCAGTTCCTGTTCTGGAAAACCGG 
JC243 AAGCTTGCATGCCTGCAGGTCGACTCTAGATTATTTCAGCCCCAGAGC 
JC244 CAGGAACTGCAACTGCATTCAACCATTTGTTGATTC 
JC245 CAAATGGTTGAATGCAGTTGCAGTTCCTGTTCTGGAAAACCGGG 
JC246 CTTGAAACTGCAACTGCTTTCAGCCCCAGAGCGGC 
JC247 TCTGGGGCTGAAAGCAGTTGCAGTTTCAAGATATTTAATATACTATAACATTATTTTATT 
JC248 AAGCTTGCATGCCTGCAGGTCGACTCTAGATCAATTCACAAAATGTGTTG 
 
Deletion of genes by allelic exchange 
 Deletion of genes were performed by allelic exchange as described in (311) with some 
modifications. The pKOR1 plasmids containing ~1kb homologous regions flanking upstream 
and downstream of the gene to be deleted were prepared using NEB Hi-Fi assembly 
according to manufacturer’s suggestions. The pKOR1 backbone was amplified by PCR using 
JC291/292 which produces a linear product not including the attB recombination sites. The 
~1kb flanking regions were amplified from S. aureus Newman genomic DNA. Deletions were 
confirmed by PCR using isolated genomic DNA and complemented by providing the gene in 
cis or trans.  For hemX, flanking regions were amplified using JC105/106 (upstream flanking) 
and JC108/109 (downstream flanking). The allelic exchange protocol to create an in-frame 
unmarked deletion of hemX was performed in S. aureus WT, pbgS, sodA sodM, and ΔchdC. 
Deletion of hemX was confirmed by PCR using JC184/185. For deletion of gtrR-hemX, which 
are co-transcribed from adjacent positions in the chromosome, allelic exchange was 
performed as described above. The ~1kb flanking regions were amplified from S. aureus 
Newman genomic DNA using JC103/104 (upstream flanking) and JC107/109 (downstream 
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flanking). The allelic exchange protocol to create an in-frame unmarked deletion of gtrR-hemX 
was performed in S. aureus WT. Deletion was confirmed by PCR using JC184/185. 
 
pOS1 PisdA-gfp cloning 
The sequence for codon optimized gfp was amplified from pGFP-F (328) using primers 
CG38/39 and subsequently assembled using Gibson Assembly into pOS1 that was digested 
with NdeI and BamHI.  PisdA was amplified from S. aureus Newman genomic DNA using 
primers CG50/51 and was ligated into pOS1 gfp after digestion with EcoRI and NdeI to 
produce pOS1 PisdAgfp.  
 
pOS1 PlgtgtrR and PlgtgtrR-hemX cloning 
gtrR was amplified from S. aureus Newman genomic DNA using primers JC101/102, 
while gtrR-hemX was amplified using JC101/155 and ligated into pOS1 Plgt after digestion of 
PCR products and vector with NdeI and BamHI to produce pOS1 PlgtgtrR and pOS1 PlgtgtrR-
hemX 
 
hemX chromosomal integration 
Chromosomal complementation was performed by cloning Plgt or PlgthemX into 
pJC1111. Plgt was PCR amplified from pOS1 Plgt using JC158/229, and subsequently cloned 
into the multiple cloning site of pJC1111 after restriction digest with SalI and BamHI. hemX 
was cloned into pOS1 Plgt by amplifying hemX flanked by NdeI and BamHI sites from S. 
aureus Newman genomic DNA using primers JC157/155, and ligated (T4 ligase) into multiple 
cloning site of pOS1 Plgt after restriction digest with NdeI and BamHI. PlgthemX was amplified 
from pOS1 PlgthemX using JC158/155 and subsequently cloned into the SalI and BamHI sites 
of pJC1111 after restriction digest with SalI and BamHI. pJC1111 Plgt and pJC1111 PlgthemX 
were integrated into the chromosome of strain RN9011 as described (325), then transduced 
into S. aureus Newman WT or ΔhemX as noted. Transductions of pJC1111 loci were 
performed with φ-85 as described in (312), with some modifications: after incubation of donor 
phage with recipient strains and washing with sodium citrate, cells were allowed to recover for 
4 h in TSB with 40 mM sodium citrate at 37°C with shaking and plated to TSA containing 0.15 
mM cadmium chloride.  
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Transduction of transposon library alleles 
katA::Tn (NE1366), cysG::Tn (NE1931), nirD::Tn (NE1279), and hrtB::Tn 
(PhiNE01762) transposon alleles were transduced to S. aureus Newman and ΔhemX as listed 
in Table 8 as described previously (312) using bacteriophage φ-85; alleles were confirmed by 
an inverse PCR method and Sanger sequencing (279).  
 
hemX site-directed mutagenesis 
pOS1 PlgthemX was subjected to site-directed mutagenesis according to NEB Q5 Site-
directed mutagenesis kit. Following mutagenesis, the plasmid was transformed to DH5α, 
subjected to sequencing (GeneWiz) using primers JC228/229, transformed to RN4220 by 
electroporation, and transformed into ΔhemX by electroporation. Primers JC283/284 were 
used for Y17A, primers JC285/286 for H135A, JC287/288 for G203A, and JC289/290 for 
Y231A. pOS1 PlgthemX_Y231A was successfully created but no colonies were ever recovered 
following transformation into RN4220 despite multiple attempts.  
 
HemX-alkaline phosphatase fusions  
HemX-PhoA fusions were generated by NEB Hi-Fi assembly. Full length hemX without 
stop codon was amplified from S. aureus Newman genomic DNA using JC240/241; JC240 
incorporates a Shine-Dalgarno sequence. phoA was amplified from E. coli MG1655 genomic 
DNA with JC242/243, which do not amplify the signal sequence or first five amino acids of 
mature PhoA, but do include sequence for an AVAV linker at the N-terminus. The PCR 
products of JC240/241 and JC242/243 were assembled with pBAD33 digested with SmaI and 
XbaI according to manufacturer’s instructions. Site directed mutagenesis was performed in 
pBAD33 hemX_phoA using NEB Q5 Site Directed Mutagenesis kit with primers JC283/284 
(for Y17A), JC285/286 (for H135A), JC287/288 (for G203A), and JC289/290 (for Y231A). To 
create pBAD33 hemX:N244_phoA, the nucleotide sequence for HemX residues 1-244 was 
amplified from S. aureus Newman genomic DNA using JC240/244; JC240 incorporates a 
Shine-Dalgarno sequence. HemX sequence encoding residues 245-271 was amplified from 
S. aureus Newman genomic DNA using JC247/248. phoA was amplified from E. coli MG1655 
genomic DNA with JC245/246, which do not amplify the signal sequence or first five amino 
acids of mature PhoA, but do include sequence for an AVAV linker at the N- and C-termini. 
hemX(1-244)-phoA-hemX(245-271) were assembled in pBAD33 using NEB HiFi assembly 
according to manufacturer’s instructions. Following assembly, plasmids were transformed into 
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DH5α, reisolated, and subjected to sequencing by GeneWiz. Plasmids were subsequently 
transformed to E. coli  
 
hrtAB::kan selection strain 
 hrtAB were replaced with a kanamycin resistance cassette by allelic exchange using 
pKOR1 as described above. The upstream flanking region was amplified from Newman 
genomic DNA using primers JC634/635, the downstream flanking region was amplified from 
Newman genomic DNA using primers JC638/639. The kanamycin resistance gene (below) 
was amplified using primers JC636/637, and the three fragments were ligated with NEB HiFi 
assembly. The kanamycin resistance gene ahpA-3 was synthesized by IDT with a S. aureus 
codon optimized sequence based on pKAN (328) preceded by a 5’ terminator, the Phrt 
sequence, 5’ PstI, XbaI, and SalI sites, and 3’ BamHI and KpnI sites. The fragment sequence 
was cloned into pJC1111 (not further utilized) and then only the ahpA-3 protein coding 
sequence was amplified using primers JC636/637 such that the gene is under control of the 
native chromosomal Phrt. The sequence of codon optimized ahpA-3:  
ATGGCGAAGATGCGTATATCACCTGAGTTGAAAAAGTTAATCGAAAAATATAGATGCGT
GAAGGACACTGAAGGTATGTCACCGGCTAAGGTATACAAATTAGTAGGCGAGAATGAG
AACTTATATTTAAAAATGACGGATTCAAGATACAAGGGCACTACTTACGATGTAGAAAGA
GAGAAAGATATGATGTTATGGTTGGAGGGTAAGTTACCAGTCCCGAAGGTGTTGCATTT
CGAACGTCACGATGGATGGTCTAACTTGTTGATGTCAGAAGCTGACGGCGTCTTATGTT
CAGAGGAATACGAAGACGAACAAAGTCCTGAGAAAATAATTGAGTTATATGCGGAATGT
ATCAGATTGTTCCATTCTATAGACATTTCAGATTGCCCATATACGAACTCATTGGACAGT
CGTTTGGCAGAATTGGATTACTTGTTGAATAATGACTTGGCGGATGTGGACTGTGAGAA
TTGGGAGGAGGACACACCATTCAAAGATCCGCGAGAGTTGTACGATTTTTTAAAGACAG
AGAAACCTGAAGAAGAGTTGGTTTTTTCACATGGAGATTTAGGAGATAGTAACATATTTG
TGAAGGACGGCAAGGTGTCTGGATTCATCGATTTAGGCCGATCTGGTAGAGCTGATAA
ATGGTACGATATTGCATTTTGCGTGCGTAGTATACGTGAGGATATTGGTGAAGAGCAAT
ACGTCGAGTTATTCTTCGACTTATTAGGCATAAAGCCAGACTGGGAGAAGATTAAATAC
TACATCTTATTGGACGAATTGTTCTAA 
The allelic exchange of pKOR1-hrtAB::kan was performed in S. aureus Newman WT, 
ΔhemX, and ΔhssRS.  
 
Catalase activity 
To assess catalase activity, strains were grown for 16 h in TSB then 50 µL of each 
culture was spotted to a TSA plate and streaked for isolation. After 24 h of growth at 37°C, 50 
µL of 30% H2O2 was added to each strain and immediately imaged.  
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LC-MRM-MS/MS 
Strains were streaked to TSA and grown for 24 h at 37° C. Cultures were started from 
single colonies in 5 ml of RPMI+1% cas-amino acids and grown at 37° C for 15 h. Overnight 
cultures were subcultured 1:100 into RPMI+1% cas-amino acids and grown until mid-
exponential phase. For small colony variants without chemical complementation, overnight 
cultures were sub-cultured 1:25. For conditions in which heme was added, 2 µM was used; 
for menaquinone, 12.5 µM of menaquinone/vitamin K2 was used.  
For anaerobic experiments, a Coy (Grass Lake, MI) anaerobic chamber was used, 
filled with a mix of 90% nitrogen, 5% carbon dioxide, and 5% hydrogen gases, and hydrogen 
levels are monitored to ensure a minimum of 2% hydrogen concentration. Palladium catalysts 
(Coy) were used to remove any residual oxygen by reaction with hydrogen. A Coy static 
incubator was maintained at 37° C. Solutions and plastic-ware were allowed to equilibrate for 
>24 h inside the glove-box before use. For anaerobic samples, strains were streaked to TSA 
and grown aerobically for 24 h at 37° C.  Cultures were started from single colonies in 5 ml of 
anaerobic TSB and grown at 37° C for 15 h. Overnight cultures were subcultured 1:100 into 
anaerobic TSB containing 40 mM sodium nitrate and grown until mid-exponential phase. 
Protein was collected, tryptically digested, and subjected to LC-MRM-MS/MS as described 
below.  
Cells were collected by centrifugation, washed in PBS, and resuspended in 500 µl of 
TSM (100 mM Tris, pH 7; 500 mM sucrose; 10 mM MgCl2) containing 4 µg of lysostaphin. 
Cells were incubated for 60 min at 37° C. Protoplasts were collected by centrifugation and 
resuspended in 150 µl of PBS containing 100 µM PMSF. Protoplasts were lysed by sonication 
and the soluble lysate was collected after centrifugation to remove unlysed protoplasts. 
Protein content was quantified using the Pierce BCA Assay (Thermo) and lysate was added 
to 4X NuPAGE LDS sample buffer with reducing agent (Thermo) and 100 µg of total protein 
for each replicate was subject to brief SDS-PAGE in NuPAGE gel (Thermo) according to 
manufacturer’s instructions.  
The gel regions were excised and subjected to in-gel trypsin digestion and peptide 
extraction as previously described (331). Proteins were quantified with multiple reaction 
monitoring (332). Representative peptides for each protein were selected based on theoretical 
trypsin digest. Skyline software (University of Washington, MacCoss lab (333) was used to 
set up scheduled, targeted MRM methods and three to five MS/MS transitions were monitored 
per peptide. 
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The 20 μL digest was transferred to an autosampler vial and 4 μL sample per run was 
injected via autosampler (NanoAcuity HPLC system, Waters) onto a vented column setup 
utilizing a 40 mm by 0.1 mm (Jupiter 5 micron, 300A) kasil fritted trap followed by a 250 mm 
by 0.1 mm (Jupiter 3 micron, 300A), self-packed analytical column coupled directly to a TSQ-
Vantage (Thermo Scientific) via a nanoelectrospray source. After trapping and equilibration, 
peptides were resolved using a 90-minute aqueous to organic gradient (solvent A = 0.1% FA 
in water and B = 0.1% FA in ACN) operating at 400 nL/min. A series of unscheduled runs 
determined retention times and the most useful transitions to monitor and then a scheduled 
instrument method encompassing a 8-minute window around the measured retention time 
along with calculated collision energies was created using Skyline. Q1 peak width resolution 
was set to 0.7, collision gas pressure was 1 mTorr, and utilized an EZ method cycle time of 3 
seconds. The resulting RAW instrument files were imported into Skyline for peak-picking and 
quantitation. Transition or fragment ion peak areas were summed to represent the intensity of 
endogenous peptides, and normalized to S. aureus Newman GyrA as noted. 
 
Purification of recombinant GtrR and heme binding assay 
The gene encoding GtrR was cloned from Newman genomic DNA using primers JC 
101/102 and ligated (NEB T4 DNA ligase)into pET15b (REF) after the vector and insert were 
digested with NdeI and BamHI-HF (NEB) and transformed into DH5α. The plasmid was re-
isolated and subjected to sequencing using GeneWiz and subsequently transformed into 
BL21 DE3 pRIL using 50 µg/ml carbenicillin and 34 µg/ml chloramphenicol for selection.  
For protein expression and purification, BL21 DE3 pRIL pET15b.gtrR was grown 
overnight in LB containing 50 µg/ml carbenicillin and 34 µg/ml chloramphenicol for 14 h at 37° 
with shaking, then subcultured 1:100 into 1.5L Terrific broth (Sigma) in a 2.8 L Fernbach flask 
supplemented with 50 µg/ml carbenicillin and 34 µg/ml chloramphenicol. Growth at 37° with 
shaking at 200 rpm was monitored and when the culture OD600 reached 0.5, the incubator 
was changed to 30° and expression was induced with 0.5 mM IPTG. After overnight growth, 
cells were collected by centrifugation for 10 minutes at 5,000xg and resuspended in 30 ml of 
50 mM Tris  (pH 8) containing 300 mM NaCl, 1 mM EDTA, 10 mM imidazole, 10% glycerol, 
and a protease inhibitor table (Roche). 40 µg/ml deoxyribonuclease I from bovine pancreas 
(Sigma) was added and the suspension was incubated on ice for 15 min, then 1 mg/ml 
lysozyme was added and suspension was incubated at room temperature for 20 min. The 
resulting suspension was lysed using an Emulsaflex. The solution was clarified by 
ultracentrifugation at 100,000xg for 45 min at 4°. GtrR was affinity purified using 7 ml of Ni-
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NTA resin in a gravity column. The resin was washed with 50 ml of 50 mM Tris (pH 8) 
containing 300 mM NaCl, 1 mM EDTA, 10 mM imidazole, 10% glycerol. Cell lysate was 
applied to the column, washed with 75 ml of the same buffer, and GtrR was eluted from the 
column with 50 mM Tris  (pH 8) containing 300 mM NaCl, 1 mM EDTA, 80 mM imidazole, 
10% glycerol. This eluate was dialyzed at 4° in 50 mM Tris (pH 8) containing 200 mM NaCl, 
1 mM EDTA, 10 mM imidazole, 10% glycerol for 1 h, then in 50 mM Tris (pH 8) containing 
100 mM NaCl, 1 mM EDTA, 10 mM imidazole, 10% glycerol for 1 h, then overnight in 50 mM 
Tris (pH 8) containing 1 mM EDTA, 10 mM imidazole, 10% glycerol. Purified protein was 
quantified by BCA, assessed for purity by SDS-PAGE, and stored at -20°.  
For heme binding, GtrR was diluted in 20 mM Tris (pH7.4) to 10 µM. Heme (hemin 
chloride) was prepared fresh in 0.1 M NaOH at 10 mM, then diluted in 20 mM Tris (pH7.4). 
Solutions of GtrR, heme, or combined were added to spectrophotometric cuvette and 
incubated for 5 min, then absorbance was measured in a Cary WinUV from 300 to 650 nm.  
 
GtrR structure modeling  
GtrR structure was modeled on Arabidopsis thaliana glutamyl tRNA reductase (334), 
PDB:4N7R using SWISS-MODEL (335).  
 
XylE reporter assay 
XylE abundance in cellular lysate was assessed spectrophotometrically by measuring 
formation of 2-hydroxymuconic acid from catechol after growth in TSB containing 
chloramphenicol vehicle, ALA (aminolevulinic acid HCl; stock prepared at 50 mg/ml in water), 
or heme, as described previously (244). 
 
Heme toxicity and adaptation growth curves 
Strains were streaked to TSA and grown for 24 h at 37°C. Single colonies were used 
to start 5 mL cultures of TSB and grown for 16 h at 37°C supplemented with or without heme 
or ALA as noted.  One µL of each culture was added to 199 µL of medium containing vehicle 
or heme as noted in a 96 well round-bottomed plate, and growth was monitored over time at 
37°C by measuring OD600 in a BioTek Synergy2 spectrophotometer and analyzed with BioTek 
Gen5 software. 
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Hydrogen peroxide killing assay 
S. aureus strains were grown in biological triplicate overnight in aeration tubes in 5 ml 
TSB at 37° from single colonies. The cultures were subcultured 1:100 into 5 ml TSB in aeration 
tubes and allowed to grow for 3.5 h at 37°. Cells were collected, washed in 1 ml sterile PBS, 
and resuspended in 600 µl PBS. 40 µl of the cell suspension was added to 560 µl of PBS with 
or without H2O2 at a final concentration of 0.25%. The suspension was incubated at 37° with 
shaking in Eppendorf microcentrifuge tube. At each time point noted, 40 µl was removed, 
added to 40 µl of PBS containing 2000 U/ml catalase (filter sterilized; Sigma), serially diluted, 
and plated to TSA for enumeration.  
 
Growth in paraquat 
For growth in carbon-limited medium, overnight cultures in four biological replicates of 
each strain were grown in 5 ml TSB in aeration tube at 37. After 14 h, cultures of each strain 
were normalized for density by measuring OD600, equal OD units were centrifuged, the cells 
were washed twice in PBS, and diluted 1:100 in carbon limited medium (CLM) containing 
glucose as described (287) containing 0 or 0.5 mM paraquat in a round bottomed 96 well plate 
and growth was monitored over time at 37°C by measuring OD600 in a BioTek Synergy2 
spectrophotometer and analyzed with BioTek Gen5 software. 
For growth in TSB, overnight cultures of each strain were grown in 3 ml TSB in aeration 
tube at 37° in biological triplicate. After 14 h, strains were subcultured 1:200 in TSB containing 
0 or 10 mM paraquat in a round bottomed 96 well plate and growth was monitored over time 
at 37°C by measuring OD600 in a BioTek Synergy2 spectrophotometer and analyzed with 
BioTek Gen5 software. 
 
Anaerobic growth curves 
S. aureus Newman WT, ΔhemX, cysG, ΔhemX cysG, nirD, and ΔhemX nirD were 
streaked to TSA and grown aerobically for 24 h at 37° C. Cultures were started from single 
colonies in 3 ml of anaerobic TSB and grown at 37° C for 15 h. Overnight cultures were 
subcultured 1:200 in round-bottomed 96-well plates with 200 μL of anaerobic TSB containing 
40 mM sodium nitrate or an equal volume of sterile water, and covered with Breathe-Easy gas 
permeable seal (Sigma). Growth was monitored by optical density over time in a BioTek 
Synergy H1.  
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Quantitative reverse-transcriptase polymerase chain reaction 
Strains were streaked to TSA and grown at 24 h at 37° C. Cultures were started from 
single colonies in 5 ml of RPMI+1% cas-amino acids and grown at 37° C for 15 h. Overnight 
cultures were subcultured 1:100 (WT and ΔhemX) or 1:25 (pbgS ΔhemX pbgS) into RPMI+1% 
cas-amino acids and grown until mid-exponential phase. An equal volume of ice-cold acetone: 
ethanol was added and the mixture was stored in -80. RNA was isolated using TRI reagent, 
chloroform, and precipitated with isopropanol. Isolated RNA were treated with DNAse I 
(Thermo) according to manufacturer’s instructions, and RNA was re-isolated using Qiagen 
RNeasy kit. cDNA was synthesized from 2 µg of RNA by incubating with M-MLV reverse 
transcriptase (Thermo), using transcript specific primers (JC83/84 for gyrA, JC53/54 for gtrR, 
and JC55/56 for gsaM). Quantitative PCR was performed using SYBR Green (Thermo) 
according to manufacturer’s instructions, using primers JC81/82 for gyrA, HS1/2 for gtrR, and 
HS for gsaM. Transcript abundance was quantified using the ΔΔCT method after normalization 
to gyrA abundance.  
 
ALA quantification 
ALA quantification was modified from (336).  S. aureus WT and ΔhemX were streaked 
to TSA and grown for 18 h at 37°C. Single colonies were used to start 5 mL cultures in TSB 
and grown for 12 h at 37°C, then 1 mL was inoculated into 100 mL of TSB in a 250 mL 
Erlenmeyer flask and grown at 37°C for 14h. The cell wall was removed by incubation in TSM 
+ 40 µg/mL lysostaphin and incubated at 37°C for 45 minutes. Protoplasts were collected by 
centrifugation and resuspended in 1 mL 10% TCA. Samples were incubated on ice and 
intermittently lysed by sonication. The soluble fraction was collected by centrifugation and 
neutralized to pH 7 with 6M NaOH, then added to a Dowex 1x-4 resin in column converted to 
acetate form before use. In this form, the column retains porphobilinogen but allows ALA to 
flow-through. Six hundred µL of flow-through was added to 200 µL of 8% acetylacetone in a 
2 M sodium acetate buffer, incubated for 15 min at 90°C to form the pyrrolic condensation 
product, and cooled to room temperature. Five hundred µL of sample was added to 500 µL of 
modified Ehrlich’s reagent, incubated for 10 min at room temperature, and the resulting 
absorbance was measured at 552 and 650 nm in a Cary 50 Bio UV-Vis spectrophotometer. 
The relative concentration of ALA was calculated based on an extinction coefficient of 7.2x10-
4 M-1 cm-1. 
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LC-qTOF-MS porphyrin quantification 
S. aureus strains were streaked to TSA and grown for 18 h at 37°C. For WT, ΔhemX, 
hrtB, and ΔhemX hrtB, single colonies were used to start 5 mL cultures in TSB and grown for 
10 h at 37°C. One hundred µL of this culture was inoculated into 50 mL of TSB in a 250 mL 
Erlenmeyer flask and grown at 37°C for 14 h. For ΔchdC and ΔhemX ΔchdC, multiple colonies 
colonies were used to start 5 mL cultures in TSB containing 2 µM heme and grown for 10 h 
at 37°C. Four hundred µL of this culture was inoculated into 200 mL of TSB in a 500 mL 
Erlenmeyer flask and grown at 37°C for 14 h. Total CFU were determined by serial dilution 
and plating to TSA for enumeration, and cells were collected by centrifugation and frozen at -
80°C. Any negligible levels of heme measured in ΔchdC or ΔhemX ΔchdC is likely carry-over 
from the heme containing initial culture.  
Porphyrin extraction. To the cell pellets, 1 mL of 1M HCl:DMSO (1:1, v/v) was added 
and samples vortexed,  sonicated (2x2 min total, 1 sec on/1 sec off, ice, Ultrasonic 
Homogenizer, Biologistics Inc. Model 3000), and centrifuged (10,000 rpm, 5 min, 4°C). 
Supernatants were collected and kept in the dark. Pellets were resuspended in 1 mL of 1M 
HCl:DMSO (1:1, v/v), vortexed vigorously for 30 s twice, and centrifuged again as above. 
Supernatants were pooled and the resuspension/centrifugation cycle repeated. The pooled 
supernatants were filtered using a 0.22 µM PES syringe filter (GE Healthcare Life Sciences) 
and subsequently diluted to 25 mL with ddH2O. The extracts were purified using a Sep-Pak® 
Vac 3cc tC18 cartridge (Waters 036815), eluted with 2 mL of acetonitrile + 0.1% TFA then 2 
mL of methanol. Extracted porphyrins were concentrated under N2(g) purge and resuspended 
in 50 µL of acetonitrile + 0.1% TFA. All samples were immediately dispensed into vials for 
analysis. Excess remaining samples were stored at -20°C in the dark.  
Preparation of standards. 2 mM stock solutions of porphyrin standards 
(porphobilinogen, uroporphyrin III, coproporphyrin I and III, coproheme III, protoporphyrin IX, 
and heme b) were individually prepared in DMSO and then mixed to make a 100 µM (final 
concentration of each porphyrin). This stock was then diluted to 0.25-6 µM in acetonitrile + 
0.1% TFA.  
 LC-qTOF-MS analysis. Twenty-five µL samples were diluted with 75 µL of ultrapure 
water immediately prior to measurement. The column (Agilent PLRP-S 100Å, 4.6x150x5 µm) 
was equilibrated to an 85:15 ratio of solvent A (ultrapure water with 0.1% formic acid) to 
solvent B (acetonitrile + 0.1% formic acid). LC separations were achieved by linear gradient 
elution, transitioning from 15% to 95% solvent B over 6 min followed by a 2 min hold at 95% 
B. The column was re-equilibrated to 15% solvent B for 2 min between injections of the same 
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sample (two technical replicates per sample). Two blank runs were implemented between 
samples (2 µL injection volume, 600 µL/min flow rate, 50°C) to ensure against column 
holdover of analytes. Electrospray ionization mass spectrometry analysis was carried out in 
positive mode with a capillary voltage of 2 Hz (Agilent 6538 UHD q-TOF).  
Data were analyzed using MassHunter Qualitative Analysis Software and MZmine 2. 
Values for m/z were determined empirically for standards. From the total ion chromatogram 
(TIC) traces, extracted ion chromatograms (EICs) were derived for each individual standard 
on the basis of its mass per charge (m/z) in positive ion mode, which is equivalent to the exact 
mass of its positive ion (parent compound plus H+). Peaks associated with each analyte were 
integrated and areas were plotted versus concentration (µM). Linear regression analysis 
(Kaleidagraph) was used to determine the correlation coefficient between integrated peak 
area and porphyrin concentration (slope of standard curve, mporph). 
All cell samples were analyzed for the full set of standards. Only analytes present 
above the limit of detection are reported; detection limits were at least 250 nM per injection; 
for a saturated culture with 109 CFU mL-1, this is equivalent to 250 x 10-9 pmoles CFU-1. For 
the quantification of analytes from cells, values for the integrated peak intensities (measured 
in units of ion counts) were converted to units of concentration (µmol/L injected) via: counts x 
(mporph)-1. The concentration of each analyte in the injected volumes [A] was subsequently 
converted to units of nmol analyte per CFU in sample as: [A] x (volume used to resuspend 
dried sample) x (CFUs in analyzed cell pellet)-1. Reported values are averages of technical 
replicates. 
 
Pyridine hemochromagen quantification 
Strains were streaked to TSA and grown for 18 h at 37°C. Single colonies were used 
to start 5 mL cultures of TSB and grown at 37°C for 10 h. Sixty µL of each culture was added 
to 6 mL of TSB and grown for 16 h at 37°C. Cells were collected by centrifugation and cell 
wall was removed by incubation in 20 mM potassium phosphate buffer pH 7.4 containing 20 
µg of lysostaphin for 45 min at 37°C. Samples were lysed by sonication, and unbroken cells 
were collected by centrifugation. Four-hundred fifty µL of the soluble supernatant was added 
to 450 µL of 0.2 M NaOH containing 40% pyridine and 500 µM potassium ferricyanide. 
Absorbance was measured in a Cary 50 Bio UV-Vis spectrophotometer from 540-590 nm. 
Ten µL of 0.5 M sodium dithionite prepared in 0.5 M NaOH was added to samples, incubated 
for 5 minutes, and absorbance was measured again from 540-590 nm. Heme quantity is 
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calculated using ΔA= (557reduced-557oxidized) - (575reduced-575oxidized) and an extinction coefficient 
of 32.4 mM-1 cm-1. 
 
Bioluminescent reporter assay 
S. aureus WT and ΔhemX with pXen-1 or PhrtluxABCDE were streaked to TSA-
chloramphenicol prepared with 0 or 20 µM heme. After 18 h, the plates were imaged using a 
Xenogen IVIS 2000. 
 
Heme killing assay 
S. aureus WT, ΔhemX, and ΔhrtB were streaked to TSA and grown for 24 h at 37°C. 
Single colonies were used to start 5 mL cultures of TSB and grown at 37°C for 14 h. Two µL 
of each culture was added to 148 µL of TSB containing different concentrations of heme in a 
96 well round-bottomed plate, and incubated at 37°C for 2 h. Samples were serially diluted in 
PBS and plated to TSA for CFU enumeration after 24 h of growth at 37°C. 
The same procedure was completed for WT pOS1 Plgt, ΔhemX pOS1 Plgt ΔhemX 
pOS1 PlgthemX, and the mutagenized hemX constructs as above, except that 10 µg/ml of 
chloramphenicol was used throughout.  
 
Systemic murine infections  
Bacterial suspensions for infections were prepared as follows: overnight cultures for 
each strain were grown from single colonies in 4 ml TSB in an aeration tube at 37° for 14 h. 
This culture was diluted 1:100 into 5 ml TSB in a 15 ml conical tube and grown for 3.5 h at 
37° in a roller drum. Bacteria were collected by centrifugation at approximately 5,000xg for 6 
minutes at 4°, washed twice in ice-cold PBS, and resuspended to OD600 of 0.4. The 
suspension was serially diluted, plated to TSA, and enumerated after 24 h of growth at 37° to 
confirm a density of 1-2x107 CFU/100 µl.  
Approximately 7-week old female Balb/c mice (Jackson) were anesthetized with 
1.25% avertin in PBS by intraperitoneal injection and then injected with 100 µl of appropriate 
bacterial suspension retro-orbitally. Infections proceeded for 96 h with daily monitoring of 
weight and health status. Mice that reached moribund status before the endpoint were 
humanely euthanized with CO2 asphyxiation. At 96 h post infection, mice were euthanized, 
organized were removed under sterile conditions, homogenized in sterile PBS, serially diluted 
and plated to TSA for enumeration following growth at 37° for 24 h.  
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Growth in minimal medium 
Chemically defined media (CDM) supplemented with 5 mg/mL glucose was prepared 
as previously described (337) with the exception that iron was not added. Strains were 
streaked to TSA and grown for 24 h at 37°C. Single colonies were used to start 5 mL cultures 
in TSB and grown for 14 h at 37°C. Cells were collected by centrifugation and washed in PBS 
twice, then resuspended in 5 mL of PBS. One µL was added to 199 µL of CDM containing 1 
µM ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) (EDDHA; LGC Standards) or equal 
volume of 0.1 M NaOH (vehicle) in a 96 well round-bottomed plate. Growth was monitored for 
24 h with shaking at 37°C in a BioTek EPOCH2 spectrophotometer and analyzed with BioTek 
Gen5 software.  
 
pOS1 PisdAgfp reporter assay  
S. aureus WT pOS1 PisdAgfp and ΔhemX pOS1 PisdAgfp were streaked to TSA-
chloramphenicol and grown for 14 h at 37°C. Single colonies were used to inoculate 5 mL 
cultures of TSB-chloramphenicol and grown at 37°C for 8.5 h. One µL of each culture was 
used to inoculate 199 µL of TSB-chloramphenicol containing 1 mM 2,2-dipyridyl or equal 
volume ethanol (vehicle). Growth was monitored over the course of 16 h by measuring OD600 
nm as well as relative fluorescence at 485 nm (excitation) and 510 nm (emission) in a BioTek 
Cytation5 spectrophotometer and analyzed with BioTek Gen5 software.  
 
Comparative genome analysis 
With over 100,000 prokaryotic genomes currently available in public databases and 
many more in the pipelines (www.genomesonline.org), it is not practical or possible to perform 
meaningful comparative analysis on all of them simultaneously.  Thus, a set of diverse 
representative prokaryotic genomes have been developed in the SEED database as follows.  
The algorithm for computing molecular operational taxonomic units (OTUs) based on DNA 
barcode data (338, 339) was used to group ∼12,600 prokaryotic genomes available in the 
SEED database in October 2013 into about 1,000 taxon groups.  One or two representative 
genomes (rarely three) for each OTU were selected based on the largest amount of published 
experimental data and the highest level of research interest within the scientific community.  
The resultant collection of 982 diverse eubacterial [928] and archaeal [54] genomes creates 
a manageable set that accurately represents the immense diversity of the over 12,000 
prokaryotic organisms with sequenced genomes.  Importantly, it is not skewed by an 
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overabundance of genomes for a handful of microbial genera (medically or industrially 
important), such as Enterobacteriaceae, streptococci, mycobacteria, etc. 
The HemX protein family was exhaustively annotated for this set of 982 representative 
microbial genomes in the SEED database (340). Contextual associations for this family were 
predicted based on the patterns of co-occurrence and/or colocalization of its members with 
other protein families using the set of tools for comparative genome analysis available in 
SEED (341)) within the functional and genomic contexts provided by the subsystem “Heme 
Biosynthesis: protoporphyrin-, coproporphyrin- and siroheme-dependent pathways”  
(http://pubseed.theseed.org//SubsysEditor.cgi?page=ShowSubsystem&subsystem=Heme_
Biosynthesis%3A_protoporphyrin-%2C_coproporphyrin-_and_siroheme-
dependent_pathways). Phylogenetic distribution of HemX protein family was mapped onto the 
Tree of Life (342) and protoheme biosynthetic pathway analysis was adapted from (51). 
 
HemX multiple sequence alignment and topology prediction 
 The HemX multiple sequence alignment was KEGG CLUSTALW ((343)); 
http://www.genome.jp; accessed 3/2017) using Staphylococcus aureus strain (str.) Newman, 
Staphylococcus epidermidis str. ATCC 12228, Bacillus anthracis str. Sterne, Chlorobioum 
tepidum str. TLS, Aquifex aeolicus str. VF5, Desulfovfibrio vulgaris str. DP4, and Geobacter 
sulfurreducens str. PCA. The transmembrane domains depicted were predicted by MEMSAT3 
(http://bioinf.cs.ucl.ac.uk; accessed 3/2017) as described (55). All models were confirmed 
using TMHMM 2.0 ((344)); (http://www.cbs.dtu.dk; accessed 3/2017) and predictions matched 
across prediction servers with the exception of Chlorobium tepidum, which TMHMM2.0 
predicts to have seven rather than eight transmembrane domains.  
 
HemX-alkaline phosphatase assays 
Single colonies were used to start 4 ml cultures of LB with chloramphenicol and grown 
for 16 h at 37° C. Each culture was streaked to LBA with chloramphenicol, 60 µg/ml 5-Bromo-
4-chloro-3-indolyl phosphate (BCIP) and 0.1% L-(+)-arabinose. After 24 h of growth at 37° C, 
plates were imaged. This assay was repeated thrice, and a representative image is shown. 
 
Statistical analysis 
All data analysis and statistical tests were performed using GraphPad Prism 6 
software. Replicate numbers and statistical tests for each experiment are listed in the figure 
legends.  
97 
 
Results 
Heme deficiency increases GtrR abundance 
To identify key steps in the regulation of heme synthesis (Figure 23A), we measured 
the abundance of each biosynthetic enzyme by liquid chromatography-multiple reaction 
monitoring-tandem mass spectrometry (LC-MRM-MS/MS). This technique allows for 
quantification with high resolution of even very-low-abundance cellular proteins (332). I  
hypothesized that comparing the S. aureus wild type (WT) to a strain incapable of synthesizing 
heme (pbgS mutant) (Figure 23A) would allow the identification of specific steps in heme 
synthesis that respond to cellular heme content, directly or indirectly. Abundance of GtrR is 
approximately 30-fold higher in the pbgS mutant relative to the WT, while the abundances of 
all other biosynthetic enzymes are nearly unchanged (Figure 23B). In WT cells, GtrR 
abundance is low relative to other heme synthesis enzymes (Figure 24). The pbgS mutant is 
a heme auxotroph and therefore adopts the respiration-deficient small-colony variant (SCV) 
phenotype. SCVs arise as the result of inactivation of respiration via inactivation of heme 
synthesis, the terminal oxidases, or the electron carrier menaquinone, and SCVs have a 
dramatically different physiology than respiration-proficient cells (101). Therefore, I sought to 
determine whether the increase in GtrR abundance in the pbgS mutant was the result of heme 
deficiency or a general defect in respiration. To confirm that the menaquinone auxotroph SCV 
ΔmenB strain and the ΔqoxB cydB strain lacking both terminal cytochrome oxidases 
synthesize heme despite being unable to respire, each strain was streaked onto agar and 
assessed for catalase activity (Figure 23C). Activity of the heme-dependent catalase KatA 
leads to the production of oxygen bubbles when hydrogen peroxide is added. The ΔmenB and 
ΔqoxB cydB mutants produce bubbles, demonstrating that these SCVs synthesize heme and 
are not heme auxotrophs. We measured GtrR abundance in a variety of SCV strains by LC-
MRM-MS/MS. GtrR abundance increases relative to the WT only in pbgS and ΔchdC strains 
(Figure 23A and D), which are heme auxotroph SCVs (Figure 23C). When chemically 
complemented with heme, GtrR abundance returned to WT levels for both strains. GtrR levels 
do not increase in the ΔmenB or ΔqoxB cydB strain. Together these data demonstrate that 
the abundance of GtrR is low in heme-proficient cells but increases specifically in response to 
heme deficiency. 
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Figure 23 Heme deficiency increases GtrR abundance. (A) The heme and siroheme 
biosynthesis pathways in S. aureus. (B) The abundance of each biosynthetic enzyme was 
measured by LC-MRM-MS/MS and quantified by integrated chromatogram peak areas. 
Graphed is the ratio of each enzyme abundance in a strain lacking pbgS relative to WT S. 
aureus; the data are the average of a single experiment performed in biological triplicate with 
standard deviation shown. Statistical significance was determined using a one-way ANOVA 
with Dunnett’s correction for multiple comparisons, using a reference value of 1.0; *** 
P<0.001. (C) S. aureus strains listed were streaked to rich agar medium plates and after 
growth, hydrogen peroxide was added at the perimeter of each streak. (D) The abundance of 
GtrR was measured by LC-MRM-MS/MS in S. aureus strains treated with vehicle, heme, or 
menaquinone (MK). The data are the average of a single experiment performed in biological 
triplicate with standard deviation shown. Statistical significance was determined using a one-
way ANOVA with Dunnett’s correction for multiple comparisons, comparing GtrR abundance 
for each condition relative to WT; * P <0.05   
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Figure 24 GtrR abundance is uniquely low among heme synthesis enzymes. Shown is 
the abundance of each heme synthesis enzyme as measured by LC-MRM-MS/MS in WT 
cells. The data are the average from a single experiment performed in biological triplicate with 
standard deviation shown.  
 
Recombinant GtrR binds heme 
Considering that GtrR levels change in abundance depending on the ability to 
synthesize heme, I hypothesized that GtrR my directly bind heme and thereby affect its own 
abundance. To assess heme-binding capabilities, GtrR was recombinantly expressed in E. 
coli and purified to homogeneity. Purified GtrR was incubated in the presence or absence of 
heme and absorbance was measured. Consistent with ability to bind heme, the presence of 
GtrR resulted in a Soret shift. The peak absorbance of heme alone was a broad peat at around 
395 nm, but in the presence of GtrR, the peak became sharper and centered around 413 nm 
(Figure 25).  
Because the prediction of non-covalent heme-coordinating motifs in hemoproteins are 
challenging to predict, we turned to structural homologs. Using SWISS-MODEL (335), we 
identified the glutamyl tRNA reductase of Arabidopsis as a GtrR homolog with solved crystal 
structure (Figure 26). We modeled GtrR and found it conformed well to the Arabidopsis 
protein, with the monomer forming one half of a predicted V-shaped dimer, as also observed 
in other glutamyl tRNA reductases (324). However, no heme ligand was observed in the 
solved crystal structure. Therefore, identification of the heme-binding residues of GtrR, and 
the impact of heme binding on GtrR regulation, remains to be investigated.  
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Figure 25 Recombinant GtrR binds heme. GtrR expressed recombinantly and purified from 
E. coli was assessed for ability to bind heme by measuring absorbance with and without 
increasing concentrations of heme added. 
 
Figure 26 A model of GtrR monomer. [H.K.] The structure of GtrR was modelled on 
Arabidopsis glutamyl tRNA reductase (PDB:4N7R), with C-terminal dimerization domain (dark 
green, truncated in model), N terminal catalytic domain in orange, and NADPH binding domain 
in blue.  
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Excess ALA is sufficient to increase heme synthesis and activate HssRS 
Upon observation that GtrR protein abundance was specifically modulated in response 
to heme deficiency, I hypothesized that changes to GtrR abundance would be sufficient to 
increase intracellular heme levels. As ALA is considered a rate-limited intermediate, and 
glutamate-1-semialdehyde is a short-lived intermediate that may spontaneously convert to 
ALA (Chapter III), I tested whether exogenous ALA could enhance endogenous heme 
biosynthesis. First, I measured activation of Phrt by HssRS as a proxy for intracellular heme 
levels, based on the supposition that excess heme synthesis could activate HssS. Indeed, 
ALA supplementation induced Phrt activation in an HssRS dependent manner (Figure 27A). 
Next, to test whether this level of Phrt induction was physiologically relevant, I measured the 
ability of ALA to pre-adapt S. aureus to heme toxicity. S. aureus grown overnight in medium 
containing heme or ALA subsequently displays a reduced lag time when grown in toxic 
concentrations of heme (Figure 27B). This pre-adaptation is the result of HssRS-mediated 
induction of the HrtAB efflux pump.  
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Figure 27 Excess ALA is sufficient to increase heme synthesis and activate HssRS. (A) 
XylE assay measuring Phrt activation in the presence or absence of the heme precursor ALA. 
(B) Heme adaptation assay in which isogenic mutants are grown in 0 or 12.5 µM heme 
following pre-growth in TSB containing vehicle, 2.5 µM heme, or ALA. For both, graphed are 
the means of three independent experiments in biological triplicate. For A ** indicates p<0.01 
by one-way ANOVA with Sidak correction for multiple comparisons.  
 
 
 
 
 
 
 
103 
 
HemX controls GtrR abundance in heme-proficient cells to regulate heme synthesis  
Among both Gram-negative and Gram-positive bacteria, regulation of GtrR abundance 
is a common feature of heme synthesis regulation pathways (70, 75, 82). In the model 
organism Bacillus subtilis, which is also a member of the Firmicutes phylum, GtrR abundance 
is impacted by the membrane protein HemX through an unknown mechanism (75, 345). While 
S. aureus is in the same Bacillales order as B. subtilis, S. aureus heme homeostasis is distinct 
because of its access to host heme and its resistance to heme toxicity mediated by HssRS. 
Both B. subtilis and S. aureus encode an operon comprised of gtrR-hemX-hmbS-uroS-pbgS-
gsaM (formerly hemAXCBDL) (47, 346). I therefore hypothesized that in S. aureus, HemX 
also impacts GtrR abundance in heme-proficient cells. I created an in-frame unmarked 
deletion of hemX and integrated either pJC1111 Plgt or PlgthemX at a neutral site in the 
chromosome (24). GtrR abundance was measured by LC-MRM-MS/MS and is increased in 
ΔhemX::Plgt relative to WT::Plgt (Figure 28A). The phenotype can be complemented when 
hemX is provided in cis, showing that it is the result of deletion of hemX and not other effects 
of disrupting the operon. These data are consistent with the hypothesis that HemX regulates 
GtrR abundance in heme-proficient cells (75, 345).  
I next sought to determine whether the increase in GtrR at the protein level in both 
pbgS and ΔhemX is the result of an increase in mRNA transcript abundance of gtrR. 
Therefore, pbgS and ΔhemX were grown to mid-exponential phase and RNA was isolated, 
converted to cDNA, and quantified with quantitative polymerase chain reaction (Figure 28C). 
The steady state mRNA abundance of gtrR transcript is unchanged in ΔhemX or pbgS relative 
to WT, suggesting that the increase in GtrR abundance in these strains is not the result of a 
transcriptional change. Additionally, the increase in GtrR levels in pbgS is not affected by the 
insertion of ermB to interrupt the pbgS gene, which is upstream of gsaM in the operon; there 
is no change in the transcript abundance of gsaM in pbgS relative to WT (Figure 29).  
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Figure 28 HemX regulates heme synthesis by maintaining low levels of GtrR in heme 
proficient cells [A.I.C: panel D]. (A) The abundance of GtrR was measured by LC-MRM-
MS/MS in multiple S. aureus strains.  The data are the average of a single experiment 
performed in biological triplicate with standard deviation shown. Statistical significance was 
determined using a one-way ANOVA with Dunnett’s correction for multiple comparisons, 
comparing GtrR abundance for each strain relative to ΔhemX::Plgt; *** P<0.001. (B) Steady 
state transcript abundance of gtrR mRNA isolated from mid-exponential growth of S. aureus 
strains was measured by q-RT-PCR and is graphed as fold change relative to WT. Data are 
combined from two independent experiments with biological triplicate and standard deviation 
shown. ns indicates no significance by one-way ANOVA with Dunnett’s correction for multiple 
comparisons, comparing fold change of pbgS and ΔhemX to WT. (C) δ-aminolevulinic acid 
(ALA) abundance was measured in S. aureus strains by a spectrophotometric quantification. 
Graphed is fold change of ALA in ΔhemX relative to WT, with data combined from two 
independent experiments with three biological replicates with standard error of the means 
shown. (D) Uroporphyrinogen III (detected as uroporphyrin III), coproporphyrin III, coproheme 
III and heme were quantified by LC-qTOF-MS. Graphed is fold change of metabolite 
abundance in ΔhemX relative to WT, from a single experiment performed in biological 
triplicate with standard error of the means shown. For C and D, statistical significance was 
determined with Student’s t-test comparing ΔhemX to WT before data transformation to fold 
change; * P<0.05, *** P<0.0001.  
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Figure 29 The pbgS allele is not polar on gsaM transcription. Steady-state transcript 
abundance of gsaM mRNA isolated from mid-exponential growth of S. aureus strains was 
measured by qRT-PCR and is graphed as fold change relative to the WT. Data are combined 
from two independent experiments in biological triplicate with standard deviation shown. “ns” 
indicates no significance by one-way ANOVA with Dunnett’s correction for multiple 
comparisons, comparing fold change of the pbgS mutant to the WT. 
 
I hypothesized that the increase in GtrR observed in ΔhemX would increase the 
amount of heme synthesized by increasing abundance of the heme precursors downstream 
of GtrR. As glutamate-1-semialdehyde is unstable and can convert to δ–aminolevulinic acid 
(ALA) in the absence of enzyme (45), I measured ALA abundance via a colorimetric method. 
ALA abundance increases approximately 50% in ΔhemX relative to WT (Figure 28C). We 
subsequently sought to determine the impact of increased ALA availability on downstream 
heme intermediates and heme abundance. Total cellular porphyrins were extracted from WT 
and ΔhemX and analyzed by quantitative exact-mass liquid chromatography-quadrupole time 
of flight mass spectrometry (LC-qTOF-MS); total extracted ion chromatograms for porphyrins 
that were observed above the limits of detection are shown in Figure 30, where a dramatic 
change in porphyrin levels is visible. Based on standard curves for individual porphyrins 
(including porphobilinogen, uroporphyrin I and III, coproporphyrin I and III, coproheme III, 
protoporphyrin IX, and heme b) and enumeration of colony forming units, absolute 
quantifications were obtained and referenced per cell for each porphyrin molecule; data are 
presented in Figure 28D in terms of fold-change relative to WT. As shown in Figure 28D; 
ΔhemX exhibits increased abundance of uroporphyrin III, coproporphyrin III, coproheme III, 
and heme b relative to WT. Notably, because samples were prepared aerobically, the 
metabolite uroporphyrinogen III was detected as  uroporphyrin III, in which its methylene-
bridge carbons have spontaneously oxidized in air; likewise, any coproporphyrinogen III that 
might have been present would be detected as the oxidation product, coproporphyrin III, which 
is also the product of the enzyme CgoX (Figure 23). Hydroxymethylbilane spontaneously 
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cyclizes to uroporphyrinogen I, which is decarboxylated by UroD to coproporphyrinogen I. The 
absence of uroporphyrin or coproporphyrin I isomers indicates that hydroxymethylbilane did 
not accrue in ΔhemX. I hypothesize that, in the presence of excess GtrR, the initial step of the 
pathway may no longer be rate limiting. This may allow other subsequent steps in the pathway 
to become partly rate-limiting, leading to the observed pattern of metabolite accumulation. 
Finally, the increase in heme abundance in ΔhemX observed by LC-qTOF-MS is 
complemented when hemX is provided in cis from a neutral site in the chromosome as 
measured by the pyridine hemochromagen method (Figure 32A). Together, these data 
demonstrate that inactivation of hemX results in increased GtrR abundance, which increases 
abundances of both early and late-pathway biosynthetic precursors and cellular heme. 
Therefore, dysregulation of GtrR alone is sufficient to disrupt heme homeostasis.  
 
Figure 30 Representative extracted ion chromatograms of extracted porphyrins [A.I.C.]. 
Chromatograms of (A) the S. aureus WT and (B) the ΔhemX mutant; each is quantified and 
shown in Figure 29. Chromatograms for porphyrins above the limits of detection (250 nM) are 
shown. 
 
Excess endogenous heme synthesis in ΔhemX activates the heme stress response  
The unregulated GtrR abundance in ΔhemX results in greater cellular heme levels 
(Figure 29D), which I hypothesized would activate the heme sensor system HssRS in the 
absence of exogenous heme, leading to transcriptional induction of the hrtAB efflux pump. 
WT and ΔhemX were transformed with plasmids containing the luminescence producing 
operon luxABCDE cloned from Photorhabdus luminescens without a promoter (pXen-1) or 
controlled by the HssRS-regulated promoter Phrt. Phrt promoter activity, visualized by 
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luminescent imaging, shows that HssRS is activated in ΔhemX in the absence of exogenous 
heme whereas HssRS is not activated in WT (Figure 31A). The Phrtlux activity in WT becomes 
apparent when 20 µM exogenous heme is added to the agar medium, and luminescence 
depends on the heme-responsive Phrt. To more quantitatively measure Phrt activity as a 
readout of HssRS activation by endogenous heme, I transformed WT, ΔhemX, and ΔhssRS 
with the pOS1 PhrtxylE plasmid. These strains report Phrt activity with the production of the 
XylE catechol oxidase enzyme, which can be quantified spectrophotometrically from cell 
lysate. Data in Figure 31B demonstrate that in the absence of exogenous heme, Phrt is induced 
in ΔhemX. Phrt activity does increase in WT and ΔhemX in a dose-dependent manner as 
exogenous heme is added, but Phrt activity remains higher in ΔhemX than WT at all tested 
heme concentrations. Additionally, XylE activity in this system is dependent on the HssRS 
two-component system. Taken together, these data suggest that excess endogenous heme 
synthesized in ΔhemX is sufficient to activate the HssRS two-component system.  
 I next hypothesized that the intermediate levels of HssRS activation in ΔhemX, in the 
absence of exogenous heme (Figure 31A-B), would be sufficient to pre-adapt ΔhemX to heme 
toxicity. As the HssRS-HrtAB heme stress response provides resistance to heme toxicity, pre-
treatment with subtoxic concentrations of heme adapts S. aureus to subsequent growth in 
toxic concentrations of heme by activating HssRS and increasing the abundance of HrtAB 
(10). WT grown in 10 µM heme without pre-adaptation has a severe growth defect evident by 
a six hour lag time (Figure 31C). When pre-adapted in 2 µM heme, WT demonstrates a 
reduced lag time and greater overall growth, albeit at a lower rate and yield than when grown 
without heme. In contrast, ΔhemX grown in 10 µM heme with or without pre-adaptation 
exhibits increased growth as compared to WT. The enhanced growth of ΔhemX in 10 µM 
heme is dependent on the HrtAB efflux system, as ΔhemX hrtB does not grow in 10 µM heme 
(Figure 31C). Additionally, pre-adaptation of ΔhemX in this assay can be complemented by 
providing hemX in the chromosome (Figure 32B). Similarly, ΔgtrR-hemX pOS1 PlgtgtrR is 
resistant to heme toxicity, but becomes sensitive again when hemX is introduced on the 
plasmid (Figure 32C). This is further evidence that HemX control of GtrR is not transcriptional, 
as HemX exerts its effect independent of the native gtrR promoter and ribosome binding site 
in this assay.  Further, ΔhemX is resistant to the bactericidal effects of acute heme toxicity, 
compared to a 4-log reduction in viable WT cells after 2 h in the presence of 20 µM heme 
(Figure 31D). In sum, these data demonstrate that increased cellular heme in ΔhemX is 
sufficient to activate HssRS and cause expression of HrtAB, which leads to resistance to heme 
toxicity.  
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Figure 31 Excess heme synthesis in ΔhemX activates the heme stress response. (A) 
Bioluminescence was imaged on agar medium plates containing vehicle or heme to which 
strains were streaked. All four plates were imaged simultaneously, and luminescence was 
converted to a heat map with scale shown on right. (B) XylE catechol oxidase activity was 
measured in S. aureus strains after growth in vehicle or increasing concentrations of heme. 
The data are the average of three independent experiments each with biological triplicate with 
standard deviation shown. Statistical significance was determined using a two-way ANOVA 
with Tukey’s correction for multiple comparisons, comparing log-transformed data for ΔhemX 
pOS1 PhrtxylE at each heme concentration abundance to each other strain; * P<0.01,** 
P<0.001, *** P<0.0001. (C) Growth as measured by optical density (600 nm) was monitored 
over time for S. aureus strains in medium containing either vehicle or 10 µM heme. Prior to 
the measured growth, the strains were pre-grown to stationary phase in medium containing 
vehicle or 2 µM heme. The data are the average of the means of at least three independent 
experiments each with biological triplicate, with standard error of the means shown. (D) Viable 
bacteria from S. aureus strains were enumerated after incubation for 2 h in medium containing 
vehicle or increasing amounts of heme. The data are the average of the means of three 
independent experiments each with biological triplicate with standard error of the means 
shown. The y-axis is set to the limit of detection. Statistical significance was determined using 
a two-way ANOVA with Tukey’s correction for multiple comparisons, comparing log-
transformed data for WT and ΔhrtB to ΔhemX at each heme concentration abundance; * 
P<0.01, *** P<0.0001. 
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Figure 32 Excess heme and resistance to heme toxicity in the ΔhemX mutant can be 
complemented. (A) Heme abundance was quantified using a pyridine hemochromagen 
assay in S. aureus strains. Data are combined from three independent experiments with four 
biological replicates with standard error of the mean shown. Statistical significance was 
determined by a one-way ANOVA with Tukey’s correction for multiple comparisons, 
comparing each strain against the others. **, P < 0.005. (B) Growth as measured by optical 
density (600 nm) was monitored over time for S. aureus strains in medium containing 0 or 
10 µM heme. Strains were grown overnight to the stationary phase in medium alone before 
inoculation of the growth curve. The data are the average of the means from three 
independent experiments each in biological triplicate with standard error of the mean shown. 
(C) Growth as measured by optical density (600 nm) was monitored over time for S. aureus 
strains in medium containing chloramphenicol and 0 or 12.5 µM heme. Strains were grown 
overnight to stationary phase in medium alone before inoculation of the growth curve. The 
data are means from three biological replicates with standard error of the mean shown from 
a single experiment, representative of at least three independent experiments. 
 
Inactivation of hrtB affects heme synthesis in ΔhemX 
Considering the increase in heme levels observed in ΔhemX, I hypothesized that a mutant 
lacking HemX-mediated control of heme synthesis and the heme exporter HrtB would 
accumulate further intracellular heme. To test this hypothesis, porphyrins were measured in 
WT, ΔhemX, hrtB, and ΔhemX hrtB as described above. Surprisingly, ΔhemX hrtB 
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demonstrated reduced heme levels compared to ΔhemX alone, suggesting there is some 
cross-talk between heme synthesis and efflux. The conversion of coproporphyrin to 
coproheme appears to be inhibited in ΔhemX hrtB, as this strain accumulates less coproheme 
despite equal levels of coproporphyrin (Figure 33).  
 
 
Figure 33 Inactivation of hrtB affects heme synthesis in ΔhemX [A.I.C.]. 
Uroporphyrinogen III (detected as uroporphyrin III), coproporphyrin III, coproheme III and 
heme were quantified by LC-qTOF-MS. Graphed are data from a single experiment performed 
in biological triplicate with standard error of the means shown. 
 
ΔhemX is not more sensitive to oxidants despite higher amounts of intracellular heme 
 Inactivation of hemX results in increased intracellular heme, which imparts resistance 
to heme toxicity due to activation of HssS. However, I hypothesized that ΔhemX would be 
more susceptible to oxidants, based on our previous observations that excess heme induces 
superoxide formation and oxidative damage (237). I first tested this hypothesis by assessing 
survival of WT and ΔhemX in the presence of hydrogen peroxide (Figure 34A). Contrary to 
our hypothesis, there was no difference between WT and ΔhemX. Next, I tested growth in the 
presence of the superoxide donor paraquat and again observed no difference between WT 
and ΔhemX (Figure 34B). To test whether the presence of cytoplasmic superoxide dismutase 
enzymes was masking the sensitivity of ΔhemX to superoxide, I created a mutant lacking 
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hemX and both sodA and sodM, and assessed its growth in the presence of paraquat. Again, 
no difference was noted for superoxide sensitivity in the presence or absence of HemX (Figure 
35). 
 
 
Figure 34 HemX is not more sensitive to oxidants despite higher amounts of 
intracellular heme. (A) Survival of WT and ΔhemX following incubation in 0.25% H2O2. (B) 
Growth in carbon-limited medium supplemented with glucose of WT and ΔhemX in the 
presence of vehicle or 0.5 mM paraquat. For both, graphed are the means with standard 
deviation of (A) two independent experiments in biological triplicate and (B) the means of a 
single experiment in biological quadruplicate.  
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Figure 35 Inactivation of superoxide dismutases does not sensitize ΔhemX to paraquat. 
Growth in TSB of S. aureus strains in the presence of vehicle or 10 mM paraquat as measured 
by OD600. Shown are the means from a single experiment (representative of two) in biological 
triplicate with standard deviation.  
 
Excess heme synthesis disrupts iron homeostasis  
Considering that every molecule of heme contains an atom of iron, I hypothesized that 
unregulated heme synthesis in ΔhemX would consume high levels of iron and alter iron 
homeostasis. To test this hypothesis, growth in minimal medium containing the iron chelator 
EDDHA was compared to growth in minimal medium alone. As shown in Figure 36A, 
ΔhemX::Plgt demonstrates reduced total yield after growth for 24 h relative to WT::Plgt and the 
complemented strain ΔhemX::PlgthemX. To corroborate this finding, I assessed promoter 
activity using a PisdAgfp reporter plasmid. PisdA is controlled by the ferric uptake regulator (Fur) 
and is de-repressed in iron-deplete conditions (113). Data in Figure 36B show that after growth 
in rich medium with an alternative iron chelator 2,2-dipyridyl, ΔhemX pOS1 PisdAgfp has 
enhanced PisdA activity relative to WT pOS1 PisdAgfp. These data suggest excess heme 
synthesis depletes the cell of available iron. 
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Figure 36 Unregulated heme synthesis alters iron homeostasis. (A) Growth was 
measured in minimal medium containing vehicle or 1 µM of the iron chelator EDDHA. Graphed 
is the final growth as measured by optical density at 600 nm for each S. aureus strain in 
medium containing EDDHA relative to vehicle. The data are the average of the means of five 
independent experiments each with at least biological triplicate, with standard error of the 
means shown. Statistical significance was determined using a one-way ANOVA with 
Dunnett’s correction for multiple comparisons, comparing ΔhemX::Plgt to each other strain; * 
P<0.05 (B) The activity of the iron-limitation responsive promoter PisdA was measured by 
recording fluorescence intensity over time in rich medium containing vehicle or the iron 
chelator 2,2-dipyridyl. The data are the average of the means of three independent 
experiments each with biological triplicate, with standard error of the means shown. Statistical 
significance was determined using a one-way ANOVA with Sidak’s correction for multiple 
comparisons, comparing data for WT and ΔhemX under each condition; ** P<0.01. 
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Inactivation of hemX does not alter pathogenesis in a murine model of S. aureus 
infection 
I next hypothesized that the effect of unregulated heme synthesis on iron homeostasis 
in the ΔhemX mutant would result in reduced fitness during infection, as iron uptake and 
homeostasis is a critical determinant of S. aureus virulence. I infected mice retro-orbitally 
which allows for dissemination to the organs and subsequent replication. At four days post-
infection, mice were humanely euthanized and the bacterial burdens across organs were 
enumerated. No difference was observed between WT and ΔhemX (Figure 37A). I therefore 
sought to test the hypothesis that the intrinsic heme resistance of the ΔhemX mutant is a 
fitness advantage that might compensate for the defect incurred by excess iron consumption. 
Therefore, I tested the virulence of WT, ΔhemX, hrtB, and ΔhemX hrtB in the same model, 
and found that inactivation of heme efflux in the ΔhemX background does not reduce in vivo 
fitness (Figure 37B).  
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Figure 37 Inactivation of hemX does not alter pathogenesis in a murine model of S. 
aureus infection. (A and B) bacterial burdens in noted organs following 96 h of systemic 
infection of S. aureus Newman and isogenic mutants following retroorbital injection of 
approximately 2x107 CFU. (A) Data are combined from two independent experiments and (B) 
a single experiment where each dot indicates a single mouse. No significance by Kruskal-
Wallce test with Dunn’s correction for multiple comparisons, comparing burdens between 
genotypes for each organ. In (A), gray indicates the limit of detection.  
 
Inactivation of hemX reduces GtrR abundance in heme-deficiency 
Based on the observations that HemX and cellular heme both impact GtrR abundance, 
I hypothesized that measuring GtrR abundance in a strain lacking hemX and unable to 
synthesize heme would uncover the nature of the relationship between HemX, heme, and 
GtrR. Surprisingly, GtrR abundance in ΔhemX pbgS is unchanged from ΔhemX  and lower 
than pbgS (Figure 38A), and this effect is not the result of a change in gtrR transcription in 
ΔhemX pbgS relative to pbgS (Figure 39)  Similarly, ΔhemX ΔchdC has lower levels of GtrR 
than ΔchdC (Figure 38A).  To corroborate these findings, we measured total cellular 
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porphyrins by LC-qTOF-MS as before; total extracted ion chromatograms are shown in Figure 
41. Consistent with the abundance of GtrR, porphyrin intermediates are drastically increased 
in ΔhemX relative to WT (Figure 38B). ΔchdC demonstrates intermediate buildup through 
coproheme because of elevated GtrR levels but is unable to convert coproheme to heme (see 
Figure 23A). As expected based on the reduced GtrR abundance shown in Figure 38A, the 
porphyrin intermediates are at lower levels in ΔhemX ΔchdC relative to ΔhemX or ΔchdC. 
These data suggest that heme and HemX do not independently and directly repress GtrR 
levels, because if so, removal of both would likely have an additive effect on GtrR abundance. 
Instead, the relationship between HemX, heme synthesis and GtrR levels is still unclear. 
However, the data are consistent with a model whereby the increase in GtrR levels in heme 
deficient strains is dependent on the activity of HemX. 
 
 
Figure 38 Inactivation of hemX reduces GtrR abundance in heme-deficient strains 
[A.I.C.: panel B]. (A) The abundance of GtrR was measured by LC-MRM-MS/MS in multiple 
S. aureus strains.  The data are the average of a single experiment performed in biological 
triplicate with standard deviation shown. Statistical significance was determined using a one-
way ANOVA with Dunnett’s correction for multiple comparisons, comparing GtrR abundance 
for each strain relative to WT; * P<0.05. (B) Uroporphyrinogen III (detected as uroporphyrin 
III), coproporphyrin III, coproheme III and heme were quantified by LC-qTOF-MS. Graphed is 
fold change of metabolite abundance in each mutant relative to WT, from a single experiment 
performed in biological triplicate with standard error of the means shown. 
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 Figure 39 gtrR transcription is unchanged in the ΔhemX and ΔhemX pbgS strains 
compared to the pbgS strain. Steady-state transcript abundance of gtrR mRNA isolated 
from mid-exponential growth of S. aureus strains was measured by qRT-PCR and is graphed 
as fold change relative to the WT. Data are combined from two independent experiments in 
biological triplicate with standard deviation shown. “ns” indicates no significance by one-way 
ANOVA with Dunnett’s correction for multiple comparisons, comparing fold change of the 
ΔhemX mutant and ΔhemX pbgS strains to the pbgS strain.  
 
 
 
Figure 40 Chromatograms for Figure 39 [A.I.C.]. Representative extracted ion 
chromatograms of extracted porphyrins of (A) the S. aureus WT and (B) the ΔhemX, (C) 
ΔchdC, and (D) ΔhemX ΔchdC strains. Each is quantified and shown in Figure 39B. 
Chromatograms for porphyrins above the limits of detection (250 nM) are shown. 
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Siroheme synthesis impacts GtrR levels under conditions of nitrite reduction  
 The increase in GtrR levels identified in ΔhemX likely impacts siroheme synthesis, as 
the cofactor siroheme is synthesized in S. aureus from the shared uroporphyrinogen III 
intermediate (Figure 23A; (51)). I therefore hypothesized that siroheme levels might also affect 
GtrR abundance. In experiments presented thus far, in which S. aureus is grown aerobically, 
siroheme has likely not been synthesized. The siroheme synthesis and siroheme-dependent 
nitrite reductase genes are transcribed primarily in anaerobic conditions (347). To therefore 
test the role of siroheme, I first identified conditions in which siroheme synthesis via CysG, 
and siroheme-dependent nitrite reduction by the NirD nitrite reductase, were important for 
growth. As demonstrated in Figure 41, when grown anaerobically, the growth of WT is 
enhanced when the terminal electron acceptor nitrate is provided. Mutants lacking cysG or 
nirD cannot grow to WT levels when nitrate is provided, suggesting that WT cells synthesize 
siroheme and utilize it in NirD. It is thought that in these conditions, the anaerobic nitrate 
reductase will reduce nitrate to nitrite, followed by NirD-dependent reduction of nitrite. Deletion 
of hemX does not overtly impact nitrite reduction, as ΔhemX grows well in nitrate, ΔhemX nirD 
phenocopies nirD, and ΔhemX cysG phenocopies cysG.  Therefore, GtrR abundance was 
measured by LC-MRM-MS/MS after growth in TSB containing nitrate (Figure 42). The strain 
lacking cysG, which can make heme but not siroheme, does not demonstrate elevated GtrR 
levels. However, ΔhemX cysG has reduced levels compared to ΔhemX, suggesting that 
siroheme synthesis could impact GtrR regulation.  
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Figure 41 Nitrite reductase and the cofactor siroheme are required for full growth with 
nitrate as an alternative terminal electron acceptor. Shown is growth anaerobically as 
measured by optical density (600 nm) monitored over time for S. aureus strains in medium 
containing 0 or 40 mM NO3. Strains were grown overnight to the stationary phase in medium 
alone before inoculation of the growth curve. The data are means from three independent 
experiments with at least three biological replicates.  
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Figure 42 Siroheme synthesis impacts GtrR levels under conditions of nitrite 
utilization. GtrR was measured by LC-MRM-MS/MS in multiple S. aureus strains grown 
anaerobically with NO3 provided as the terminal electron acceptor.  The data are the average 
of a single experiment performed in biological triplicate with standard deviation shown. 
Statistical significance was determined using a one-way ANOVA with Dunnett’s correction for 
multiple comparisons, comparing GtrR abundance for each strain relative to WT; *** P<0.001. 
 
HemX co-occurs with capacity for heme biosynthesis and the corresponding genes 
often co-localize on the chromosome 
We hypothesized that B. subtilis HemX and S. aureus HemX might represent only a 
subset of HemX homologs that exist across bacterial phyla and function to regulate heme 
synthesis. Diverse genomes from 978 organisms (924 bacterial and 54 archaeal) were 
analyzed for the presence of hemX. Of these, 113 encode HemX; representative members of 
this analysis are shown in Figure 43A. These newly identified homologs expand past the 
Bacillales order, of which representative HemX homologs were previously identified and 
shown to share function (75). HemX appears to represent an ancient protein family, as it is 
present in some of the evolutionarily oldest taxa, including Firmicutes, Aquificae, and 
Planctomycetes. The distribution of hemX strongly correlates with the capacity for de novo 
heme synthesis, as hemX never occurs in a genome without gtrR, and hemX never occurs 
without the capacity for de novo heme synthesis. This correlation holds across the microbial 
kingdom, where hemX never occurs in taxa lacking heme biosynthesis genes (within any 
representatives with sequenced genomes now available), e.g. Thermotogae, Fusobacteria, 
Mollicutes. Additionally, the distribution of hemX among the Firmicutes phylum supports this 
correlation; hemX is present largely in Bacillales but does not occur in Lactobacillales and 
only rarely in Clostridia (in 2 out 91 genomes analyzed), which is consistent with the frequent 
capacity for heme synthesis in Bacillales relative to Lactobacillales and Clostridia. Notably, 
the genomic co-occurrence of hemX and gtrR holds true in organisms that synthesize heme 
via any of the 3 heme biosynthetic pathways identified to date: coproporphyrin-dependent, 
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siroheme-dependent, or the classic protoporphyrin-dependent route (presented in Figure 
43A). 
Interestingly, HemX is more commonly found in organisms that encode the ability to 
synthesize both heme and siroheme (Figure 44A) than in organisms that synthesize heme 
and not siroheme. This suggests that HemX likely impacts siroheme synthesis as a 
consequence of affecting GtrR abundance by increasing abundance of uroporphyrinogen III, 
the final shared biosynthetic intermediate. The co-occurance of hemX, gtrR, and cysG is also 
consistent with our findings in Figure 6 that siroheme synthesis impacts GtrR abundance. 
Next we examined the genomic context of hemX homologs across 113 organisms 
encoding hemX, as genes associated with the same pathway or area of metabolism tend to 
colocalize in prokaryotic genomes (348). In 106 (94%) out of these 113 genomes the hemX 
and gtrR are adjacently encoded and likely co-transcribed, which is very strong indicator of 
their functional association. Seven representatives of these organisms are shown in Figure 
43B, highlighting the common genomic context of hemX, gtrR, and other genes involved in 
uroporphyrinogen synthesis (hmbS, uroS, pbgS, gsaM) and siroheme synthesis (cysG).  
 
HemX homologs share predicted membrane topology and residues  
Comparative genome analysis identified several contextual characteristics of HemX 
homologs. I therefore investigated the sequences of representative HemX homologs. A 
multiple sequence alignment revealed relatively low overall identity among HemX sequences 
(Figure 43B); however, the alignment presented in Figure 44B shows that each HemX 
homolog shares the same predicted eight transmembrane domain topology with N- and C-
termini predicted to be extra-cytoplasmic. Additionally, these divergent homologs share four 
conserved residues, all in predicted transmembrane domains. Taken together with 
comparative genome analysis, identification of HemX across bacteria uncovered a strong 
correlation between gtrR, hemX, and de novo heme synthesis, suggesting that HemX control 
of GtrR to modulate heme synthesis is a common regulatory strategy among bacteria.  
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Figure 43. hemX is conserved across bacterial phyla, and invariably co-occurs (A) and 
co-localizes (B) with gtrR [S.Y.G.].  (A) The occurrence of hemX (star), gtrR (circle), and 
alaS (square) homologs (outermost rings) was mapped onto the Tree of Life (342). The 
pathway by which protoheme is synthesized in each of the analyzed organisms is presented 
in the middle ring as follows (adapted from (51)): classic protoporphyrin-dependent pathway 
(teal), coproporphyrin-dependent path (purple) or siroheme-dependent path (gold).  Gray 
rectangles mark the organisms that contain unusual combinations of genes normally involved 
in different pathways for protoheme synthesis (hybrid paths, (51)). The absence of a rectangle 
in the middle ring indicates the absence of any known route for protoheme synthesis in an 
organism.  Likewise, the absence of a circle (gtrR) or square (alaS) in the outermost ring 
shows the inability of an organism to produce tetrapyrroles of any kind.  Note, that hemX does 
not occur in such organisms.  (B) The immediate genomic neighborhood of the hemX gene in 
seven representative genomes, with CLUSTALW alignment scores for HemX and GtrR for 
each organism relative to S. aureus. 
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Figure 44 hemX co-occurs with heme synthesis and shares conserved secondary 
structure and residues [with S.Y.G.]. (A) The genomes shown in  Figure 43 were analyzed 
for the capacity to synthesize heme or both heme and siroheme, as well as the presence 
of hemX. (B) Alignment of HemX for each of the seven representative organisms, with 
predicted transmembrane domains in yellow, conserved residues in red, and moderately 
conserved residues marked with “:” to show conservation among strongly similar amino acids 
or “.” to show conservation among weakly similar amino acids.   
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Mutations to conserved HemX residues impact function 
I hypothesized that each of the four conserved HemX residues would be important for 
function, considering their conservation among divergent HemX homologs. To test this 
hypothesis, each residue was mutagenized to an alanine in a plasmid-borne copy of hemX. 
The heme killing assay was then performed to assess whether mutagenized hemX would 
complement ΔhemX to the same extent as a wildtype copy of hemX. As shown in Figure 46A, 
H135 and G203 amino acids contribute to the function of HemX in this assay. Mutagenesis of 
Y17, on the other hand, did not impact HemX function (Figure 46A). Of note, while pOS1 
PlgthemX Y231A could be readily created by site-directed mutagenesis and replicated in E. 
coli, it was unable to be transformed into S. aureus despite multiple efforts. This suggests that 
Y231A alters HemX in a way that makes it toxic to S. aureus.  
I next created HemX-alkaline phosphatase fusions. The alkaline phosphatase enzyme 
(PhoA) is only active when translocated across the inner membrane. By creating in-frame 
translational fusions, I could experimentally validate the predicted topology of HemX and test 
the impact of mutagenesis on expression and membrane insertion of HemX in E. coli. As 
presented in Figure 46B, HemX-PhoA is blue on agar containing BCIP which demonstrates 
that when PhoA is a C-terminal fusion, it is enzymatically active and is in the periplasm. PhoA 
is inactive in the HemX:N244-PhoA fusion; N244 is in a predicted inner membrane loop 
between transmembrane domains 7 and 8 (highlighted in Figure 45). Together, these alkaline 
phosphatase fusions confirm the predicted HemX topology. Mutagenesis of the four 
conserved residues in HemX-PhoA fusions did not affect PhoA activity, suggesting that this 
mutagenesis did not impact ectopic expression of HemX or its membrane topology, and 
supporting the hypothesis that H125 and G203 impact HemX function through means 
unrelated to secondary structure.  
 
126 
 
 
Figure 45 Predicted topology and conservation of HemX. A model of HemX topology 
based on multiple transmembrane domain prediction tools. Dark blue are residues conserved 
in B. subtilis, light blue are highly similar residues in B. subtilis, red are four conserved residues 
across species indicated in Figure 44, and yellow are residues following which alkaline 
phosphatase fusions were inserted (Figure 46).  
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Figure 46 Conserved HemX residues impact function without disrupting membrane 
topology and expression. (A) Resistance to killing by heme was measured after incubation 
for 2.5 h and serial dilution of WT, ΔhemX, and ΔhemX complemented with wildtype of 
mutagenized hemX. pOS1 PlgthemX Y231A was unable to be transformed into S. aureus. (B) 
Alkaline phosphatase activity was monitored in E. coli lacking endogenous phoA gene on LB 
agar containing IPTG to induce expression of hemX:N244_phoA in frame insertion, C-terminal 
phoA fusion, and mutagenized C-terminal fusion, and BCIP to measure activity of alkaline 
phosphatase.  
 
A heme-inducible selection strain  
 Finally, I sought to design a genetic selection that could be used to further investigate 
heme homeostasis. Taking advantage of the Phrt activation by endogenous heme in the 
ΔhemX strain (Figure 31), I performed an allelic exchange of the native hrtAB genes with a 
kanamycin resistance cassette. Therefore, when HssRS activates the Phrt, kanamycin 
resistance will be induced and can be used to select for mutants with enhanced Phrt activity 
(See Chapter VI for further discussion).  
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Discussion 
In this report, I identify GtrR abundance as a critical regulator of S. aureus heme 
biosynthesis. GtrR catalyzes the initial step in the heme biosynthetic pathway, is maintained 
at low levels in WT cells proficient for heme biosynthesis, but specifically increases in 
response to heme deficiency (Figure 23B). In this study, I used heme auxotrophs to stimulate 
production of GtrR (Figure 23B,D), but I would predict that in particular niches during infection 
an increase in heme synthesis is required and GtrR abundance increases to accommodate 
this need. Host-imposed nitrosative stress, oxidative stress, and hypoxia, for example, all 
cause S. aureus to increase expression of heme-dependent cytochrome oxidases, catalase, 
and nitric oxide synthase (349-351).  
The drastic difference in GtrR enrichment between the heme auxotrophs pbgS and 
ΔchdC (Figures 23 and 38), with deficits in genes at the beginning and end of the heme 
biosynthetic pathway respectively, suggests that GtrR abundance during heme deficiency 
could be impacted by mechanisms other than heme availability. This is an interesting 
observation in light of the comparative genome analysis of hemX, which suggests that HemX 
could impact siroheme synthesis as well as heme synthesis. It is possible that GtrR 
abundance is impacted by differences in heme or siroheme abundance as well as abundance 
in earlier precursor levels, explaining the difference in GtrR levels in pbgS relative to ΔchdC.  
 In addition to the impact of heme-deficiency on GtrR, I also identify HemX as a key 
regulator of GtrR in heme-proficient cells (Figure 28A). Our broad genomic analysis has 
identified HemX homologs across bacterial phyla, suggesting that HemX control of heme 
synthesis via GtrR is a conserved strategy (Figure 43 and 44). This finding is consistent with 
the model set forth by Hederstedt and colleagues (75, 345); in both B. subtilis and now S. 
aureus, it appears that HemX regulates GtrR abundance post-transcriptionally (Figure 28B) 
through an as-yet-undefined mechanism. B. subtilis HemX is sufficient to affect GtrR 
abundance when both are expressed ectopically in E. coli (75); however, the contribution of 
heme or conserved E. coli proteins in this system is unclear, making it challenging to conclude 
if HemX directly interacts with GtrR.  Together, our findings are consistent with a model 
whereby GtrR is regulated by heme abundance and HemX through a multi-protein 
mechanism. Our finding that GtrR abundance is reduced in pbgS hemX relative to pbgS and 
not increased supports this model; heme and HemX both do not directly repress GtrR levels 
(Figure 38). In Salmonella, which do not encode HemX, GtrR is regulated by N-terminal 
proteolysis by ClpAP and Lon proteases to keep levels low (71). Additionally, Salmonella GtrR 
binds excess heme through a cysteine-170 residue (72). Mutagenesis of the N-terminus 
129 
 
degradation sequence or heme binding cysteine disrupts regulation, and it has been proposed 
that heme-bound GtrR but not apo-GtrR is a substrate for the proteases (71, 73). The 
mechanism by which Salmonella GtrR is regulated by proteases via its N-terminus and heme 
binding is not fully understood, and these regulatory amino acids are not conserved in S. 
aureus GtrR. However, here I identify that S. aureus GtrR binds heme in vitro, suggesting 
heme binding by GtrR may contribute to its regulation as observed in Gram-negative bacteria 
(Figure 26). Likewise, further work is needed to dissect the unique regulatory effects of heme 
and HemX on GtrR levels, and the potential involvement of proteolysis in this process in S. 
aureus.  
 In the absence of HemX, S. aureus synthesizes excess heme. The increase in heme 
synthesis disrupts intracellular iron homeostasis (Figure 36), which could additionally disrupt 
the expression of the staphyloferrin B siderophore biosynthetic genes, which were recently 
identified to be under the control of a transcriptional activator that is inactive when bound to 
heme (133). This altered iron homeostasis would likely reduce the function of many important 
Fe-S cluster-containing enzymes critical to staphylococcal physiology. Additionally, excess 
heme synthesized in ΔhemX activates the heme stress response (Figure 31). While activation 
of the HssRS two-component system was first recognized as the result of exogenous heme, 
our findings add to a growing body of literature that supports a model whereby endogenous 
and exogenous heme both contribute to HssRS activation and heme toxicity. We have 
previously identified small molecule activators of heme synthesis that increase intracellular 
heme and activate HssRS (36-38), adding to our genetic evidence presented in this work that 
endogenous heme activates HssRS. Here, the increase in endogenous heme in ΔhemX is 
not toxic because of the HssRS-HrtAB detoxification response. Rather, endogenous heme 
activation of HssRS provides resistance to heme toxicity through preadaptation and 
expression of hrtAB (Figure 31). The impact of inactivating hemX on the fitness of pathogens 
that do not encode the HssRS-HrtAB system would offer insight into whether dysregulated 
heme synthesis is sufficient to induce heme toxicity from within.  
While excess heme synthesis in ΔhemX results in a modest disruption of iron 
homeostasis (Figure 36), no virulence phenotype was detected in a murine model of systemic 
infection. Even in a strain lacking heme efflux, deletion of hemX has no defect. This 
underscores our lack of understanding of the mechanism of heme toxicity and the niches in 
which S. aureus experiences heme toxicity. No virulence defect has been measured in S. 
aureus mutants lacking various components of HssRS-HrtAB. In terms of the mechanism of 
heme toxicity, superoxide formation has been found to contribute, yet the ΔhemX mutant, 
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which has about ten-fold more intracellular heme, is not more sensitive to oxidants even in 
the absence of cytoplasmic superoxide dismutase enzymes. Further, HssRS has been 
bioinformatically predicted to induce expression of sodA. This would suggest heme toxicity 
could directly induce superoxide dismutase activity, but remains to be investigated (352). 
  This study found that regulating GtrR abundance is sufficient to regulate total heme 
synthesis (Figure 28), consistent with multiple reports that ALA formation is a critical rate-
limiting step in heme synthesis (51). In line with these data, exogenous ALA is sufficient to 
drive excess heme synthesis, suggesting ALA formation is a rate-limiting step in S. aureus as 
well (Figure 27) Indeed, regulation of ALA synthesis via control of either GtrR or ALAS has 
emerged as a theme across kingdoms. In metazoans, two ALAS isoforms exist and are 
impacted by heme (reviewed in (353)). In the plant model organism Arabidopsis thaliana, ALA 
synthesis is regulated by degradation of GluTR via Clp proteolysis from the N-terminus as 
well as stabilization and activation of a regulatory binding protein (334, 354). In Gram-negative 
model organisms, as mentioned above, GtrR abundance is regulated by heme and proteolysis 
(71). Our findings extend this paradigm further into the Firmicutes phylum of bacteria.  
  The specific mechanism by which HemX impacts GtrR abundance remains 
undefined. HemX is annotated as a member of the cytochrome c assembly protein family 
(Pfam:PF01578) suggesting that it may be involved in heme binding and trafficking at the 
membrane. However, S. aureus does not encode c-type cytochromes.  The capacity of HemX 
to bind heme has not been experimentally validated, but excess heme does accumulate in 
the membrane (96) suggestive of a potential role for membrane-localized heme reservoirs or 
chaperones. Additionally, three of the four highly conserved amino acids in HemX, some of 
which contribute to the function of HemX, are classical heme-coordinated amino acids and 
localized to transmembrane domains, implicating them as potential heme binding residues 
(Figure 45). The limited regions of HemX predicted to be cytoplasmic suggest that protein-
protein interactions likely occur between other membrane proteins, but no HemX-interacting 
partners have been identified to date. Additionally, GtrR residues that impact regulation by 
either heme or HemX are unknown, but would offer information as to the regulatory steps 
between heme, HemX, and GtrR, which appear to be complex. Although heme-dependent 
inhibition of S. aureus was first proposed in 1962 (112), the impact of HemX and heme on 
GtrR abundance continue to warrant further investigation. 
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Introduction 
Animals possess a variety of molecular factors that effectively sequester essential 
metals from invasive microbes, contributing to an innate immune function termed nutritional 
immunity (6, 22). Iron, as a critical cofactor for many host and bacterial enzymes, has provided 
the paradigm for our current understanding of nutritional immunity. Since the discovery of iron 
limitation by egg white ovotransferrin in the 1940s (355), mechanisms underlying nutritional 
immunity and bacterial iron scavenging have been the subject of intense study (24). Many 
vertebrate-associated bacteria encode high affinity uptake systems targeting heme, an 
abundant iron-containing porphyrin cofactor (317).  
The most abundant source of heme-iron in the mammalian host is hemoglobin, which 
mediates oxygen transport within circulating erythrocytes. The predominant adult hemoglobin 
consists of a tetramer containing two α-globin and two β-globin protein subunits, each of which 
binds a single heme molecule for coordination of oxygen. The Gram-positive bacterium 
Staphylococcus aureus is well-adapted to the human host and is a leading cause of skin and 
soft tissue infections, endocarditis, osteomyelitis, and bacteremia (318). In order to acquire 
iron during infection, S. aureus has evolved a high-affinity hemoglobin binding and heme 
extraction system, termed the iron regulated surface determinant (Isd) system (113).  
Following the lysis of proximal erythrocytes via secreted bacterial toxins, released hemoglobin 
is captured by receptors at the S. aureus cell surface (114, 118). The Isd system of S. aureus 
in part consists of cell-wall anchored IsdB and IsdH, which bind hemoglobin and haptoglobin-
hemoglobin, respectively (118, 120). 
We and others have shown that IsdB is the primary hemoglobin receptor for S. aureus 
and critical for pathogenesis in murine infection models (94, 95, 118, 134). Additionally, IsdB 
132 
 
is highly expressed in human blood (356) and a promising vaccine target (218), underscoring 
its importance in human disease. IsdB extracts heme from hemoglobin, and heme is 
subsequently passed across the cell wall and into the cytoplasm for degradation by the heme 
oxygenases IsdG and IsdI, liberating iron (122, 125, 127, 129, 357). Underscoring the 
importance of IsdB for pathogenesis, heme is the preferred iron source of S. aureus during 
murine infection (96). The cell-wall anchored IsdABCH proteins share between one and three 
NEAT (near transporter) domains for coordination of hemoglobin or heme. IsdB NEAT1 binds 
hemoglobin while NEAT2 binds heme, tethered by an intervening linker (119). Consistent with 
adaptation of S. aureus to colonize and infect humans, we previously found that S. aureus 
IsdB binds human hemoglobin more effectively than mouse hemoglobin, the common 
laboratory animal used to model S. aureus infection (94). These results suggest that 
hemoglobin variation among mammals could dictate effective heme acquisition by S. aureus 
and other Gram-positive bacteria. 
Previous work has demonstrated that pathogens can promote rapid adaptation of host 
immunity genes through repeated bouts of positive selection (358-360). While adaptation 
during such evolutionary conflicts can take many forms, theoretical and empirical studies 
indicate that an elevated rate of nonsynonymous to synonymous substitutions in protein-
coding genes is often indicative of recurrent positive selection (361, 362). To date, most 
empirical studies of host-pathogen ‘arms races’ have focused on viruses (363-366). Recently 
it was shown that the transferrin family of iron-binding proteins has undergone extremely rapid 
evolution in primates at protein surfaces bound by iron-acquisition receptors from Gram-
negative bacteria (226, 367). These findings are consistent with the existence of a long-
standing evolutionary conflict for nutrient iron, whereby mutations in iron binding proteins that 
prevent bacterial scavenging protect the host from infection and are favored by natural 
selection. While these studies have expanded our understanding for how pathogens shape 
the evolution of host genomes, they also raise the question of whether other components of 
nutritional immunity might be subject to similar evolutionary dynamics. 
In addition to its role as the principal bloodstream oxygen transporter, hemoglobin has 
provided an important biological model for diverse areas of the life sciences. Elegant studies 
have illustrated how hemoglobin variation underlies multiple instances of adaptation to high 
altitudes in diverse vertebrate taxa (368-371). Hemoglobin alleles have also likely been 
subject to balancing selection in human populations, where mutations that produce sickle-cell 
disease also confer resistance to severe malaria (372) and have reached high frequencies in 
regions where malaria is endemic. Despite its long history of study, the consequences of 
133 
 
hemoglobin evolution for vertebrate nutritional immunity remain unclear. In the present study, 
we set out to investigate the evolution of hemoglobin family proteins in primates and determine 
whether primate hemoglobin evolution impacts the ability to sequester heme-iron from 
bacterial pathogens.   
 
Materials and methods 
Bacterial strains  
Bacterial strains and plasmids used in this study are listed in Table 11. For E. coli 
strains, LB agar and broth (Fisher, Hampton, NH) were routinely used and grown at 37°C. For 
selection of pHUG21, 12.5 µg/ml of carbenicillin (Fisher) was used; for selection of pHb0.0, 5 
µg/ml of tetracycline hydrochloride (Alfa Aesar, Havermill, MA) was used, and for selection of 
pOS1 Plgt, 50 µg/ml of carbenicillin was used. Staphylococcus strains were grown at 37°C 
using tryptic soy agar and broth (Fisher), except when noted throughout. For selection of 
pOS1 Plgt 10 µg/ml chloramphenicol (Fisher) was used. Strains were streaked to agar from 
stocks stored at -80°C two days prior to each experiment.  
 
Table 11 Bacterial strains and plasmids used in Chapter V 
Bacterial Strain Source 
Escherichia coli DH5α Laboratory stock, Thermo Fisher 
Escherichia coli BL21(DE3) pHUG21 Douglas Henderson (University of Texas of the Permian Basin); 
(373) 
Staphylococcus aureus RN4220 (280) 
S. aureus Newman Laboratory stock; (277) 
S. aureus Newman ΔisdB::erm (113) 
S. argenteus MSHR1132 DSMZ 
S. schweitzeri FSA084 DSMZ 
Plasmid Source 
pHb0.0-human John Olson (Rice University); (373) 
pHb0.0-white-cheeked gibbon This work 
pHb0.0-baboon This work 
pHb0.0-talapoin This work 
pHb0.0-marmoset This work 
pHb0.0-alphahumanbetababoon This work 
pHb0.0-alphababoonbetahuman This work 
pHb0.0-human αT8K This work 
pHb0.0-human αA5D;T8K;N9H This work 
pHb0.0-human αN78Q This work 
pHb0.0-human αN78H This work 
pHb0.0-human βS9N This work 
pHb0.0-human βS9T This work 
pHb0.0-human βS9K This work 
pHb0.0-human βS9A This work 
pHb0.0-human βA76N This work 
pHb0.0-human βA76T This work 
pOS1 Plgt (314) 
pOS1 PlgtisdBaureus This work 
pOS1 PlgtisdBschweitzeri This work 
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pOS1 PlgtisdBargenteus This work 
pOS1 PlgtisdBaureus Q162R This work 
pOS1 PlgtisdBaureus S170T This work 
pOS1 PlgtisdBaureus Q162R;S170T This work 
 
Hemoglobin cloning and genetic manipulation 
We compiled a subset of α- and β-globin sequences from GenBank, as well as cloned 
α-globin orthologs from cDNA derived from primate cell lines and β-globin orthologs from 
primate genomic DNA. Hemoglobin gene sequences have been deposited in GenBank 
(accession numbers MH382883- MH382906). Hemoglobin gene sequences obtained from 
GenBank: olive baboon, bonobo, white-headed capuchin, chimpanzee, Angolan colobus, 
northern white-cheeked gibbon, green monkey, human, drill, crab-eating macaque, common 
marmoset, Sumatran orangutan, rhesus macaque, black snub-nosed monkey, golden snub-
nosed monkey, and squirrel monkey. Primate cell lines were purchased from the Coriell 
Institute for Medical Research (Camden, NJ). The α-globin orthologs cloned from cDNA (with 
Coriell ID numbers): African green monkey (PR01193), black-and-white colobus (PR00240), 
white-handed gibbon (PR01131), Western lowland gorilla (AG05251), Francois’ leaf monkey 
(PR01099), black crested mangabey (PR01215), white-faced marmoset (PR00789), Nancy 
Ma’s night monkey (PR00627), patas monkey (AG06116), proboscis monkey, Allen’s swamp 
monkey (PR01231), talapoin (PR00716), and Wolf’s guenon (PR00486). The β-globin 
orthologs cloned from genomic DNA: crested macaque (PR01215), Bolivian red howler 
monkey (PR00708), pigtailed macaque, black-crested mangabey (PR01215), Nancy Ma’s 
night monkey(PR00627), patas monkey (AG06116), white-faced saki (PR00239), island 
siamang (PR00722), Allen’s swamp monkey (PR01231), talapoin (PR00716), Spix’s saddle-
back tamarin (AG05313), dusky titi (PR00742), Wolf’s guenon (PR00486), and common 
woolly monkey (PR00525).  
Primate hemoglobin cDNA was cloned into pHb0.0 using Gibson assembly (New 
England Biolabs [NEB], Ipswich, MA). In general, each α- and β-globin gene cDNA was 
amplified from template (above) using Phusion 2X Master Mix (Thermo, Waltham, MA) with 
primers that also had homology to pHb0.0. All primers are listed in Table 12. Because of cDNA 
sequence homology, some primers were used for multiple species. pHb0.0-human was 
digested with PacI (NEB) and HindIII-HF (NEB) and the double-digested vector was isolated 
by gel purification (Qiagen, Germantown, MD). PCR products were assembled with digested 
pHb0.0, transformed to DH5α, re-isolated by mini-prep (Thermo) and were confirmed by 
sequencing (GeneWiz, South Plainfield, NJ) with pHb0.0_for/pHb0.0_rev. Globin cDNA was 
amplified for assembly as follows: white-cheeked gibbon α-globin-primers AF327/328, white-
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cheeked gibbon β-globin-primers AF329/330, baboon α-globin-primers AF331/332,  baboon 
β-globin-primers AF329/330, talapoin α-globin-primers AF327/328, talapoin β-globin-primers 
AF329/330, marmoset α-globin-primers AF333/334, and marmoset β-globin-primers 
AF329/335. 
 
Table 12 Primers used in Chapter V.  
Primer 
name 
Sequence Description 
AF327 TTCACTAAGGAGGTTAATTAATGGTGCTGTCTCCT
GCC 
Forward primer for white-cheek gibbon and 
talapoin α-globin 
AF328 TCTAGATCATTAACGGTATTTGGAGGTCAGC Reverse primer for white-cheeked gibbon 
and talapoin α-globin 
AF329 TACCGTTAATGATCTAGATAAGGAGGTAAATATAT
G 
Forward primer for white-cheeked gibbon, 
baboon, talapoin, and marmoset β-globin 
AF330 GAGCCTTTCGTTTTATTTAAGCTTCATTAGTGGTA
CTTGTGG 
Reverse primer for white-cheeked gibbon, 
baboon, and talapoin β-globin 
AF331 TTCACTAAGGAGGTTAATTAATGGTGCTGTCTCCT
GAC 
Forward primer for baboon α-globin 
AF332 TCTAGATCATTAACGGTATTTGGAGGTCAG Reverse primer for baboon α-globin 
AF333 TTCACTAAGGAGGTTAATTAATGGTGCTGTCTCC
CGCC 
Forward primer for marmoset α-globin 
AF334 TCTAGATCATTAACGGTATTTGGAGGTCAGCAC Reverse primer for marmoset α-globin 
AF335 GAGCCTTTCGTTTTATTTAAGCTTCATTAGTGGTA
CTTGTGAG 
Reverse primer for marmoset β-globin 
AF289 CTGTCTCCGGCCGATAAAAAGAACGTTAAAGCTG
CTTGG 
Forward primer to create T8K in human α-
globin 
AF290 CCAAGCAGCTTTAACGTTCTTTTTATCGGCCGGA
GACAG 
Reverse primer to create T8K in human α-
globin 
JC112 TCTCCGGCCGATAAAAAGCACGTTAAAGCTGCTT
GGGGT 
Forward primer to create N9H in human α-
globin using pHb0.0-human αT8K as 
template 
JC113 ACCCCAAGCAGCTTTAACGTGCTTTTTATCGGCC
GGAGA 
Reverse primer to create N9H in human α-
globin pHb0.0-human αT8K as template 
JC114 TAATTAATGCTGTCTCCGGACGATAAAAAGCACG
TTAAA 
Forward primer to create A5D in human α-
globin using pHb0.0-human αT8K;N9H as 
template 
JC115 TTTAACGTGCTTTTTATCGTCCGGAGACAGCATTA
ATTA 
Reverse primer to create A5D in human α-
globin using pHb0.0-human αT8K;N9H as 
template 
AF291 CACGTTGATGATATGCCGCAGGCGTTGTCTGCTC
TGTC 
Forward primer to create N78Q in human 
α-globin 
AF292 GACAGAGCAGACAACGCCTGCGGCATATCATCAA
CGTG 
 
Reverse primer to create N78Q in human 
α-globin 
AF293 CACGTTGATGATATGCCGCACGCGTTGTCTGCTCT
GTC 
 
Forward primer to create N78H in human 
α-globin 
AF294 GACAGAGCAGACAACGCGTGCGGCATATCATCA
ACGTG 
Reverse primer to create N78H in human 
α-globin 
AF303 CTGACTCCGGAAGAAAAAAACGCGGTTACTGCTC
TG 
Forward primer to create S9N in human β-
globin 
AF304 CAGAGCAGTAACCGCGTTTTTTTCTTCCGGAGTC
AG 
Reverse primer to create S9N in human β-
globin 
AF307 CTGACTCCGGAAGAAAAAACCGCGGTTACTGCTC
TG 
Forward primer to create S9T in human β-
globin 
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AF308 CAGAGCAGTAACCGCGGTTTTTTCTTCCGGAGTC
AG 
Reverse primer to create S9T in human β-
globin 
AF305 CTGACTCCGGAAGAAAAAAAGGCGGTTACTGCTC
TG 
Forward primer to create S9K in human β-
globin 
AF306 CAGAGCAGTAACCGCCTTTTTTTCTTCCGGAGTC
AG 
Reverse primer to create S9K in human β-
globin 
AF309 CTGACTCCGGAAGAAAAAGCCGCGGTTACTGCT
CTG 
Forward primer to create S9A in human β-
globin 
AF310 CAGAGCAGTAACCGCGGCTTTTTCTTCCGGAGTC
AG 
Reverse primer to create S9A in human β-
globin 
AF313 GCTTTCTCTGACGGTCTGAATCACCTGGACAACC
TG 
Forward primer to create A76N in human 
β-globin 
AF314 CAGGTTGTCCAGGTGATTCAGACCGTCAGAGAAA
GC 
Reverse primer to create A76N in human 
β-globin 
AF311 GCTTTCTCTGACGGTCTGACTCACCTGGACAACC
TG 
Forward primer to create A76T in human β-
globin 
AF312 CAGGTTGTCCAGGTGAGTCAGACCGTCAGAGAA
AGC 
Reverse primer to create A76T in human β-
globin 
pHb0.0
_for 
CGACTGGAAAGCGGGCAG Forward sequencing primer for pHb0.0 
pHb0.0
_rev 
GCATTGTTAGATTTCATACACG Reverse sequencing primer for pHb0.0 
JC343 AAATACAATTGAGGTGAACATATGATGAACAAACA
GCAAAAAG 
Forward primer to clone S. aureus isdB into 
pOS1 Plgt by Hi-fi assembly 
JC344 AAACACTACCCCCTTGTTTGGATCCTTAGTTTTTA
CGTTTTCTAGGTAATAC 
Reverse primer to clone S. aureus isdB into 
pOS1 Plgt by Hi-fi assembly 
JC218 AAATACAATTGAGGTGAACATATGATGAACAAACA
GCAAAAAG 
Forward primer to clone S. schweitzeri isdB 
into pOS1 Plgt by Hi-fi assembly 
JC219 AAACACTACCCCCTTGTTTGGATCCTTAGTTTTTA
CGTTTTCTAGGTAATAC 
Reverse primer to clone S. schweitzeri 
isdB into pOS1 Plgt by Hi-fi assembly 
JC216 AAATACAATTGAGGTGAACATATGATGAACAAACA
GCAAAAAG  
Forward primer to clone S. argenteus isdB 
into pOS1 Plgt by Hi-fi assembly 
JC217 AAACACTACCCCCTTGTTTGGATCCTTAGTTTTTA
CGTTTTCGAGG 
Reverse primer to clone S. argenteus isdB 
into pOS1 Plgt by Hi-fi assembly 
JC317 TTATGCAAGTACTGTTAAACCTG 
 
Forward primer, creates S170T in pOS1 
PlgtisdB aureus 
JC318 TGATAAAACTGTTGAGTTCC Reverse primer, creates S170T in pOS1 
PlgtisdB aureus 
JC315 AGATGGAACTAGACAGTTTTATCATTATG 
 
Forward primer, creates Q162R in pOS1 
PlgtisdB aureus 
JC316 TTCTTTTTCATTTCAAAATCAATTG Reverse primer, creates Q162R in pOS1 
PlgtisdB aureus 
JC319 TTATGCAAGTACTGTTAAACCTGCTAGAGTTATTT
TC 
Forward primer, simultaneously creates 
Q162R;S170T in pOS1 PlgtisdB aureus 
JC320 TGATAAAACTGTCTAGTTCCATCTTTCTTTTTCATT
TC 
Reverse primer, simultaneously creates 
Q162R; S170T in pOS1 PlgtisdB aureus 
JC228 TAAGAAGAGATGTAAGAGTAGGG pOS1 Plgt forward sequencing primer  
JC229 GGGGGAAACACTACCCCCTTG pOS1 Plgt reverse sequencing primer 
 
Chimeric hemoglobins were prepared by subcloning the α-globins. To enable digestion 
with XbaI (NEB) (which is sensitive to dam methylation) pHb0.0-human and pHb0.0-baboon 
were transformed and re-isolated from E. coli K1077 (dam- dcm-). The α-globin from each 
plasmid was excised by digestion with XbaI (NEB) and PacI (NEB) and the α-globin and 
double-digested pHb0.0 containing β-globin were separately isolated by gel purification 
(Qiagen). Human α-globin was ligated into pHb0.0 containing baboon β-globin and baboon α-
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globin was ligated (T4 ligase; NEB) into pHb0.0 containing human β-globin. Chimeras were 
confirmed by sequencing (GeneWiz) with pHb0.0_for/pHb0.0_rev.  
pHb0.0-human was mutagenized using QuikChange Site-Directed Mutagenesis Kit 
(Agilent, Santa Clara, CA) to create changes in the α-gene: T8K (primers AF289/290), 
T8K;N9H (primers JC112/113; using pHb0.0-human αT8K  as template), A5D;T8K;N9H 
(primers JC114/115; using pHb0.0-human αT8K;N9H  as template), N78Q (primers 
AF291/292) and N78H (primers AF293/294). Changes in the human β-gene were as follows: 
S9N (primers AF303/304), S9T (primers AF307/308), S9A (primers AF309/310), S9K (primers 
AF305/306), A76N (primers AF313/314), and A76T (primers AF311/312).  
 
Phylogenetic analyses 
 Hemoglobin DNA sequence alignments were performed using MUSCLE. Input 
phylogenies were based upon supported species relationships (374) as well as maximum-
likelihood gene phylogenies generated using PhyML with SPR topology search and 1000 
bootstraps for branch support (375). Tests for positive selection were performed using codeml 
from the PAML software package with the F3X4 codon frequency model. Likelihood ratio tests 
(LRTs) were performed by comparing pairs of site-specific models (NS sites): M1 (neutral) 
with M2 (selection), M7 (neutral, beta distribution of dN/dS<1) with M8 (selection, beta 
distribution, dN/dS>1 allowed). Additional tests which also account for synonymous rate 
variation and recombination, including FUBAR, FEL, and MEME, were performed using the 
HyPhy software package via the Datamonkey server (376, 377). Sites under positive selection 
were mapped onto three-dimensional molecular structures using Chimera (378) 
(http://www.cgl.ucsf.edu/chimera/). 
The staphylococcal DNA gyrase gene tree was generated using PhyML with 1000 
bootstraps as above. M. caseolyticus DNA gyrase was included as an outgroup. The similarity 
of IsdB in S. argenteus and S. schweitzeri relative to S. aureus is shown at right (Figure 57). 
 
Recombinant purification of hemoglobin 
Hemoglobin expression strains [BL21(DE3) pHUG21 pHb0.0] were streaked to LB 
agar containing 12.5 µg/ml carbenicillin and 5 µg/ml tetracycline hydrochloride. pHb0.0 
encodes both α- and β-globin genes, and proper folding and tetramerization require sufficient 
intracellular heme. Therefore, pHUG21, which encodes a heme uptake system is co-
expressed, and hemin is supplemented in the medium (373). Single colonies were inoculated 
into 5 ml of LB broth supplemented with 12.5 µg/ml carbenicillin and 5 µg/ml tetracycline 
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hydrochloride and grown for 14 h at 37°C with shaking. This culture was used to inoculated 
1:500 into 1.5 L of LB  with 12.5 µg/ml carbenicillin, 5 µg/ml tetracycline hydrochloride, 100 
µM hemin (prepared fresh at 10 mM in 0.1 M NaOH; Sigma St. Louis, MO), and 50 µg/ml of 
the iron chelator ethylenediamine-di(o-hydroxyphenylacetic acid (EDDHA [LGC Standards, 
Teddington, UK; solid added directly to medium) in a 2.8 L Fernbach flask. Cultures were 
grown at 37°C until OD600 reached 0.6-0.8. The expression of hemoglobin was induced with 
40 µg/ml IPTG (RPI, Mount Prospect, IL). After 16 h post-induction at 37°, cells were collected 
by centrifugation. The cell pellet was resuspended in 20 ml PBS containing 10 mM imidazole 
(Fisher), 5 mM MgCl2 (Sigma), 1 Roche Protease inhibitor tablet (Fisher), approximately 1 
mg/ml of lysozyme (Thermo) and 100 µg/ml deoxyribonuclease from bovine pancreas 
(Sigma). The cell pellet resuspended with rocking for 20 min at room temperature following 
incubation on ice. Cells were lysed using an Emulsaflex (Avestin, Ottawa, CA) then cell lysate 
was clarified by ultracentrifugation (60 min at 17,000 g). Cell lysate was applied to a 3 mL of 
Ni-NTA resin (Qiagen) in a gravity column, to which hemoglobin binds, washed with 50 ml 
PBS with10 mM imidazole. Hemoglobin was eluted with 6 ml PBS with 500 mM imidazole, 
with the first 1 ml of eluate discarded. The hemoglobin-containing eluate was dialyzed twice 
sequentially in PBS at 4°C. Purified hemoglobin was filter sterilized with a 0.45 micron filter 
and stored in aliquots in liquid nitrogen. Hemoglobin concentration was measured with 
Drabkin’s reagent (Sigma) using human hemoglobin as a standard, ranging from 2-6 mg/ml. 
Relative purity was assessed using SDS-PAGE before use in experiments, as shown in Figure 
47.  
 
Whole cell hemoglobin binding assay 
S. aureus strains were streaked on tryptic soy agar (containing 10 µg/ml 
chloramphenicol for strains carrying plasmids) and grown at 37°C for 24 h. Single colonies 
were used to inoculate 3 ml of RPMI containing 1%cas-amino acids and 0.5 mM 2,2’-dipyridyl 
(Acros/Fisher) to induce expression of chromosomal isdB) or 10 µg/ml chloramphenicol (for 
strains carrying plasmids with constitutive isdB expression). After 14-16 h of growth at 37°C 
with shaking, 2 OD600 units (except for experiments shown in part in Figure 53D and Figure 
54C, were 1 OD600 unit was used) were collected by centrifugation in a 1.5 ml Eppendorf tube. 
The cell pellet was resuspended with 1 ml PBS or PBS containing recombinant hemoglobin. 
10 µg/ml (chromosomal IsdB) or 2.5 µg/ml (plasmid-borne IsdB) of hemoglobin was used. The 
cells were incubated with hemoglobin or PBS for 30 min at 37°C with shaking, then cells were 
collected by centrifugation at 4°C at 8,000x g. Cells were washed thrice by pipetting with 1 ml 
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ice-cold PBS, centrifuging at 4°C at 8,000x g. After the final wash, the cells were resuspended 
in 30 µl 0.5 M Tris pH 8.0 (Fisher) containing 4% SDS (Fisher) and heated at 90°C for 5 min 
to remove surface bound proteins. Cells were collected by centrifugation at 8,000x g, and 
eluate was added to 6X loading buffer and heated at 90°C for 5 min. Samples were subjected 
to 12 or 17.5% SDS-PAGE and silver stained (GE, Boston, MA). Gels were imaged using an 
Alpha Innotech Alpha Imager or BioRad ChemiDoc MP imaging system. Quantification was 
performed by densitometry analysis with Image J (NIH) according to software instructions, 
and quantifying the area under the peak that corresponds to the hemoglobin band, excluding 
background density. Because of variation in stain intensity and quantity of non-specific bands 
across gels, all comparisons were made within the same gel, and relative density was 
calculated for each biological replicate within the same gel; the comparison was either to 
human hemoglobin or wildtype IsdB, depending on assay. Additionally, PBS only samples 
and S. aureus ΔisdB::erm were used to verify that hemoglobin binding in this assay is IsdB 
dependent (Figures 50, 55, and 57)  as previously observed, and that recombinant human 
hemoglobin is bound equally as well as hemoglobin purified from human blood (Figure 49) 
(94, 95).  
 
Growth with hemoglobin as sole iron source 
For hemoglobin variants (Figure 50 and Figure 52) S. aureus Newman WT was 
streaked to tryptic soy agar and allowed to grow for 24 h at 37°C. A few colonies were used 
to inoculate 5 ml of RPMI (Corning, Corning, NY) supplemented with 1% cas-amino acids 
(Fisher) and 0.5 mM of EDDHA (prepared fresh in ethanol). After growth to stationary phase 
at 37°C with shaking, approximately 16 h, 4 µl of culture was inoculated into 196 µl of medium 
in a 96 well plate and OD600 at 37°C with shaking was monitored over time using a BioTek 
plate reader. Medium was RPMI containing 1% cas-amino acids that had been stripped of 
cations with Chelex 100 (Sigma) according to manufacturer’s instructions, filter sterilized, and 
supplemented with 25 μM ZnCl2, 25 μM MnCl2, 100 μM CaCl2, and 1 mM MgCl2  (all from 
Fisher) to restore non-iron cations, 1.5 mM EDDHA to chelate any remaining free iron, and 
2.5 µg/ml of recombinant purified hemoglobin as the sole iron source.  
For IsdB variants (Figure 59), S. aureus strains were streaked to tryptic soy agar 
containing 10 µg/ml chloramphenicol and allowed to grow for 24 h at 37°C. A single colony 
was resuspended in 120 µl RPMI containing 1 µM EDDHA (prepared fresh in 0.1 M NaOH)  
and 5 µg/ml chloramphenicol and 100 µl was added to 2 ml of RPMI containing 1 µM EDDHA 
and 5 µg/ml chloramphenicol and grown at 37° with shaking in aeration tubes for 8 h. The 
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OD600 was measured of each culture and normalized to 1, and 5 µl was  used to inoculate 2 
ml of RPMI containing 1 µM EDDHA, 5 µg/ml chloramphenicol, and 50 nM hemoglobin or no 
hemoglobin (for ΔisdB pOS1 PlgtisdB). Growth was monitored every 12 h by removed 50 µl of 
culture and adding to 150 µl PBS and measuring OD600 with pathlength correction in a BioTek 
plate reader. supplemented with 1% cas-amino acids (Fisher) and 0.5 mM of EDDHA 
(prepared fresh in ethanol). Growth using hemoglobin as a sole iron source in both assays is 
IsdB dependent (94, 95, 119).  
 
Cloning of isdB 
The full length coding sequences of IsdB were amplified from genomic DNA using 
Phusion 2X High-Fidelity Master Mix (Thermo); cells were treated with  20 µg of lysostaphin 
(AMBI Products, Lawrence, NY) and DNA was isolated with Wizard genomic DNA extraction 
kit (Promega, Madison, WI). S. aureus isdB (NWMN_1040) was amplified using primers 
JC343/344, S. schweitzeri isdB (ERS140239_01018) using primers JC218/219, and S. 
argenteus isdB (SAMSHR1132_09750) using primers JC216/217. Each primer pair included 
homology to pOS1 Plgt digested with NdeI and BamHI-HF (NEB), and PCR products were 
ligated to pOS1 Plgt with Hi-Fi assembly (NEB), transformed into E. coli DH5α and re-isolated 
by miniprep (Thermo). All plasmids were sequence confirmed by sequencing (GeneWiz). 
Plasmids were transformed into RN4220 by electroporation, re-isolated, and transformed into 
S. aureus Newman ΔisdB::erm by electroporation. 
 
S. aureus IsdB site-directed mutagenesis 
pOS1 PlgtisdBaureus was subjected to site-directed mutagenesis by PCR with Q5 Site 
Directed Mutagenesis (NEB). Primer pairs with desired mutation were used to create Q162R 
(primers JC315/316), S170T (primers 317/318) and Q162R;S170T (primers JC319/320).  
PCR products were transformed to DH5α. Plasmids were isolated and subjected to Sanger 
sequencing with primers JC228/229 (GeneWiz) to identify successful incorporation of the 
desired mutation. Plasmids were transformed into RN4220 by electroporation, re-isolated, and 
transformed into S. aureus Newman ΔisdB::erm by electroporation. 
 
Quantification and statistical analysis 
Specific statistical details for each experiment can be found in the corresponding figure 
legend. Data analysis and statistical tests were performed in Prism 6 (Graphpad).  
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Results 
Parallel signatures of positive selection in primate hemoglobins at the IsdB binding 
interface 
To investigate how natural selection has shaped hemoglobin diversity in simian 
primates, orthologs of the α- and β-globin genes were cloned and sequenced from primate 
cell lines as well as compiled from publically available databases. In total, 27 α-globin and 30 
β-globin orthologs were assembled for phylogenetic analyses using the PAML and HyPhy 
software packages (Figure 47A, Materials and Methods), which use nonsynonymous and 
synonymous substitution rates to infer signatures of positive selection. Because globin genes 
have been shown to undergo gene conversion which can distort inferred phylogenetic 
relationships (379, 380), all analyses were performed using both a well-supported species 
tree as well as gene trees generated using PhyML. All tests detected significant evidence of 
positive selection acting on both α- and β-globin using both species and gene phylogenies 
(Appendix B). Multiple analyses repeatedly identified two sites in α- and β-globin exhibiting 
strong signatures of positive selection (Figure 47A). It became apparent that these rapidly-
evolving sites localized to similar regions of the α- and β-globin proteins, specifically the N-
terminal A helix and the hinge region between the E and F helices (Figure 47B). In fact, the 
two sites exhibiting signatures of selection in the α- and β-globin A helices are at homologous 
positions. These parallel signatures of selection between α- and β-globin could indicate that 
a similar selective pressure has driven this divergence between primate species. To 
investigate whether bacterial heme scavenging receptors could be one such selective 
pressure, rapidly evolving sites were mapped onto a recently solved co-crystal structure 
between human hemoglobin and the IsdB protein from S. aureus (119). Notably, all four 
rapidly-diverging hemoglobin residues are localized to the IsdB binding interface, in close 
proximity to the NEAT1 domain (Figure 47C). Together these findings indicate that primate 
globins have undergone rapid divergence at specific sites proximal to the binding interface of 
the S. aureus hemoglobin receptor IsdB. 
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Figure 47 Parallel signatures of positive selection among primate hemoglobins at the 
bacterial IsdB binding interface [M.F.B]. (A) Species phylogenies for 27 α-globin and 30 β-
globin orthologs analyzed (left). Alignments from representative species across hominoid 
(orange), Old World monkey (purple) and New World monkeys (brown) are shown, the full 
phylogenetic trees are displayed in Figures 3 and 4. Amino acid sites under positive selection 
were identified in α-globin and β-globin (blue arrows) using PAML with both species and gene 
trees (posterior probabilities >0.95). (B) Amino acid alignment of human α-globin and β-globin 
proteins. The position of conserved helices A-H are shown, and identity between globins is 
noted as conserved (*), highly similar (:), and similar (.). (C) The residues of α-globin (red) 
and β-globin (salmon) under positive selection (blue spheres) at the interface of hemoglobin 
capture by Staphylococcus aureus IsdB (gray) (PDB:5VMM). 
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Primate hemoglobin variation dictates S. aureus binding and heme-iron acquisition  
To assess how hemoglobin divergence among primates impacts recognition by S. 
aureus, recombinant hemoglobin from human, white-cheeked gibbon, baboon, talapoin, and 
marmoset were purified, providing broad representation from our phylogenetic dataset. An 
established biochemical assay was used to measure binding of hemoglobin by S. aureus, in 
which S. aureus cells recognize recombinant human hemoglobin as well as hemoglobin 
purified from blood in an IsdB-dependent manner (Figure 48). S. aureus exhibited significantly 
reduced binding of baboon and marmoset hemoglobin to the cell surface (Figure 50 and 
Figure 51). It was noted that binding patterns do not strictly match predictions based on host 
phylogeny, suggesting discrete large-effect substitutions in hemoglobin may contribute 
disproportionately to recognition by S. aureus. I next determined the ability of primate 
hemoglobins to support growth of S. aureus as the sole iron source. Consistent with whole-
cell binding data, hemoglobins that were bound by S. aureus with low affinity were unable to 
support optimal bacterial growth, indicating that the capability to bind hemoglobin is a measure 
of the ability to utilize hemoglobin as an iron source (Figure 50B and Figure 52). Together 
these results demonstrate that variation among primate globins dictates bacterial hemoglobin 
capture and heme-dependent growth. 
 
Figure 48 SDS-PAGE of representative purified hemoglobins used throughout this 
study. One microgram of hemoglobin was subjected to SDS-PAGE (4-20% gradient) and 
stained with Imperial Protein Stain. Molecular weight markers are indicated, with arrow 
showing hemoglobin band. High molecular weight bands may be contamination or unresolved 
dimers and tetramers.  
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Figure 49 The whole cell hemoglobin (Hb) binding assay allows for IsdB-dependent, 
species-specific quantification of bound recombinant Hb. A representative silver-stained 
SDS-PAGE gel used to assess binding of hemoglobin to the surface of S. aureus. 100 ng of 
purified recombinant Hb was loaded (lane 2) to demonstrate apparent molecular weight in this 
gel; the 15 kDa marker is marked, with an arrow indicating hemoglobin. The apparent 
hemoglobin band is specific to Hb, as it is not visible when S. aureus is incubated with PBS 
alone (lane 3). S. aureus binds human hemoglobin purified recombinantly from E. coli (lane 
4) as well as Hb purified from blood (lane 5). Binding of Hb purified from mouse blood (lane 
6) is significantly diminished, as first reported in (94). Binding of Hb is dependent on IsdB, as 
demonstrated in lanes 7-9, where the same hemoglobins were incubated with S. aureus 
lacking isdB.  An approximately equivalent amount of S. aureus was used, as demonstrated 
by equal loading of non-Hb specific bands across the top of the gel.  
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Figure 50 Primate hemoglobin variation dictates S. aureus binding and heme-iron 
acquisition [A.J.F]. (A) S. aureus binding of recombinant hemoglobin of various primate 
species. Iron-starved S. aureus wildtype was incubated with purified recombinant hemoglobin 
from representative species across hominoid (orange), Old World monkey (purple) and New 
World monkeys (brown). Hemoglobin bound to the surface of S. aureus was eluted and 
analyzed by SDS-PAGE; relative hemoglobin abundance was measured by densitometry 
analysis (Image J) and compared to human hemoglobin for each replicate. (B) Growth of S. 
aureus in iron-deplete medium with 2.5 µg/ml of purified recombinant hemoglobin as the sole 
iron source. Shown is the final growth yield of S. aureus after 48 hours. Growth of each 
replicate is compared to growth using human hemoglobin. For A, graphed are the means of 
two independent experiments in biological triplicate; for B, graphed are the means of three 
independent experiments with 2-3 biological replicates;  +/- SEM, ** p<0.005; *** p<0.0005 by 
two-way ANOVA with Sidak correction for multiple comparisons comparing transformed 
(percent value) data. 
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Figure 51 Representative silver stained SDS-PAGE gel of hemoglobin binding assay 
shown in Figure 50 [A.J.F.]. Each gel represents a biological replicate from independent 
binding assays. Molecular weight markers are indicated, with arrow showing hemoglobin 
band.  
 
Figure 52 Growth of S. aureus using primate hemoglobin as the sole iron source 
[A.J.F.]. Graphed are the OD600 values at 24 and 48 h post inoculation with S. aureus wildtype 
of iron-deplete medium containing hemoglobin of various primate species. Each dot is a single 
biological replicate from three independent experiments, with one replicate missing for 
talapoin.  
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Species-specific diversity in α-globin restricts heme scavenging by S. aureus 
The identification of rapidly evolving sites at the IsdB binding interface in both α-globin 
and β-globin suggest that both globin subunits may contribute to S. aureus species-specific 
hemoglobin capture. I therefore exploited the enhanced binding of human hemoglobin relative 
to baboon to examine the role of each globin subunit in this biochemical interaction. The ability 
of S. aureus to bind chimeric hemoglobins was measured, which revealed that both globins 
contribute to species-specificity (Figure 53A and Figure 54A), as chimeras containing either 
human α- or β-globin were bound more effectively than baboon hemoglobin. However, α-
globin appears to have a greater effect on human-specific capture, as the α-human β-baboon 
chimera was bound significantly better than α-baboon β-human. Focusing on phylogenetic 
variation at the protein binding interface, α-globin T8 and N78 are both proximal to the NEAT1 
domain of IsdB (Figure 53B, C). Mutagenesis of the N-terminal alpha helix of human α-globin 
revealed that substituting the Thr residue of human with the Lys residue of baboon at position 
8 reduced binding by S. aureus (Figure 53D and Figure 54). Additionally, substituting A5D, 
T8K, and N9H in human α-globin, which converts this seven amino acid region (Figure 53B) 
to that of baboon, leaves S. aureus binding nearly indistinguishable from that of baboon 
hemoglobin. These results demonstrate that the N-terminal helix of α-globin makes a major 
contribution to human-specific hemoglobin recognition by S. aureus. Next, the relative 
importance of the rapidly evolving N78 residue in α-globin was assessed, which lies N-
terminal to the sixth alpha helix (Figure 53B). Substitution of N78 to glutamine (present in 
baboon, talapoin, and other Old World primates) or to histidine, reduced binding of human 
hemoglobin (Figure 54E and Figure 55D). Thus, substitutions at multiple residues in α-globin 
that exhibit signatures of repeated positive selection are sufficient to disrupt the ability of S. 
aureus to recognize human hemoglobin.  
 
 
 
 
 
 
 
148 
 
 
 
 
 
 
149 
 
Figure 53 Species-specific diversity in α-globin restricts heme scavenging by S. aureus 
[M.F.B: panel B]. (A) Iron-starved S. aureus wildtype was incubated with purified recombinant 
hemoglobin and bound hemoglobin was quantified. (B) Species phylogenies and sequence 
alignments surrounding positions exhibiting signatures of positive selection in α-globin. (C) 
Residues 8 and 78 of human α-globin (red) interact closely with IsdB (gray) (PDB:5VMM). (D) 
Iron-starved S. aureus wildtype was incubated with purified recombinant hemoglobin, 
including mutagenized human hemoglobin, and bound hemoglobin was quantified.  (E) Iron-
starved S. aureus wildtype was incubated with purified recombinant hemoglobin, including 
mutagenized human hemoglobin, and bound hemoglobin was quantified. For A graphed are 
the means of 3 independent experiments with 2-3 biological replicates, for D, graphed are the 
means of 6 independent experiments with 2-3 biological replicates for E, graphed are the 
means of 2 independent experiments with 3 biological replicates +/- SEM, ns: no significance, 
* p<0.05, ** p<0.005; *** p<0.0005 by two-way ANOVA with Sidak correction for multiple 
comparisons comparing transformed (percent value) data. 
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Figure 54 Representative silver stained SDS-PAGE gel of hemoglobin binding assay 
shown in Figure 53 [A.J.F.: panel D]. (A) corresponds to Figure 53A, (B-C) correspond to 
Figure 53D where (C) shows results of experiments using OD600 unit of 1 instead of 2 used 
throughout, and (D) corresponds to figure 53E. Each gel represents a biological replicate from 
independent binding assays. Molecular weight markers are indicated, with arrow showing 
hemoglobin band.  
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β-globin divergence contributes to S. aureus hemoglobin binding 
S. aureus was capable of binding α-baboon β-human chimeric hemoglobin with higher 
affinity than baboon hemoglobin (Figure 53A), signifying that β-globin also contributes to S. 
aureus species-specific hemoglobin capture. Therefore, the contribution of rapidly evolving 
residues in β-globin to this binding interaction were investigated (Figure 55A). Both S9 and 
A76 interact closely with the NEAT1 domain of IsdB (Figure 55B). The effect of substituting 
human β-globin S9 and A76 with residues found in other primate species analyzed in this 
work was systematically tested, which revealed that A76 is particularly important for binding 
by S. aureus (Figure 55C and Figure 56). Notably, baboon and human β-globin differ at both 
positions 9 and 76, suggesting that these residues may contribute to the inability of IsdB to 
bind baboon hemoglobin. These differences might also explain the binding affinity between 
human hemoglobin and the α-human β-baboon chimera, observed in Figure 53A. As for α-
globin, no single residue substitution improved binding by S. aureus IsdB, consistent with the 
hypothesis that IsdB has specifically adapted to bind human hemoglobin. Taken together with 
earlier data, residues at the IsdB interface of both α-globin and β-globin contribute to 
recognition of hemoglobin by S. aureus. This is consistent with the NEAT1 domain of multiple 
IsdB monomers engaging in hemoglobin capture by binding both α- and β-globins, as 
observed in the reported co-crystal structure (119).  
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Figure 55 β-globin divergence contributes to S. aureus hemoglobin binding [M.F.B: 
panel A]. (A) Species phylogenies and sequence alignments surrounding positions exhibiting 
signatures of positive selection in β-globin. (B) Residues 9 and 76 of human β-globin (salmon) 
interact closely with IsdB (gray) (PDB:5VMM). (C) Iron-starved S. aureus wildtype was 
incubated with purified recombinant human hemoglobin or variants of human hemoglobin 
encoding variants in β-globin, and bound hemoglobin was quantified.  Graphed are the means 
of four independent experiments with 3 biological replicates +/- SEM, * p<0.05; ** p<0.005 by 
two-way ANOVA with Sidak correction for multiple comparisons comparing transformed 
(percent value) data 
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Figure 56 Representative silver stained SDS-PAGE gel of hemoglobin binding assay 
shown in Figure 55 [A.J.F. in part]. Each gel represents a biological replicate from 
independent binding assays. Molecular weight markers are indicated, with arrow showing 
hemoglobin band. 
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IsdB diversity among related staphylococcal strains impacts primate-specific 
hemoglobin capture 
Given the observed differences in S. aureus binding between diverse primate 
hemoglobins, I considered how genetic variation in IsdB might impact this interaction. The 
IsdB NEAT1 subdomain Q162R-S170T is critical for hemoglobin recognition and is completely 
conserved among more than three thousand S. aureus clinical isolates (95). Therefore, IsdB 
variation among congeneric S. argenteus and S. schweitzeri was assessed. These recently 
diverged taxa (Figure 57A) are both primate-associated and, unlike most other staphylococci, 
encode IsdB. I measured the ability of IsdB from S. argenteus and S. schweitzeri to bind 
hemoglobin by expressing them ectopically in S. aureus lacking the native isdB gene. 
Consistent with their overall high sequence identity, S. schweitzeri and S. argenteus IsdB bind 
primate hemoglobin with a similar pattern of species preference as S. aureus (Figure 57B and 
Figure 58).  However, both the IsdB of S. schweitzeri and S. argenteus display reduced 
binding of talapoin hemoglobin, and S. argenteus IsdB does not bind marmoset hemoglobin 
significantly less than human hemoglobin. These data indicate that variation among IsdB 
impacts species-specific hemoglobin capture.  
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Figure 57 IsdB diversity among related staphylococcal strains impacts primate-specific 
hemoglobin capture [M.F.B.: panel A]. (A) Maximum likelihood phylogeny of the DNA 
gyrase A protein from representative staphylococci generated using PhyML. M. caseolyticus 
was included as an outgroup. The similarity of IsdB in S. argenteus and S. schweitzeri relative 
to S. aureus is shown at right.  Bootstrap values above 80 are indicated. (B) S. aureus lacking 
native isdB but encoding constitutively expressed plasmid-borne isdB variants were incubated 
with purified recombinant hemoglobin, from hominoid (orange), Old World monkey (purple) 
and New World monkeys (brown) and bound hemoglobin was quantified. Graphed are the 
means of three independent experiments with 3 biological replicates +/- SEM, * p<0.05; **** 
p<0.0001 by two-way ANOVA with Sidak correction for multiple comparisons, comparing 
transformed (percent value) data. 
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Figure 58 Representative silver stained SDS-PAGE gel of hemoglobin binding assay 
shown in Figure 57. Each gel represents a biological replicate from independent binding 
assays. Molecular weight markers are indicated, with arrow showing hemoglobin band. 
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IsdB NEAT1 domain diversity among staphylococci modulates human 
hemoglobin recognition  
Closer examination of the Q162R-S170T region of IsdB NEAT1 revealed variation 
between related staphylococci, but no variation in the critical heme-binding region of NEAT2 
(Figure 59A). This region of NEAT1 closely interacts with the N-terminal helices of either α-
globin and β-globin, in close proximity to both discrete sites bearing signatures of adaptive 
evolution in α-globin and β-globin (Figure 59B). To determine the functional consequences of 
variation in this NEAT1 domain, Q162 and S170T were mutagenized in S. aureus IsdB to 
mimic the sequence of S. schweitzeri and S. argenteus. These residues are not expected to 
disrupt IsdB tertiary structure, as they already exist in related IsdB proteins. Variations at both 
of these positions reduced affinity for human hemoglobin, showing that in the context of S. 
aureus IsdB, Q162 and S170 are required for high affinity hemoglobin binding (Figure 59C 
and Figure 60). Additionally, mutagenized IsdB failed to fully support the growth of S. aureus 
using human hemoglobin as the sole iron source (Figure 59D), which supports the conclusion 
that this NEAT1 subdomain of S. aureus has evolved for optimal binding and utilization of 
human hemoglobin.  
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Figure 59 IsdB NEAT1 domain diversity among staphylococci modulates human 
hemoglobin recognition. (A) An alignment of the NEAT1 subdomain critical for hemoglobin 
binding shows variation among staphylococcal IsdB, while no variation is observed for the 
NEAT2 subdomain required for heme binding. (B) The Q162-S170 subdomain of NEAT1 
(cyan) is proximal to helices containing T8 and N78 of α-globin (red). (C) S. aureus lacking 
native isdB but encoding constitutively expressed plasmid-borne S. aureus isdB variants were 
incubated with purified recombinant human hemoglobin and bound hemoglobin was 
quantified. (D) Growth of S. aureus lacking native isdB but encoding constitutively expressed 
plasmid-borne S. aureus isdB variants using hemoglobin as the sole iron source was 
monitored over time. For C, graphed are the means of three independent experiments with 3 
biological replicates +/- SEM,  ** p<0.005, *** p<0.0005 by two-way ANOVA with Sidak 
correction for multiple comparisons, comparing transformed (percent value)  data. For D, 
graphed are the results of two independent experiments with six biological replicates each +/- 
standard deviation.  
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Figure 60 Representative silver stained SDS-PAGE gel of hemoglobin binding assay 
shown in Figure 59. Each gel represents a biological replicate from independent binding 
assays. Molecular weight markers are indicated, with arrow showing hemoglobin band. 
 
Discussion 
In this work we report that recurrent positive selection acting on primate α- and β-
globin proteins restricts hemoglobin binding and nutrient acquisition by pathogenic S. aureus. 
Estimations of divergence in the Staphylococcus genus have been lacking, however the Kloos 
hypothesis (381) contends that staphylococci have coevolved with their mammalian hosts 
over long evolutionary timescales. In support of this concept, primate-specificity among 
staphylococci has been reported including S. aureus, S. epidermidis, and S. warneri, as well 
as avian (S. gallinarum), equine (S. equorum), and other taxa. Indeed, it has been proposed 
that the canine-associated S. pseudointermedius diverged from S. aureus simultaneously with 
the divergence of Primate and Carnivora orders (382). Most staphylococci are commensal 
organisms, while S. aureus is uniquely adapted to infect deep tissue and cause disease. As 
such, the IsdB system is only encoded by S. aureus and closely related primate-associated 
staphylococci. By narrowing our analysis of hemoglobin evolution to primates, we are thus 
able to assess specific biological features of primate-associated staphylococci.  
An outstanding question in the study of S. aureus evolution has been determining the 
selective pressures responsible for human-specific virulence factors. S. aureus 
asymptomatically colonizes the anterior nares of approximately one third of the human 
population, yet is capable of causing a wide range of invasive diseases. While some bacterial 
colonization factors have been implicated in pathogenesis, many virulence factors have 
evolved highly specific targets that are not obviously involved in nasal colonization (383). As 
such, we cannot definitively conclude that IsdB evolution has been driven by selection during 
invasive disease. It is also likely that variation across IsdB of S. aureus, S. argenteus, and S. 
schweitzeri may be the results of antigenic variation to evade the immune system. By focusing 
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on the hemoglobin binding pocket of IsdB, we have been able to pinpoint critical variation for 
hemoglobin specificity.  
Our phylogenetic analyses revealed strikingly parallel signatures of positive selection 
between the α- and β-globin genes across primates. In particular, rapidly evolving sites in the 
α- and β-globin A-helices are predicted to be homologous based on predicted protein 
alignments. Our results suggest that these correlations reflect selection in response to NEAT 
domain-containing bacterial receptors like IsdB with conserved globin binding sites. A well-
established body of literature has shown that other selective pressures play an important role 
in patterns of hemoglobin polymorphism and divergence across vertebrates, including 
adaptation to high altitude and malaria resistance (368, 372). It is therefore possible that 
signatures of selection detected in our study have been driven by pressures other than 
nutritional immunity. Nonetheless, our empirical results demonstrate that variation in 
hemoglobins at discrete sites has important functional consequences for bacterial iron 
acquisition. 
 Previous studies have illustrated how mutations in hemoglobin coding or regulatory 
regions can have highly deleterious effects on heme binding, oxygen affinity, and protein 
stability (384, 385). In addition to aforementioned sickle-cell alleles, dozens of hemoglobin 
mutations in humans have been reported that contribute to genetic disease, including anemia 
and thalassemia (386). Thus, despite identifying particular sites that are highly divergent 
among primates, much of the globin gene content is constrained due to purifying selection. In 
future work it would be useful to determine how variation among primate globins impacts other 
biochemical functions, including as heme binding and oxygen affinity. Such insights could 
improve our fundamental understanding of hemoglobin biology and the mechanisms 
underlying human hemoglobinopathies. 
  In conclusion, this work illustrates how rapid, site-specific hemoglobin variation 
restricts heme acquisition by the prominent human pathogen S. aureus. These findings 
provide a fundamental new perspective on vertebrate globin evolution, highlighting nutritional 
immunity as a selective pressure that could strongly impact divergence and natural selection. 
Future studies will assist in illuminating how these combinations of adaptive mutations 
contribute to hemoglobin function and host physiology. Understanding the genetic and 
molecular determinants of bacterial pathogenicity is critical for developing new antimicrobial 
treatment strategies, particularly as major pathogens like S. aureus continue to develop 
resistance to existing antibiotics. Combining comparative genetics with molecular 
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experimentation in turn provides not only a historical perspective of host-microbe evolutionary 
conflict but also mechanistic insights on modern human infectious disease. 
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CHAPTER VI 
 
 
SUMMARY 
 
 
Conclusions 
Investigation into the physiology that supports the pathogenesis of Staphylococcus 
aureus in recent years has yielded a consensus that metabolism and virulence are highly 
interconnected and research can no longer study one without the other. In this thesis, I 
investigated alterations in Fe-S cluster and heme cofactor biosyntheses, as well as heme 
uptake, in order to understand critical staphylococcal processes that contributed to 
pathogenesis.  
Previous work in our laboratory had identified a small molecule, ‘882, that displayed 
two activities in S. aureus: activation of heme biosynthesis and inhibition of anaerobic growth. 
Extensive structure activity relationship studies chemically separated the two activities, 
confirming that ‘882 had two distinct targets in the cell (109). A genetic selection strategy 
identified CgoX as the enzyme activated by ‘882 to increase heme synthesis (110, 111), while 
our genetic and biochemical approaches identified SufC as the target of ‘882 which induced 
toxicity when grown in the absence of respiration (312). Inhibition of SufC led to disrupted Fe-
S cluster synthesis, which has pleiotropic effects in the cell (Chapter II). We fortuitously 
worked with strain Newman, which encodes a constitutive active virulence program through 
SaeS; this constitutive activity of SaeS is required for the toxicity of ‘882, as the dual metabolic 
drains of Fe-S cluster inhibition and excess virulence factor production inhibits growth in the 
energy-limited conditions of anaerobic growth and fermentation (Chapter II). Together, this 
work connected metabolism, essential cofactor synthesis, and control of the staphylococcal 
virulence program, consistent with other reports that pathogens must balance energy 
production and virulence to cause disease.  
There are many parallels between Fe-S cluster biogenesis and heme synthesis. Both 
require intracellular iron to form cofactors, both cofactors are required for the function of critical 
energy production, and S. aureus specific data on the regulation of biogenesis is lacking. 
Additionally, disruption of either is costly to virulence (97, 98, 283), While Fe-S cluster 
biogenesis is essential for growth; the metabolic flexibility of S. aureus allows heme synthesis 
to be dispensable, albeit costly. S. aureus can use fermentation to derive energy from carbon 
sources in the absence of an active heme-dependent respiratory chain, which enable our 
studies of heme synthesis. In this work, I genetically identified heme synthesis genes required 
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for heme biosynthesis, with two key findings: (i) neither of the two annotated glutamate-1-
semialdehyde-2,1-amniomutase genes are required for heme synthesis, and (ii) the cgoX 
gene encoding coproporphyrinogen III oxidase is required for both anaerobic and aerobic 
heme synthesis (Chapter III).  
Work in Chapter IV aimed to illuminate a major gap in knowledge highlighted by recent 
research in accurately describing the unique properties of terminal heme synthesis in S. 
aureus. Paired with a lack of understanding of the biochemical properties of heme synthesis 
is the lack of information concerning regulation of heme synthesis. Combining genetics with 
quantitative mass spectrometry, I found that abundance of GtrR is regulated in response to 
intracellular heme and the membrane protein HemX. In the absence of HemX-mediated 
regulation, excess heme is synthesized which consumes iron and thus disrupts iron 
homeostasis, activates the heme stress response, and therefore identifies GtrR as a key 
regulatory node in S. aureus heme synthesis. The nature of this regulation remains shrouded 
and will be explored further in Future Directions (below).  
Finally turning to heme acquisition by S. aureus, work in this thesis has uncovered 
rapid evolution at the interface of human hemoglobin and the hemoglobin receptor IsdB 
(Chapter V). This work helps to fill the gap in knowledge first identified by Pishchany and 
colleagues (94): the molecular mechanism by which S. aureus prefers human hemoglobin 
relative to the laboratory mouse, and how this preference has evolved. We find that primate 
hemoglobin has undergone rapid evolution at parallel positions in α- and β-globins, which 
localize to the binding interface of IsdB (Chapter V). S. aureus IsdB binds human hemoglobin 
the best, which is consistent with S. aureus having evolved to be a human-specific commensal 
and pathogen. Mutagenesis of the rapidly evolving hemoglobin residues disrupts binding by 
S. aureus, further underscoring this particular binding interface to the host-pathogen 
interaction. To further support our hypothesis, we identified variation in the hemoglobin 
binding pocket of IsdB in closely related species of Staphylococcus which reduced binding of 
human hemoglobin when recreated in S. aureus IsdB. Together our work suggests that the 
IsdB-hemoglobin binding interface has been the site of repeated bouts of evolution driven by 
IsdB. Mutations in hemoglobin of primate ancestors of humans that would disrupt the interface 
would be selected for in the population owing to resistance to S. aureus infection. Mutations 
in IsdB would be rapidly selected for and this evolutionary arms race would continue until the 
present state: modern S. aureus IsdB has evolved to best bind modern human hemoglobin.   
In sum, this work identified the protein target of a small molecule to uncover the unique 
connection between virulence and Fe-S metabolism, discovered a heme synthesis regulatory 
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process, and described evolution at the interface of heme acquisition. The findings that HemX 
and heme regulate GtrR abundance to control heme synthesis have led to further 
investigations and many outstanding questions, discussed below.  
 
Future directions 
Potential for a S. aureus heme chaperone 
 Investigation into the potential of NWMN_1486 acting as an oxygen-independent 
coproporphyrinogen III oxidase (Chapter III), which was ruled out on the basis that CgoX 
performs this function aerobically and anaerobically (Figure 22), led to the hypothesis that 
NWMN_1486 is a heme chaperone. The comparison between NWMN_1486 and E. coli HemN 
(Figure 21) identifies two critical differences: NWMN_1486 lacks the first 47 amino acids 
required for substrate recognition and the catalytic CxxxCxxCxC radical SAM motif. Indeed, 
these missing features define a sub-clade of the HemN protein family whose members include 
recently defined heme chaperones in L. lactis and E. coli (315, 316). Biochemical evidence 
supports a model that these NWMN_1486 homologs bind heme and may deliver it to heme 
dependent enzymes. Based on our laboratory’s genetic tools for studying heme homeostasis 
in S. aureus, an exciting future direction would be to confirm that NWMN_1486 is a heme 
chaperone based on biochemical characteristics, then study the impact on heme homeostasis 
of a heme chaperone. The contribution of NWMN_1486 to bNOS, KatA, and 
QoxABCD/CydABC enzymes can be quantified by measuring nitric oxide production, catalase 
activity, and respiration, respectively. Targeted detection of interactions would be assessed 
using the biomolecular fluorescence complementation using split fluorophores (387) to detect 
in vivo interactions between NWMN_1486 and potential partners. These would include the 
heme uptake system (IsdF, IsdG, IsdI), terminal heme synthesis (ChdC), respiratory enzymes 
(Qox, Cyd, and Nir proteins), bNOS, KatA, heme efflux (HrtA), and proteins which might 
regulate heme homeostasis (GtrR and HemX). Unbiased immunoprecipitations of 
NWMN_1486 paired with mass spectrometry could identify interactions that would illuminate 
the function of a staphylococcal heme chaperone.  
 
An integrated model for heme homeostasis in S. aureus 
Evidence for a heme chaperone (above), new insights from literature, and a series of 
experiments mentioned below support a model for integrated heme homeostasis in S. aureus 
that coordinates heme acquisition, synthesis, efflux, and utilization. Chapter IV of this work 
set out to define regulation of heme biosynthesis based on the simple hypothesis that heme 
synthesis is regulated to ensure sufficient heme is available but excess is not made, 
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preventing heme toxicity. Experiments in Chapter IV identified regulation based on 
intracellular heme availability, and that excess heme activates the HssRS-HrtAB heme stress 
response. It is likely, therefore, that these new findings fit into a larger coordinated heme 
homeostatic pathway that coordinates all aspects of heme. Recent studies by other groups 
have found intersections at heme uptake. Siderophore based iron acquisition is repressed 
when host heme is present, ensuring that the Isd mediated heme-iron source is utilized during 
infection (133). Secondly, the IsdG heme oxygenase was found to bind CpfC to inhibit heme 
synthesis (388). This study suggests that when host heme is available, heme synthesis is 
inhibited, either to prevent excess heme buildup or to prevent costly heme synthesis when 
other sources are available. This finding also adds support to the model that host heme can 
be incorporated into S. aureus hemoproteins. Further evidence for interactions between Isd 
heme uptake and heme utilization exist in a yeast-two-hybrid experiment in which IsdI was 
found to interact with the heme-dependent enzyme Hmp (data not shown).  
Additional experiments conducted in our laboratory support a model of integrated 
heme homeostasis. In support of HssRS responding to endogenous heme, various conditions 
have been found to activate HssRS in the absence of exogenous heme: small molecule 
activation of heme synthesis (109-111), genetic dysregulation of heme synthesis (Chapter 
IV;(389)) ; and deletion of hemoproteins (induction of HrtAB was found in ΔqoxB cydB; not 
shown) suggesting that HssRS-HrtAB can respond to changes in intracellular heme conditions 
absent of host heme. I would predict that measuring Phrt induction would find activation of 
HssRS when other hemoproteins are deleted (bNOS, katA, for example) while over-
expression of hemoproteins would reduce Phrt induction in a ΔhemX mutant, which 
synthesizes excess heme. If the model for a heme chaperone (above) is correct, a heme 
chaperone mutant might synthesize excess heme to overcome the absence of the heme 
chaperone, resulting in HssRS activation.  
Ongoing investigations into the heme chaperone, IsdI-Hmp interactions, and a genetic 
selection for heme homeostasis (below) will contribute new findings to the hypothesis of an 
integrated heme homeostatic network that modulates synthesis based on availability of host 
heme, requirement for hemoproteins, and available synthesized heme to connect synthesis 
with uptake, efflux, and utilization.  
 
Regulatory heme binding by GtrR 
Based on data in Chapter IV, which show that GtrR levels increase in heme-deficient 
strains, and that recombinant GtrR can bind heme in vitro, I propose a model in which one 
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layer of GtrR regulation is based on binding of excess heme to reduce GtrR levels through 
proteolysis or another post-translational mechanism. Efforts are underway to determine the 
heme-binding residues in GtrR by alanine mutagenesis of potential heme-coordinated 
residues (Lys, His, Tyr, Ser, Val, Asp, Ile, and Glu) in both the pOS1 PlgtgtrR and pOS1 
PlgtgtrR-hemX plasmids encoded by the ΔgtrR-hemX mutant. Utilizing the heme adaptation 
assay (Figure 32) in which ΔgtrR-hemX pOS1 PlgtgtrR is heme adapted because of excess 
GtrR, but ΔgtrR-hemX pOS1 PlgtgtrR-hemX is not heme adapted, mutagenized GtrR will be 
evaluated for enhanced or reduced heme toxicity sensitivity in the presence or absence of 
hemX to identify mutations that impact GtrR levels. Interesting mutants will be recreated in a 
plasmid encoding gtrR for recombinant protein expression, purified to homogeneity, and 
evaluated for heme binding using the Soret shift assay (Figure 25). This strategy should 
identify amino acids required for heme-dependent regulation. Additionally, the crystal 
structure of GtrR is an ongoing effort with the laboratory of Borden Lacy to further GtrR; amino 
acids identified here will be mapped to the crystal structure. Mutations that truncate GtrR to 
prevent dimerization have been created (stop codon inserted at R312 and G340). Taken 
together these integrated strategies should determine the contribution of heme binding to GtrR 
regulation, mutants incapable of binding excess heme can be used to probe how GtrR levels 
change in response to heme-deficiency and will allow for the genetic dissection of HemX-
dependent and –independent regulation.  
 
Genetic selection for disrupted heme homeostasis 
 For an unbiased approach to uncover genes required for heme homeostasis, I 
developed a genetic selection in which kanamycin resistance is induced by HssRS. Using 
allelic exchange, ahp-A3 encoding kanamycin resistance was inserted in the chromosome in 
the place of the hrtAB genes (see Chapter IV Materials and Methods). This strain hrtAB::kan 
is sensitive to kanamycin unless exogenous heme is used to activate HssRS (Figure 61A). 
Any disruption of heme homeostasis which increases HssS activation by endogenous heme 
would result in activation of Phrtkan and can be selected for by plating hrtAB::kan on kanamycin 
in the absence of exogenous heme. Kanamycin resistant mutants will be screened for (i) 
stable kanamycin resistance and (ii) activation of a second Phrt promoter, encoded in pOS1 
PhrtxylE before being subject to whole genome sequencing. I expect this strategy will select 
for mutations in known genes: activating mutations in HssRS, mutations that inactivate HemX, 
or mutations that reduce regulation of GtrR will all result in kanamycin resistance (Figure 61B). 
Outside of these expected hits, I predict that this untargeted approach will identify novel gene 
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products involved in coordinating heme synthesis. This approach will uncover mechanisms 
by which GtrR is regulated, by which HemX functions, and add to our understanding of heme 
homeostasis as described above.  
 
 
Figure 61 A genetic selection strategy to study heme homeostasis. (A) hrtAB::kan 
demonstrates heme-induced kanamycin resistance [left], which is dependent on HssRS 
[middle]. As a proof of principle, inactivation of hemX results in constitutive kanamycin 
resistance [right]. (B) A schematic of the hrtAB::kan strain which expresses kanamycin 
resistance when HssRS is induced. Mutations upstream of HssS activation (stars) could 
activate HssS in the absence of exogenous heme to induce kanamycin resistance.  
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Appendix A Table 1. Microarray data comparing NM +'882 and ΔsaeRS+'882 anaerobically*† 
 
 
NM Locus ID USA300 Locus ID fold 
change 
gene 
name 
description 
Protein synthesis 
NWMN_1175 SAUSA300_1158 -2.48 - conserved hypothetical protein  
NWMN_1497 SAUSA300_1554 -3.24 - conserved hypothetical protein TIGR00253, RNA 
binding protein 
NWMN_1957 SAUSA300_2002 -2.12 rimJ ribosomal-protein-alanine acetyltransferase, 
putative  
NWMN_2022 SAUSA300_2072 -2.21 prfA peptide chain release factor 1 
NWMN_2146 SAUSA300_2198 -2.15 rpsC/rplF ribosomal protein L6 
NWMN_2147 SAUSA300_2199 -2.12 rplV ribosomal protein L22 
NWMN_2150 SAUSA300_2202 -2.65 rplW ribosomal protein L23 
Nucleic Acid 
NWMN_0249 SAUSA300_0307 -3.24 - acid phosphatase5-nucleotidase, lipoprotein e(P4) 
family  
Co-factor Synthesis 
NWMN_0553 SAUSA300_0572 -2.1 mvk/mva
K1 
mevalonate kinase 
NWMN_0554 SAUSA300_0573 -2.37 mvaD mevalonate diphosphate decarboxylase 
NWMN_0926 SAUSA300_0959 -2.03 fmt Synthesizes THF and F-met-tRNA 
Cell signaling 
NWMN_0484 between SAUSA300_0700/ 0701 -2.11 ctsR conserved hypothetical protein: repressor of class 
III stress genes homologue 
NWMN_1130 SAUSA300_1113 -2.08 pknB  serine/threonine-protein kinase 
NWMN_1852 SAUSA300_1895 -2.13 - nitric-oxide synthase, oxygenase subunit; 
converts Arg to citrulline to make NO 
Energy Production 
NWMN_0071 SAUSA300_0129 3.6 - acetoin reductase 
NWMN_0171 SAUSA300_0229 5.05 - propionate CoA-transferase, putative;  
NWMN_1616 SAUSA300_1669 2.13 - aminotransferase, class V  
NWMN_1617 SAUSA300_1670 2.16 serA D-3-phosphoglycerate dehydrogenase 
NWMN_2110 SAUSA300_2165 -5.67 budA1 alpha-acetolactate decarboxylase; converts 
pyruvate to acetoin 
NWMN_2111 SAUSA300_2166 -4.16 budB acetolactate synthase, catabolic 
NWMN_2499 SAUSA300_2537 4.61 ldh L-lactate dehydrogenase 2 
Cell Envelope 
NWMN_0193 SAUSA300_0253 -2.59 scdA cell wall synthesis 
NWMN_1145 SAUSA300_1128 -2.01 - cell division protein FtsY, putative; FtsY recognizes 
signal peptide for secretion 
NWMN_1342 SAUSA300_1324 -2.92 - membrane protein, putative  
NWMN_1309 SAUSA300_1291 2.95 hipO peptidase, M20/M25/M40 family  
NWMN_1310 SAUSA300_1292 3.09 alr2 alanine racemase family protein, pyridoxal 
5'phosphate dependent 
Amino acid metabolism 
Cys/Met 
NWMN_0011 SAUSA300_0012 2.6 - homoserine O-acetyltransferase, putative  
NWMN_0348 SAUSA300_0357 2.82 metE 5-methyltetrahydropteroyltriglutamate--
homocysteine methyltransferase (metE)  
NWMN_0351 SAUSA300_0360 2.08 - trans-sulfuration enzyme family protein  
NWMN_0426 SAUSA300_0435 3.28 - ABC transporter, ATP-binding protein; predicted to 
transport methionine 
NWMN_0427 SAUSA300_0436 3.19 - ABC transporter, permease protein  
NWMN_0428 SAUSA300_0437 3.04 - ABC transporter, substrate-binding protein  
NWMN_2021 SAUSA300_2071 -2.13 - SAM-dependent modification methylase, HemK 
family  
Asp     
NWMN_1239 SAUSA300_1224 2.05 thrA aspartate kinase  
NWMN_1241 SAUSA300_1226 2.39 hom homoserine dehydrogenase 
NWMN_1242 SAUSA300_1227 2.71 thrC threonine synthase 
NWMN_1243 SAUSA300_1228 2.89 thrB homoserine kinase 
Lys 
NWMN_1305 SAUSA300_1286 2.18 asd aspartate-semialdehyde dehydrogenase 
NWMN_1306 SAUSA300_1287 2.39 dapA dihydrodipicolinate synthase 
NWMN_1307 SAUSA300_1288 2.65 dapB dihydrodipicolinate reductase 
NWMN_1308 SAUSA300_1289 2.74 dapD 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-
succinyltransferase 
Val, Leu, Ile     
NWMN_1960 SAUSA300_2005 4.45 ilvD dihydroxy-acid dehydratase 
NWMN_1961 SAUSA300_2006 4.48 ilvB acetolactate synthase, large subunit, biosynthetic 
type 
NWMN_1963 SAUSA300_2008 4.94 ilvC ketol-acid reductoisomerase 
NWMN_1964 SAUSA300_2009 4.64 leuA 2-isopropylmalate synthase 
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NWMN_1965 SAUSA300_2010 4.85 leuB 3-isopropylmalate dehydrogenase 
NWMN_1966 SAUSA300_2011 4.27 leuC 3-isopropylmalate dehydratase, large subunit 
NWMN_1967 SAUSA300_2012 3.97 leuD 3-isopropylmalate dehydratase, small subunit 
NWMN_1968 SAUSA300_2013 2.56 ilvA2 threonine dehydratase 
Glu 
NWMN_0145 SAUSA300_0202 2.33 - peptide ABC transporter, permease protein  
NWMN_0147 SAUSA300_0204 2.29 ggt gamma-glutamyltranspeptidase; releases cysteine 
from glutathione 
NWMN_0436 SAUSA300_0445 2.42 gltB glutamate synthase, large subunit 
NWMN_0437 SAUSA300_0446 2.72 gltD glutamate synthase, small subunit 
His 
NWMN_0692 SAUSA300_0708 2.68 hisC histidinol-phosphate aminotransferase 
 
Transport 
NWMN_0856 SAUSA300_0887 2.43 oppB oligopeptide ABC transporter, permease 
protein 
NWMN_0857 SAUSA300_0888 2.27 oppC oligopeptide ABC transporter, permease protein 
NWMN_0858 SAUSA300_0889 2.47 oppD oligopeptide ABC transporter, ATP-binding protein 
NWMN_0859 SAUSA300_0890 2.86 oppF oligopeptide ABC transporter, ATP-binding protein 
NWMN_0860 SAUSA300_0891 2.69 oppA oligopeptide ABC transporter, oligopeptide-binding 
protein  
NWMN_2303 SAUSA300_2349 -2.27 - formate/nitrite transporter family protein  
NWMN_2500 SAUSA300_2538 2.32 - amino acid permease  
NWMN_2581 SAUSA300_2616 2.75 - cobalt transport family protein  
NWMN_2582 SAUSA300_2617 3.67 - ABC transporter, ATP-binding protein  
NWMN_2584 SAUSA300_2619 3.61 - conserved hypothetical protein  
Virulence factors 
and exoproteins 
NWMN_0362 SAUSA300_0370 68.74 - staphylococcal enterotoxin, putative  
NWMN_0388 SAUSA300_0395 12.85 ssl1nm exotoxin 3, putative  
NWMN_0389 SAUSA300_0396 23.62 ssl2nm/
set7 
exotoxin 1, putative  
NWMN_0390 SAUSA300_0397 7.81 ssl3nm exotoxin 8  
NWMN_0392 SAUSA300_0399 5.48 ssl5nm exotoxin 3  
NWMN_0393 SAUSA300_0400 5.81 ssl6nm exotoxin  
NWMN_0395 SAUSA300_0402 21.35 ssl8nm exotoxin 12  
NWMN_0396 SAUSA300_0403 29.33 ssl9nm exotoxin 5, putative  
NWMN_0397 SAUSA300_0404 14.54 ssl10 exotoxin 4, putative  
NWMN_0758 SAUSA300_0774 53.71 empbp/
ssp 
secretory extracellular matrix and plasma binding 
protein 
NWMN_1067 SAUSA300_1053 60.29 - hypothetical protein, formyl peptide receptor-like 1 
inhibitory protein 
NWMN_1246 SAUSA300_1232 2.25 katA catalase  
NWMN_1075 SAUSA300_1059 14.62 - exotoxin 1, putative  
NWMN_1076 SAUSA300_1060 22.31 - exotoxin 4, putative  
NWMN_1077 SAUSA300_1061 69.11 - exotoxin 3, putative  
NWMN_1872 SAUSA300_1917 137.5 map map protein, authentic frameshift 
NWMN_1926 SAUSA300_1973 64.33 hlb phospholipase C 
NWMN_2318 SAUSA300_2365 94.07 hlgA gamma-hemolysin, component A 
NWMN_2320 SAUSA300_2367 135.74 hlgC gamma hemolysin, component C 
NWMN_2321 SAUSA300_2368 47.03 hlgB gamma hemolysin, component B 
Hypothetical     
NWMN_0150 SAUSA300_0207 2.45 - M23/M37 peptidase domain protein  
NWMN_0206 SAUSA300_0266 -2.5 - hypothetical protein  
NWMN_0402 SAUSA300_0409 114.43 - hypothetical protein  
NWMN_0896 SAUSA300_0929 2.1 - hypothetical protein  
NWMN_2370 SAUSA300_2417 2.39 - transporter, putative  
NWMN_2579 SAUSA300_2614 2.06 - hypothetical protein  
NWMN_2608 SAUSA300_2642 -2.71 - conserved hypothetical protein  
*bold indicates genes for which the corresponding NARSA mutant allele was transduced into NM 
†transcript fold change in NM +'882 relative to ΔsaeRS+'882 
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Appendix A-Table 2.  Proteomic results of protein abundance changes  in NM WT treated with 20 µM ‘882 relative to DMSO1 
Protein 
(accession 
number) 
‘882 
peptides2 
DMSO 
peptides2 
t-test 
fold-
change 
Locus NM locus ID Product Name 
gi|151221945 120 193 3.51E-05 1.6083 prsA NWMN_1733 peptidyl-prolyl cis/trans-isomerase 
gi|151220665 185 97 8.21E-05 -1.9072 metS NWMN_0453 methionyl-tRNA synthetase 
gi|151221286 34 66 8.92E-05 1.9412 - NWMN_1074 hypothetical protein NWMN_1074 
gi|151220882 42 15 9.89E-05 -2.8 nagA NWMN_0670 
N-acetylglucosamine-6-phosphate 
deacetylase 
gi|151221298 284 148 0.000101162 -1.9189 - NWMN_1086 hypothetical protein NWMN_1086 
gi|151221814 112 55 0.000108276 -2.0364 - NWMN_1602 proline dipeptidase-like protein 
gi|151221378 152 777 0.000124937 5.1118 rpsB NWMN_1166 30S ribosomal protein S2 
gi|151221577 184 89 0.000157226 -2.0674 asnC NWMN_1365 asparaginyl-tRNA synthetase 
gi|151220323 26 7 0.000177551 -3.7143 - NWMN_0111 
heme-degrading monooxygenase 
IsdI 
gi|151221350 7 25 0.000219511 3.5714 - NWMN_1138 
fatty acid biosynthesis 
transcriptional regulator 
gi|151220765 25 8 0.000274562 -3.125 mvaK1 NWMN_0553 mevalonate kinase 
gi|151221480 118 233 0.000352366 1.9746 parC NWMN_1268 DNA topoisomerase IV subunit A 
gi|151221001 151 98 0.000381207 -1.5408 sufB NWMN_0789 FeS assembly protein SufB 
gi|151220621 6 17 0.000388171 2.8333 lpl6nm NWMN_0409 staphylococcal tandem lipoprotein 
gi|151222473 16 1 0.000447238 -16 - NWMN_2261 
ABC transporter ATP-binding 
protein 
gi|151221781 391 198 0.000470873 -1.9747 tig NWMN_1569 trigger factor 
gi|151221893 263 186 0.000485872 -1.414 pckA NWMN_1681 
phosphoenolpyruvate 
carboxykinase 
gi|151222821 47 159 0.000499214 3.383 - NWMN_2609 
chromosome partioning ParB 
family protein 
gi|151221315 322 187 0.000525274 -1.7219 ileS NWMN_1103 isoleucyl-tRNA synthetase 
gi|151222723 24 48 0.000608185 2 - NWMN_2511 hypothetical protein NWMN_2511 
gi|151221053 99 48 0.000740347 -2.0625 cdr NWMN_0841 coenzyme A disulfide reductase 
gi|151222358 107 307 0.000767274 2.8692 rpsC NWMN_2146 30S ribosomal protein S3 
gi|151222347 69 318 0.000798972 4.6087 rpsE NWMN_2135 30S ribosomal protein S5 
gi|151221385 161 92 0.000849973 -1.75 proS NWMN_1173 prolyl-tRNA synthetase 
gi|151222221 262 858 0.000913352 3.2748 atpA NWMN_2009 F0F1 ATP synthase subunit alpha 
gi|151222721 22 57 0.000940196 2.5909 - NWMN_2509 choline dehydrogenase 
gi|151222398 55 26 0.000942743 -2.1154 - NWMN_2186 
acyl-CoA dehydrogenase-related 
protein 
gi|151221947 139 234 0.000988493 1.6835 - NWMN_1735 hypothetical protein NWMN_1735 
gi|151220881 32 64 0.001026183 2 fruA NWMN_0669 fructose specific permease 
gi|151221427 16 4 0.001057565 -4 - NWMN_1215 hypothetical protein NWMN_1215 
gi|151222459 35 23 0.001057565 -1.5217 idi NWMN_2247 
isopentenyl pyrophosphate 
isomerase 
gi|151220693 349 185 0.001059972 -1.8865 - NWMN_0481 pyridoxal biosynthesis lyase PdxS 
gi|151222266 53 22 0.001158554 -2.4091 - NWMN_2054 
haloacid dehalogenase-like 
hydrolase 
gi|151221390 196 754 0.001194869 3.8469 infB NWMN_1178 translation initiation factor IF-2 
gi|151221838 320 159 0.001220027 -2.0126 acs NWMN_1626 acetyl-CoA synthetase 
gi|151220217 335 879 0.001278516 2.6239 gyrA NWMN_0005 DNA gyrase A subunit 
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gi|151220675 298 217 0.00128691 -1.3733 prs NWMN_0463 
ribose-phosphate 
pyrophosphokinase 
gi|151221795 297 816 0.001290135 2.7475 polA NWMN_1583 DNA polymerase I 
gi|151221789 40 22 0.001292978 -1.8182 dnaI NWMN_1577 primosomal protein DnaI 
gi|151221065 60 31 0.001297077 -1.9355 - NWMN_0853 
3-oxoacyl-(acyl carrier protein) 
synthase III 
gi|151220939 201 422 0.001323433 2.0995 uvrA NWMN_0727 excinuclease ABC subunit A 
gi|151220681 4 12 0.001323897 3 divIC NWMN_0469 cell-division initiation protein 
gi|151221703 22 6 0.001323897 -3.6667 comEB NWMN_1491 
competence protein ComEB 
required for DNA binding and 
uptake 
gi|151220987 236 706 0.001326405 2.9915 - NWMN_0775 hypothetical protein NWMN_0775 
gi|151221499 201 347 0.001376803 1.7264 femB NWMN_1287 
methicillin resistance expression 
factor FemB 
gi|151221323 44 22 0.001473119 -2 pyrB NWMN_1111 
aspartate carbamoyltransferase 
catalytic subunit 
gi|151220659 42 112 0.001508079 2.6667 - NWMN_0447 hypothetical protein NWMN_0447 
gi|151222650 150 349 0.001539661 2.3267 poxB NWMN_2438 pyruvate oxidase 
gi|151220725 463 182 0.001574935 -2.544 - NWMN_0513 chaperone protein HchA 
gi|151222352 57 124 0.001779752 2.1754 rplE NWMN_2140 50S ribosomal protein L5 
gi|151221372 83 175 0.001854005 2.1084 topA NWMN_1160 DNA topoisomerase I 
gi|151221645 115 276 0.001854908 2.4 efp NWMN_1433 elongation factor P 
gi|151220933 289 1600 0.002008593 5.5363 - NWMN_0721 sigma 54 modulation protein 
gi|151222474 11 1 0.002110646 -11 - NWMN_2262 hypothetical protein NWMN_2262 
gi|151220327 351 50 0.002205477 -7.02 - NWMN_0115 hypothetical protein NWMN_0115 
gi|151221870 181 72 0.002269462 -2.5139 putA NWMN_1658 proline dehydrogenase 
gi|151221141 63 75 0.002278426 1.1905 qoxB NWMN_0929 quinol oxidase polypeptide I QoxB 
gi|151222219 706 1372 0.002291477 1.9433 atpD NWMN_2007 F0F1 ATP synthase subunit beta 
gi|151221082 400 219 0.002293937 -1.8265 - NWMN_0870 oligoendopeptidase F 
gi|151220954 372 127 0.002314277 -2.9291 pgk NWMN_0742 phosphoglycerate kinase 
gi|151222223 97 263 0.002397959 2.7113 atpF NWMN_2011 F0F1 ATP synthase subunit B 
gi|151221643 68 117 0.002449811 1.7206 accC NWMN_1431 
acetyl-CoA carboxylase biotin 
carboxylase subunit 
gi|151222268 282 177 0.002473311 -1.5932 glmS NWMN_2056 
glucosamine--fructose-6-
phosphate aminotransferase 
gi|151220694 49 34 0.002570261 -1.4412 - NWMN_0482 
glutamine amidotransferase 
subunit PdxT 
gi|151222055 14 29 0.002570261 2.0714 pcrA NWMN_1843 ATP-dependent DNA helicase 
gi|151221406 72 126 0.002659609 1.75 recA NWMN_1194 recombinase A 
gi|151222220 40 101 0.002765088 2.525 atpG NWMN_2008 
F0F1 ATP synthase subunit 
gamma 
gi|151222084 59 112 0.002771281 1.8983 map NWMN_1872 MHC class II analog protein 
gi|151222797 539 232 0.002826024 -2.3233 - NWMN_2585 hypothetical protein NWMN_2585 
gi|151221709 15 2 0.002890007 -7.5 - NWMN_1497 hypothetical protein NWMN_1497 
gi|151221805 152 87 0.002890007 -1.7471 pfk NWMN_1593 6-phosphofructokinase 
gi|151221716 38 67 0.002915557 1.7632 - NWMN_1504 hypothetical protein NWMN_1504 
gi|151220867 162 357 0.002961871 2.2037 - NWMN_0655 MarR family regulatory protein 
gi|151221021 61 152 0.003000305 2.4918 - NWMN_0809 hypothetical protein NWMN_0809 
gi|151220711 47 254 0.003044078 5.4043 rplK NWMN_0499 50S ribosomal protein L11 
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gi|151220712 64 123 0.003061925 1.9219 rplA NWMN_0500 50S ribosomal protein L1 
gi|151220579 14 5 0.003125589 -2.8 - NWMN_0367 
phosphoglycerate mutase family 
protein 
gi|151221519 20 11 0.003125589 -1.8182 dapB NWMN_1307 dihydrodipicolinate reductase 
gi|151222130 2 11 0.003125589 5.5 - NWMN_1918 phage anti repressor 
gi|151222349 49 85 0.003125589 1.7347 rplF NWMN_2137 50S ribosomal protein L6 
gi|151220947 18 43 0.00334135 2.3889 - NWMN_0735 hypothetical protein NWMN_0735 
gi|151221420 82 36 0.003436385 -2.2778 glpK NWMN_1208 glycerol kinase 
gi|151220404 138 200 0.003441777 1.4493 - NWMN_0192 
glycosyl transferase group 2 family 
protein 
gi|151221872 36 5 0.003441777 -7.2 ribA NWMN_1660 riboflavin biosynthesis protein 
gi|151221641 39 15 0.003448385 -2.6 nusB NWMN_1429 
transcription antitermination 
protein NusB 
gi|151221253 199 73 0.00348785 -2.726 isdA NWMN_1041 
iron-regulated heme-iron binding 
protein IsdA 
gi|151222070 200 517 0.003502201 2.585 - NWMN_1858 aldehyde dehydrogenase 
gi|151220763 232 156 0.003601086 -1.4872 eutD NWMN_0551 phosphotransacetylase 
gi|151221452 60 30 0.003602233 -2 metL NWMN_1240 homoserine dehydrogenase 
gi|151220219 94 38 0.003792218 -2.4737 hutH NWMN_0007 histidine ammonia-lyase 
gi|151220733 40 21 0.003862848 -1.9048 - NWMN_0521 
hydrolase, haloacid dehalogenase-
like protein 
gi|151222140 20 82 0.004099666 4.1 lukS NWMN_1928 
leukocidin/hemolysin toxin subunit 
S 
gi|151221485 71 31 0.004300386 -2.2903 msrA NWMN_1273 methionine sulfoxide reductase A 
gi|151222243 115 64 0.004361708 -1.7969 pyrG NWMN_2031 CTP synthetase 
gi|151220721 1828 891 0.004457132 -2.0516 fus NWMN_0509 elongation factor G 
gi|151220593 273 171 0.004465448 -1.5965 guaA NWMN_0381 GMP synthase 
gi|151220637 57 21 0.004493713 -2.7143 metB NWMN_0425 cystathionine gamma-synthase 
gi|151221379 1117 593 0.004722975 -1.8836 tsf NWMN_1167 elongation factor Ts 
gi|151221162 445 160 0.004932672 -2.7813 - NWMN_0950 
phosphoenolpyruvate-protein 
phosphatase 
gi|151220685 282 559 0.004945259 1.9823 ftsH NWMN_0473 
ATP-dependent metalloprotease 
FtsH 
gi|151221301 37 62 0.005023998 1.6757 mraW NWMN_1089 
S-adenosyl-methyltransferase 
MraW 
gi|151222320 50 24 0.005179626 -2.0833 - NWMN_2108 HAD family hydrolase 
gi|151221761 12 1 0.005328128 -12 rplU NWMN_1549 50S ribosomal protein L21 
gi|151220999 113 62 0.005329977 -1.8226 sufS NWMN_0787 
cysteine desulfurase SufS 
subfamily protein 
gi|151220634 32 15 0.005784564 -2.1333 - NWMN_0422 hypothetical protein NWMN_0422 
gi|151222274 105 69 0.005820687 -1.5217 glmM NWMN_2062 phosphoglucosamine-mutase 
gi|151221756 17 29 0.005820687 1.7059 ruvA NWMN_1544 
Holliday junction DNA helicase 
RuvA 
gi|151221815 115 61 0.006107227 -1.8852 ald NWMN_1603 alanine dehydrogenase 
gi|151220378 10 37 0.006107227 3.7 coa NWMN_0166 staphylocoagulase precursor 
gi|151221252 35 8 0.006107227 -4.375 isdB NWMN_1040 
iron-regulated heme-iron binding 
protein IsdB 
gi|151221720 39 11 0.006122257 -3.5455 accB NWMN_1508 
acetyl-CoA carboxylase, biotin 
carboxyl carrier protein 
gi|151221740 19 82 0.006219215 4.3158 - NWMN_1528 hypothetical protein NWMN_1528 
gi|151221328 47 16 0.006340451 -2.9375 pyrE NWMN_1116 orotate phosphoribosyltransferase 
gi|151221867 92 376 0.006427365 4.087 - NWMN_1655 
staphylococcal accessory 
regulator Rot 
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gi|151220401 139 80 0.006721869 -1.7375 ispD NWMN_0189 
2-C-methyl-D-erythritol 4-
phosphate cytidylyltransferase 
gi|151221261 40 17 0.006777398 -2.3529 pheS NWMN_1049 
phenylalanyl-tRNA synthetase 
subunit alpha 
gi|151222607 34 18 0.007182329 -1.8889 gtaB NWMN_2395 
UTP-glucose-1-phosphate 
uridyltransferase 
gi|151221308 460 801 0.007404485 1.7413 ftsZ NWMN_1096 cell division protein FtsZ 
gi|151221334 42 89 0.00743653 2.119 priA NWMN_1122 primosomal protein N' 
gi|151222808 46 22 0.007467447 -2.0909 - NWMN_2596 N-acetyltransferase family protein 
gi|151221410 12 2 0.007490434 -6 porA NWMN_1198 
pyruvate flavodoxin ferredoxin 
oxidoreductase, alpha subunit 
gi|151221476 9 4 0.007490434 -2.25 - NWMN_1264 hypothetical protein NWMN_1264 
gi|151222139 19 39 0.007490434 2.0526 lukF NWMN_1927 
leukocidin/hemolysin toxin subunit 
F 
gi|151222497 14 9 0.007490434 -1.5556 - NWMN_2285 hypothetical protein NWMN_2285 
gi|151222023 3 13 0.007490434 4.3333 - NWMN_1811 phage anti-repressor 
gi|151220226 62 103 0.007640728 1.6613 rplI NWMN_0014 50S ribosomal protein L9 
gi|151221624 113 59 0.007760254 -1.9153 zwf NWMN_1412 
glucose-6-phosphate 1-
dehydrogenase 
gi|151220827 13 20 0.007762603 1.5385 - NWMN_0615 hypothetical protein NWMN_0615 
gi|151220894 22 8 0.007762603 -2.75 pabA NWMN_0682 
para-aminobenzoate synthase 
component II 
gi|151221745 48 21 0.007875643 -2.2857 hisS NWMN_1533 histidyl-tRNA synthetase 
gi|151221397 15 28 0.007966202 1.8667 ftsK NWMN_1185 
DNA translocase FtsK/SpoIIIE 
family protein 
gi|151221831 3 15 0.008049893 5 - NWMN_1619 
PTS system, N-
acetylglucosamine-specific IIBC 
component 
gi|151222133 99 190 0.008089287 1.9192 - NWMN_1921 phage cI-like repressor 
gi|151221160 128 290 0.008095296 2.2656 - NWMN_0948 hypothetical protein NWMN_0948 
gi|151221191 259 182 0.008104933 -1.4231 pycA NWMN_0979 pyruvate carboxylase 
gi|151220953 1456 1005 0.008152054 -1.4488 gapA NWMN_0741 
glyceraldehyde 3-phosphate 
dehydrogenase 1 
gi|151221638 78 250 0.008169004 3.2051 ahrC NWMN_1426 arginine repressor 
gi|151221731 151 64 0.008258683 -2.3594 alaS NWMN_1519 alanyl-tRNA synthetase 
gi|151222284 108 45 0.008801167 -2.4 - NWMN_2072 hypothetical protein NWMN_2072 
gi|151220813 652 1172 0.008813809 1.7975 - NWMN_0601 hypothetical protein NWMN_0601 
gi|151221652 304 115 0.0089689 -2.6435 gcvPA NWMN_1440 glycine dehydrogenase subunit 1 
gi|151221816 747 448 0.009096334 -1.6674 - NWMN_1604 
universal stress protein family 
protein 
gi|151220344 61 30 0.009121205 -2.0333 ipdC NWMN_0132 indole-3-pyruvate decarboxylase 
gi|151221012 49 24 0.009140759 -2.0417 - NWMN_0800 hydrolase 
gi|151220268 82 147 0.009201503 1.7927 sarH1 NWMN_0056 accessory regulator A-like protein 
gi|151220793 33 60 0.009307737 1.8182 - NWMN_0581 
iron compound ABC transporter, 
iron compound-binding protein 
gi|151220544 41 20 0.009337848 -2.05 - NWMN_0332 NADH-dependent FMN reductase 
gi|151221127 157 97 0.009411161 -1.6186 memB NWMN_0915 naphthoate synthase 
gi|151220351 87 127 0.009436154 1.4598 hsdR NWMN_0139 
type-I restriction-modification 
system restriction endonuclease 
subunit 
gi|151221780 79 119 0.009662137 1.5063 clpX NWMN_1568 
ATP-dependent protease ATP-
binding subunit ClpX 
gi|151222422 112 47 0.009799436 -2.383 - NWMN_2210 
formate dehydrogenase-like 
protein 
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gi|151222823 51 21 0.009813833 -2.4286 gidA NWMN_2611 
tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme GidA 
gi|151222407 181 486 0.010006124 2.6851 sarR NWMN_2195 
staphylococcal accessory 
regulator R 
gi|151220955 321 212 0.010046876 -1.5142 tpiA NWMN_0743 triosephosphate isomerase 
gi|151220648 17 4 0.01005971 -4.25 gltB NWMN_0436 glutamate synthase, large subunit 
gi|151221481 9 29 0.01011969 3.2222 - NWMN_1269 
sodium:alanine symporter family 
protein 
gi|151221517 59 37 0.010127315 -1.5946 asd NWMN_1305 
aspartate semialdehyde 
dehydrogenase 
gi|151222054 84 142 0.010142733 1.6905 lig NWMN_1842 DNA ligase, NAD-dependent 
gi|151220734 103 23 0.010177401 -4.4783 - NWMN_0522 hypothetical protein NWMN_0522 
gi|151221847 63 32 0.010255349 -1.9688 - NWMN_1635 hypothetical protein NWMN_1635 
gi|151222260 162 76 0.010304362 -2.1316 - NWMN_2048 hypothetical protein NWMN_2048 
gi|151221884 774 445 0.010350876 -1.7393 - NWMN_1672 putative translaldolase 
gi|151221490 127 88 0.010547909 -1.4432 - NWMN_1278 hypothetical protein NWMN_1278 
gi|151220333 25 10 0.010636628 -2.5 - NWMN_0121 formate dehydrogenase 
gi|151220216 207 375 0.010919323 1.8116 gyrB NWMN_0004 DNA gyrase B subunit 
gi|151221395 204 134 0.010978961 -1.5224 pnpA NWMN_1183 
polynucleotide 
phosphorylase/polyadenylase 
gi|151221343 17 7 0.011056493 -2.4286 - NWMN_1131 hypothetical protein NWMN_1131 
gi|151221813 83 43 0.011056493 -1.9302 - NWMN_1601 
metallo-beta-lactamase 
superfamily protein 
gi|151220730 22 6 0.011354999 -3.6667 - NWMN_0518 hypothetical protein NWMN_0518 
gi|151220397 90 34 0.011446913 -2.6471 - NWMN_0185 
2-C-methyl-D-erythritol 4-
phosphate cytidylyltransferase 
gi|151221348 149 98 0.011639195 -1.5204 - NWMN_1136 hypothetical protein NWMN_1136 
gi|151221807 30 80 0.011825976 2.6667 accD NWMN_1595 
acetyl-CoA carboxylase subunit 
beta 
gi|151221942 54 122 0.011872451 2.2593 - NWMN_1730 hypothetical protein NWMN_1730 
gi|151220236 96 174 0.011930492 1.8125 - NWMN_0024 hypothetical protein NWMN_0024 
gi|151221938 97 45 0.012026824 -2.1556 - NWMN_1726 RNAIII-activating protein TRAP 
gi|151221368 357 173 0.012224495 -2.0636 sucD NWMN_1156 
succinyl-CoA synthetase subunit 
alpha 
gi|151222749 30 74 0.012296869 2.4667 isaB NWMN_2537 immunodominant antigen B 
gi|151221828 33 18 0.012348477 -1.8333 - NWMN_1616 aminotransferase, class V 
gi|151221856 235 115 0.012568373 -2.0435 - NWMN_1644 dipeptidase PepV 
gi|151220717 1321 2382 0.012698763 1.8032 rpoC NWMN_0505 
DNA-directed RNA polymerase 
subunit beta' 
gi|151220325 566 365 0.012892338 -1.5507 aldA NWMN_0113 
aldehyde dehydrogenase-like 
protein 
gi|151220291 38 61 0.012939917 1.6053 - NWMN_0079 hypothetical protein NWMN_0079 
gi|151220640 47 75 0.012950548 1.5957 - NWMN_0428 
ABC transporter, substrate-binding 
protein 
gi|151220570 113 190 0.013005517 1.6814 - NWMN_0358 
single-strand DNA-binding family 
protein 
gi|151222740 30 10 0.013011949 -3 estA NWMN_2528 tributyrin esterase 
gi|151221125 54 14 0.013011949 -3.8571 memD NWMN_0913 
2-succinyl-6-hydroxy-2,4-
cyclohexadiene-1- carboxylic acid 
synthase 
gi|151220821 11 5 0.0132356 -2.2 tagB NWMN_0609 
teichoic acid biosynthesis protein 
B 
gi|151222032 17 41 0.0132356 2.4118 - NWMN_1820 hypothetical protein NWMN_1820 
gi|151222598 86 181 0.013442364 2.1047 - NWMN_2386 hypothetical protein NWMN_2386 
197 
 
gi|151221937 46 20 0.013501854 -2.3 hemE NWMN_1725 uroporphyrinogen decarboxylase 
gi|151220713 27 85 0.013610614 3.1481 rplJ NWMN_0501 50S ribosomal protein L10 
gi|151221479 53 93 0.013771647 1.7547 parE NWMN_1267 DNA topoisomerase IV subunit B 
gi|151221800 812 500 0.014039412 -1.624 citZ NWMN_1588 citrate synthase 
gi|151220319 7 18 0.014172595 2.5714 capM NWMN_0107 
capsular polysaccharide 
biosynthesis protein CapM 
gi|151221852 14 3 0.014172595 -4.6667 - NWMN_1640 hypothetical protein NWMN_1640 
gi|151221518 39 28 0.014172595 -1.3929 dapA NWMN_1306 dihydrodipicolinate synthase 
gi|151222470 51 122 0.014203042 2.3922 tcaR NWMN_2258 
teicoplanin resistance operon 
transcriptional regulator TcaR 
gi|151220569 58 107 0.014361861 1.8448 rpsF NWMN_0357 30S ribosomal protein S6 
gi|151220251 27 14 0.014720594 -1.9286 - NWMN_0039 hypothetical protein NWMN_0039 
gi|151221341 18 5 0.014720594 -3.6 - NWMN_1129 hypothetical protein NWMN_1129 
gi|151220859 263 792 0.01509707 3.0114 - NWMN_0647 hypothetical protein NWMN_0647 
gi|151221399 37 14 0.015274813 -2.6429 - NWMN_1187 hypothetical protein NWMN_1187 
gi|151220907 64 30 0.01530106 -2.1333 - NWMN_0695 hypothetical protein NWMN_0695 
gi|151220486 136 219 0.015352974 1.6103 - NWMN_0274 hypothetical protein NWMN_0274 
gi|151221214 136 219 0.015352974 1.6103 - NWMN_1002 hypothetical protein NWMN_1002 
gi|151222018 136 219 0.015352974 1.6103 - NWMN_1806 hypothetical protein NWMN_1806 
gi|151220349 24 43 0.015465343 1.7917 - NWMN_0137 transcriptional regulator 
gi|151220902 19 50 0.015657535 2.6316 - NWMN_0690 
osmoprotectant ABC transporter, 
ATP-binding protein 
gi|151221811 22 31 0.015799848 1.4091 - NWMN_1599 CBS domain-containing protein 
gi|151220480 2 11 0.015799848 5.5 - NWMN_0268 phage anti-repressor protein 
gi|151220896 14 5 0.015799848 -2.8 pabC NWMN_0684 4-amino-4-deoxychorismate lyase 
gi|151221070 37 55 0.015799848 1.4865 oppD NWMN_0858 
oligopeptide transport ATP-binding 
protein 
gi|151221100 32 14 0.015799848 -2.2857 murE NWMN_0888 
UDP-N-acetylmuramoylalanyl-D-
glutamate--L-lysine ligase 
gi|151222708 31 16 0.016010966 -1.9375 panB NWMN_2496 
3-methyl-2-oxobutanoate 
hydroxymethyltransferase 
gi|151220402 90 37 0.016044187 -2.4324 - NWMN_0190 hypothetical protein NWMN_0190 
gi|151222669 6 14 0.01613009 2.3333 - NWMN_2457 
cation-transporting ATPase E1-E2 
family protein 
gi|151222680 9 5 0.01613009 -1.8 - NWMN_2468 
acetyltransferase, GNAT family 
protein 
gi|151222438 33 7 0.01660851 -4.7143 - NWMN_2226 hypothetical protein NWMN_2226 
gi|151220844 78 33 0.016649338 -2.3636 - NWMN_0632 hypothetical protein NWMN_0632 
gi|151221407 47 107 0.016729656 2.2766 - NWMN_1195 phosphodiesterase 
gi|151221458 986 706 0.016746882 -1.3966 katA NWMN_1246 catalase 
gi|151222397 53 78 0.016777901 1.4717 - NWMN_2185 
iron compound ABC transporter, 
iron compound-binding protein 
gi|151221421 305 616 0.01693016 2.0197 glpD NWMN_1209 
aerobic glycerol-3-phosphate 
dehydrogenase 
gi|151222230 56 17 0.016965564 -3.2941 - NWMN_2018 hypothetical protein NWMN_2018 
gi|151221812 191 407 0.017292431 2.1309 - NWMN_1600 
universal stress protein family 
protein 
gi|151221629 359 259 0.017345406 -1.3861 gnd NWMN_1417 
6-phosphogluconate 
dehydrogenase 
gi|151220831 71 42 0.017388558 -1.6905 - NWMN_0619 hypothetical protein NWMN_0619 
gi|151222197 51 34 0.017540467 -1.5 - NWMN_1985 
ATP-dependent RNA helicase 
DEAD box family protein 
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gi|151221653 137 95 0.017547374 -1.4421 gcvT NWMN_1441 
glycine cleavage system 
aminomethyltransferase T 
gi|151222671 44 20 0.017641016 -2.2 - NWMN_2459 D-lactate dehydrogenase 
gi|151220331 39 24 0.017947913 -1.625 - NWMN_0119 hypothetical protein NWMN_0119 
gi|151220228 146 109 0.018185682 -1.3394 purA NWMN_0016 adenylosuccinate synthetase 
gi|151220687 1121 729 0.019387291 -1.5377 - NWMN_0475 cysteine synthase-like protein 
gi|151221793 42 19 0.019416074 -2.2105 coaE NWMN_1581 dephospho-CoA kinase 
gi|151221627 21 31 0.019441768 1.4762 marR NWMN_1415 
maltose operon transcriptional 
repressor 
gi|151222739 32 42 0.019441768 1.3125 - NWMN_2527 hypothetical protein NWMN_2527 
gi|151220658 12 2 0.019441768 -6 tmk NWMN_0446 thymidylate kinase 
gi|151222559 60 40 0.019441768 -1.5 opuCA NWMN_2347 
glycine betaine/L-proline transport 
ATP-binding subunit 
gi|151222718 169 120 0.019617515 -1.4083 - NWMN_2506 hypothetical protein NWMN_2506 
gi|151221979 751 304 0.019697083 -2.4704 - NWMN_1767 ThiJ/PfpI family protein 
gi|151221863 132 82 0.019987658 -1.6098 leuS NWMN_1651 leucyl-tRNA synthetase 
gi|151221869 59 82 0.020277578 1.3898 - NWMN_1657 hypothetical protein NWMN_1657 
gi|151221151 63 32 0.02074071 -1.9688 purM NWMN_0939 
phosphoribosylaminoimidazole 
synthetase 
gi|151222673 46 18 0.021267756 -2.5556 crtN NWMN_2461 squalene synthase 
gi|151220923 21 12 0.021311641 -1.75 - NWMN_0711 hypothetical protein NWMN_0711 
gi|151222465 18 9 0.021311641 -2 - NWMN_2253 
drug resistance transporter 
EmrB/QacA subfamily protein 
gi|151221788 299 246 0.021797036 -1.2154 thrS NWMN_1576 threonyl-tRNA synthetase 
gi|151221618 133 220 0.022010296 1.6541 - NWMN_1406 iron uptake regulatory protein 
gi|151221039 338 273 0.022311467 -1.2381 rocD NWMN_0827 ornithine--oxo-acid transaminase 
gi|151220676 17 36 0.022948261 2.1176 rplY NWMN_0464 
50S ribosomal protein L25/general 
stress protein Ctc 
gi|151222429 45 108 0.023086213 2.4 - NWMN_2217 
phosphosugar-binding 
transcriptional regulator RpiR 
family protein 
gi|151221646 260 161 0.023132649 -1.6149 - NWMN_1434 proline dipeptidase 
gi|151220660 10 2 0.023215158 -5 holB NWMN_0448 DNA polymerase III delta subunit 
gi|151220789 8 40 0.023215158 5 adh1 NWMN_0577 alcohol dehydrogenase 
gi|151221268 19 11 0.023215158 -1.7273 mutS2 NWMN_1056 
recombination and DNA strand 
exchange inhibitor protein 
gi|151222551 2 10 0.023215158 5 - NWMN_2339 hypothetical protein NWMN_2339 
gi|151221412 19 11 0.023215158 -1.7273 - NWMN_1200 hypothetical protein NWMN_1200 
gi|151222337 37 94 0.023240291 2.5405 rplQ NWMN_2125 50S ribosomal protein L17 
gi|151220686 51 24 0.023245708 -2.125 hslO NWMN_0474 Hsp33-like chaperonin 
gi|151221024 117 63 0.023245708 -1.8571 ampA NWMN_0812 cytosol aminopeptidase 
gi|151220889 739 1588 0.023714348 2.1488 - NWMN_0677 hypothetical protein NWMN_0677 
gi|151221148 99 64 0.02371943 -1.5469 purQ NWMN_0936 
phosphoribosylformylglycinamidine 
synthase I 
gi|151221995 14 31 0.023911192 2.2143 - NWMN_1783 phage major tail protein 
gi|151222272 55 38 0.023911192 -1.4474 mtlD NWMN_2060 
mannitol-1-phosphate 5-
dehydrogenase 
gi|151220838 11 1 0.024110111 -11 - NWMN_0626 hypothetical protein NWMN_0626 
gi|151220858 16 26 0.024110111 1.625 - NWMN_0646 hypothetical protein NWMN_0646 
gi|151221152 35 25 0.024110111 -1.4 purN NWMN_0940 
phosphoribosylglycinamide 
formyltransferase 
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gi|151222681 119 18 0.024577562 -6.6111 - NWMN_2469 immunodominant antigen A 
gi|151222053 61 87 0.024764921 1.4262 camS NWMN_1841 
CamS sex pheromone cAM373 
precursor 
gi|151222588 25 18 0.024896163 -1.3889 - NWMN_2376 hypothetical protein NWMN_2376 
gi|151221473 11 18 0.024896163 1.6364 - NWMN_1261 glycine betaine transporter 1 
gi|151220728 116 81 0.024896163 -1.4321 ilvE NWMN_0516 
branched-chain amino acid 
aminotransferase 
gi|151221472 13 6 0.024896163 -2.1667 mscL NWMN_1260 
large-conductance 
mechanosensitive channel 
gi|151221742 21 14 0.024896163 -1.5 - NWMN_1530 hypothetical protein NWMN_1530 
gi|151222161 14 21 0.024896163 1.5 scrR NWMN_1949 sucrose operon repressor 
gi|151222173 13 6 0.024896163 -2.1667 ilvB NWMN_1961 
acetolactate synthase large 
subunit 
gi|151221843 288 596 0.024942029 2.0694 - NWMN_1631 hypothetical protein NWMN_1631 
gi|151222753 15 4 0.025386448 -3.75 - NWMN_2541 mannose-6-phosphate isomerase 
gi|151221131 24 13 0.025386448 -1.8462 - NWMN_0919 aminotransferase, class I 
gi|151221817 255 164 0.025422803 -1.5549 ackA NWMN_1605 acetate kinase 
gi|151220242 17 4 0.025481481 -4.25 - NWMN_0030 hypothetical protein NWMN_0030 
gi|151221784 14 1 0.025481481 -14 rplT NWMN_1572 50S ribosomal protein L20 
gi|151220674 55 29 0.025481481 -1.8966 glmU NWMN_0462 
UDP-N-acetylglucosamine 
pyrophosphorylase 
gi|151220441 70 163 0.0256229 2.3286 - NWMN_0229 hypothetical protein NWMN_0229 
gi|151220853 35 58 0.025644709 1.6571 - NWMN_0641 hypothetical protein NWMN_0641 
gi|151220335 58 17 0.025697274 -3.4118 - NWMN_0123 hypothetical protein NWMN_0123 
gi|151220403 27 15 0.025721421 -1.8 - NWMN_0191 hypothetical protein NWMN_0191 
gi|151221693 9 3 0.025721421 -3 prmA NWMN_1481 ribosomal protein L11 methylase 
gi|151221707 18 6 0.025721421 -3 - NWMN_1495 hypothetical protein NWMN_1495 
gi|151222028 12 0 0.025721421 -- - NWMN_1816 hypothetical protein NWMN_1816 
gi|151222034 15 3 0.025721421 -5 vraR NWMN_1822 
DNA-binding response regulator 
VraR 
gi|151222235 18 12 0.025721421 -1.5 tdk NWMN_2023 thymidine kinase 
gi|151220533 52 90 0.025946556 1.7308 - NWMN_0321 oxidoreductase family protein 
gi|151221326 222 173 0.026110988 -1.2832 carB NWMN_1114 
carbamoyl phosphate synthase 
large subunit 
gi|151221834 79 39 0.026536326 -2.0256 tyrS NWMN_1622 tyrosyl-tRNA synthetase 
gi|151222361 32 48 0.026997302 1.5 rplB NWMN_2149 50S ribosomal protein L2 
gi|151221104 23 39 0.026997302 1.6957 htrA NWMN_0892 serine protease HtrA 
gi|151221237 14 30 0.026997302 2.1429 - NWMN_1025 phage major tail protein 
gi|151221594 2180 3560 0.027053617 1.633 - NWMN_1382 DNA-binding protein HU 
gi|151222255 330 209 0.027091194 -1.5789 - NWMN_2043 hypothetical protein NWMN_2043 
gi|151222158 166 448 0.027213759 2.6988 agrA NWMN_1946 
staphylococcal accessory gene 
regulator A 
gi|151221806 57 109 0.027476558 1.9123 accA NWMN_1594 
acetyl-CoA carboxylase 
carboxyltransferase subunit alpha 
gi|151221426 7 22 0.028460203 3.1429 - NWMN_1214 hypothetical protein NWMN_1214 
gi|151221013 34 6 0.028658204 -5.6667 - NWMN_0801 
D-isomer specific 2-hydroxyacid 
dehydrogenase 
gi|151220863 31 62 0.02876031 2 - NWMN_0651 hypothetical protein NWMN_0651 
gi|151220804 25 43 0.028768335 1.72 - NWMN_0592 site-specific recombinase 
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gi|151220745 378 281 0.028865914 -1.3452 - NWMN_0533 hypothetical protein NWMN_0533 
gi|151222634 71 38 0.029010766 -1.8684 - NWMN_2422 D-lactate dehydrogenase 
gi|151220610 137 251 0.030034749 1.8321 hsdM NWMN_0398 
type I restriction-modification 
system, methyltransferase subunit 
gi|151221892 87 47 0.030272878 -1.8511 metK NWMN_1680 S-adenosylmethionine synthetase 
gi|151222604 27 9 0.030319669 -3 - NWMN_2392 hypothetical protein NWMN_2392 
gi|151222238 321 568 0.030328107 1.7695 - NWMN_2026 
aldehyde dehydrogenase family 
protein 
gi|151222679 36 13 0.030337364 -2.7692 - NWMN_2467 O-acetyltransferase OatA 
gi|151221912 134 245 0.030367536 1.8284 hsdM NWMN_1700 
type I restriction-modification 
system, methyltransferase subunit 
gi|151221050 62 41 0.030510813 -1.5122 rexA NWMN_0838 exonuclease RexA 
gi|151220705 39 68 0.031000144 1.7436 - NWMN_0493 hypothetical protein NWMN_0493 
gi|151221663 52 33 0.031125634 -1.5758 glk NWMN_1451 glucokinase 
gi|151221680 358 718 0.031396071 2.0056 glyS NWMN_1468 glycyl-tRNA synthetase 
gi|151221596 47 17 0.031824836 -2.7647 engA NWMN_1384 GTP-binding protein EngA 
gi|151220716 772 1076 0.032007992 1.3938 rpoB NWMN_0504 
DNA-directed RNA polymerase 
subunit beta 
gi|151221205 154 262 0.032238532 1.7013 - NWMN_0993 hypothetical protein NWMN_0993 
gi|151221523 38 21 0.032505371 -1.8095 lysA NWMN_1311 diaminopimelate decarboxylase 
gi|151221405 30 16 0.032532525 -1.875 cinA NWMN_1193 
competence/damage-inducible 
protein 
gi|151221563 93 52 0.032546532 -1.7885 - NWMN_1351 hypothetical protein NWMN_1351 
gi|151222433 17 5 0.032677923 -3.4 - NWMN_2221 
haloacid dehalogenase-like 
hydrolase 
gi|151221181 14 26 0.032677923 1.8571 - NWMN_0969 hypothetical protein NWMN_0969 
gi|151221750 11 2 0.033471745 -5.5 recJ NWMN_1538 
single-stranded-DNA-specific 
exonuclease RecJ 
gi|151221989 2 11 0.033471745 5.5 - NWMN_1777 hypothetical protein NWMN_1777 
gi|151220875 19 10 0.033471745 -1.9 - NWMN_0663 hypothetical protein NWMN_0663 
gi|151220746 28 18 0.034109423 -1.5556 - NWMN_0534 hypothetical protein NWMN_0534 
gi|151222029 113 70 0.03413741 -1.6143 pepS NWMN_1817 aminopeptidase PepS 
gi|151221651 198 101 0.03439011 -1.9604 gcvPB NWMN_1439 glycine dehydrogenase subunit 2 
gi|151221846 74 61 0.034415859 -1.2131 - NWMN_1634 
FtsK/SpoIIIE (DNA translocase 
stage III) family protein 
gi|151222663 7 14 0.035168453 2 - NWMN_2451 MmpL efflux pump 
gi|151221548 59 93 0.035186827 1.5763 - NWMN_1336 hypothetical protein NWMN_1336 
gi|151222755 44 74 0.035262876 1.6818 - NWMN_2543 
N-acetylmuramoyl-L-alanine 
amidase 
gi|151222391 42 89 0.035307924 2.119 modA NWMN_2179 
molybdenum ABC transporter, 
periplasmic molybdate-binding 
protein 
gi|151221537 267 429 0.035486781 1.6067 sucB NWMN_1325 
dihydrolipoamide 
succinyltransferase 
gi|151222049 412 191 0.035565471 -2.1571 gatB NWMN_1837 
aspartyl/glutamyl-tRNA 
amidotransferase subunit B 
gi|151221946 59 95 0.035874451 1.6102 - NWMN_1734 3'-5' exoribonuclease YhaM 
gi|151221169 57 31 0.035955539 -1.8387 def NWMN_0957 peptide deformylase 
gi|151221723 43 68 0.036190628 1.5814 greA NWMN_1511 
transcription elongation factor 
GreA 
gi|151222525 266 437 0.03629684 1.6429 - NWMN_2313 
amino acid ABC transporter, 
amino acid-binding protein 
gi|151222277 153 61 0.036731704 -2.5082 - NWMN_2065 arginase 
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gi|151221388 88 33 0.036952847 -2.6667 nusA NWMN_1176 
transcription elongation factor 
NusA 
gi|151222063 48 33 0.037590112 -1.4545 nadC NWMN_1851 
nicotinate 
phosphoribosyltransferase 
gi|151220587 99 202 0.03760864 2.0404 - NWMN_0375 hypothetical protein NWMN_0375 
gi|151222338 625 406 0.037932441 -1.5394 rpoA NWMN_2126 
DNA-directed RNA polymerase 
subunit alpha 
gi|151222527 746 436 0.037948342 -1.711 gpmA NWMN_2315 
2,3-bisphosphoglycerate-
dependent phosphoglycerate 
mutase 
gi|151221051 701 471 0.038291218 -1.4883 - NWMN_0839 
fumarylacetoacetate hydrolase 
family protein 
gi|151222159 34 16 0.038306255 -2.125 - NWMN_1947 hypothetical protein NWMN_1947 
gi|151222024 35 17 0.038306255 -2.0588 - NWMN_1812 phage repressor 
gi|151221507 101 45 0.038514275 -2.2444 pepF NWMN_1295 oligoendopeptidase F 
gi|151222265 41 120 0.038968806 2.9268 - NWMN_2053 SAP domain-containing protein 
gi|151222342 67 75 0.039020527 1.1194 infA NWMN_2130 translation initiation factor IF-1 
gi|151221683 11 3 0.039020527 -3.6667 - NWMN_1471 cytidine deaminase 
gi|151222369 24 1 0.039161395 -24 - NWMN_2157 GCN5-related N-acetyltransferase 
gi|151221347 61 134 0.03973141 2.1967 - NWMN_1135 hypothetical protein NWMN_1135 
gi|151221521 31 12 0.039778363 -2.5833 hipO NWMN_1309 hippurate hydrolase 
gi|151222244 69 87 0.039941968 1.2609 rpoE NWMN_2032 
DNA-directed RNA polymerase 
subunit delta 
gi|151221150 56 42 0.040545533 -1.3333 purF NWMN_0938 amidophosphoribosyltransferase 
gi|151222709 24 11 0.040642089 -2.1818 panE NWMN_2497 2-dehydropantoate 2-reductase 
gi|151222079 162 360 0.04096118 2.2222 - NWMN_1867 
ABC transporter ATP-binding 
protein 
gi|151220895 53 32 0.041150473 -1.6563 pabB NWMN_0683 
anthranilate/para-aminobenzoate 
synthase component I 
gi|151221515 124 61 0.041419765 -2.0328 - NWMN_1303 
ABC transporter ATP-binding 
protein 
gi|151220729 39 15 0.04179468 -2.6 - NWMN_0517 
haloacid dehalogenase-like 
hydrolase 
gi|151221072 53 92 0.042400297 1.7358 - NWMN_0860 hypothetical protein NWMN_0860 
gi|151220800 1641 2248 0.042565657 1.3699 sarA NWMN_0588 
staphylococcal accessory 
regulator A 
gi|151221079 225 450 0.043079419 2 spxA NWMN_0867 transcriptional regulator Spx 
gi|151222523 23 41 0.04324409 1.7826 - NWMN_2311 
amino acid ABC transporter, ATP-
binding protein 
gi|151220592 513 382 0.043943631 -1.3429 guaB NWMN_0380 
inosine-5'-monophosphate 
dehydrogenase 
gi|151222071 137 101 0.044491833 -1.3564 - NWMN_1859 hypothetical protein NWMN_1859 
gi|151222447 55 33 0.044619278 -1.6667 hutG NWMN_2235 formimidoylglutamase 
gi|151221774 63 35 0.04465345 -1.8 hemB NWMN_1562 
delta-aminolevulinic acid 
dehydratase 
gi|151221040 512 336 0.045090505 -1.5238 gudB NWMN_0828 
NAD-specific glutamate 
dehydrogenase 
gi|151220940 59 31 0.045343299 -1.9032 hprK NWMN_0728 HPr kinase/phosphorylase 
gi|151222703 74 26 0.045770336 -2.8462 - NWMN_2491 hypothetical protein NWMN_2491 
gi|151222692 193 112 0.046002431 -1.7232 - NWMN_2480 hydrolase 
gi|151220850 45 65 0.04606216 1.4444 - NWMN_0638 hypothetical protein NWMN_0638 
gi|151222350 39 59 0.04606216 1.5128 rpsH NWMN_2138 30S ribosomal protein S8 
gi|151221798 52 122 0.046255938 2.3462 phoP NWMN_1586 
alkaline phosphatase synthesis 
transcriptional regulatory protein 
gi|151221773 99 55 0.04629759 -1.8 hemL NWMN_1561 
glutamate-1-semialdehyde 
aminotransferase 
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gi|151221186 58 34 0.046476751 -1.7059 - NWMN_0974 GTP-binding protein TypA 
gi|151220784 66 28 0.046479363 -2.3571 - NWMN_0572 aldo/keto reductase family protein 
gi|151221273 178 280 0.04666274 1.573 sdhA NWMN_1061 
succinate dehydrogenase 
flavoprotein subunit 
gi|151221566 29 13 0.047420656 -2.2308 - NWMN_1354 hypothetical protein NWMN_1354 
gi|151221970 4 8 0.047420656 2 - NWMN_1758 
ABC transporter ATP-binding 
protein 
gi|151222077 11 7 0.047420656 -1.5714 - NWMN_1865 hypothetical protein NWMN_1865 
gi|151220756 20 47 0.048074518 2.35 ung NWMN_0544 uracil-DNA glycosylase 
gi|151221676 172 284 0.048332922 1.6512 sigA NWMN_1464 
RNA polymerase sigma factor 
RpoD 
gi|151222611 78 92 0.048811551 1.1795 fnbA NWMN_2399 
fibronectin binding protein A 
precursor 
gi|151220692 10 24 0.048811551 2.4 - NWMN_0480 GntR family regulatory protein 
gi|151221173 901 508 0.049235597 -1.7736 pdhC NWMN_0961 
branched-chain alpha-keto acid 
dehydrogenase subunit E2 
gi|151221118 42 63 0.049741244 1.5 - NWMN_0906 
glycosyl transferase, group 1 
family protein 
gi|151221149 221 114 0.049750673 -1.9386 purL NWMN_0937 
phosphoribosylformylglycinamidine 
synthase II 
gi|151221578 39 57 0.049948092 1.4615 - NWMN_1366 DnaQ family exonuclease 
1for peptides with calculated p value <0.05 
2the sum of peptides detected in three biological replicates 
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Appendix B Table 1  PAML Dataset 
Model Tree 
length 
lnL dN/dS Statistical inference Amino acid 
site 
Posterior 
probability 
dN/dS (+/- error) 2d p-value 
Hemoglobin alpha (HBA) Tree: species (27 species) 
M1 0.85769 -1199.0014 0.1829 
      
M2 0.89659 -1191.5734 0.2901 Naïve Empirical Bayes 8T 1.000** 4.55 
  
     
19A 0.737 3.616 
  
     
78N 0.959* 4.404 
  
    
Bayes Empirical Bayes 8T 0.999** 4.516+-1.363 
  
     
19A 0.787 3.650+-1.769 
  
     
78N 0.963* 4.358+-1.461 14.855998 0.000594376 
M7 0.8883 -1199.5302 0.212 
      
M8 0.90418 -1191.9496 0.2981 Naïve Empirical Bayes 8T 1.000** 4.541 
  
     
19A 0.79 3.786 
  
     
78N 0.972* 4.444 
  
    
Bayes Empirical Bayes 8T 1.000** 3.557+-1.088 
  
     
19A 0.959* 3.427+-1.174 
  
     
25G 0.715 2.678+-1.561 
  
     
71A 0.706 2.563+-1.378 
  
     
78N 0.996** 3.544+-1.097 15.161196 0.000510256 
Model Tree 
length 
lnL dN/dS Statistical inference Amino acid 
site 
Posterior 
probability 
dN/dS (+/- error) 2d p-value 
Hemoglboin alpha (HBA) Gene: species (27 species) 
M1 0.77035 -1153.8583 0.2026 
      
M2 0.79051 -1151.7888 0.2518 Naïve Empirical Bayes 8T 0.967* 3.969 
  
    
Bayes Empirical Bayes 8T 0.960* 2.882+-1.590 
  
     
19A 0.605 1.914+-1.161 
  
     
21A 0.522 1.786+-1.215 
  
     
25G 0.567 1.925+-1.341 2.069454 0.126254698 
M7 0.77202 -1154.0221 0.2106 
      
M8 0.78543 -1152.289 0.2722 Naïve Empirical Bayes 8T 1.000** 1.595 
  
     
12A 0.998** 1.591 
  
     
15G 0.82 1.314 
  
     
18G 0.952* 1.52 
  
     
19A 1.000** 1.595 
  
     
21A 0.993** 1.585 
  
     
23E 0.999** 1.593 
  
     
24Y 0.845 1.354 
  
     
25G 0.994** 1.586 
  
     
57G 0.998** 1.592 
  
     
64D 0.909 1.454 
  
     
67T 1.000** 1.595 
  
     
68N 1.000** 1.595 
  
     
71A 0.999** 1.594 
  
     
78N 1.000** 1.595 
  
     
82A 0.958* 1.531 
  
     
113L 0.973* 1.552 
  
     
116E 0.975* 1.557 
  
    
Bayes Empirical Bayes 8T 0.996** 2.037+-0.714 
  
     
12A 0.638 1.387+-0.698 
  
     
19A 0.918 1.906+-0.726 
  
     
21A 0.803 1.707+-0.812 
  
     
23E 0.729 1.550+-0.719 
  
     
24Y 0.524 1.158+-0.923 
  
     
25G 0.826 1.753+-0.814 
  
     
57G 0.677 1.453+-0.705 
  
     
67T 0.836 1.740+-0.698 
  
     
68N 0.83 1.728+-0.696 
  
     
71A 0.77 1.625+-0.726 
  
     
78N 0.85 1.767+-0.701 
  
     
113L 0.54 1.202+-0.741 
  
     
116E 0.555 1.229+-0.743 1.733127 0.176730907 
Model Tree 
length 
lnL dN/dS Statistical inference Amino acid 
site 
Posterior 
probability 
dN/dS (+/- error) 2d p-value 
Hemoglobin beta (HBB) Tree: species (30 species) 
M1 1.02343 -1355.5177 
       
M2 1.0674 -1342.483 
 
Naïve Empirical Bayes 5P 0.549 2.56 
  
     
6E 0.601 2.71 
  
     
9S 1.000** 3.844 
  
     
13A 0.679 2.93 
  
     
43E 0.94 3.675 
  
     
50T 0.896 3.55 
  
     
76A 0.999** 3.841 
  
     
87T 0.709 3.016 
  
     
125P 0.916 3.604 
  
    
Bayes Empirical Bayes 5P 0.528 2.537+-1.556 
  
     
6E 0.571 2.662+-1.544 
  
     
9S 1.000** 4.163+-0.944 
  
     
13A 0.646 2.909+-1.540 
  
     
43E 0.915 3.823+-1.179 
  
     
50T 0.887 3.763+-1.286 
  
     
76A 0.999** 4.160+-0.949 
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87T 0.677 3.016+-1.530 
  
     
125P 0.919 3.904+-1.239 26.069494 2.18314E-06 
M7 0.96435 -1354.4734 
       
M8 1.06678 -1342.6481 
 
Naïve Empirical Bayes 5P 0.805 2.96 
  
     
6E 0.886 3.203 
  
     
9S 1.000** 3.543 
  
     
13A 0.919 3.299 
  
     
43E 0.997** 3.534 
  
     
50T 0.981* 3.485 
  
     
56G 0.531 2.141 
  
     
76A 1.000** 3.543 
  
     
87T 0.93 3.334 
  
     
125P 0.976* 3.471 
  
    
Bayes Empirical Bayes 5P 0.748 2.983+-1.479 
  
     
6E 0.833 3.271+-1.300 
  
     
9S 1.000** 3.849+-0.676 
  
     
13A 0.877 3.426+-1.191 
  
     
43E 0.991** 3.817+-0.731 
  
     
50T 0.972* 3.759+-0.841 
  
     
76A 1.000** 3.849+-0.677 
  
     
87T 0.894 3.487+-1.142 
  
     
125P 0.972* 3.760+-0.852 23.650616 7.31702E-06 
Model Tree 
length 
lnL dN/dS Statistical inference Amino acid 
site 
Posterior 
probability 
dN/dS (+/- error) 2d p-value 
Hemoglobin beta (HBB) Tree: gene (30 species) 
M1 0.88184 -1280.4927 0.1544 
      
M2 0.89868 -1274.4497 0.2662 Naïve Empirical Bayes 5P 0.942 2.414 
  
     
6E 0.965* 2.448 
  
     
9S 0.998** 2.499 
  
     
13A 0.965* 2.449 
  
     
21D 0.728 2.065 
  
     
22E 0.574 1.569 
  
     
43E 0.964* 2.447 
  
     
50T 0.885 2.323 
  
     
56G 0.904 2.357 
  
     
76A 0.986* 2.481 
  
     
87T 0.968* 2.454 
  
     
104R 0.774 2.144 
  
     
125P 0.979* 2.47 
  
    
Bayes Empirical Bayes 5P 0.707 2.480+-1.116 
  
     
6E 0.811 2.730+-1.050 
  
     
9S 0.994** 3.179+-0.795 
  
     
13A 0.808 2.719+-1.048 
  
     
43E 0.771 2.608+-1.055 
  
     
50T 0.515 1.995+-1.170 
  
     
56G 0.545 2.082+-1.100 
  
     
76A 0.928 3.018+-0.910 
  
     
87T 0.827 2.768+-1.033 
  
     
125P 0.915 3.009+-0.962 12.086108 0.002374297           
M7 0.94438 -1281.2449 0.2 
      
M8 0.89947 -1274.3967 0.2664 Naïve Empirical Bayes 5P 0.984* 2.483 
  
     
6E 0.997** 2.512 
  
     
9S 1.000** 2.519 
  
     
13A 0.997** 2.512 
  
     
21D 0.656 1.743 
  
     
22E 0.577 1.551 
  
     
43E 0.999** 2.516 
  
     
50T 0.9 2.294 
  
     
56G 0.965* 2.439 
  
     
76A 1.000** 2.518 
  
     
87T 0.997** 2.513 
  
     
104R 0.737 1.926 
  
     
125P 0.997** 2.512 
  
    
Bayes Empirical Bayes 5P 0.844 2.716+-1.064 
  
     
6E 0.934 2.956+-0.855 
  
     
9S 0.999** 3.123+-0.636 
  
     
13A 0.934 2.955+-0.854 
  
     
43E 0.93 2.940+-0.851 
  
     
50T 0.569 1.938+-1.354 
  
     
56G 0.693 2.294+-1.230 
  
     
76A 0.984* 3.087+-0.693 
  
     
87T 0.943 2.979+-0.830 
  
     
125P 0.968* 3.050+-0.760 13.696394 0.001061368 
NOTE: amino acid numbering is based on removal of N-terminal methionine 
Phylogenetic analysis by maximum likelihood (PAML) performed using simian primate sequences (Figure 3B). Analysis was performed using both conserved species and maximum 
likelihood gene trees (see Materials and Methods for additional details). 
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Appendix B Table 2 
Hemoglobin alpha (HBA) data 
Test Codon a b- Pr[b=b-] b+ Pr[b=b+] p-value q-value 
     
MEME 18 0 0 0.910193 14.3338 0.0898074 0.0656901 1 
     
 
67 0 0 0.75422 18.392 0.24578 0.0574455 1 
     
 
68 0.00798137 0.00730452 0.816103 26.2233 0.183897 0.0430483 1 
     
FEL 4 
            
 
23 
            
 
43 
            
 
44 
            
 
50 
            
 
55 
            
 
72 
            
 
81 
            
 
84 
            
 102 
            
 
111 
            
 
114 
            
 
116 
            
 
124 
            
 
131 
            
 
71 
            
SLAC 43 
            
 
50 
            
 
72 
            
 
84 
            
 
102 
            
 
111 
            
REL 8 
            
 
12 
            
 
19 
            
 
67 
            
 
68 
            
 
71 
            
 
78 
            
 
113 
            
 
4 
            
 
26 
            
 
43 
            
 
44 
            
 
50 
            
 
55 
            
 
66 
            
 
72 
            
 
81 
            
 
83 
            
 
84 
            
 
88 
            
 
101 
            
 
102 
            
 
105 
            
 
108 
            
 
111 
            
 
114 
            
 
124 
            
 
130 
            
 
131 
            
              
Test 
(cont'd) 
Codon 
(cont'd) 
dS dN dN/dS dN-dS Normalized 
dN-dS 
p-value E[dS] E[dN] Normalized 
E[dN-dS] 
Posterior 
Probability 
Bayes Factor Selection 
MEME 18 
           
episodic 
purifying  
67 
           
episodic 
purifying  
68 
           
episodic 
purifying 
FEL 4 2.93937 0 0 
 
-11.1833 0.0471894 
     
negative  
23 45.1096 2.10936 0.047 
 
-163.602 0.0488065 
     
negative 
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43 94.7368 0 0 
 
-360.442 0.000109565 
     
negative  
44 6.09185 0 0 
 
-23.1775 0.0159847 
     
negative  
50 15.0581 0 0 
 
-57.2909 0.0149202 
     
negative  
55 3.56477 0 0 
 
-13.5628 0.0392927 
     
negative  
72 32.555 0 0 
 
-123.861 0.0101873 
     
negative  
81 2.76418 0 0 
 
-10.5168 0.085434 
     
negative  
84 25.2724 0 0 
 
-96.153 0.00988594 
     
negative  
102 32.555 0 0 
 
-123.861 0.00899011 
     
negative  
111 7.46451 0 0 
 
-28.4 0.00617556 
     
negative  
114 2.58747 0 0 
 
-9.84445 0.098816 
     
negative  
116 73.6674 1.42197 0.019 
 
-274.87 0.0357135 
     
negative  
124 2.79306 0 0 
 
-10.6267 0.0846156 
     
negative  
131 2.89817 0 0 
 
-11.0266 0.0417009 
     
negative  
71 3.16E-15 3.84127 1.21461E+15 
 
14.6148 0.0920853 
     
negative 
SLAC 43 
   
-8.99446 -34.2205 0.00823006 
     
negative  
50 
   
-4.49723 -17.1103 0.0907197 
     
negative  
72 
   
-4.49723 -17.1103 0.0907197 
     
negative  
84 
   
-4.49723 -17.1103 0.0907197 
     
negative  
102 
   
-4.49723 -17.1103 0.0907197 
     
negative  
111 
   
-3.67189 -13.9701 0.037037 
     
negative 
REL 8 
      
1.02514 2.85362 1.82848 1 5.19E+12 positive  
12 
      
0.710751 2.84953 2.13878 0.999442 1583.68 positive  
19 
      
1.86895 2.85362 0.984669 0.999999 1.59E+06 positive  
67 
      
0.696934 2.85347 2.15654 0.99998 45098 positive  
68 
      
0.847512 2.85342 2.0059 0.999967 2.67E+04 positive  
71 
      
0.671969 2.85351 2.18154 0.999986 62309.9 positive  
78 
      
1.83124 2.85362 1.02238 1 6.03E+08 positive  
113 
      
0.76883 2.84829 2.07946 0.999212 1122.21 positive  
4 
      
1.86914 0.076952 -1.79219 0.993884 183.703 negative  
26 
      
1.86913 0.0786563 -1.79047 0.993275 166.983 negative  
43 
       
1.86914 0.0652868 -1.80385 0.998029 negative  
44 
       
1.86914 0.0769634 -1.79217 0.993879 negative  
50 
       
1.869 0.0702911 -1.7987 0.996245 negative  
55 
       
1.86914 0.0783505 -1.79079 0.993385 negative  
66 
       
1.86913 0.0844826 -1.78464 0.991197 negative  
72 
       
1.86905 0.0701687 -1.79888 0.996292 negative  
81 
       
1.86914 0.0709109 -1.79823 0.996035 negative  
83 
       
1.86913 0.0844826 -1.78464 0.991197 negative  
84 
       
1.86911 0.0639924 -1.80512 0.998483 negative  
88 
       
1.86914 0.0786405 -1.7905 0.993281 negative  
101 
       
1.86914 0.0847781 -1.78436 0.991092 negative  
102 
       
1.86909 0.0640284 -1.80507 0.998468 negative  
105 
       
1.8687 0.0854985 -1.7832 0.990823 negative  
108 
       
1.86914 0.0717289 -1.79741 0.995743 negative  
111 
       
1.86914 0.0786363 -1.7905 0.993283 negative  
114 
       
1.86913 0.0769662 -1.79216 0.993878 negative  
124 
       
1.86914 0.0709103 -1.79823 0.996035 negative  
130 
       
1.86914 0.0786363 -1.7905 0.993282 negative  
131 
       
1.86914 0.0709099 -1.79823 0.996035 negative               
Hemoglobin beta (HBB) data 
Test Codon a b- Pr[b=b-] b+ Pr[b=b+] p-value q-value 
     
MEME 5 0 0 0.87038 18.7966 0.12962 0.0310067 1 
     
 
13 0 0 1.00E-09 2.69248 1 0.0877052 1 
     
 
56 0 0 0.823708 10.1067 0.176292 0.0611889 1 
     
 
76 0 0 0.14923 6.26513 0.85077 0.0223575 1 
     
 
125 1.34367 0.00574856 0.876098 22.6673 0.123902 0.0861075 1 
     
FEL 13 
            
 
76 
            
 
2 
            
 
7 
            
 
8 
            
 
11 
            
 
12 
            
 
17 
            
 
19 
            
 
21 
            
 
34 
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38 
            
 
42 
            
 
46 
            
 
64 
            
 
66 
            
 
68 
            
 
73 
            
 
80 
            
 
83 
            
 
84 
            
 
87 
            
 
97 
            
 
98 
            
 
100 
            
 
102 
            
 
108 
            
 
111 
            
 
118 
            
 
121 
            
 
124 
            
 
132 
            
 
141 
            
 
142 
            
REL 5 
            
 
9 
            
 
13 
            
 
43 
            
 
50 
            
 
56 
            
 
76 
            
 
104 
            
 
125 
            
 
0 
            
 
2 
            
 
4 
            
 
7 
            
 
8 
            
 
10 
            
 
12 
            
 
17 
            
 
27 
            
 
30 
            
 
36 
            
 
38 
            
 
40 
            
 
44 
            
 
49 
            
 
51 
            
 
53 
            
 
55 
            
 
57 
            
 
59 
            
 
61 
            
 
62 
            
 
63 
            
 
65 
            
 
66 
            
 
68 
            
 
70 
            
 
72 
            
 
77 
            
 
80 
            
 
82 
            
 
84 
            
 
86 
            
 
89 
            
 
92 
            
 
93 
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95 
            
 
97 
            
 
100 
            
 
102 
            
 
108 
            
 
111 
            
 
112 
            
 
115 
            
 
117 
            
 
118 
            
 
120 
            
 
121 
            
 
123 
            
 
124 
            
 
128 
            
 
129 
            
 
132 
            
 
135 
            
 
138 
            
 
140 
            
 
142 
            
                            
Test 
(cont'd) 
Codon 
(cont'd) 
dS dN dN/dS dN-dS Normalized 
dN-dS 
p-value E[dS] E[dN] Normalized 
E[dN-dS] 
Posterior 
Probability 
Bayes Factor Selection 
MEME 5 
            
 
13 
            
 
56 
            
 
76 
            
 
125 
            
FEL 13 0 2.10144 infinite 
 
6.58518 0.0918563 
     
positive  
76 3.01E-15 3.94962 1.31355E+15 
 
12.3767 0.0317138 
     
positive  
2 7.62968 0 0 
 
-23.9087 0.00146618 
      
 
7 8.58608 0 0 
 
-26.9057 0.0224143 
      
 
8 6.1291 0 0 
 
-19.2064 0.00349089 
      
 
11 2.81636 0 0 
 
-8.82548 0.0479094 
      
 
12 7.40161 0 0 
 
-23.194 0.000100501 
      
 
17 9.1354 0 0 
 
-28.6271 0.0139439 
      
 
19 4.273 0.422265 0.099 
 
-12.0668 0.0574594 
      
 
21 7.84395 1.27037 0.162 
 
-20.5993 0.0626165 
      
 
34 2.66941 0 0 
 
-8.36497 0.0516265 
      
 
38 1.24566 0 0 
 
-3.90347 0.0914441 
      
 
42 2.11589 0 0 
 
-6.63045 0.0851162 
      
 
46 2.63085 0 0 
 
-8.24413 0.0762976 
      
 
64 2.59332 0 0 
 
-8.12655 0.040055 
      
 
66 5.40855 0 0 
 
-16.9485 0.00434612 
      
 
68 3.85901 0 0 
 
-12.0928 0.0104218 
      
 
73 2.01287 0 0 
 
-6.30761 0.0901901 
      
 
80 1.95794 0 0 
 
-6.1355 0.0636718 
      
 
83 2.55789 0 0 
 
-8.01552 0.0409329 
      
 
84 1.23056 0 0 
 
-3.85613 0.0924171 
      
 
87 44.0784 2.3855 0.054 
 
-130.651 0.0158841 
      
 
97 7.40883 0 0 
 
-23.2166 0.00150941 
      
 
98 2.48851 0 0 
 
-7.79811 0.0970344 
      
 
100 1.4271 0 0 
 
-4.47201 0.0964693 
      
 
102 10.0584 0 0 
 
-31.5194 0.000125309 
      
 
108 2.14545 0 0 
 
-6.72307 0.0581598 
      
 
111 8.85059 0 0 
 
-27.7346 0.00297945 
      
 
118 4.27332 0 0 
 
-13.3911 0.0147849 
      
 
121 1.50332 0 0 
 
-4.71088 0.0964152 
      
 
124 10.0344 0 0 
 
-31.4441 0.000157485 
      
 
132 1.47855 0 0 
 
-4.63324 0.0730412 
      
 
141 1.98623 0 0 
 
-6.22413 0.0924969 
      
 
142 1.96552 0 0 
 
-6.15925 0.0777414 
      
REL 5 
      
0.482549 2.11607 1.63352 0.991654 1443.55 positive  
9 
      
1.1786 2.11769 0.939086 0.813629 53.0398 positive  
13 
      
0.474529 2.11762 1.64309 0.994451 2177.38 positive  
43 
      
0.833337 2.11769 1.28435 0.902322 112.232 positive  
50 
      
0.482243 2.1176 1.63536 0.992461 1599.45 positive 
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56 
      
0.492065 2.11416 1.6221 0.988304 1026.59 positive  
76 
      
0.486525 2.11769 1.63117 0.991405 1401.35 positive  
104 
      
0.557437 1.79752 1.24008 0.823768 56.7903 positive  
125 
      
0.708036 2.11403 1.406 0.932868 168.828 positive  
0 
      
0.999999 0.0248461 -0.975153 0.999571 191.94 negative  
2 
      
4.17485 0.0266203 -4.14823 0.999939 1360.39 negative  
4 
      
0.482199 0.0243741 -0.457825 0.999718 291.842 negative  
7 
      
2.24873 0.0283573 -2.22037 0.998837 70.6747 negative  
8 
      
3.4882 0.0244914 -3.46371 0.999919 1018.98 negative  
10 
      
0.687723 0.0268239 -0.660899 0.998663 61.4984 negative  
12 
      
4.3394 0.0243747 -4.31503 0.999999 159988 negative  
17 
      
2.3106 0.0247531 -2.28585 0.999757 338.923 negative  
27 
      
0.474512 0.0268238 -0.447688 0.998585 58.1069 negative  
30 
      
0.519849 0.0257652 -0.494084 0.999091 90.4992 negative  
36 
      
0.482199 0.0254614 -0.456738 0.999223 105.796 negative  
38 
      
0.65393 0.0243741 -0.629556 0.999731 305.443 negative  
40 
      
0.519849 0.0257652 -0.494084 0.999091 90.4992 negative  
44 
      
0.474512 0.0256345 -0.448878 0.999141 95.7564 negative  
49 
      
0.637502 0.0258303 -0.611672 0.99909 90.4011 negative  
51 
      
0.482199 0.0254614 -0.456738 0.999223 105.796 negative  
53 
      
0.482199 0.026824 -0.455375 0.998588 58.2187 negative  
55 
      
0.999999 0.0248461 -0.975153 0.999571 191.94 negative  
57 
      
0.524688 0.0246784 -0.500009 0.999586 198.682 negative  
59 
      
0.849545 0.0247926 -0.824752 0.999574 193.17 negative  
61 
      
0.849545 0.0247926 -0.824752 0.999574 193.17 negative  
62 
      
0.482199 0.026824 -0.455375 0.998588 58.2187 negative  
63 
      
0.528371 0.0266605 -0.50171 0.998681 62.3018 negative  
65 
      
0.849545 0.0247926 -0.824752 0.999574 193.17 negative  
66 
      
3.36156 0.0244697 -3.33709 0.999908 898.079 negative  
68 
      
4.10148 0.0332232 -4.06826 0.999718 292.234 negative  
70 
      
0.474512 0.0268238 -0.447688 0.998585 58.1069 negative  
72 
      
0.528371 0.024626 -0.503745 0.99961 211.124 negative  
77 
      
0.524688 0.0262728 -0.498415 0.998858 72.0049 negative  
80 
      
1.04628 0.0246847 -1.0216 0.99964 228.285 negative  
82 
      
0.849545 0.0247926 -0.824752 0.999574 193.17 negative  
84 
      
0.644758 0.0243772 -0.620381 0.999728 302.982 negative  
86 
      
0.474512 0.0268238 -0.447688 0.998585 58.1069 negative  
89 
      
0.528371 0.024626 -0.503745 0.99961 211.124 negative  
92 
      
0.524688 0.0262728 -0.498415 0.998858 72.0049 negative  
93 
      
0.528371 0.0265321 -0.501839 0.998741 65.2861 negative  
95 
      
0.849545 0.0247926 -0.824752 0.999574 193.17 negative  
97 
      
4.16567 0.0264225 -4.13924 0.99994 1365.35 negative  
100 
      
0.748533 0.0254658 -0.723068 0.999274 113.303 negative  
102 
      
4.32538 0.0247354 -4.30064 0.999997 31286.3 negative  
108 
      
1.14182 0.0246859 -1.11713 0.999649 234.748 negative  
111 
      
4.21955 0.036883 -4.18267 0.999798 406.533 negative  
112 
      
0.528371 0.0265321 -0.501839 0.998741 65.2861 negative  
115 
      
0.654767 0.026824 -0.627943 0.998651 60.9462 negative  
117 
      
0.524688 0.0262728 -0.498415 0.998858 72.0049 negative  
118 
      
2.98177 0.0283646 -2.95341 0.999218 105.215 negative  
120 
      
0.486501 0.0241845 -0.462317 0.999801 414.314 negative  
121 
      
0.775172 0.0261162 -0.749056 0.998995 81.8086 negative  
123 
      
0.474512 0.024374 -0.450138 0.999718 291.283 negative  
124 
      
4.32806 0.0254632 -4.30259 0.999996 22158.6 negative  
128 
      
0.482199 0.026824 -0.455375 0.998588 58.2187 negative  
129 
      
0.474512 0.0268238 -0.447688 0.998585 58.1069 negative  
132 
      
0.761318 0.0241986 -0.737119 0.999809 431.264 negative  
135 
      
0.716714 0.0268242 -0.689889 0.998674 61.9843 negative  
138 
      
0.731618 0.0268241 -0.704794 0.998679 62.2416 negative  
140 
      
0.569697 0.0268243 -0.542872 0.99862 59.5657 negative  
142 
      
1.04851 0.026366 -1.02215 0.998972 79.9894 
 
NOTE: amino acid numbering is based on removal of N-terminal methionine 
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APPENDIX C 
 
 
HUMAN PHEWAS IDENTIFIES PATHOLOGICAL ROLE OF FACTOR X DURING 
ACINETOBACTER BAUMANNII INFECTION 
 
 
Introduction 
Phenome-Wide Association Studies (PheWAS) are an efficient discovery tool to 
identify novel associations between clinical outcomes and genotypes. PheWAS explore the 
association between nuclear single nucleotide polymorphisms (SNPs) and phenotypes 
represented in electronic health records (EHR) (1). PheWAS have successfully revealed novel 
SNP/phenotype associations, and have been used to explore pleiotropy (2, 3), disease 
heritability (4), therapeutic and adverse medication effects (5, 6), and drug repurposing 
opportunities (7, 8). One aim of PheWAS is to discover new applications for therapeutics by 
investigating clinical phenotypes of patients with variation in a known drug target.  
One biological pathway attractive to drug repurposing efforts is coagulation. 
Coagulation plays a considerable role in hemostasis and as such perturbations to coagulation 
affect many disease outcomes. Additionally, work in murine models of inflammation and 
infection have identified many examples of the crosstalk between coagulation and immunity 
(9-11). Therefore, PheWAS of genes encoding coagulation proteins offers opportunity to find 
new diseases associated with altered coagulation and new indications for current coagulation 
therapeutics.  
Blood-coagulation factor X (FX) is a vitamin K-dependent serine protease that 
functions upstream in the blood coagulation cascade. FX is synthesized in the liver and 
secreted into the bloodstream in an inactive form until the coagulation pathway is activated by 
an injury that damages blood vessels. Both the extrinsic and intrinsic pathways of coagulation 
initiation converge on FX, which is activated to FXa and subsequently interacts with other 
coagulation factors to convert prothrombin to its active form, thrombin. Thrombin converts 
fibrinogen into fibrin, which then forms a blood clot (12). Current treatment of bleeding 
disorders includes FX replacement therapy using fresh-frozen plasma, FIX plasma 
concentrates, and prothrombin complex concentrations (PCCs) (13). Additionally, FDA-
approved therapeutics are used to inhibit FXa as anticoagulants. The specificity of these drugs 
has several advantages over more general anticoagulants that inhibit vitamin K. Enoxaparin  
binds antithrombin to irreversibly inactivate FXa (14, 15) and is used to treat deep vein 
thrombosis, pulmonary embolism, and for thromboprophylaxis in a variety of surgical 
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procedures (16). Enoxaparin is well tolerated with good bioavailability and is approved in many 
countries. We leveraged PheWAS to find potential links between coding variants in F10, the 
gene that encodes FX, and novel clinical phenotypes that are not currently well-treated or 
understood. The goal was to repurpose approved coagulation therapeutics for a new 
therapeutic use. 
PheWAS analysis was focused on F10 SNP rs3211783 which denotes a Gly192Arg 
residue substitution in the N-terminal portion of the protein. The functional effect of the FX 
Gly192Arg SNP is unknown. Residue 192 resides very close to the cleavage site within the 
activation peptide of the protein (17). Substitution of Glycine 192 to Arginine did not affect 
coagulation activity and catalytic activity of the enzyme as compared with wild-type (18). 
However, it must be noted that this was an in vitro study and did not explore in vivo effects. 
This study also did not explore any direct effects of the SNP on FX, focusing instead on its 
activated form. 
FX deficiency causes bleeding disorders that can range in severity from hemorrhagic 
symptoms to asymptomatic. The condition can be hereditary or acquired as a result of liver 
disease, cancer, or infections (12). The inherited form is autosomal recessive and very rare. 
The homozygous and most severe hereditary forms have an incidence rate of approximately 
one in a million (19) and are due to polymorphisms in F10. Individuals with FX deficiency from 
the Friuli region of Italy contain a homozygous mutation in the F10. Affected individuals had a 
moderate bleeding tendency since early childhood, with epistaxis, bleeding from the gums, 
posttraumatic hemarthroses, and bleeding after dental extractions and other surgical 
procedures. Laboratory studies showed prolonged prothrombin and partial thromboplastin 
clotting times, and factor X activity levels between 4 to 9% of normal (20). 
Acinetobacter baumannii is a Gram-negative bacterium that has emerged as a 
critically important pathogen with high rates of anti-microbial resistance. Owing to its ability to 
survive dessication, environmental extremes, and antimicrobials, A. baumannii is a frequent 
cause of hospital-acquired infections of the critically ill and is a leading cause of ventilator-
associated pneumonia and burn wounds (21). Most infections are caused by strains of A. 
baumannii that are resistant to multiple classes of antibiotics which leads to treatment failures 
(22).  A. baumannii are classified as a Centers for Disease Control threat “Serious” and a 
“Priority 1: Critical” WHO priority pathogen for antibiotic development (23). Thus, identifying 
novel therapeutics that might aid the ability of the immune response to limit bacterial 
replication during infection is an attractive goal until new antibiotics become available.  
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In this study, we used PheWAS to identify novel clinical phenotypes associated with a 
SNP in coagulation Factor X. In addition to the expected phenotypes relevant to hemostasis, 
the SNP was associated with altered risk for multiple types of microbial infections. Factor X 
deficiency was modeled in mice and found to protect from systemic A. baumannii infection, 
suggesting that in some infections, Factor X may play a pathological role during the early 
innate immune response. Additionally, inhibition of Factor X with an FDA-approved 
therapeutic reduced bacterial burden in wildtype mice following infection, serving as a proof-
of-principal for the use of PheWAS in drug repurposing by identifying a potential new 
adjunctive treatment for A. baumannii infection.  
 
Materials and methods 
PheWAS Methods 
The BioVU biorepository at Vanderbilt University Medical Center contains 
approximately 250,000 de-identified DNA samples extracted from excess patient blood 
samples collected during routine clinical testing that would otherwise be discarded. The 
specimens are linked to corresponding, longitudinal clinical and demographic data derived 
from the Synthetic Derivative, a de-identified EHR built for research purposes (24-26). This 
study leveraged data from approximately 36,000 subjects in BioVU genotyped on using the 
Illumina Infinium Exomechip. PheWAS was conducted using previously reported methods (1, 
6, 27, 28); analysis was focused on 29,722 patients of European ancestry with Exomechip 
data and phenotype data in SD to achieve maximum statistical power. Our variant of focus for 
these studies was the F10 missense SNP rs3211783 (Gly192Arg).  
 
Mice 
F10F/F mice (29) sperm was kindly provided by P. Margaratis (CHOP) and rederived 
in the C57BL/6J (Jackson) background by the Vanderbilt Transgenic Mouse/Embryonic Stem 
Cell Shared Resource and maintained as a homozygous colony in specific pathogen-free 
housing. Mice were genotyped according to Tai et al (29). Age- and sex-matched C57BL/6J 
(Jackson) were used after one week of acclimation. All infections were performed at the 
Vanderbilt University Medical Center under the principles and guidelines described in the 
Guide for the Care and Use of Laboratory Animals using Institutional Animal Care and Use 
Committee (IACUC)-approved protocol M1600123-00. Vanderbilt University Medical Center 
is an American Association for Laboratory Animal Science (AALAS)-accredited facility. The 
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Vanderbilt University Medical Center is registered with the Office of Laboratory Animal Welfare 
(OLAW), assurance number A-3227-01. 
 
A. baumannii infection 
A. baumannii strain ATCC17978 was streaked to lysogeny broth agar (LBA) from -80° 
stock. After 24 h at 37°C, a single colony was used to inoculate 3 ml of  LB  in a 15 ml aeration 
culture tube, and grown overnight for 16 h at 37° with shaking. 10 µl of this culture was 
inoculated into 10 ml of LB in a 50 ml conical tube and grown for 3.5 h at 37° with shaking. 
Bacteria were collected by centrifugation, washed twice in ice-cold PBS, and resuspended in 
ice-cold PBS to a concentration of 1-3x109 CFU/ml. For each infection, the inoculum was 
serially diluted in PBS and plated to LBA for enumeration. Mice were anaesthetized with 
avertin by intraperitoneal injection and subsequently injected with 100 µl of the A. baumannii 
suspension retroorbitally. For most experiments, mice were sacrificed at times noted by CO2 
asphyxiation, and organs were sterilely collected in PBS, homogenized with Next Advance 
Bullet Blender (Navy Lysis tubes), serially diluted in PBS, and plated to LBA for enumeration 
following incubation at 37° for 24 h. For survival experiments, mice were infected as above 
and weighted daily monitored daily for death or moribund status. Mice were sacrificed if they 
exhibited signs of infection (lack of grooming, hunched posture) and if they were unable to 
right themselves within 5 seconds of being placed on side. For infection with heat-killed 
bacteria, A. baumannii was grown and prepared as above, except resuspended in PBS to a 
final density of approximately 2x1010 CFU/ml , and then heated in a 70°C water bath for 45 
minutes, cooled to room temperature, then placed on ice. A portion of the inoculum was plated 
to LBA to ensure no viable bacteria were detected.   
 
Pathology and immunohistochemistry 
Tissues were fixed in 10% neutral buffered formalin immediately following euthanasia 
of the mice. Unbiased, standardized sectioning of the liver [30] was performed and spleens 
were submitted whole for histological processing. Fixed tissues were routinely processed 
using a standard 8 hour processing cycle of graded alcohols, xylenes, and paraffin wax, 
embedded and sectioned at 4-5 microns, floated on a water bath, and mounted on positively 
charged or hydrophobic glass slides. 
Hematoxylin and eosin (H&E) staining was performed on the Gemini autostainer 
(Thermo Fisher Scientific, Waltham, MA). Immunohistochemical (IHC) staining for thrombosis 
was performed using an anti-fibrinogen/fibrin (FGA) antibody on a Leica Bond-Max IHC 
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autostainer (Leica Biosystems Inc., Buffalo Grove, IL). All steps besides dehydration, clearing 
and coverslipping were performed on the Bond-Max. Slides were deparaffinized. Enzymatic-
induced antigen retrieval was performed using Proteinase K (Dako, Agilent, Santa Clara, CA) 
for 5 minutes. Slides were incubated with anti-FGA (A0080, DAKO/Agilent Technologies, Inc, 
Carpinteria, CA) for 1 hour at a 1:5000 dilution. The Bond Polymer Refine Detection system 
was used for visualization. Slides were then dehydrated, cleared and coverslipped. 
All histopathologic interpretation was conducted by a board-certified veterinary 
pathologist under masked conditions. Semiquantitative lesion scoring in H&E stained sections 
of the liver (hepatitis [31], thrombosis) and spleen (lymphocytolysis, thrombosis) was 
completed on a 5-point scale. Quantitation of hepatic thrombosis was performed on digitized, 
FGA-stained IHC slides using the Aperio ImageScope positive pixel count v9 algorithm. 
 
Cytokine and chemokine analysis 
Cytokines were quantified using Milliplex MAP Mouse Cytokine/Chemokine Magnetic 
Kit (Millipore #MCYTOMAG-70K-PMK; Premixed beads MCYPMK25-MAG) Multiplex Assays 
according to manufacturer’s instructions and analyzed with a Luminex FLEXMAP 3D 
instrument. Tissues were removed immediately following euthanasia and were homogenized 
in  PBS containing 1 mM phenylmethane sulfonyl fluorise (PMSF), homogenized using a Next 
Advance Bullet Blender (Navy Lysis tubes), and protein content was quantified by BCA 
(Thermo).Whole blood was collected by blind cardiac puncture following euthanasia and 
allowed to clot at room temperature for at least 30 minutes, then serum was collected by 
centrifugation at 6500 x g for 10 minutes at 4°C. All samples were stored at -80°C until 
analysis. Tissue samples were analyzed undiluted and cytokine values were normalized to 
total protein content, while diluted 1:1 in serum matrix buffer, except for samples of limited 
volume, which were diluted 1:2. Analyte values were corrected for dilution.  
 
Cell population analysis by flow cytometry 
Organs and blood were harvested from the mice and single cells suspensions were 
created from the kidney and spleen. Red blood cells were lysed from organ cell suspensions 
and peripheral blood followed by the introduction of a Live/Dead stain (Invitrogen, L23105) on 
ice for 20 min. Samples were spun, aspirated, and fixed in 4% paraformaldehyde at room 
temperature, and transferred onto ice for 15 min. Samples were spun, aspirated and 
resuspended in mouse Fc Block (BD Pharmigen, clone 2.4G2) diluted in fluorescence-
activated cell sorting (FAC) media (PBS +2% FBS +0.02% NaAz) for 20 min on ice. Following 
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block, samples were spun, aspirated, and resuspended in FACs media containing surface 
markers for 20 min on ice.  To stain for Tregs, samples were spun, aspirated, and 
resuspending in saponin permeabilization buffer (PBS +0.05% saponin +0.5% BSA) 
containing anti-FOXP3. Finally, samples were spun, aspirated, and resuspended in FACs 
media for flow cytometry. Data were collected using a BD LSRII flow cytometer with 
FACSDIVA software and analyzed using FlowJo. 
 
Enoxaparin inhibitor 
Seven-week old female C57BL/6J (Jackson) mice were anaesthetized with avertin by 
intraperitoneal injection followed by injection with 100 µl of either PBS or 1.9 mg/ml enoxaparin 
(Fresenius Kabi #FK562586) for final dose of approximately 10 mg/kg. Mice were then 
injected with 100 µl of A. baumannii 17978 in PBS to final inoculation of 2-3x108 CFU. Mice 
were sacrificed at 24 hpi by CO2 asphyxiation, organs were sterilely collected in PBS, 
homogenized with Next Advance Bullet Blender (Navy Lysis tubes), serially diluted in PBS, 
and plated to LBA for enumeration following incubation at 37° for 24 h.  
 
Results 
PheWAS identifies predicted and novel disease associations with F10 SNP.  
The electronic health records of approximately 30,000 patients and their associated 
exome sequencing was scanned for novel associations between ICD-9 medical codes and 
F10 rs3211783 (32), a SNP that results in Gly192Arg in FX (Table 1). The Gly192Arg minor 
allele is found in about 3% of the world population and is most abundant in those of African 
descent (11%) (33). Importantly, carriers of this SNP minor allele display an increased 
incidence compared to non-carriers of a number of hematological conditions in their EHR as 
indicated by odd ratios (ORs) >1 (Table 2). These phenotypes were expected based on the 
known function of FX in blood clotting and thus serve as validation phenotype supporting the 
integrity of the PheWAS results. Interestingly, PheWAS analysis here identified unexpected 
phenotypes regarding the liver, which is the site of FX synthesis (Table 2). 
In addition to the validating phenotypes, the PheWAS analysis revealed unexpected 
associations between rs3211783 and a cluster of infection-related phenotypes, including 
postoperative infection, mycoses, and cellulitis and abscess of trunk (Table 2). Both 
phenotype clusters had positive ORs, indicating SNP carriers are at an increased risk of 
developing these conditions. To better understand the pathogens driving a subset of the 
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infectious phenotypes, we reviewed microbiology lab results; the cultures of the case carriers 
in this group had positive tests a variety of Gram-positive and Gram-negative bacterial 
pathogens were isolated from patients (Table 3). Based on these findings, we hypothesized 
that FX contributes to the innate immune response to bacterial infection and that FX might 
affect the ability to resist infection by a variety of pathogens. 
 
SNP rsID Mutation SIFT PP2 Exome 
MAF 
Variant 
frequency 
Populations with highest 
MAF 
Gly192Arg rs3211783 Missense 0.31 0.195 0.14% 3% African 11% 
 
Table 1. Predicted consequences and minor allele frequencies (MAF) of rs3211783 based on 
the 1000 Genomes Project (33). 
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 Condition 
PheWAS 
Code 
p Value 
Odds 
Ratio 
Affected 
Cases 
Total 
Cases 
Controls 
Expected 
(validating) 
phenotypes 
Other diseases of blood 
and blood-forming 
organs 
289 1.2E-03 4.65 5 481 18328 
Pernicious anemia 281.11 1.3E-02 6.41 2 195 15680 
Hematemesis 578.1 2.5E-02 5.08 2 155 20426 
Abnormality of red blood 
cells 
289.9 3.3E-02 8.84 3 51 18328 
Polycythemia vera, 
secondary 
289.8 1.3E-04 10.25 3 188 20349 
 Condition 
PheWAS 
Code 
p Value 
Odds 
Ratio 
Affected 
Cases 
Total 
Cases 
Controls 
Unexpected 
infection-
related 
phenotypes 
Mycoses 117 7.8E-07 8.62 6 278 21953 
Athlete’s foot 110.12 2.3E-05 13.19 3 106 21953 
Cellulitis and abscess of 
trunk 
681.7 2.7E-04 5.60 5 357 21003 
Tuberculosis 010 3.2E-02 8.99 2 46 21520 
Cholangitis 575.1 5.5E-03 5.24 3 221 23497 
Endocarditis 420.3 2.7E-02 4.98 2 160 23314 
Viral infection 079 3.9E-02 2.96 4 459 21250 
 Condition 
PheWAS 
Code 
p Value 
Odds 
Ratio 
Affected 
Cases 
Total 
Cases 
Controls 
Unexpected 
liver-related 
phenotypes 
Primary biliary cirrhosis 571.6 2.0E-07 9.91 6 232 19711 
Other disorders of biliary 
tract 
575.8 5.5E-04 6.05 4 251 23497 
Other biliary tract 
disease 
575 1.6E-03 3.88 6 587 23497 
Jaundice (not of 
newborn) 
573.5 2.0E-03 5.09 4 316 19711 
Liver replaced by 
transplant 
573.2 2.4E-03 4.92 4 327 19711 
Other disorders of liver 573 2.7E-02 3.17 4 510 19711 
Cirrhosis of liver without 
mention of alcohol 
571.51 2.8E-02 2.84 5 709 19711 
Chronic liver disease 
and cirrhosis 
571 2.9E-02 2.42 7 1,149 19711 
Malignant neoplasm of 
liver, primary 
155.1 3.9E-02 4.47 2 174 21458 
Cholangitis  575.1 5.5E-03 5.24 3 221 23497 
 
Table 2. Phenotypes identified by PheWAS of F10  rs3211783 
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Table 3. Culture reports from 12 mycoses, athlete's foot, and endocarditis patients 
 
FX deficient mice demonstrate reduced bacterial burdens after systemic A. baumannii 
infection. 
To assess the role of FX during infection, we used A. baumannii as a model 
opportunistic Gram-negative pathogen. Mice with the Friuli allele of F10 (referred to as F10F/F 
throughout), which have reduced FX activity, were used to model the F10 rs3211783 variant 
and FX-deficiency in general. As deletion of F10 is embryonic lethal, this is a well-
characterized murine model of FX-deficiency (29).  Age- and sex-matched wildtype C57BL/6J 
and F10F/F mice were infected retroorbitally with A. baumannii to establish systemic infection. 
As early as 4 hours post infection (hpi), F10F/F mice demonstrated reduced bacterial burdens 
Culture reports from 12 mycoses, athlete's foot, and endocarditis patients 
isolated organism(s) number of 
culture 
reports 
number of 
subjects 
Staphylococcus coagulase (aureus) 23 6 
Escherichia coli 12 2 
Klebsiella pneumoniae 12 3 
Scedosporium apiospermum 11 1 
Candida albicans 8 2 
Pseudomonas aeruginosa 6 1 
Mycobacterium avium 5 1 
Pseudomonas aeruginosa mucoid 5 1 
Enterobacter cloacae 4 1 
Enterobacter cloacae, Acinetobacter baumannii 4 1 
Candida albicans, Scedosporium apiospermum 3 1 
Pseudomonas aeruginosa non-mucoid 3 1 
Pseudomonas aeruginosa, Stenotrophomonas maltophilia 3 1 
Streptococcus bovis 3 1 
Bacillus species not anthracis 2 1 
Cryptococcus neoformans 2 1 
Unidentified Nontuberculous Mycobacterium 2 1 
Aspergillus flavus 1 1 
Candida parapsilosis 1 1 
candida, NOT albicans, probable parapsilosis 1 1 
Diphtheroids aerobic 1 1 
Enterococcus faecalis 1 1 
Escherichia coli, Proteus mirabilis 1 1 
Haemophilus influenzae, Diphtheroids aerobic 1 1 
Mycobacterium 1 1 
Mycobacterium simiae 1 1 
Neisseria species 1 1 
Probable atypical Mycobacterium 1 1 
Proteus mirabilis 1 1 
Pseudomonas aeruginosa mucoid, Stenotrophomonas maltophilia 1 1 
Staphylococcus epidermidis 1 1 
Streptococcus agalactiae (group B) 1 1 
Yeast, probable Candida glabrata 1 1 
Black text indicates Gram-positive bacteria, red indicates Gram-negative bacteria, grey is other 
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in the blood, and at 24 hpi, less A. baumannii was recovered from the blood and every organ 
tested of F10F/F mice (Figure 1A-B). Contrary to our hypothesis, these data suggest FX is 
pathological during systemic A. baumannii infection. 
Because Gram-negative bacteria can induce clotting dysregulation, including 
microthrombi and disseminated intravascular coagulation, we hypothesized that reduced FX 
activity in F10F/F mice would protect from infection-induced hypercoagulation. Histopathology 
of mock and infected mice at 24 hpi detected no differences between C57BL/6J and F10F/F 
mice, measuring liver hepatitis and thrombosis, and spleen lymphocytolysis and thrombosis 
(Figure 1C). To further assess A. baumannii induced thrombosis, liver thrombi formation was 
measured using immunohistochemistry against fibrin, fibrinogen, and fibrinogen fragments D 
and E. Again, no difference between mouse genotypes at 24 hpi was observed (Figure 1D). 
 
Figure 1. FX deficient mice exhibit reduced bacterial burdens after systemic A. 
baumannii infection. Approximately 3x108 CFU of A. baumannii 17978 was injected retro-
orbitally. Mice were sacrificed and tissues removed at (A) 4 and (B) 24 hpi.  (C-D) Mice were 
infected with approximately 3x108 CFU of A. baumannii 17978 retro-orbitally and sacrificed at 
24 hpi. Tissue were fixed and (C) scored blindly or (D) hepatic thrombosis was quantified 
using anti-fibrin/fibrinogen immunohistochemistry. Each dot represents a single mouse, and 
data are compiled from (A) two experiments, (B) three experiments, or (C-D) one experiment. 
For A and B, * indicates P<0.05, **P<0.01, and ***P<0.001 by Mann-Whitney test. For C and 
D, no statistical difference was found by two-way ANOVA with Sidak’s correction for multiple 
comparisons 
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F10F/F mice demonstrate reduced serum immune response to systemic A. baumannii 
infection 
 As no difference was observed for infection-induced coagulation, we therefore 
hypothesized that an altered early immune response is responsible for the difference in 
bacterial burdens between C57BL/6J and F10F/F mice. To test this hypothesis, cytokines and 
chemokines were quantified from serum at 4 and 24 hpi using a multiplexed analysis. F10F/F 
mice exhibited reduced levels of a variety of cytokines by 24 hpi, including both pro-
inflammatory (TNF, IL6) and anti-inflammatory (IL10) cytokines (Figure 2A; Table 4). 
Chemokines, including the IFNG-induced CXCL10 and chemoattractants CXCL1, CXCL2, 
and CCL4 were reduced by 4 or 24 hpi (Figure 2B). These data suggest that C57BL/6J mice 
experience a rapid induction of inflammatory response to A. baumannii, and this induction is 
blunted in F10F/F mice. 
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Figure 2.  F10F/F mice exhibit reduced inflammatory response to systemic A. baumannii 
infection. Serum (A) cytokines and (B) chemoattractants at 4 and 24 hours following retro-
orbital infection with approximately 3x108 CFU of A. baumannii 17978 were quantified by 
Luminex analysis. For A and B, each dot represents data from a single mouse, from two 
experiments. * indicates P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 by one-way 
ANOVA with Sidak’s correction for multiple comparisons, comparing genotypes at each time 
point. For graphing and statistical tests, values that exceeded the limit of detection were set 
to the limit for each analyte. 
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 WT-4 hpi F10F/F-4 hpi WT-24 hpi F10F/F-24 hpi 
Analyte Mean St.Dev n Mean St.Dev n Mean St.Dev n Mean St.Dev n 
CSF2 
(GM-
CSF) 
327.7025 62.08024 8 485.3343 633.2576 7 314.92 14.65961 7 139.8075 7.470375 8 
INFG 131.3987 49.28693 8 270.0657* 387.877 7 252.3229 110.9572 7 10.3025 5.887055 8 
IL1A 1426.055 269.1899 8 1565.874 1382.498 7 1628.929 248.8949 7 610.66* 89.3456 8 
IL1B 300.79 136.8141 8 276.3 372.6778 7 195.4514 43.40271 7 44.5775 3.660827 8 
IL2 50.95375 9.210788 8 42.53429 16.88327 7 53.88857 11.92116 7 21.9625* 7.378582 8 
IL4 5.64625 1.103875 8 7.72 6.058107 7 6.091429 1.672239 7 1.9625* 0.428744 8 
IL5 93.1325 25.05097 8 107.4171 48.32001 7 114.68 23.35679 7 61.0375* 9.267175 8 
IL6 83708.63 20310.59 8 54250.36* 33562.25 7 83778 0 7 2071.1* 1560.823 8 
IL7 19.98 5.374511 8 36.98571* 16.89109 7 18.8 6.819306 7 12.5275 3.239082 8 
IL10 18073.26 9993.004 8 13851.27 12037.68 7 23510.57 5547.001 7 2258.51* 1594.731 8 
IL-12B 96.81875 24.53519 8 55.08* 33.3248 7 103.8571 25.24159 7 19.6875* 6.630544 8 
IL-12 
(p70) 
186.0263 35.90669 8 135.1543* 48.97088 7 161.2514 23.4808 7 38.3025* 6.535524 8 
IL13 594.8137 142.1335 8 310.7972* 143.792 7 510.3714 80.17876 7 62.5125* 12.13332 8 
IL15 444.51 100.3283 8 343.9514 163.53 7 438.2543 112.3424 7 158.2125* 43.14843 8 
IL17A 54.225 14.38015 8 132.2057 146.2406 7 62.34 21.28257 7 9.995 1.986778 8 
CXCL10 12543.88 4920.522 8 5403.249* 3631.554 7 17238.57 2396.865 7 2024.805* 386.9841 8 
CXCL1 45385.88 11141.4 8 39404.29 14597.6 7 47253.72 5201.075 7 12543.75* 5948.964 8 
CCL2 27695 7126.445 8 17280.57 10272.27 7 30874 0 7 13482.5* 3444.329 8 
CCL3 21335.75 10605.42 8 5453.72* 9361.949 7 15283.71 5151.298 7 537.4325* 105.578 8 
CCL4 29500.88 7123.949 8 10942.61* 11935.94 7 27470.29 4507.604 7 1307.733* 475.3569 8 
CXCL2 19013.93 7818.556 8 12383.54* 7729.882 7 12400.29 6624.862 7 1248.693* 981.7016 8 
CCL5 3741.504 2101.41 8 4356.406 5266.379 7 6365.106 3163.374 7 526.2425* 148.9296 8 
TNF 699.9313 284.0037 8 351.8914 504.584 7 421.2743 109.8479 7 42.8925* 6.345617 8 
Red text indicates compiled data includes values from the upper or lower limit of detection 
* indicates statistical significance comparing F10F/F to WT within each time point by one-way ANOVA with Sidak’s correction for multiple 
comparisons 
Table 4. Total Luminex analysis of 4 and 24 hpi cytokines 
 
Factor X activity is required for induction of rapid immune response and subsequent 
mortality after injection of heat-killed A. baumannii 
 The reduction in cytokine and chemokine levels in F10F/F mice at 24 hpi could be the 
result of either 1) correlation with reduced abundance of bloodstream A. baumannii or 2) an 
intrinsically different immune response to A. baumannii. To test this hypothesis, cytokines and 
chemokines were quantified at 24 h following injection with PBS (mock) or heat-killed A. 
baumannii. For both mouse genotypes, the presence of heat-killed A. baumannii induced 
immune signaling (Figure 3A,B; Table 5). Chemokines and cytokines previously observed to 
be reduced in F10F/F mice following infection compared to C57BL/6J mice were also reduced 
following injection with heat killed bacteria. Together, these data suggest that during A. 
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baumannii infection, the innate immune response is triggered rapidly, and this response is 
reduced in F10F/F mice, regardless of the abundance of viable bacteria.  
 Thus far, it has been established that C57BL/6J mice demonstrate a strong induction 
of inflammatory signaling during infection of A. baumannii, and at 24 hpi, bacteria burdens are 
increased compared to F10F/F mice across organs. We hypothesized that the inflammatory 
response in C57BL/6J mice is pathological during A. baumannii infection regardless of the 
ability of A. baumannii to replicate in organs. Therefore, heat-killed A. baumannii was injected 
into mice and survival was monitored for 8 days. C57BL/6J mice succumbed to this treatment 
at a greater rate compared to F10F/F mice (Figure 3C), suggesting that the inflammatory 
response, which requires FX activity, is pathological during systemic A. baumannii infection.  
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Figure 3. FX mice are protected from hyperactivated immune response and subsequent 
mortality after injection of heat-killed A. baumannii. Serum (A) cytokines and (B) 
chemoattractants following retro-orbital injection with PBS (mock) or approximately 1-2x109 
CFU of heat-killed A. baumannii 17978 were quantified by Luminex analysis after mice were 
sacrificed at 24 hpi. (C) Survival of mice injected with approximately 1-2x109 CFU of heat-
killed A. baumannii 17978. For A-B, each dot represents data from a single mouse, from two 
experiments. For A and B, * indicates P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 by 
one-way ANOVA with Sidak’s correction for multiple comparisons, comparing genotypes 
within each treatment group. For graphing and statistical tests, values that exceeded the limit 
of detection were set to the limit for each analyte. For C data are combined from two 
independent experiments with n=13 for C57/BL6J and n=17 for F10F/F, * indicates P<0.05 by 
Logrank (Mantel-Cox) Survival test.  
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 WT-heat-killed F10F/F-heat killed WT-mock F10F/F-mock 
Analyte Mean St.Dev n Mean St.Dev n Mean St.Dev n Mean St.Dev n 
CSF2 
(GM-
CSF) 
259.5875 91.54469 8 78.83* 53.53201 5 8.793333 1.060063 3 7.74 0 3 
INFG 662.3362 538.0319 8 8.668* 6.295278 5 2.28 1.247077 3 1.56 0 3 
IL1A 8036.625 2800.238 8 4771.8 3182.584 5 3106.16 1626.119 2 8946.667 3128.198 3 
IL1B 131.4063 68.8995 8 21.81* 11.68858 5 4.026667 3.554678 3 1.973333 0.8386498 3 
IL2 127.8588 35.05793 8 24.23* 10.61529 5 27.46667 39.63065 3 6.826667 9.260698 3 
IL4 2.65875 0.8803641 8 2.596 1.297027 5 0.5266666 0.1747379 3 0.98 1.039231 3 
IL5 72.6875 22.64867 8 26.592 6.569727 5 161.2667 245.793 3 20.18 9.200586 3 
IL6 30542.38 12765.34 8 2535.328* 2098.501 5 20.37333 10.39703 3 3.7 2.298173 3 
IL7 12.9525 4.833525 8 2.964* 1.213623 5 1.18 0 3 1.18 0 3 
IL10 4574.797 2649.544 8 1308.91* 598.7396 5 3.513333 1.119345 3 2.32 0 3 
IL-12B 54.93625 13.04581 8 32.856 39.19164 5 14.57333 6.223836 3 19.21333 7.366365 3 
IL-12 
(p70) 
225.0875 89.26364 8 33.522* 19.62103 5 6.4 0 3 10.64 4.442207 3 
IL13 447.645 220.784 8 59.378* 45.09955 5 29.44 25.70114 3 23.39333 6.572924 3 
IL15 289.3175 116.5687 8 79.41* 73.52285 5 28.4 0 3 38.64 17.7362 3 
IL17A 140.7275 83.73083 8 10.902* 6.713943 5 1.08 0 3 1.08 0 3 
CXCL10 9974.25 3918.134 8 3343.4* 258.0403 5 316.5267 78.18846 3 286.5067 92.51986 3 
CXCL1 21661.38 8957.103 8 5909.872* 4096.94 5 98.44 89.73907 3 166.4133 232.2218 3 
CCL2 20907.38 10364.18 8 6146* 2069.581 5 59.33333 31.76177 3 14.91333 4.206772 3 
CCL3 705.775 258.1041 8 197.22* 40.3411 4 66.09 57.74234 2 36.80667 22.34282 3 
CCL4 7088.273 4665.535 8 1278.752* 368.3191 5 87.59333 66.03769 3 20.02 0 3 
CXCL2 17586.15 11917.55 8 959.06* 854.0344 5 117.3867 157.9053 3 46.86 35.74953 3 
CCL5 1991.095 654.0701 8 652.026* 335.7575 5 40.18 32.66029 3 50.72667 20.53968 3 
TNF 108.4313 46.77999 8 24.696* 4.237556 5 2.913333 0.9047284 3 2.113333 0.3695042 3 
Red text indicates compiled data includes values from the upper or lower limit of detection 
* indicates statistical significance comparing F10F/F to WT within either heat-killed or mock by one-way ANOVA with Sidak’s correction for multiple 
comparisons 
Table 5. Total Luminex analysis of mock and heat-killed cytokines at 24 hpi 
 
F10F/F mice exhibit enhanced Teffector response  
 To understand the cellular response to A. baumannii in C57BL/6J and F10F/F mice, we 
quantified populations of CD4+, CD8+, and CD11b+ cells in mock and infected spleen, kidney, 
and blood. A variety of changes were observed between infected C57BL/6J and F10F/F mice. 
Total blood CD11b+ cells are increased in F10F/F mice, driven by an increase in neutrophils 
and macrophages (Figure 4A, Figure 5A). C57BL/6J mice demonstrate a reduction in splenic 
neutrophils which results in neutropenia. The magnitude of this phenomenon is reduced in 
F10F/F mice, resulting in a greater percentage of splenic neutrophils (Figure 5A). Additionally, 
F10F/F mice have higher percent neutrophils in the blood during infection. On the other hand, 
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the percent of CD11b+ cells that stain as dendritic cells is reduced in infected F10F/F mice in 
the spleen and blood.  
Consistent with the ability to restrict A. baumannii burdens during infection, F10F/F mice 
demonstrated a stronger induction total CD8+ cells in the spleen and increased CD8+ Teffector 
cells  in the spleen and kidney. concomitant with this increase in Teff cells, CD8+ naive and 
CD4+ regulatory T cells populations were decreased (Figure 4B, Figure 5B). A similar trend 
was observed in CD4+ cells; spleen and kidney CD4+ Teff cell populations were increases and 
reduced percentat goe of CD4+ Tnaive were observed in the spleen and blood, and reduced 
Treg cell population was incuded in the kidney (Figure 4C).  Together, these differential cell 
populations suggest F10F/F mice are better prepared to kill A. baumannii and restrict bacterial 
replication during systemic infection.  
 
 
Figure 4. F10F/F mice exhibit enhanced Teffector response. (A) CD11b+ populations, (B) 
CD8+ populations, and (C) CD4+ populations were quantified from spleen, kidney, and blood 
of mice injected with either PBS (mock) or approximately 2-3x108 CFU  A. baumannii 17978 
at 24 hpi using flow cytometry. For A-C, each dot represents data from a single mouse, from 
two experiments. * indicates P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 by two-way 
ANOVA with Tukey’s correction for multiple comparisons.  
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Figure 5. Additional cell population changes at 24 hpi.  (A) CD11b+ populations, (B) CD8+ 
populations, and (C) CD4+ populations were quantified from spleen, kidney, and blood of mice 
injected with either PBS (mock) or approximately 2-3x108 CFU  A. baumannii 17978 at 24 hpi 
using flow cytometry. For A-C, each dot represents data from a single mouse, from two 
experiments. * indicates P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 by two-way ANOVA 
with Tukey’s correction for multiple comparisons. 
 
Cytokines and chemokine levels are reduced in infected tissues of F10F/F mice 
 From the serum cytokines measured in Figure 3, it was unclear whether the reduced 
induction of cytokines and chemokines at 24 hpi was a global change in F10F/F mice, or 
whether tissue levels of pro-inflammatory cytokines and chemokines would be elevated in 
F10F/F mice at 24 hpi, resulting in increased neutrophils and Teff cells found in infected tissue 
(Figure 4). Therefore, we measured cytokines and chemokines at 24 hpi and compared levels 
of immune signaling molecules between PBS treated (mock) and infected C57BL/6J and 
F10F/F mice. In general, as observed in the serum, the cytokines (Figure 6A; Table 6) and 
chemokines (Figure 6B) measured were reduced in tissue of infected F10F/F mice. However, 
IL-15 levels were increased in the infected spleens of F10F/F mice. In general, these data 
suggest that in the absence of FX activity, global innate immune is blunted during systemic A. 
baumannii infection.  
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Figure 6. Cytokines and chemokine levels are reduced in infected tissues of F10F/F mice 
(A) cytokines and (B) chemoattractants following retro-orbital injection of PBS (mock) or 
approximately 2-3x108 CFU of A. baumannii 17978 were quantified by Luminex analysis at 24 
hpi from spleen, kidney, and serum. Each dot represents data from a single mouse, from two 
experiments. * indicates P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 by one-way 
ANOVA with Sidak’s correction for multiple comparisons, comparing the infected group of 
each genotypes and tissue. For graphing and statistical tests, values that exceeded the limit 
of detection were set to the limit for each analyte. 
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 SPLEEN 
 C57BL/6J-mock C57BL/6J-infected F10F/F-mock F10F/F-infected 
Analyte Mean St.Dev Mean St.Dev Mean St.Dev Mean St.Dev 
CSF2 (GM-
CSF) 
37.4 15.8 153.6 118.5 32.5 8.9 113.1 42.5 
INFG 7.9 1.5 397.1 429.2 9.7 4.7 53.8* 37.7 
IL1A 153.5 15.7 3442.4 1247.0 122.9 23.8 2853.0 1638.5 
IL1B 30.3 6.9 229.3 118.9 32.2 9.4 159.9 51.2 
IL2 8.5 3.4 25.9 30.4 14.0 11.4 21.9 18.3 
IL4 7.4 3.6 6.8 2.0 4.7 1.3 10.2 5.7 
IL5 29.2 38.9 36.2 9.8 10.7 5.4 27.1 6.5 
IL6 16.1 9.5 5184.6 4907.4 9.7 1.6 609.3 477.7 
IL7 10.5 2.4 16.2 5.6 7.8 1.9 39.1 58.3 
IL10 22.7 9.7 151.3 69.7 23.4 2.5 143.7 35.8 
IL-12B 0.7 0.1 17.6 11.8 5.5 7.7 10.4 8.7 
IL-12 (p70) 14.8 14.1 36.2 14.7 8.6 1.7 41.8 19.3 
IL13 3.6 2.6 19.0 12.5 2.4 1.0 17.8 20.2 
IL15 45.7 33.7 93.8 40.5 34.4 14.2 252.5* 393.5 
IL17A 2.9 1.4 128.0 130.5 2.4 0.8 46.4* 26.7 
CXCL10 638.5 66.0 2705.2 1532.2 403.4 156.5 1643.1 633.2 
CXCL1 137.9 163.2 5253.1 2776.6 49.2 7.7 2726.3 1282.8 
CCL2 83.9 44.9 3061.3 1643.1 49.0 4.2 2184.2 721.7 
CCL3 56.9 7.5 2845.5 1802.7 44.4 11.6 1460.5* 688.6 
CCL4 110.6 26.6 2968.3 2068.9 106.5 42.8 2296.5 1090.3 
CXCL2 59.1 13.1 4411.6 3407.0 57.6 13.2 1448.2 1238.2 
CCL5 151.8 22.7 698.1 466.8 106.6 50.7 451.3* 233.2 
TNF 7.0 1.6 30.8 14.3 5.6 0.7 26.5 9.2 
 KIDNEY 
 C57BL/6J-mock C57BL/6J-infected F10F/F-mock F10F/F-infected 
Analyte Mean St.Dev Mean St.Dev Mean St.Dev Mean St.Dev 
CSF2 (GM-
CSF) 
52.9 11.9 144.2 119.5 57.2 17.4 83.8 24.1 
INFG 25.2 6.1 110.8 114.2 22.9 7.0 25.4 9.8 
IL1A 200.7 82.0 343.8 66.0 146.4 30.1 268.1 46.3 
IL1B 57.1 26.0 95.1 22.1 57.9 29.8 89.2 34.4 
IL2 64.7 13.7 42.9 16.1 50.6 10.9 39.7 17.7 
IL4 6.6 4.3 5.3 3.0 5.0 2.2 4.7 2.7 
IL5 53.7 39.8 58.0 30.9 36.8 9.7 41.2 18.0 
IL6 53.4 54.9 8451.0 6128.1 26.0 4.7 1078.0 668.8 
IL7 40.2 12.0 38.3 9.7 33.4 9.3 35.8 12.1 
IL10 49.2 16.0 289.6 357.8 47.8 16.8 125.8 49.0 
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IL-12B 72.8 21.7 70.8 8.6 45.4 12.3 63.6 21.4 
IL-12 (p70) 57.0 13.6 54.2 17.5 51.2 17.9 47.3 18.9 
IL13 9.7 3.9 19.6 16.0 7.8 6.7 4.7* 3.4 
IL15 171.5 76.3 211.6 47.0 157.1 61.8 202.7 79.1 
IL17A 12.8 3.7 26.3 13.1 10.6 3.3 14.5 5.2 
CXCL10 226.7 72.6 2641.2 1674.5 174.2 45.5 607.6* 165.6 
CXCL1 115.0 111.9 8437.6 3149.4 80.9 15.8 3480.7* 1760.0 
CCL2 115.1 72.7 6108.3 3194.0 73.9 18.7 2890.1 778.3 
CCL3 48.6 15.3 630.5 303.7 38.6 9.6 261.6 52.9 
CCL4 22.8 2.7 2132.4 1007.7 23.5 9.1 645.0* 148.7 
CXCL2 104.0 32.1 5815.6 3303.5 98.4 29.5 1025.7* 438.6 
CCL5 11.3 1.8 284.4 86.4 10.0 2.8 181.0 46.2 
TNF 8.1 3.1 33.3 7.8 6.9 1.2 26.1 4.9 
 SERUM 
 C57BL/6J-mock C57BL/6J-infected F10F/F-mock F10F/F-infected 
Analyte Mean St.Dev Mean St.Dev Mean St.Dev Mean St.Dev 
CSF2 (GM-
CSF) 
15.8 27.3 148.9 150.7 2.2 0.0 70.0 40.6 
INFG 9.2 16.4 438.9 609.1 1.1 0.3 20.3* 21.8 
IL1A 951.4 459.4 482.2 173.8 779.6 267.7 347.9 104.7 
IL1B 120.7 238.5 126.6 71.7 2.3 0.5 44.3 17.8 
IL2 4.7 8.8 9.6 5.7 0.3 0.0 6.4 4.9 
IL4 31.6 61.6 3.1 1.2 0.8 0.0 2.5 1.5 
IL5 236.7 435.9 76.3 31.1 8.6 2.9 60.4 37.9 
IL6 89.9 172.0 23948.1 19002.0 2.3 1.7 2720.9* 3475.7 
IL7 0.7 0.2 20.3 11.2 0.6 0.0 12.7 10.3 
IL10 74.2 146.7 4870.8 8673.8 1.2 0.3 1450.9 1286.1 
IL-12B 2.7 0.6 4.3 3.9 2.4 0.0 2.4 0.3 
IL-12 (p70) 136.3 269.6 39.4 21.9 1.5 0.0 27.6 35.5 
IL13 3.5 0.8 17.8 17.3 3.1 0.0 3.8* 1.5 
IL15 1.1 0.2 85.2 43.2 0.9 0.0 34.7 23.0 
IL17A 11.5 21.4 39.6 34.9 1.7 0.6 10.8 9.3 
CXCL10 381.0 188.1 4958.1 3386.0 324.0 69.7 1737.6* 566.6 
CXCL1 189.3 316.4 17725.4 8573.9 73.2 15.6 6255.4* 4889.8 
CCL2 97.9 163.8 14872.8 7406.3 24.9 6.4 5755.8* 2309.3 
CCL3 64.2 116.5 1023.7 1081.3 5.9 0.0 281.6 70.9 
CCL4 7.2 1.6 2627.4 2175.6 6.4 0.0 494.6* 163.8 
CXCL2 145.1 10.2 12365.4 10491.3 142.2 67.0 1231.7* 1327.7 
CCL5 6.5 10.7 335.7 186.8 3.2 1.6 103.3* 44.9 
TNF 15.2 28.1 95.2 60.2 1.2 0.0 25.7* 7.1 
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Red text indicates compiled data includes values from the upper or lower limit of detection 
* indicates statistical significance comparing F10F/F to WT within either heat-killed or mock by one-way ANOVA with Sidak’s correction for 
multiple comparisons 
n=4 mock infected per genotype, 11 C57BL/6J infected and 9 F10F/F infected 
Table 6. Total Luminex analysis of serum, kidney, and spleen cytokines at 24 hpi 
 
An FDA-approved Factor Xa inhibitor reduces bacterial burdens in C57BL/6J mice 
To test whether pharmacological inhibition of FXa could reduce the bacterial burdens 
observed in WT mice infected with A. baumannii, enoxaparin was administered at the time of 
infection and bacteria was enumerated across organs at 24 hpi. Consistent with a pathological 
role of FX during systemic A. baumannii infection, bacterial burdens were reduced in the heart, 
liver, and spleen of wildtype mice after a single treatment with enoxaparin (Figure 7).  
 
 
 
Figure 7. An FDA-approved Factor Xa inhibitor reduces bacterial burdens in WT mice. 
Bacterial burdens 24 hpi following infection with 2x108 CFU A. baumannii 17978 after 
treatment with PBS (vehicle) or 10 mg/kg enoxaparin, intraperitoneal, at the time of infection. 
Each dot represents data from a single mouse, from three experiments. * indicates P<0.05 by 
one-way ANOVA with Sidak’s correction for multiple comparisons, comparing the infected 
group of each genotypes and tissue.  
 
Discussion 
In this study, we discovered associations between a polymorphism in a known drug 
target and novel disease phenotypes using PheWAS. Individuals with a SNP in coagulation 
FX demonstrated validating phenotypes of hemostatic disorders but also increases odds ratio 
of being hospitalized for a variety of infection-related disorders (Table 2). Consistent with a 
critical role of FX in innate immunity to bacterial infection, FX-deficient mice display enhanced 
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clearance of A. baumannii (Figure 1) associated with reduced induction of cytokine and 
chemokine production in the serum and infected organs.  Heat-killed A. baumannii induces a 
strong innate response which is blunted in FX deficient mice, resulting in increased survival 
relative to C57BL/6J mice. Together, these data suggest FX activity is pathological during 
systemic A. baumannii infection. While the mechanism is not clear, our work suggests the 
interplay between FX and immune signaling is responsible, as no changes were detected 
between mouse genotypes when assessing pathogen-induced hypercoagulation (Figure 1). 
Instead, we detected widespread changes to the immune cell populations (Figures 4,5) and 
signaling molecules (Figure 6) that suggest A. baumannii induces FX-dependent widespread 
activation of the immune system that results in poor ability to limit replication and increased 
mortality as the result of immune activation (Figure 3). As a proof of principle for the use of 
PheWAS to drive novel therapeutic development, we found that the FDA approved FXa 
inhibitor enoxaparin was able to reduce bacterial burdens in C57BL/6J mice, suggesting 
anticoagulants might offer new treatment for Gram-negative sepsis (Figure 7). 
The interplay between FX and antibacterial immunity adds to a growing body of 
literature suggesting FX, and coagulation more broadly, is a critical determinant of the immune 
response to bacterial or viral infection. For instance, Factor XII deficient mice are protected in 
Klebsiella pneumonia, but Factor XI deficient mice are more susceptible to Klebsiella 
pneumonia. Additionally, Factor XI deficient mice have increased survival in models of cecal 
ligation and puncture sepsis (34, 35). Interestingly, the survival advantage was partially 
attributed to changes in the cytokine response, where FXI-/- mice demonstrated reduced TNF 
and IL10 induction compared WT mice, as observed in this study, but increased IL6 induction, 
which was the opposite in our study (34).  Consistent with our study, inhibition of FXa and 
thrombin was recently shown to improve outcomes of Gram-negative sepsis in baboons by 
attenuating DIC and inhibiting IL6 induction (36). Taken together, coagulation appears to be 
a previously overlooked contributor of the innate immune response to bacterial infection. 
Additionally, this work highlights the potential use of human clinical PheWAS to drive basic 
discovery using laboratory models and validate potential treatments.  
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